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1004-57	 Earlier	Detection	of	Doxorubicin-Induced	
Cardiomyopathy	in	Rats	Using	Radial	Strain	Obtained	
by	2D	Strain	Echocardiography
Raymond Q. Migrino, Deepika Aggarwal, Eugene Konorev, Tejas Brahmbhatt, 
Balaraman Kalyanaraman, Medical College of Wisconsin, Milwaukee, WI
Background: Doxorubicin (DOX), one of the most effective chemotherapy agents, causes 
dose-dependent cardiac injury. M-mode derived fractional shortening (FS), a conventional 
measure of cardiac function, is insensitive in detecting early injury. 2D strain echo (2DSE) 
is a novel technique that measures radial strain (RS) from B-mode images.
Aim: We tested whether 2DSE RS can detect early DOX injury as compared to FS.
Methods: 15 Sprague Dawley rats (240-260 g) were given doxorubicin 2.5 mg/kg IV per 
week and 17 controls received saline. 2DSE at 0, 4, 8, 10 and 12 weeks was done using 
General Electric Vivid 7 echo. 2D images of the mid-LV short axis view (papillary muscle level) 
were obtained. M-mode through the anteroseptum and posterior walls was used to measure 
FS. The ventricle was divided into 6 equal regions; using Q analysis software, peak RS was 
measured in each region and the global RS was calculated as the average of all regions.
Results: See figure. Control rats did not have a significant change in RS and FS versus 
baseline. RS was significantly reduced in DOX versus controls starting at 8 weeks of treatment 
whereas FS showed a difference between the 2 groups only after 12 weeks of treatment.
Conclusions: 1. RS obtained by 2DSE allows for earlier detection of doxorubicin-induced 
cardiomyopathy compared to conventional M-mode measurement of FS. 2. 2DSE is a 
novel measure of myocardial function and its ability to assess early stages of systolic 
dysfunction may be useful in patients being treated with doxorubicin.
9:00 a.m.
1004-58	 Long-Term	Therapy	with	Ranolazine	Decreases	
mRNA	and	Protein	Expression	of	the	Transcriptional	
Repressor	Nab1	and	the	Transcription	Factor	Egr1	in	
Dogs	with	Chronic	Heart	Failure
Sharad Rastogi, Juan Bernal, Valerio Zaca, Luiz Belardinelli, Brent Blackburn, Hani N. 
Sabbah, Henry Ford Health System, Detroit, MI, CV Therapeutics, Inc., Palo Alto, CA
Background:	Nab1 is a repressor of the transcription factor early growth response gene 
(Egr1) a key regulator of pathological cardiac hypertrophy. We previously showed that 
in dogs with heart failure (HF), chronic therapy with ranolazine (RAN), a blocker of the 
late sodium current, alone and in combination with the enalapril (ENA) or metoprolol 
(MET), improved left ventricular (LV) function and attenuated LV hypertrophy. This study 
examined the effect of RAN alone and in combination ENA and MET on mRNA and 
protein expression of Nab1 and Egr1 in LV myocardium of the same cohort of dogs.
Methods: RNA and homogenates were prepared from LV tissue obtained from dogs 
randomized to 3 months therapy with RAN alone (n=7), RAN + MET (n=7), RAN + ENA (n=7), 
or placebo (PL, RAN vehicle, n=7). LV tissue was also obtained from 7 normal (NL) dogs. 
mRNA expression of Nab1 and Egr1 was measured using RT-PCR and protein expression 
was measured using Western blotting. Bands were quantified in densitometric units (du).
Results: In PL-treated dogs, mRNA and protein expression of Nab1 and Egr1 increased 
significantly compared to NL dogs. RAN alone and in combination with MET or ENA 
prevented the increase in Nab1 and Egr1 (Table).
Conclusions: In dogs with HF, therapy with RAN alone and in combination with MET 
or ENA prevents the increase in expression of Nab1 and Egr1. This may explain the 
attenuation of the pathological cardiac hypertrophy observed in HF seen following chronic 
therapy with RAN alone and in combination with MET or ENA. 
NL PL RAN RAN+MET RAN+ENA
Nab1 mRNA (du) 1166 ± 62 2299 ± 74* 1505 ± 55† 1611 ± 102† 1146 ± 65†
Egr1 mRNA (du) 1170 ± 50 1837 ± 93* 1395 ± 33† 1026 ± 82† 1345 ± 58†
Nab1 Protein (du) 369 ± 16 683 ± 43* 382 ± 32† 376 ± 27† 266 ± 24†
Egr1 Protein (du) 252 ± 23 505 ± 18* 276 ± 30† 206 ± 8† 269 ± 29†
* = p<0.05 vs. NL; † = p<0.05 vs. PL
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1004-55	 Chronic	Atrial	Fibrillation	Is	Associated	with	
Dysregulation	of	Sarcoplasmic	Reticular	Ca2+-ATPase	
and	Protein	Kinase	A-mediated	Ser	16-phosphorylated	
Phospholamban
David Silverman, Alexander Yang, Joseph Thomas, Eugene Kim, Jonathan Hammond, 
Bruce Liang, University of Connecticut Health Center, Farmington, CT
Background: Atrial fibrillation (AF) initiates a process of dual electrical and structural 
remodeling. We tested the hypothesis that chronic AF is associated with alterations in key 
sarcoplasmic reticulum Ca2+ handling proteins in a pattern previously observed in human 
ventricular cardiomyopathy.
Methods	 and	Results: Right atrial biopsies and baseline echocardiographic (ECHO) 
data were obtained from patients undergoing cardiopulmonary bypass for heart surgery. 
Thirteen patients with documented permanent or paroxysmal AF were matched with 
patients in NSR for age (±5 yrs) and LVEF (±5%). ECHO variables including LA dimension 
and LVEF were recorded. Levels of sarcoplasmic reticular Ca2+-ATPase (SERCA 2A), 
phospholamban in both its protein kinas A-mediated Ser 16 phosphorylated (Ser 16 
PPLBN) and dephosphorylated forms (PLBN), and calsequestrin (CSQ) were compared 
using quantitative immunoblotting. Pairs were compared by Wilcoxon Rank test matched 
for each pair of NSR and AF subjects.
There was no significant difference in age (74±7 yrs vs. 76±12 yrs), LA dimension (41±6 
mm vs. 41±7 mm, p=.10) or LVEF (54±9% vs. 52±12%, p=.75) between patients with AF AF 
compared to NSR). The data show that levels of SERCA 2A and PPLBN were significantly 
lower in AF than NSR subjects while the levels of CSQ and PLBN were similar.
Conclusions:	 In patients with AF vs those with NSR, regulation of intracellular Ca2+ 
handling proteins parallels that of the same proteins in the failing vs. non-failing human 
ventricles. The data support the hypothesis that AF produces an atrial myopathy similar to 
that seen in ventricular myopathy. Dysfunctional regulation of key sarcoplasmic reticular 
Ca2+ handling proteins may play a role in the development or progression of human AF.
9:00 a.m.
1004-56	 In	Situ	Cardiomyogenic	Transdifferentiation	
Potential	Of	Human	Uterine	Endometrium-derived	
Mesenchymal	Cell.
Nobuhiro Nishiyama, Shunichiro Miyoshi, Naoko Hida, Yukinori Ikegami, Kazuma 
Okamoto, Taro Uyama, Tatsuya Shimizu, Kenji Miyado, Kaoru Segawa, Tohru Kiyono, 
Satoru Kyo, Hiroko Tsuji, Teruo Okano, Michiie Sakamoto, Akihiro Umezawa, Satoshi 
Ogawa, Keio Univsersity School of Medicine, Tokyo, Japan, National Research Institute 
for Child Health and Development, Tokyo, Japan
Background: We have established human mesenchymal stem cell line obtained from 
uterine endometrium (EMC), and the efficacy of in vitro cardiomyogenic differentiation 
(CMD) was extremely high (60 to 90%). Since co-culture with fetal murine cardiomyocyte 
(FMCM) was essential in vitro, the environmental factor has been one of the keys to 
CMD in EMC. Therefore, we hypothesized that the host heart itself can be an adequate 
environmental factor for CMD, when we transplanted EMC into a recipient heart.
Methods	 &	 Results:	 Endometrium-derived cells were obtained from a 52-year-old 
woman by limiting dilution method. We prolonged life span of the endometrium-derived 
cells by infecting them with retrovirus encoding HPV16, E6/E7 and hTERT. Consequently, 
we established monoclonal cell line (EMC). Two weeks after the transplantation of GFP-
labeled EMC into the nude rat heart, the heart was analyzed immunohistochemically. 
(1) Isolated 2x106 EMCs were injected into the heart muscle. Massive rod-shaped GFP-
positive cardiomyocyte having clear striations of sarcomeric α-actinin (clear striation) and 
intercalated disk with stained connexin 43 were observed around the needle injection site. 
In some areas, GFP/actinin double-positive cells connected to the adjacent myocardium 
with narrow stalk and intercalated disk, and looked like budding of regenerated 
cardiomyocyte. (2) GFP-labeled EMC graft tissue (4x106 cell-sheet) was made by fibrin 
polymer coated dish as described previously, and was transplanted onto the epicardial 
surface of the recipient heart. Two weeks later, about 50μm of GFP-positive EMC tissue 
layer was observed on the epicardial surface. Surprisingly, throughout the whole layer of 
engrafted EMC, clear striations with stained sarcomeric α-actinin and cardiac troponin-I 
were observed, suggesting extremely high in vivo CMD ability. This data suggested that 
CMD of EMC was caused by cell fusion-independent mechanism.
Conclusions:	 We have established monoclonal cell line having an extremely high 
CMD potential not only in vitro but also in vivo. The environmental factor of host heart 
is essential and adequate to induce cardiomyogenesis in EMC for the transplantation of 
EMC into a recipient heart.
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1004-59	 Baroreflex	Activation	Therapy	Normalizes	Gene	
Expression	of	Components	of	the	Beta-Adrenergic	
Receptor	Signaling	Pathway	in	LV	Myocardium	of	Dogs	
with	Chronic	Heart	Failure
Ramesh C. Gupta, Makoto Imai, Robert J. Cody, Eric D. Irwin, Martin A. Rossing, Hani 
N. Sabbah, Henry Ford Health System, Detroit, MI, CVRx, Inc., Maple Grove, MN
Background: In heart failure (HF), cardiac β-adrenergic receptor (β-AR) signaling is 
impaired leading to desensitization of the myocardium to catecholamines. We previously 
showed that chronic electrical carotid baroreflex activation therapy (BAT) with the RheosTM 
System (CVRx, Inc.) improves LV function in dogs with coronary microembolization-
induced advanced HF (LV ejection fraction ~25%). This study examined the effects of 3 
months BAT on mRNA expression of β1-AR, β2-AR, inhibitory (Gi) and stimulatory (Gs) 
guanine nucleotide binding proteins and β-adrenergic receptor kinase-1 (BARK-1) in LV 
myocardium of the same HF dogs.
Methods: RNA was extracted from LV myocardium of 8 BAT-treated HF dogs, 6 untreated-
HF dogs, and 6 normal (NL) dogs. mRNA expression of β1-AR, β2-AR, Gi, Gs, BARK-1, 
and the housekeeping gene GAPDH was determined using RT-PCR and bands quantified in 
densitometric units (du) and normalized to GAPDH.
Results: Compared to NL dogs, mRNA expression of β1-AR decreased, Gi and BARK-1 
increased, and Gs and β2-AR were unchanged in untreated HF dogs. BAT normalized mRNA 
expression of β1-AR, Gi and BARK-1 without affecting expression of Gs and β2-AR.
Conclusions: In LV myocardium of dogs with HF, BAT normalizes mRNA expression of 
key components of the β-AR signal transduction pathway. Reversal of this maladaptive 
gene expression is likely to restore sensitivity of the failing myocardium to catecholamines 
and explains, in part, the improvement of LV function seen following chronic BAT.
* = p<0.05 vs. NL; † = p<0.05 vs. HF-Untreated
NL HF-Untreated HF + BAT
β1-AR (du) 0.55 + 0.02 0.26 + 0.02* 0.51 + 0.03†
β2-AR (du) 0.23 + 0.01 0.26 + 0.01 0.25 + 0.01
Gs (du) 0.25 + 0.01 0.24 + 0.01 0.25 + 0.01
Gi (du) 0.12 + 0.01 0.28 + 0.01* 0.13 + 0.01†
BARK-1 (du) 0.28 + 0.02 1.22 + 0.03* 0.54 + 0.02†
9:00 a.m.
1004-60	 β2-Adrenergic	Receptors	Agonists	-	a	New	Therapeutic	
Strategy	for	the	Treatment	of	Chronic	Heart	Failure
Ismayil Ahmet, Suresh Poosala, Edward G. Lakatta, Mark I. Talan, NIA/NIH, Baltimore, MD
Background: In the model of post-myocardial infarction (MI) Dilated Cardiomyopathy 
(DCM) in rats, we have reported that therapeutic effectiveness of pharmacological 
stimulation of β2AR to attenuate the cardiac remodeling either alone or in combination 
with β1AR blockade exceeded the effectiveness of β1AR blockade. Here, in the same 
experimental model, we present the results of a 1-year preclinical trial of the effects 
of long-term pharmacological manipulation of βAR subtypes with survival as a primary 
outcome.
Methods: DCM in rats was induced by ligation of the left coronary artery. Two weeks 
later, the survivals were assigned into 4 different treatment groups with the similar MI 
size: no treatment (Control); treated with β2AR agonist, fenoterol, (β2); treated with β1AR 
blocker, metoprolol, (β1), or treated with a combination of both (β1β2). Drugs were added 
into drinking water. Cardiac remodeling and function was monitored for one year by 
monthly echocardiography.
Results: At the end of the year the mortality in Control was 73%. Only in the β1β2 it reduced 
significantly (p=0.014) and 65% of animals remained alive (Figure). A progressive cardiac 
remodeling observed in Control and β1 was significantly attenuated in β1β2 during the first 
six months of treatment, but only for 2 months in β2. The MI expansion was arrested in 
β1β2 only.
Conclusions: The results suggest an alternative therapeutic strategy for the treatment of 
chronic heart failure using the combination of β2AR agonists and β1AR blockade. 
9:00 a.m.
1004-61	 In	Patients	With	Heart	Failure	Elevated	Soluble	Tumor	
Necrosis	Factor	Receptor	1	Is	Associated	With	Higher	
Risk	of	Depression
Alec J. Moorman, Dariush Mozaffarian, Charles W. Wilkinson, Richard L. Lawler, George 
B. McDonald, Barbara A. Crane, John A. Spertus, Joan E. Russo, April S. Stempien-
Otero, Mark D. Sullivan, Wayne C. Levy, University of Washington, Seattle, WA
Background: Pro-inflammatory cytokines have been implicated in the development and 
progression of both heart failure (HF) and depression. We investigated whether systemic 
inflammation, as assessed by circulating levels of inflammatory cytokines, was associated 
with co-morbid depression in patients with heart failure.
Methods: Clinical variables, cytokines, neurohormones and inflammatory markers were 
measured in a cohort study of 141 ambulatory HF patients. Depression was defined from 
antidepressant use or validated interview. Differences in baseline characteristics were 
compared using Student’s t test for scale variables and chi-square analysis for categorical 
variables. Mean soluble tumor necrosis factor receptor 1 (sTNFr1) level was significantly 
higher in the depressed group so this relationship was further evaluated with multivariate 
logistic regression modeling. A multivariate linear regression model was then used to 
analyze the association between sTNFr1 and Hamilton Depression (HAM-D) Rating 
Scale score, a continuous measure of depression.
Results:	 In bivariate (unadjusted) comparisons, patients with depression had 
significantly higher levels of sTNFr1 (p=0.01). After adjustment for age, gender, ejection 
fraction, systolic blood pressure, New York Heart Association class, and creatinine, 
individuals in the highest quartile of sTNFr1 levels had a nearly 5-fold higher risk of 
depression (OR=4.9, 95% CI=1.4-17.5), compared to individuals in the lowest quartile 
(p for trend=0.005). There was also a significant positive correlation between sTNFr1 
level and HAM-D score (r=0.271, p=0.003). Comparing patients adequately treated on 
antidepressants to the reference group demonstrated that sTNFr1 levels remained nearly 
60% higher (p=0.068).
Conclusions: We found that the circulating sTNFr1 levels were significantly higher in 
HF patients with depression, and that the highest quartile of sTNFr1 levels is associated 
with a nearly 5-fold risk of depression. Futhermore, HF patients with adequately treated 
depression had a trend toward higher levels of sTNFr1.
9:00 a.m.
1004-62	 Pure	HNO	donors	Increase	Myofilament	Ca2+	
Responsiveness	in	Cardiac	Muscle
Ye Tian, Xin Sha, Bruce King, Gianfrancesco Cormaci, Carlo G. Tocchetti, David 
A. Kass, Nazareno Paolocci, Wei Dong Gao, Johns Hopkins Medical Institutions, 
Baltimore, MD, Wake Forest University, Winston-Salem, NC
Background: Nitroxyl (HNO) generated by Angeli’s salt (AS) exerts positive inotropy 
in both intact hearts and isolated cardiac muscles. In the latter, AS increases maximal 
Ca2+ activated force. Whether HNO donors can also sensitize cardiac muscle to Ca2+ is 
still unclear. To this aim, we tested a newly developed HNO donor, 1-nitrosocyclohexyl 
acetate (NCA). This compound is chemically unrelated to AS and a pure HNO donor. 
Differently from AS, NCA does not co-release nitrite (NO2-) that may partially counter HNO 
effect on myofilaments.
Methods: Trabeculae were dissected from the right ventricules of the rat hearts and 
mounted between a force transducer and a motor arm. The muscles were superfused with 
K-H solution (pH 7.4) at room temperature. Fura-2 salt was loaded into the trabeculae via 
electrophoresis and sarcomere length was set at 2.2 µm.
Results:	Twitch force increased in a dose dependent manner in the presence of NCA, 
from 20~100 µmol/L. At 0.5 mmol/L [Ca2+]
o
, NCA (100 µmol/L) increased force up to 
32.3±4.8 mmHg/mm2 (p<0.001 vs 8.8 mmHg/mm2 in control muscles, n=6). Yet, [Ca2+]i 
transients remained unchanged (0.39±0.08 vs. 0.27±0.06 µmol/L control, P=0.23). Both 
diastolic force and [Ca2+]i were not affected by NCA. During steady-state activations, NCA 
(20 µmol/L) increased maximal Ca2+ activated force (F
max
) (124±15 vs 90±5 mN/mm2, P 
= 0.05) and decreased Ca2+ required for 50% activation (Ca50) (0.39±0.01 vs 0.57±0.03 
µmol/L, P<0.004) as compared to control. The Hill coefficient was not affected (4.92±0.84 
vs 3.94±0.18 control, P>0.05). When compared to AS, NCA significantly decreased Ca50 
(0.39±0.01 vs 0.52±0.04 µmol/L, P=0.05). NCA dose (50 µmol/L) required to achieve 
significant augmentation in force (100% increase) was substantially lower than the AS 
one (250 µmol/L).
Conclusions:	Our data clearly show that donors of HNO represent a new class of agents 
capable of directly sensitizing cardiac myofilaments to Ca2+. Likely, in cardiac muscle 
HNO potency is a function of the donor ability to release more (pure) HNO. Ongoing 
studies aim to identify the molecular mechanisms underlying HNO force augmentation as 
well as its efficacy on cardiac muscles from failing hearts.
9:00 a.m.
1004-63	 The	Presence	or	Development	of	New	
Electrocardiographic	Strain	Pattern	is	Associated	
With	an	Increased	Risk	of	New	Heart	Failure	During	
Antihypertensive	Treatment:	The	LIFE	Study
Peter M. Okin, Lasse Oikarinen, Matti Viitasalo, Lauri Toivonen, Sverre E. Kjeldsen, 
Markku S. Nieminen, Jonathan M. Edelman, Björn Dahlöf, Richard B. Devereux, Cornell 
Medical Center, New York, NY
Background:Presence of the ECG strain pattern at baseline has been associated with 
an increased risk of developing heart failure (HF). However, the relationship of new HF to 
regression vs persistence vs development of new ECG strain is unclear.
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Methods:ECG strain was evaluated at baseline and year-1 in 7265 hypertensive 
patients with no history of HF randomized to losartan- or atenolol-based antihypertensive 
treatment. Only new HF after year-1 was considered for analyses.
Results:During a mean follow-up of 3.9±0.7 years after the year-1 ECG, new HF 
developed in 154 patients (2.1%). Compared with the absence of strain on both ECGs, 
new or persistent ECG strain had the highest 5-year HF rates and hazard ratios in 
univariate analyses; regression of strain had an intermediate rate and risk of new HF. 
In multivariate Cox analyses adjusting for in-treatment ECG left ventricular hypertrophy, 
systolic and diastolic pressure, standard HF risk factors and treatment effect, new or 
persistent strain and regression of ECG strain all had an approximately 2-fold increased 
risk of developing subsequent HF.
Conclusions:Development of new ECG strain or persistence of ECG strain between 
baseline and year-1 are associated with an increased risk of new HF. Regression of ECG 
strain between baseline and year-1does not convey a decreased risk of developing HF. 
These findings highlight the highly adverse prognostic value of ECG strain, even if not 
persistent between ECG evaluations, for new HF in treated hypertensive patients.
New Heart Failure in Relation to Presence or Absence of ECG Strain at 
Baseline and Year-1
No Strain Baseline/
No Strain Year 1:
Absence of Strain
(n=6236)
Strain Baseline/
No Strain Year 1:
Regression of 
Strain
(n=236)
Strain 
Baseline/Strain 
Year 1:
Persistent 
Strain
(n=517)
No Strain 
Baseline/Strain 
Year 1:
Development of 
New Strain
(n=276)
P value
Heart Failure 
Rate (%) 1.6 5.4 7.1 7.0 <0.0001
Hazard Ratios and 95% Confidence Intervals
Univariate 
Cox Model 1
3.2
(1.7 - 6.1)
4.5
(3.1 - 6.7)
4.4
(2.6 - 7.4) <0.001
Multivariate 
Cox Model 1
2.4
(1.2 - 4.7)
1.9
(1.2 - 3.2)
2.1
(1.2 - 3.9) <0.001
9:00 a.m.
1004-64	 Urinary	B-type	Natriuretic	Peptide	Levels	in	the	
Diagnosis	and	Prognosis	of	Heart	Failure	Patients
Raquel Cortes, Miguel Rivera, Antonio Salvador, Jose Ramon Juanatey, Vicente Miro, 
Jose Ramon Calabuig, Teresa Lozano, Francisco Sogorb, Esther Rosello, Luis Martinez 
Dolz, Placido Orosa, Vicente Mora, Begoña Sevilla, Vicente Climent, Luis Almenar, 
Alejandro Jordan, Fernando Garcia de Burgos, Ricardo Valero, Pedro Morillas, Vicente 
Bertomeu, Luis Mainar, Ricardo Gomez, Maria Jose Sancho Tello, Francisco Marin, 
Isabel Antorrena, Jose Luis Perez Bosca, Rafael Paya, Manuel Portoles, Hospital La Fe, 
Valencia, Spain
Background:	Plasma B-type natriuretic peptide (BNP) is a useful biomarker for diagnosis 
and prognosis of heart failure (HF), however urine BNP has never been calculated. We 
sought to compare urinary and plasma BNP levels, and to investigate the potential 
diagnostic and prognostic value of this peptide in HF.
Methods:	Urine and plasma BNP levels were measured in 92 HF patients and 15 control 
subjects.
Results: For the whole population urine BNP was 3.3±4.2 pg/ml. Urinary BNP levels 
were higher in HF patients than in control subjects (p<0.0001), correlating with plasma 
BNP levels (r=0.59, p<0.0001). Urine BNP was a good tool for the diagnosis of HF, 
the area under the curve (AUC) being 0.86±0.06 (p<0.0001). Urinary BNP levels had 
prognostic power for cardiac events (cardiac admissions + mortality) with an odds ratio 
of 6.6 (p<0.05). To determine the prognostic power of urinary BNP in detecting 12-month 
cardiac mortality, we obtained an AUC of 0.76±0.6 (p=0.014).
Conclusions:	 The data suggest that	 urine	 BNP is a new candidate marker for the 
diagnosis and prognosis of HF mortality and cardiac events. This raises the possibility 
of using this relatively simple non-invasive test in primary care settings or in specific 
conditions where the collection of blood samples could be difficult.
9:00 a.m.
1004-65	 The	Benefits	of	the	Fixed-Dose	Combination	of	
Isosorbide	Dinitrate	and	Hydralazine	in	A-HeFT	are	not	
Influenced	by	the	Absence	or	Presence	of	Diabetes
Alan Miller, Clyde W. Yancy, Michael L. Sabolinski, Virginia M. Braman, Manuel Worcel, 
NitroMed, Inc., Lexington, MA
Background: Diabetes mellitus (DM) confers a worse prognosis in patients with 
advanced heart failure (HF), and may impact endothelial function. In A-HeFT, the fixed-
dose combination of isosorbide dinitrate and hydralazine (I/H) plus standard therapy 
decreased the risks of mortality, first HF hospitalization, and improved self-reported 
functional status.
Methods: Subgroup analysis was performed on the 1,050 A-HeFT patients with or 
without DM at baseline. Time-to-event analyses were performed by Kaplan Meier method. 
Interactive p-values were determined by Proportional Hazards Models.
Results: Compared to the group without DM (59.1%), patients with DM (40.9%) were 
older, had more females and ischemic HF etiology, more hypertension, and had higher 
baseline weight, and systolic blood pressure (BP). There was no significant difference 
in hypertensive, idiopathic and valvular HF etiologies, baseline diastolic BP, LVEF 
and LVIDD, use of ACE-I, beta blockers, diuretics, spironolactone, and digoxin. There 
was a significant increase in ARB use in DM group (25.9% vs. 20.1%, p=0.029) but a 
3.6% higher use of ACE-I in non-DM group. Patient’s functional status measurement at 
endpoint trended to improvement by I/H in DM group by 4.2 points, p=0.077, and in non-
DM group by 4.6 points, p=0.014. The treatment effect of I/H on morbidity and mortality 
are statistically comparable in both DM and non-DM groups (Table 1). Conclusion: In 
A-HeFT, the benefits of I/H treatment are independent of DM.
Table 1: A-HeFT Outcomes [Data expressed as Hazard Ratios]
Outcome Diabetic
n=429 P value
Non-diabetic
n=621 P value
Interactive
P value
Mortality 0.56 0.11 0.59 0.063 0.927
Mortality or first  
HF Hospitalization 0.69 0.047 0.59 0.002 0.508
First HF Hospitalization 0.68 0.062 0.54 0.001 0.372
9:00 a.m.
1004-66	 Liver	Function	Test	Abnormalities	and	Outcome	in	
Patients	with	Chronic	Heart	Failure:	Data	from	the	
Candesartan	in	Heart	failure	Assessment	of	Reduction	
in	Mortality	and	morbidity	(CHARM)	Program
Larry A. Allen, G. Michael Felker, Stuart J. Pocock, John J.V. McMurray, Marc A. Pfeffer, 
Karl Swedberg, Duolao Wang, Salim Yusuf, Eric L. Michelson, Christopher B. Granger, 
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background: Liver dysfunction arising from heart failure (HF) is a known clinical 
syndrome, but systematic classification of liver function test (LFT) abnormalities in a 
broad HF population, including both impaired and preserved systolic function, is limited.
Methods: We evaluated LFTs in 2679 North American patients with symptomatic chronic 
HF enrolled in the CHARM program, and assessed the relationship between LFTs and 
clinical outcomes using Cox proportional hazards models.
Results: LFT abnormalities were found in the minority of HF patients. A cholestatic 
pattern was far more common than a hepatocellular pattern. Among LFT measures, total 
bilirubin was the strongest predictor of the composite outcome of cardiovascular death 
or heart failure hospitalization (adjusted hazard ratio 1.14 per 1 SD increase, p<0.0001). 
Bilirubin was among the most powerful overall statistical predictors (Chi square [X2] 
20.7) from 66 considered, with only age (X2 41.3), cardiomegaly (X2 28.2), elevated 
red cell distribution width (X2 24.8), and recent heart failure hospitalization (X2 21.1), 
demonstrating a greater association with outcome.
Conclusions: Bilirubin levels are independently associated with increased morbidity and 
mortality in a broad spectrum of chronic HF patients. Elevations in total bilirubin potentially 
provide greater prognostic information than many traditional HF measures of risk such as 
creatinine, and may help describe underlying pathophysiology in chronic HF.
Baseline LFTs in CHARM divided by outcome
Lab	Parameter CV	Death	or	HF	Hospitalization
Without	Event	
(N=1727)
With	Event	
(N=952)
Mean SD Mean SD
Bilirubin Total (mg/dL) 0.61 0.32 0.72 0.47
Bilirubin Direct (mg/dL) 0.16 0.12 0.20 0.19
ALT (SGPT) (U/L) 21.9 18.6 21.0 15.1
AST (SGOT) (U/L) 21.6 12.5 22.1 15.4
Alkaline Phosphatase (U/L) 84.6 33.0 92.3 47.7
Albumin (mg/dL) 4.15 0.31 4.07 0.33
9:00 a.m.
1004-67	 Left	Atrial	Volume	and	Ventricular	Filling	Pattern	in	Mild	
Heart	Failure:	the	AREA-IN-CHF	Study.
Marcello Chinali, Giovanni de Simone, Gian Francesco Mureddu, Giuseppe Cacciatore, 
Francesca D’Amico, Andrea Di Lenarda, Fabio Zacà, Aldo P. Maggioni, Alessandro 
Boccanelli, on behalf of the AREA-IN-CHF investigators, Federico II University, Naples, 
Italy, San Giovanni-Addolorata Hospital, Roma, Italy
Background: Whether increased left atrial (LA) volume (V) is an indicator of LV filling 
pattern in mild chronic heart failure (CHF) is unclear.
Methods:	The AREA-in-CHF (AntiRemodeling Effect of Aldosterone receptors blockade 
with canrenone IN mild Chronic Heart Failure) is a prospective, randomized, double 
blind study on anti-aldosterone treatment in patients with Class 2 NYHA chronic heart 
failure (CHF) and ejection fraction≤45%. Among 505 participants undergoing Doppler-
echocardiography, we evaluated 303 subjects (mean age 63± 10 yrs, 49 women) with 
available LAV and without valvular or rhythm abnormalities. Orthogonal LA diameters 
were measured in parasternal short-axis and apical 4-chamber view. LAV was calculated 
using biplane linear dimensions by the ellipsoidal model. LA was considered dilated 
when >53mL for women or >59mL for men, as recommended. LV end-diastolic pressure 
(LVEDP) was computed from pulmonary and mitral A velocity signal durations, applying 
an invasively-validated equation.
Results: LAV correlated positively to male gender (r=0.14), LV mass (r=0.31), mitral E/A 
ratio (r=0.36), and LVEDP (r=0.34) and negatively to ejection fraction it (r=-0.20) and 
isovolumic relaxation time (IVRT; r=-0.29) (all p<0.001). No correlation was found with 
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age, heart rate, blood pressure or mitral peak E deceleration time. Among participants, 
110 had dilated LA (36.3% of population). Patients with dilated atria had similar mean age, 
heart rate and blood pressure compared to patients with normal atrial volume, but higher 
body mass index, LV mass, mitral peak E/A ratio, lower ejection fraction, relative wall 
thickness and shorter IVRT (all p<0.01). After controlling for age, gender, blood pressure, 
ejection fraction, left ventricular mass and relative wall thickness, patients with dilated 
atria confirmed higher mitral E/A ratio (1.38±1.15 vs 0.98±0.57) higher LVEDP (16.8±7.8 
vs 13.9±9.6 mmHg) and shorter IVRT (75.1±21.1 vs 85.9±21.2 msec; p for all<0.01).
Conclusions: In class 2 NYHA CHF patients with systolic dysfunction, in sinus rhythm, 
dilated LA is frequent (36.3%) and associated with restrictive LV physiology independently 
of demographics, LV geometry and pump function.
9:00 a.m.
1004-68	 Effect	Of	Nesiritide	On	Renal	Functions	In	Patients	With	
Acute	Decompensated	Congestive	Heart	Failure
Sandeep Arora, Kamran Khan, Anju Arora, Kofi Clarke, Venkatraman Srinivasan, 
Western Pennsylvania Hospital, Pittsburgh, PA
Indroduction: Studies addressing the effect of nesiritide on renal function in patients 
hospitalized for congestive heart failure (CHF) have shown conflicting results. We studied 
the effect of nesiritide on renal function in patients admitted for decompensated CHF.
Methods: We did a retrospective chart review of patients admitted with acute 
decompensated CHF from year 2003-2005. Patients who received nesiritide were 
compared with those who received conventional therapy alone. Serum creatinine levels 
and body weight were measured on admission (or within 4 hours of administration of 
diuretics/nesiritide) and were compared with levels at day 3 or till the end of the therapy 
whichever is later. Worsening renal function was defined as rise in serum creatinine of 0.3 
mg/dl or more from baseline and final creatinine level > 1.3 mg/dl. To negate the effect 
of excessive diuresis on serum creatinine, a parameter “change in creatinine/change in 
weight/day” was calculated for both groups.
Results: A total of 176 charts were reviewed (90 controls and 86 nesiritide group). There 
was higher incidence of chronic renal insufficiency (baseline serum creatinine >1.5 mg/dl) 
in nesiritide group than control group (p= .028). Twenty seven out of 90 (30%) of patients 
in control group and 25 out of 86 (29.1%) of patients in nesiritide group developed 
worsening of renal functions (p >0.05). Overall, mean change in creatinine in the nesiritide 
group was 0.19 mg/dl compared to 0.16 mg/dl in control group (p= 0.15). Mean change in 
weight was 2.06 kg in nesiritide group and 1.78 kg in control (p=0.17) and mean change 
in creatinine/change in weight/day was 0.28 mg/dl/kg/d in nesiritide and 0.35 mg/dl/kg/d 
in control group (p=0.24). In patients with CRI, similar outcomes were observed between 
the two groups with a trend towards better diuresis in the nesiritide group. There was no 
correlation between dose of nesiritide used and worsening of renal functions (r = -0.12). 
Nesiritide was well tolerated with 2 out of 86 patients developing transient hypotension 
compared to one out of 90 in the control group.
Conclusion: Nesiritide therapy is not associated with significant deterioration in renal 
functions compared to conventional therapy.
9:00 a.m.
1004-97	 Comparison	of	Heart	Failure	Patients	Who	Achieve,	
with	Treatment,	an	Ejection	Fraction	>35%	vs	Those	
Who	Remain	≤35%
Hannah Asghar, Peter S. Rahko, University of Wisconsin School of Medicine and Public 
Health, Madison, WI
Background: An ejection fraction (EF) of 35% is a critical value that helps determine if 
a patient is a candidate for implantable cardioverter defibrillator (ICD) therapy. In many 
cases the EF may improve following initiation of comprehensive medical treatment. We 
evaluated the history of 324 patients with symptomatic heart failure (HF), all of whom 
at entry into a HF clinic had an EF ≤35%. Patients whose EF increased to >35% were 
compared to those whose EF remained ≤35%.
Results: A total of 106 patients (33%) increased EF to >35%. There was no difference 
in age 60 ± 15 years vs 58 ± 13 years, gender 74% male vs 71% male or presence of 
atrial fibrillation 10% vs 6%, ≤35% vs >35% groups respectively. Duration of HF was 
longer in the ≤35% group. 4.5 ± 3.6 vs 3.3 ± 2.8 years, p<0.002. Patients with a QRS 
duration >120 ms were more common in the ≤ 35% group, 38% vs 26%, p<0.008. An 
ischemic etiology was more common in the ≤ 35% group 52% vs 24%, p<0.0001. Doses 
of beta blockers (BB) and ACE inhibitors were grouped by intensity of therapy. Maximum 
achieved doses were determined and are shown in the table by percent of total in each 
category. Evaluated by Chi-squared analysis. 
Beta Blockers (BB) ACE Inhibitors
Dose of Drug ≤ 35% >35% ≤ 35% >35%
None 5% 0% 5% 3%
Stopped 5% 6% 22% 21%
Low 16% 7% 28% 29%
Moderate 25% 19% 21% 34%
Maximal 49% 65% 22% 21%
Non-guideline BB 3% 4% - -
p value 0.02 0.05
Conclusions: Patients most likely to respond to medical therapy by increasing EF to >35% 
and potentially not need an ICD have HF for shorter duration, have a QRS duration <120 
ms, and have a non-ischemic etiology of HF. These patients are also characterized by 
tolerance of more complete titration of BB and ACE-inhibitor therapy to higher doses.
9:00 a.m.
1004-98	 Novel	Muscarinic	Bronchodilators	Afford	Customized	
Management	of	Chronic	Heart	Failure	Complicated	by	
Chronic	Obstructive	Pulmonary	Disease	in	Ambulatory	
Elderly	Patients
Mahoto Kato, Kazuo Komamura, Masafumi Kitakaze, National Cardiovascular Centers, 
Suita, Japan
Background: Unrecognized and latent chronic heart failure (CHF) is common in elderly 
patients with combination of chronic obstructive pulmonary disease (COPD). We sought 
to investigate if the treatment with tiotropium, a novel muscarinic bronchodilator for COPD 
may improve CHF.
Methods: Consecutive 40 patients with mild to moderate COPD and left-sided CHF 
mainly due to ischemic cardiomyopathy were randomly divided into two groups and were 
enrolled to the cross-over trial using tiotropium. In Group A [n=20, 70±10 years, ejection 
fraction (EF) 48.5±14.2%, brain natriuretic peptide (BNP) 329±113 pg/ml], an inhalation 
of tiotropium (18µmg) once a day was continued for 28 days and was withdrawn for 
another 28 days. In Group B [n=20, 70±9 years, EF 46.4±9.0%, BNP 331±134 pg/ml), the 
other patients were treated with tiotropium for 28 days following the 28 days observation. 
We measured arterial oxygen saturation (SpO2), distance of 6 minutes walk (6MW), 
laboratory markers including BNP levels and echocardiographic parameters at Day-1, 
Day-29 and Day-56 each.
Results: In both groups, 28 days inhalation of tiotropium substantially improved the 
symptoms score, 6MW and SpO2 compared with the untreated conditions. Furthermore, 
tiotropium improved both EF and BNP levels without right ventricular hemodynamics.
Conclusions: The treatment with tiotropium improved not only COPD, cardio-respiratory 
symptoms or exercise capacity, but also ameliorated the severity of CHF.
* p<0.001, †p<0.01, ¶p<0.05 ; Compared with pre-inhalation.
Group A (n=20) tiotropium ON OFF
6MW, m 405±57 424±46¶ 405±63
SpO2, % 96.2±1.7 97.0±1.3* 96.3±1.8
BNP, pg/ml 329±113 250±54† 297±75¶
EF, % 48.5±14.2 50.7±13.5† 48.4±14.1
Group B (n=20) tiotropium OFF ON
6MW, m 404±70 399±74 422±58†
Spo2, % 96.6±1.1 96.6±1.1 97.8±0.8¶
BNP, pg/ml 331±134 326±125 244±85*
EF, % 46.4±9.0 46.5±10.3 50.1±6.9†
9:00 a.m.
1004-99	 Systolic	Blood	Pressure	at	Baseline	Predicts	Efficacy	
of	Intravenous	Atrial	Natriuretic	Peptide	Anole	Therapy	
for	Acute	Exacerbation	of	Chronic	Heart	Failure	in	
Patients	with	Dilated	Cardiomyopathy
Katsuya Kajimoto, Yukiko Sashida, Masayuki Mizuno, Eri Watanabe, Hiroshi Kasanuki, 
Tokyo Women’s Medical University, Tokyo, Japan
Background: In patients with acute exacerbation of chronic heart failure (AE-CHF) due to 
dilated cardiomyopathy (DCM), a role of initiation of vasodilator remains uncertain. In this 
study, we evaluated whether an efficacy of initial monotherapy of intravenous atrial natriuretic 
peptide (ANP) for AE-CHF can be predicted by hemodynamic parameters at baseline.
Methods:	 Thirty consecutive DCM patients with AE-CHF (mean LVEF=27%, NYHA 
IV) were enrolled. Inclusion criteria were LVEF<40%, systolic blood pressure (S-BP) 
>100mmHg, and a pulmonary-capillary wedge pressure (PCWP)>18mmHg at baseline. 
Hemodynamic parameters by right-heart catheterization and plasma BNP levels were 
evaluated before and after an intravenous administration of ANP alone. The efficacy of 
ANP alone was defined as a significant reduction of PCWP to <15mmHg within 24 hrs 
after an intravenous administration of ANP.
Results:	Among 30 patients, 21 patients (70%) showed effective for ANP alone. The 
logistic regression analysis identified S-BP≥112 mmHg and cardiac index ≥2.3L/min/m2, 
which were calculated by ROC analysis, as independent predictors of the efficacy of ANP 
alone in DCM patients with AE-CHF (Table).
In addition, a criteria of S-BP≥112mmHg gave a sensitivity of 95%, a specificity of 67% 
and a total accuracy of 87% for predicting the efficacy of ANP alone therapy in AE-CHF.
Conclusions: These results suggest that systolic BP at baseline is useful in predicting 
the efficacy of intravenous ANP alone for AE-CHF in patients with DCM. 
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1004-100	 Heterogeneity	of	Diastolic	Characteristics	by	the	Same	
Level	of	Systolic	Dysfunction	in	Mild	Heart	Failure:	The	
AREA-IN-CHF	Study
Giovanni de Simone, Gian Francesco Mureddu, Margherita Benincasa, Giuseppe 
Cacciatore, Alessandro Santoro, Antonello Gavazzi, Franco Rusconi, Aldo P. Maggioni, 
Alessandro Boccanelli, on behalf of the AREA-IN-CHF investigators, “Federico II” 
University Hospital, Napoli, Italy, San Giovanni-Addolorata Hospital, Rome, Italy
Background: Diastolic function is often studied in the absence of systolic function. There 
is little information on whether LV filling is related to cause of heart failure when systolic 
dysfunction is present.
Methods: The AREA-IN-CHF (AntiRemodeling Effect of Aldosterone receptors blockade 
with canrenone IN mild Chronic Heart Failure) is a prospective, randomized, double 
blind study on anti-aldosterone treatment in patients with class 2 NYHA chronic heart 
failure (CHF) and ejection fraction≤45%. Among 505 participants who underwent 
Doppler-echocardiography, we evaluated 351 subjects in sinus rhythm and no history 
of atrial fibrillation: 154 had coronary heart disease (CHD, 8% women), 116 idiopatic 
cardiomyopathy (IDCM, 28% women) and 41 load mismatch (LM, 37% women, 
p<0.0001), including hypertension (88%), valve disease (10%) and alcohol (2%).
Results:	Age, heart rate and BMI were not statistically different among etiology groups. 
Blood pressure was expectedly higher in participants with LM than in the other groups 
(p<0.001). After adjusting for age and sex, no differences were detected in ejection fraction 
(39±8% in CHD, 39±9% in IDCM, 41±6% in LM) and stroke volume by Simpson rules 
(61±19 mL/beat in CHD, 61±18 mL/beat in ICMP, 63±23 mL in LM). LV mass index was 
higher in LM and IDCM than in CHD (p<0.001), whereas relative wall thickness (RWT) was 
indistinguishable. Transmitral E velocity was highest in CHD, intermediate in IDCM and 
lowest in LM (p<0.0001) with transmitral A-velocity having the opposite trend (p<0.001). 
Thus, E/A ratio was highest in CHD (1.3±0.92), intermediate in ICMP (1.04±0.77) and 
lowest in LM (0.73±0.32; p<0.001). Isovolumic relaxation time was shorter in CHD than 
in the other groups (p<0.04). Difference between duration of pulmonary backward and 
transmitral forward velocities during atrial contraction indicated that myocardial stiffness 
was greatest in CHD, intermediate in IDCM and smallest in LM (p<0.007).
Conclusions: At similar level of systolic dysfunction and abnormal LV geometry, signs 
and symptoms of low-grade CHF (class 2 NYHA) are associated with different LV diastolic 
patterns, in relation to the background myocardial alteration leading to CHF.
9:00 a.m.
1004-101	 Elevated	Pro-inflammatory	HDL	in	Primary	Systemic	
Amyloidosis:	Potential	Role	of	Oxidative	Stress	in	
Cardiac	Injury
Raymond Q. Migrino, Kirkwood Pritchard, Jingli Wang, Vi Nguyen-Liu, Phillip Pratt, Hari 
Parameswaran, Medical College of Wisconsin, Milwaukee, WI
Background: Primary systemic amyloidosis (PSA) is rare but can be fatal especially 
with cardiac involvement. Animal studies show immunoglobulin light chains in PSA cause 
oxidative injury to myocytes leading to diastolic dysfunction (DD). Systemic oxidative 
and inflammatory states have been shown to render high density lipoproteins (HDL) 
dysfunctional, pro-oxidant and pro-inflammatory, but the role of pro-inflammatory HDL 
(pHDL) in PSA is not known.
Aim: We compared pHDL in PSA versus normal controls, and determined the relationship 
between pHDL and DD.
Methods: Plasma from 10 patients with biopsy-proven PSA (5 female, 58±9 years, 7 with 
DD by echo) and 5 controls (2 female, 41±14 years) were collected and HDL and pHDL 
were measured. pHDL assay utilized rates of dichlorofluorescein fluorescence. pHDL 
in PSA was correlated with echo derived ratio of mitral and mitral annular early inflow 
velocity (E/E’), a sensitive marker of DD.
Results: see figure. There was no difference in total HDL (mg/dL, 53±7 PSA vs. 62±5 
control, p=0.4) but pHDL is higher in PSA (DCF fluorescence slope 3.1±1.6 vs. 1.7±0.3, 
p=0.02). Mean E/E’ in PSA was 13.7 (5.2-24.7). pHDL correlated strongly with E/E’ 
(R=0.8, p=0.02).
Conclusions: Pro-inflammatory HDL was elevated in PSA compared to normal controls 
and had significant correlation to E/E’, a marker of diastolic dysfunction. We speculate 
that oxidative stress and pHDL play a role in cardiac dysfunction in PSA, pointing to a 
potential novel avenue for therapy in this lethal disease.
9:00 a.m.
1004-102	 Trace	Element	Deficiency	in	Patients	with	Dilated	
Cardiomyopathy	Enhances	the	Oxidative	Stress	and	
Aggravates	the	Impairment	of	Cardiac	Function.
Yuji Hiraoka, Yasuki Kihara, Hiromu Sakurai, Kinzo Ueda, Junichi Chikawa, Otowa 
Hospital, Kyoto, Japan, Kobe City General Hospital, Kobe, Japan
Background:The possibility that the enhancement of oxidative stress may be responsible 
for the onset and progress of heart failure is considered.
Objectives: Analysis of trace elements in the hair and serum of patients with dilated 
cardiomyopathy (DCM) was conducted and the relation between trace element deficiency 
and antioxidase activity was examined. In addition, hematological and histological 
examination was conducted concerning the enhancement of oxidative stress.
Methods: Trace elements in hair of 19 DCM patients were measured using Super Photon 
ring-8 GeV (SPring-8). Serum trace elements, capacity for production of radicals and 
activities of glutathione peroxidase (GSHPx), an antioxidase related selenium, were also 
measured and compared with those of the control group. Furthermore, cardiac tissues 
obtained for biopsy were examined after staining with markers of oxidative stress, i.e., 
8-OHdG and4-hydroxy-2-nonenal.
Results: In DCM patients concentrations of selenium and zinc were markedly reduced 
(p<0.001) and the capacity for production of radicals of the blood was found to be 
significantly elevated (p<0.001). Serum GSHPx activity was significantly reduced to 214 
± 83 μmol / min / L in DCM patients compared with 328 ± 41 (p<0.001) in the control 
group, and staining of cardiac tissues with markers of oxidative stress was found to be 
augmented.
Conclusions: A deficiency of trace elements related to the activity of antioxidase 
is present in DCM patients, and the augmentation of oxidative stress may be a factor 
contributing to the aggravation of cardiac function.
9:00 a.m.
1004-103	 Interstial	Fibrosis	in	Human	Hypertrophic	
Cardiomyopathy	and	the	TIEG	Male	Null	mouse	is	a	
associated	with	an	Osteoblast	Phenotype
Nalini M. Rajamannan, Malayannan Subramaniam, Frank C. Caira, Amy L. Flores, 
Thomas C. Spelsberg, Northwestern University, Chicago, IL, Mayo Clinic, Rochester, MN
Background: Cellular mechanisms causing the interstitial fibrosis in human hypertrophic 
cardiomyopathy (HCM) are currently under intense investigation. We report a novel 
finding in the (TGFß inducible early gene) (TIEG) null mouse with cardiac hypertrophy 
and cardiac bone formation. The TIEG-/- knockout mouse was studied and compared 
to patients with HCM.
Methods: We tested for bone matrix markers in specimens from patients with human HCM 
disease. Male and female mice age 4 to 16 months were characterized (N = 86 total) using non-
invasive echocardiography, transcript profiling by gene microarray, and immunohistochemistry 
localized up-regulated genes for determination of cellular mechanism.
Results: Only the male TIEG-/- knockout mouse developed classic features of cardiac 
hypertrophy including asymmetric septal hypertrophy, an increase in ventricular size at 
age 16 mo, an increase in wall thickness in TIEG-/- mice of (1.85+ 0.21 mm), compared 
to the control (1.13+ 0.15 mm, p< 0.04). Masson trichrome staining demonstrated 
evidence of myofibroblast fibrosis. Microarray analysis of the TIEG null left ventricles 
demonstrated a 13.81 fold increase in pituitary transforming gene (Pttg1)( p<0.05). 
Evaluation for bone formation was tested using semi-quantitative RTPCR for bone matrix 
proteins osteopontin, osteoblast transcription factors sox9, cbfa1, calcein incorporation. 
Immunohistochemistry was performed to assess for the evidence of resident cardiac 
stem cell (CSC) (c-kit) and extracellular matrix marker (ostepontin). The TIEG-/- male 
expressed an increase in c-kit and osteopontin by immunohistochemistry and increase 
osteoblast bone differentiation markers. Confirmation of bone formation was performed 
with Calcein and synchotron CT. We confirmed osteopontin, bone sialoprotein and cKIT 
in areas of fibrosis in patients with HCM. We conclude that fibrosis develops secondary 
to a resident cardiac stem cell differentiation to an osteoblast like phenotype. We 
present evidence implicating TIEG in the development of a novel bone phenotype 
important in the mechanism of interstitial fibrosis in HCM.
9:00 a.m.
1004-104	 Effect	of	Iron	Supplementation	on	Cardiomyocyte	
Apoptosis	Involves	Modulation	of	Tissue	inhibitor	of	
metalloproteinases	and	Matrix	Metalloproteinase	in	a	
Model	of	Doxorubicin-induced	Cardiomyopathy
Gurusher S. Panjrath, Afshin Ghanbarinia, Raghunandan Dudda Subramanya, Carolina 
I. Valdiviezo, Diwakar Jain, Drexel University College of Medicine, Philadelphia, PA, St. 
Luke’s-Roosevelt Hospital Center, New York, NY
Background: Interaction of iron and doxorubicin (DOX) play an important role in 
DOX induced cardiomyopathy. Metalloproteinases (MMP) and tissue inhibitor of 
metalloproteinases (TIMP) are involved in regulation of extracellular matrix in heart 
failure. Effect of iron supplementation on MMP’s and Timp’s in DOX cardiomyopathy is not 
known. We used a rodent model of iron supplementation to study the effect of iron and 
DOX on MMP’s , TIMP’s and cardiomyocyte apoptosis.
Methods: An in vivo model of oral iron supplementation using carbonyl iron was used. 
Animals were treated with DOX (2.5mg/kg body wt twice a week, 5 inj ip). Regular chow 
fed controls were treated with DOX (n=3) or Saline (n=3). Iron supplemented group 
received DOX (DOX+ Iron; n=3) or Saline (Iron; n=3). Animals were sacrificed at 3 weeks 
JACC  March 6, 2007      ABSTRACTS - Cardiac Function and Heart Failure    47A 
C
ardiac Function and H
eart Failure
post injection. Microarray based analysis (Affymetrix) of ventricular tissue was performed 
to study differential gene expression. Myocardial tissue specimen were processed for 
electron microscopy (EM) and caspase-3 immunostaning was performed for detection 
of apoptosis.
Results: Iron supplementation resulted in greater pro-apoptotic signals as observed 
by gene expression. Gene expression for MMP-2 and MMP-23 were significantly 
increased in DOX + Iron group (p<0.05, both genes) compared to Saline group. TIMP-1 
was significantly elevated in both DOX +iron (8-fold; p<0.05) and DOX (3-fold; p<0.01) 
compared to Saline group. In addition expression of MMP-14 (p<0.05), MMP-23 and 
TIMP-2 were elevated in DOX + Iron group compared to Saline. EM showed greater 
extent of myocardial injury consistent with DOX cardiotoxicity. Similarly, a significantly 
increased uptake of caspase-3 immunostaining, confirming apoptosis, was observed in 
DOX + Iron compared to all the other groups.
Conclusions: Iron supplementation resulted in enhanced cardiomyocyte apoptosis 
compared to DOX alone. Observations also suggest a physiological role for the balance 
of TIMP and MMP activity in the cardiomyocytes during DOX induced cardiomyopathy. 
Differences in MMP and TIMP expression may further understanding of pathogenesis of 
DOX cardiomyopathy and role of iron. Further studies using MMP inhibitors may provide 
useful insight.
9:00 a.m.
1004-105	 Extent	and	Localization	of	Myocardial	Fibrosis	in	
Hypertrophic	Cardiomyopathy	Associated	with	
Troponin	I	Gene	Mutation:	Study	by	Magnetic	
Resonance	Imaging	with	Gadolinium	Enhancement
Eiichi Masuta, Hidekazu Ino, Noboru Fujino, Katsuharu Uchiyama, Kenshi Hayashi, 
Tetsuo Konno, Toshinari Tsubokawa, Hiromasa Katoh, Yuichiro Sakamoto, Masakazu 
Yamagishi, Matsuura hiroyuki, Division of Cardiology, Kanazawa University, Kanazawa, 
Japan, Department of Radiology, Kanazawa University Hospital, Kanazawa, Japan
Background: Hypertrophic cardiomyopathy (HCM) caused by a lysine 183 deletion 
mutation in the cardiac troponin I gene (TNNI3) is characterized by systolic dysfunction 
due to development of myocardial fibrosis. Although myocardial late gadolinium 
enhancement (LGE) of cardiovascular magnetic resonance (CMR) has been used to 
detect myocardial fibrosis, few data exist regarding extent and localization of fibrosis in 
HCM with same gene mutation. Therefore, we examined the extent and localization of 
myocardial fibrosis, and clarified the relation between cardiac function and development 
of myocardial fibrosis.
Methods: CMR and echocardiography were performed in 19 HCM patients (6 men, 
13 women, mean age 55 years) with lysine 183 deletion mutation in TNNI3 gene. CMR 
images were acquired on a 1.5T scanner and contrast-enhanced images were performed 
with a segmented inversion-recovery sequence. Analysis was performed by manually 
defining the areas of hyperenhancement on all short-axis slices from the base to apex. 
The extent of LGE was expressed as a percentage of total myocardium.
Results: On echocardiograms, none of the patients had a significant LV outflow tract 
obstruction and septal wall thickness was 14.0±4.2 mm. Percent fractional shortening 
(FS) was 31.4±9.5 %, and 13 patients (group A) showed normal left ventricular 
contraction (FS>25%) and 6 patients (group B) showed impaired left ventricular 
contraction (FS <25%). The mean age of group A patients (50.5±11.6) was younger than 
those in group B patients (65.7±13.0, p=0.02). LGE was found in 15 patients and the 
mean extent of LGE was 11.3±12.5%. LGE in the group A was found in interventricular 
septal wall predominantly, (3.4±3.5%), while LGE in the group B was extended to not 
only interventricular septal wall but also to left ventricular free wall (28.5±4.1%, p<0.001). 
There was negative correlation between the extent of LGE and FS (r=0.82 P<0.001).
Conclusions: These results demonstrate that myocardial fibrosis in HCM patients with 
the TNNI3 gene mutation develops from the interventricular septal wall to the other 
regions of left ventricular wall in accordance with aging, and may be associated with the 
development of systolic dysfunction.
9:00 a.m.
1004-106	 Low	Congestion	Score	One	Month	after	Hospitalization	
Predicts	Better	Function	and	Survival
Joseph G. Rogers, Anne S. Hellkamp, James B. Young, Daniel F. Pauly, Kirkwood F. 
Adams, Jr., Todd M. Koelling, Carl V. Leier, George Sopko, Christopher M. O’Connor, 
Lynne W. Stevenson, for the ESCAPE Investigators and Coordinators, Duke University, 
Durham, NC, Brigham and Women’s Hospital, Boston, MA
Background.	An important goal of heart failure (HF) hospitalization is to treat congestion 
and relieve symptoms. However, the ability to maintain freedom from congestion early after 
discharge may be associated with improved exercise capacity and clinical outcomes.
Methods.	After admission with > 1 sign or symptom of congestion, patients (pts) in 
the ESCAPE trial had medical therapy adjusted in hospital to eliminate congestion and 
readjusted in clinic within 2 weeks. We identified 278 pts with a congestion score (CS) 
calculated at 1 month, adding 1 point each for the presence of orthopnea, jugular venous 
pulse > 8 cm, peripheral edema, ≥ 2 pound weight gain, and the need for increased 
diuretics in the past week. Pts were stratified based upon the 1 month CS and compared 
for the following outcomes at 6 months: improvement in Minnesota Living with Heart 
Failure (MLWHF) score, 6 minute walk distance (6MW), HF hospitalizations, and mortality. 
The MLWHF score was improved if the score decreased ≤ 5.
Results.	At discharge 97% of pts were free of clinical congestion. Functional capacity, 
rehospitalizations, and deaths were related to CS at 1 month (Table).
Conclusion.	Sustained freedom from congestion	1 month following HF hospitalization 
identifies pts more likely to have improved functional capacity over the next 6 months. 
A high CS identifies pts with a 2-fold increase in hospitalizations and 3-fold increased 
mortality who need further intervention. 
Congestion	Score	(%	pts)
6	Mo.	Outcomes 0(n=74)
1-2
(n=142)
3-5
(n=74)
Improved MLWHF 50% 38% 37%
6MW Improved > 900 ft 73% 46%* 26%*
HF Hospitalizations 31% 42% 68%*
Death 9% 8% 28%*
* represents p <0.05 compared to group with congestion score=0.
9:00 a.m.
1004-107	 Cardiac	Involvement	And	Evolution	In	Familial	
Amyloidosis	According	To	The	Mutation	Type.
Vincent Algalarrondo, Sylvie Dinanian, Christophe Juin, Patrice Colin, Claude Sebag, 
Violaine Plante, Laure Sarda-Mantel, David Adams, Didier Samuel, Dominique Le 
Guludec, Michel S. Slama, CHU Antoine Beclere, Clamart, France
Background:	 Familial amyloïdosis polyneuropathy (FAP) is a dominantly inherited 
disease caused by mutated transthyretin (TTR). FAP cardiopathy is due to amyloid 
infiltration, resulting in conduction disorders, cardiac denervation, restrictive and 
hypertrophic cardiomyopathy. Orthotopic liver transplantation (OLT) is the only treatment 
that improves prognosis. We compared cardiac injury between patients with val-met30 
TTR mutation and those with other mutations.
Methods:	In a cohort of 127 patients with neurological symptoms of FAP referred for cardiac 
evaluation before OLT, we performed echocardiography, right heart catheterism, 123I-MIBG 
myocardial scintigraphy, 24 hours Holter ECG and electrophysiological study (EPS).
Results:	Results are described in the table below :
Val-met30 mutation Other mutations p
number of patients 90 36
Age (years) 41.6+-1.4 54.1+-1.3 <0.0001
Percentage of males 55.6 63.9 ns
Interventricular septum (mm) 10.68+-0.33 13.17+-0.53 <0.0001
Posterior wall (mm) 9.2+-0.2 11.2+-0.5 <0.0001
% of pulmonary capillary wedge 
pressure > 15mmHg after 500ml of 
volumic expansion
31.7 55.5 <0.05
MIBG cardiac scintigraphy (heart/
mediastinum ratio) 1.52+-0.05 1.24+-0.05 <0.05
% of SDNN < 50ms 4.1 15.6 <0.05
% of HV interval > 70ms 9.2 26.5 <0.05
Pacemaker (PM) implantation was necessary before OLT in 28.6% val-met30 patients 
and 33.3% others (NS). After OLT, we followed 46 non implanted patients during 19±3 
months (range 1 to 64). Only val-met30 patients required PM implantation for secondary 
conduction impairment after OLT (18/39 vs. 0/7 p<0.05 χ2 test). PM implantation after OLT 
was independent from age and initial EPS data.
Conclusions:	Patients with val-met 30 mutation FAP were younger and had less cardiac 
amyloid lesions than patients with other mutations when OLT was clinically considered 
in this series. Val-met30 mutation was an independant predictive factor of secondary 
conduction disorders and should be considered during follow-up after OLT.
9:00 a.m.
1004-108	 Human	Amniotic	Membrane-derived	Stem	Cell	with	
Lack	of	HLA-DR	Expression	Can	Be	a	Promising	
Cellular	Source	For	Cardiac	Stem	Cell	Therapy
Yukinori Ikegami, Hiroko Tsuji, Shunichiro Miyoshi, Hida Naoko, Hironori Asada, 
Taro Uyama, Akihiro Umezawa, Yasunori Yoshimura, Satoshi Ogawa, Keio University 
School of Medicine, Tokyo, Japan, National Research Institute for Child Health and 
Development, Tokyo, Japan
Background:	Marrow-derived mesenchymal stem cell, embryonic stem cell, and cardiac 
precursor cell are attracting cell source for cardiac stem cell based therapy, however, 
these cells do not efficiently transdifferentiate into cardiomyocytes, or enough cells are 
hard to be obtained to treat damaged heart.
Recently, human amniotic membrane is thought to be a source of pluripotent stem cell 
without any immunological reaction, thus regarded as a promising cell source for cardiac 
stem cell therapy. In the present study, we aim to induce “working” cardiomyogenic 
differentiation of hAM in vitro.
Methods	and	Results:	We established cells from hAM of male infants at delivery, and 
confirmed them as infant-derived cells by sex chromosomal analysis to exclude the 
contamination of maternal endometrial cells, and designated them as hAMCs. Five days 
after the cardiomyogenic induction, approximately half of hAMCs showed spontaneous 
beating. The rhythmical and synchronous contractions of hAMCs suggested the presence 
of tight electrical communication between the hAMCs in vitro. Immunocytochemical 
analysis using confocal laser microscopy for differentiated hAMCs revealed positive 
for cardiac troponin-I, sarcomeric a-actinin (clear striation), connexin 43 (diffused dot-
like shapes at the margin of hAMCs) and human ANP (dot-like shapes at the cytosol 
around the nucleus). The efficacy of Cardiomyogenic differentiation which was defined 
as troponin-I positive cell in hAMC, was 68 +- 2%. Before the cardiomyogenic induction, 
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RT-PCR detected constitutive expression of BNP, cardiac actin, and cardiac troponin-T. 
After the induction, Nkx2.5 and ANP were detected. Action potential was recorded by use 
of standard glass electrode and showed cardiomyocyte-specific plateau and pacemaker-
like potential (slow phase 4 depolarization). HLA-DR on the cell surface was negative in 
flowcytometric analysis of hAMC .
Conclusions:	 hAMC has high ability for cardiomyogenic in vitro (68%). Immunological 
tolerance may appear in hAMC because of no HLA-DR. hAMC can be a promising cell 
source for cardiac stem cell therapy.
9:00 a.m.
1004-109	 Medium	Term	Renal	Outcome	of	Pediatric	Heart	
Transplant	Patients	on	Reduced	Calcineurin	Inhibitor	
and	Rapamycin
Michael Zahra, Sopheak Srun, Craig Belsha, Donna Marshall, Paul Hauptman, Kenneth 
Schowengerdt, Ian Balfour, University of Miami School of Medicine, Miami, FL, St. Louis 
University School of Medicine, St Louis, MO
Background: Calcineurin inhibitors (CNI) cause nephropathy in pediatric heart transplant 
patients (pts). A lower CNI dose with Rapamycin (RAPA) may improve renal function in 
the short term and maintain immunosuppression. This study assessed in the medium 
term the renal function of pts on low CNI dose or no CNI and RAPA.
Methods: A retrospective review was done on 14 pts. CNI had been discontinued in 
5 pts. In 9 pts the CNI was reduced. RAPA and CNI levels, blood count, creatinine, 
electrolytes and lipid profile were monitored. Creatinine clearance was calculated using 
the Schwartz formula. The baseline (A), 30-day (B), and medium term (C) follow-up data 
were compared using the paired-samples t-test.
Results: At transplantation, pts were 3.1 + 4.5 yrs old (mean + 1SD). At C the pts were 
12.8 + 4.3 yrs old and had been on RAPA for 2.9 + 1.25 yrs. White cell blood counts and 
hemoglobin were similar at A and C (6.7 + 2.8 1000/cu mm vs 6.6 + 2.3 1000/cu mm, p 0.9 
and 12.0 + 2.1 g/dL vs 12.3 + 1.5 g/dL, p 0.7, respectively); triglyceride levels were higher, 
85 + 35 mg/dL at A versus 169 + 89 mg/dL at C, p 0.012. Renal function improved from A 
to B, but had worsened at C. One pt required dialysis. One pt died.
Conclusions: Initially the pts’ renal function improved. Over time their renal function 
worsened. The use of RAPA with a lower dose of CNI may slow but not prevent the 
decline in renal function in pts receiving CNI.
Renal Function Data
A B p1 (A vs B) C
p2
(A vs C)
Blood urea nitrogen mg/dL 28 + 13 20 + 11 0.02 25 + 12 0.6
Creatinine mg/dL 1.0 + 0.5 0.8 + 0.3 0.03 1.2 + 1.1 0.5
Creatinine clearance mL/
min/1.73m2 90 + 33 109 + 27 0.01 99 + 42 0.5
9:00 a.m.
1004-110	 Association	Between	the	Frequency	of	Endomyocardial	
Biopsy	and	the	Development	of	Significant	Tricuspid	
Regurgitation	Following	Cardiac	Transplantation;	A	10-
Year	Experience
Manisha Das, Jason C. Fleming, Richard Charnigo, Steven R. Steinhubl, Gill Heart 
Institute, University of Kentucky, Lexington, KY
Background	 -	 Endomyocardial biopsy (EmBx) remains the only proven method of 
diagnosing rejection in patients following cardiac transplant. While acute complications 
of a single EmBx are atypical, the incidence of tricuspid valvular dysfunction related to 
repetitive procedures is less well described.
Methods	- All adult cardiac transplant patients who survived more than 1 year following 
transplant were evaluated over a 10 year period. Mean follow-up was 40.2 months (range 
9-95 months). All patients underwent EmBx as clinically indicated, almost exclusively 
with echocardiographic guidance. The severity of tricuspid regurgitation (TR) was semi-
quantitatively assessed by Doppler color flow mapping. TR severity was designated as 
either mild (<20%), moderate (20-40%), or severe (>40%).
Results	-	 A total of 98 patients were analyzed. The mean number of EmBx per patient 
was 56.3 (range 19-100). A total of 34 out of 98 patients (34.69%) were found to have 
moderate or severe TR. Using Kaplan-Meier estimates (Figure), the risk of moderate or 
severe TR was significantly associated with the number of EmBx performed. The only 
independent risk factor for the severity of TR by multivariate analysis was the number 
of EmBx performed.
Conclusions - TR in post-cardiac transplant patients is independently associated with 
repetitive EmBx. These results emphasize the importance of developing alternative 
methods for the diagnosis of rejection
9:00 a.m.
1004-139	 Differential	Regulatory	Network	Patterns	During	
Rejection	and	Quiescence	in	Peripheral	Blood	
Mononuclear	Cells	Gene	Signatures
Martin Cadeiras, Sinha Anshu, Manuel P. Bayern, WeiKeat Lim, Russel Dedrick, Tod Klingler, 
Charles C. Marboe, Andrea Califano, Mario C. Deng, Columbia University, New York, NY
Background: Using functional genomics (high troughput array) and systems biological 
tools, we hypothesized that reconstruction of the regulatory gene network in peripheral 
blood mononuclear cell microarrays during rejection and quiescence may lead to the 
identification of key regulatory genes related to the acute cellular rejection process.
Methods: We applied an information-theoretic, reverse-engineering algorithm called 
ARACNe: Algorithm for the Reconstruction of Accurate Cellular Networks (Margolin, Nat. 
Prot. 2006) to the 285 CARGO PBMC gene arrays database (Deng, AJT. 2006). From 
7,370 genes represented on a focused microarray, we retained 3987 that had >80% 
completeness of information per gene. We generated two consensus transcription factor 
focused (TF) regulatory networks comparing differential enrichment in rejection (grade 
1R) and quiescence, and in-silico validated the well studied TF CREB. Genes were 
selected if they had pairwise statistically significant mutual information (p< 1e-7).
Results: We reconstructed the 2 regulatory network using 139 ISHLT grade 0/0R samples 
(n=139) and 62 1A/1R, 30 1B/1R and 24 3A/2R (total n=116). ARACNe-generated a 
network that allowed identifying subnetworks associated with each specific TF (validation 
rate 37% of first network neighbors of CREB). Highest differentially expressed TF-gene 
subnetworks in rejection and quiescence included genes related to signal transduction 
(STAT4, STAT3, STAT1, NFKB1, HMGB2, HCLS1, CREB1 and ATF6), apoptosis (STAT1, 
NFKB1, FOXO3A and FOXO1A), humoral immune response (POU2F2, NFKB1 and 
IRF4), production of IL-2, IL-4, IL-10 and IL-13, and activation of T-cells and regulation of 
T-cell differentiation towards T-helper 1 and 2 types (IRF4) and cell proliferation (RUNX3, 
MYC, ELF4 and CNOT8).
Conclusion: Several immune response related TF gene in the network were differentially 
enriched during both phenotypic conditions suggesting that the network structure 
surrounding them is significantly altered in quiescence or rejection.
9:00 a.m.
1004-140	 Radiofrequency	Based	Wireless	Pressure	
Sensor	Is	A	Reliable	Method	For	Hemodynamic	
Assessment	In	Ambulatory	Chronic	Heart	Failure	
Patients:	Comparison	To	Swan-Ganz	Catheter	And	
Echocardiography.
Pablo Castro, Hugo Verdejo, Robert Bourge, Roberto Concepcion, Marcela Ferrada, 
Alejandro Martinez, Milton Alcaino, Mario Alfaro, Ivan Godoy, Sergio Perrone, Pontificia 
Universidad Catolica de Chile, Santiago, Chile, Hospital DIPRECA, Santiago, Chile
Background: Ambulatory hemodynamic monitoring could help to adjust therapy and 
prevent hospitalizations in heart failure (HF). There is an increasing interest in the 
development of devices which may enable monitoring in outpatient setting. However, the 
accuracy and selection of the proper device remain uncertain.
We evaluate the accuracy of radiofrequency based HeartFailure sensor (HS) pulmonary 
artery pressure (PAP) monitoring compared with Swan-Ganz (SG) and Echocardiography 
(Echo) in the intermediate follow-up of HF patients.
Methods: We studied 12 HF patients NYHA class II-IV .The HS device is supplied 
loaded in a catheter for ease of deployment into pulmonary artery under angiography. 
PAP is transmitted wirelessly to an external antenna. A real time pressure waveform is 
displayed on the interrogator system. Two independent blind operators performed 3 HS 
measurements in each visit. Echo doppler was used for simultaneous measurements at 
2, 30, 60, 90 days. SG cath was performed at 0 and 60 days. Linear regression analysis 
was used as a measure of agreement between methods. Variability between them and 
interobserver was evaluated by Bland-Altman analysis.
Results: All patients completed 30 day follow-up and five 90 day. Mean age was 63 ±14.6. 
Etiology was ischemic in 3, valvular in 4 and idiopathic in 5 patients. Systolic PAP (SPAP) 
was 64±22 and 58±22 mmHg for HS and SG, respectively (p<0.01). Both methods 
showed a significant correlation (r2 = 0.96, p<0.01), with a mean difference of 6.2±4.5 
mmHg. Diastolic PAP (DPAP) was 23±14 and 28±16 mmHg for HS and SG, respectively 
(p=0.30) with a good correlation (r 2 = 0.84) and a mean difference of -1,6 ± 6.8 mmHg. 
SPAP was 60±20 and 62±12 mmHg for HS and Echo, respectively (p=0.47), with an 
appropriate correlation (r2 =0.75, p<0.01) and a mean difference of -2.6±11 mmHg. No 
significant difference was present between the 2 observers for HS measurements, with a 
mean difference of -0.8±6.5 and -2.5±5.7 mmHg for SPAP and DPAP.
Conclusions: HS provides an accurate and reliable method for assessment of PAP in the 
intermediate follow-up of HFpatients. Further studies are needed to evaluate the clinical 
applicability of HS in tailoring HF therapy to prevent hospitalization
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1004-141	 Segmental	Evaluation	of	LV	Remodeling	by	3D	Dynamic	
Shape	Analysis	Stratifies	Functional	Myocardial	
Performance
Ivan S. Salgo, William B. Ackerman, Roberto M. Lang, University of Chicago, Chicago, 
IL, Philips Medical Systems, Andover, MA
Introduction. Methods used to assess remodeling include 2D echocardiography-derived 
LV volumes and sphericity index. Neither assesses regional shape changes. We used 
methods of differential geometry to identify segmental shape changes in LV curvature. 
Methods. 12 normal subjects and 9 dilated cardiomyopathy patients were grouped by 
LV-EF using real-time 3D echocardiography (Philips 7500/iE33). Endocardial surface 
was segmented using semi-automated border detection without geometric assumptions 
(3DQ-Adv, QLAB). We computed numerically 460 measures of regional endocardial 
curvature, 3D surface area and volume at each point over the LV surface throughout 
the cardiac cycle. Regional curvatures included maximum, minimum, Gaussian, mean, 
circumferential and longitudinal averages and dispersions over the entire LV and for 
different anatomic groupings of LV segments. 
Results: 97 parameters were significant (p<.001; t-test for grouped independent 
samples). Changes in shape included those grouped at the septum, apex and midcavity 
at end-systole (mean -mid papillary p=.000009, maximum-septum p=.00001, difference 
max-min-apex p=.0007). 
Conclusions: 3D dynamic shape analysis demonstrates significant segmental changes 
in LV remodeling, which may correlate with wall stress alterations of LV shape. Monitoring 
changes in septal and apical shape may be more effective than diastolic sphericity alone 
in following LV remodeling post infarction or those for cardiac resynchronization therapy.
 
9:00 a.m.
1004-142	 Chronic	Therapy	with	Cardiac	Contractility	Modulation	
Electric	Signals	Normalizes	mRNA	and	Protein	
Expression	of	Titin	and	Tubulin	In	Dogs	With	Heart	Failure
Sharad Rastogi, Makoto Imai, Menjung Wang, Valerio Zaca, Hani N. Sabbah, Henry 
Ford Health System, Detroit, MI
Background: : Titin, a cytoskeletal protein that ensures elasticity of the sarcomere, is 
down-regulated in heart failure (HF), a maladaptation that leads to increased LV stiffness. 
Tubulin, a cytoskeletal protein that forms microtubules, increases in HF and leads to loss 
of myocardial compliance. We previously showed that in dogs with HF, chronic therapy 
with non-excitatory cardiac contractility modulation (CCM) electrical signals delivered 
to LV muscle during the absolute refractory period, improves LV systolic and diastolic 
function. This study examined the effects of 3 months CCM therapy on mRNA and protein 
expression of titin and tubulin-α and -β.
Methods: RNA was extracted from LV of 7 CCM-treated dogs, 7 untreated HF dogs 
(Controls) and 6 normal (NL) dogs. mRNA expression for titin and tubulin-α and -β was 
measured using RT-PCR and protein expression using Western blots. Bands were 
quantified in densitometric units (du).
Results: Compared to NL, mRNA and protein expression of titin decreased in Controls 
and normalized with CCM therapy. Compared to NL, expression of tubulin-α and -β 
increased in Controls and normalized with CCM therapy (Table).
Conclusions: In dogs with HF, mRNA and protein expression of titin is decreased and 
expression of tubulin-α and -β is increased. Chronic CCM therapy normalizes expression 
of titin and tubulin-α and -β. This restoration of key cytoskeletal proteins partly explains 
the improvement of LV diastolic function seen after chronic CCM therapy.
NL HF-Controls HF + CCM
Titin RNA (du) 248 ± 24 170 ± 14* 245 ± 11**
Tubulin-α mRNA (du) 125 ± 3 168 ± 3* 138 ± 11**
Tubulin-β mRNA (du) 70 ± 4 128 ± 4* 93 ± 5**
Titin Protein (du) 499 ± 35 230 ± 13* 285 ± 20**
Tubulin-α Protein (du) 154 ± 10 300 ± 13* 228 ± 9**
Tubulin-β Protein (du) 386 ± 16 752 ± 22* 543 ± 15**
*=p<0.05 vs. NL; **=p<0.05 vs. HF-Controls
9:00 a.m.
1004-143	 Changes	in	LV	Torsion	Following	Surgical	Ventricular	
Reconstruction	in	Patients	with	Ischemic	Heart	Failure
Randolph M. Setser, Nicholas G. Smedira, Richard D. White, Cleveland Clinic, 
Cleveland, OH
Background: Surgical ventricular reconstruction (SVR) reduces mortality and improves 
symptoms in patients with ischemic heart failure and left ventricular (LV) aneurysm. 
Because SVR restores the LV to a more “normal” elliptical shape, it has been postulated 
that LV torsion (rotation of the apex relative to the base) will improve following surgery, but 
this hypothesis has not been tested.
Methods: SPAMM tagged MRI images (TE/TR 4/90ms, α 15º, 8mm tag spacing) were 
acquired in 26 patients (62±11 years, 19M/7F) (mean±s.d.) (Siemens Sonata) before and 
233±111 days after SVR (accompanied by bypass grafting in 22 patients and/or mitral valve 
repair in 9). LV twist was computed using HARP analysis software (Diagnosoft) at the base 
and apex; torsion was defined as the difference between apical and basal twist.
Results: SVR improved both end diastolic volume (EDV) (277±86ml pre/212±55ml post) 
and ejection fraction (EF) (29±8% pre/37±10% post) (p<0.001 for each), but, on average, 
maximal LV twist did not change significantly at either the base (-4±2° pre/-3±2° post, 
p=0.42) or the apex (2±3° pre/3±3° post, p=0.40) following surgery; nor did maximal 
LV torsion change (6±3° pre/6±3° post, p=0.84). However, patients with relatively worse 
torsion before SVR did show improvement afterwards: pre-SVR, patients with torsion<6° 
(n=12) had significantly worse EDV (321ml vs 242ml, p=0.03), EF (24% vs 32%, 
p=0.01), apical twist (0° vs 4°, p=0.004) and torsion (4° vs 8°, p<0.001) than patients 
with torsion≥6°. Post-SVR, patients with torsion<6° had significantly improved apical 
twist (0±2° pre/2±2° post, p=0.03) and torsion (4±1° pre/5±1° post, p=0.004). Also, they 
showed significantly greater improvement in EF (ΔEF 15% vs 6%, p=0.005) and torsion 
(Δtorsion 1.2° vs -0.8°, p=0.01) than patients with torsion≥6°.
Conclusion: Our results indicate that, although torsion is unchanged following surgery 
on average, patients with relatively worse torsion pre-SVR do show improvement, while 
those with relatively better torsion before surgery actually worsen (on average) following 
SVR. Thus, using pre-surgical torsion as a metric, it might be possible to predict which 
patients will show functional improvement following SVR.
9:00 a.m.
1004-144	 Intramyocardial	Injection	Of	Autologous	Bone	Marrow	
Mononuclear	Cells	In	Patients	With	Severe	Post-
infarction	Heart	Failure	Is	Safe,	Reduces	Heart	Failure	
Symptoms,	Improves	Exercise	Capacity	And	Increases	
Left	Ventricular	Function
S. L.M.A. Beeres, J. J. Bax, J. van Ramshorst, P. Dibbets-Schneider, M. P.M. Stokkel, W. 
E. Fibbe, E. E. van der Wall, M. J. Schalij, D. E. Atsma, Leiden University Medical Center, 
Leiden, The Netherlands
Background: Cell therapy has recently been introduced to treat patients with chronic 
ischemic heart disease. We hypothesized that intramyocardial injection of autologous 
bone marrow cells in patients with severe post-infarction heart failure is safe, reduces heart 
failure symptoms, increases exercise duration and improves left ventricular function.
Methods: In 15 patients (63±9 yrs, 14 male) with chronic ischemic heart failure (NYHA 
functional class III-IV) and previous infarction, bone marrow was aspirated from the 
iliac crest. In the infarction border zone 94±14x106 mononuclear cells were injected 
(10 injections of 0.2 ml each) using the MyoStar injection catheter (NOGA, Biosense-
Webster). At baseline and at 3 months follow-up heart failure symptoms (NYHA functional 
class) and exercise capacity (bicycle exercise test) were assessed. Left ventricular (LV) 
volumes, LV ejection fraction and regional wall thickening were measured with the use of 
Tc-99m tetrofosmin gated SPECT at baseline and at 3 months follow-up.
Results: Bone marrow cell injection was performed 9±7 years after myocardial infarction. 
Continuous electrocardiographic monitoring revealed no sustained ventricular tachycardia 
during cell injection or hospitalization. At 2.5 months 1 patient died from sudden cardiac 
death. Mean NYHA functional class improved from 3.5±0.5 at baseline to 2.7±0.8 at 3 
months follow-up (P<0.01). Exercise testing revealed that the maximum level of stress 
achieved increased from 85±41 Watt at baseline to 100±41 Watt at 3 months (P=0.03). 
LV ejection fraction improved from 23±8% at baseline to 27±9% at 3 months (P=0.02). 
LV end-systolic volume reduced from 230±144 ml to 219±122 ml at 3 months whereas 
LV end-diastolic function remained unchanged (291±122 ml vs. 288±134 ml at 3 months; 
P=NS). Mean regional wall thickening increased from 13.5±6.5% at baseline to 16.0±8.6% 
at 3 months follow-up (P=0.03).
Conclusion: Autologous bone marrow mononuclear cell injection reduces heart failure 
symptoms, improves exercise capacity and increases left ventricular function in patients 
with ischemic heart failure.
9:00 a.m.
1004-145	 Is	There	a	Relationship	Between	Weight	and	Mortality	
Risk	in	Optimally	Managed	Heart	Failure	Patients?:	
Observations	from	the	Sudden	Cardiac	Death	in	Heart	
Failure	Trial
Chirag Sandesara, Brian Olshansky, Jill Anderson, Anne Hellkamp, George Johnson, 
Jeanne Poole, Daniel Mark, Kerry Lee, Gust Bardy, University of Iowa Hospitals and 
Clinics, Iowa City, IA
Background:	The relationship between weight and mortality in patients with congestive 
heart failure (CHF) is unknown. Hypothesis: Weight increases mortality risk in patients 
with CHF and a low ejection fraction (EF).
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Methods: The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), a multicenter 
study, randomized 2521 optimally managed functional class II or III CHF patients with 
an EF <35% to placebo (847 patients), amiodarone (845 patients), or a single-lead 
implantable cardioverter defibrillator (829 patients). Association of baseline weight 
with mortality risk was analyzed utilizing	a Cox proportional hazards model adjusting 
for all previously identified mortality predictors in SCD-HeFT, including diabetes, blood 
pressure, and ischemic heart disease.
Results:	Mortality risk was not associated with weight (p=0.65; hazard ratio=1.01 per 
10 lbs increase; 95% confidence interval = 0.98-1.03). This lack of association was 
consistent across subgroups defined by gender, age, CHF etiology, assigned treatment 
arm, NYHA functional class, and EF (all interactions tests not significant). Conclusion:	
Although there is a very gradual positive slope in the predicted risk lines, there is no 
statistical relationship between weight and mortality in optimally managed CHF patients 
with an EF < 35%.
9:00 a.m.
1004-150	 Impact	of	Obesity	on	Prognosis	of	High	Risk	Patients	
after	Myocardial	Infarction	or	Chronic	Heart	Failure	-a	
Meta-analysis	of	Individual	Patient	Data
Jawdat Abdulla, Lars Kober, Steen Abildstrom, Erik Christensen, Christian Torp-
Pedersen, Division of Cardiology, Department of Medicine, Glostrup University Hospital, 
Copenhagen, Denmark, Rigshospitalet Heart Centre, Department of Medicine, Division 
of Cardiology, Copenhagen, Denmark
Background:	Obesity is a risk factor for mortality in the general population, but a number 
of studies have shown a protective effect after acute myocardial infarction (MI) and 
chronic heart failure (HF). The aim of this meta-analysis was to explore the influence of 
obesity on long-term prognosis in a large population with MI or HF.
Methods:	Individual data of 21,581 patients from five studies were pooled. Patients were 
divided according to WHO classification into five body mass index (BMI) groups. Normal 
BMI was used as reference (BMI range: 18.5-24.9 kg/m2). Mortality rates and adjusted 
hazard ratios with 95% confidence interval for each BMI group and predictors of mortality 
were calculated using Cox proportional hazard models.
Results:	 In the multivariate model, the mortality of underweight patients (BMI < 18.5, 
mean = 17 kg/m2) was significantly increased with hazard ratio (HR) = 1.43 (1.30-1.58), 
p < 0.0001. Overweight (BMI 25-29.9 kg/ m2) was not associated with increased risk of 
death, HR= 1.00 (0.95-1.04), p = 0.958. Obese (BMI 30-34.9 kg/ m2) and extremely obese 
patients (BMI=> 35 kg/m2) were in increased risk of death with HR= 1.07 (1.02-1.16) and 
1.38 (1.22-1.55), respectively (fig.1).
Conclusion:	Underweight and obesity are associated with increased mortality risk after 
MI or HF. The relationship of BMI to mortality is U-shaped with lowest mortality in normal 
weight patients. These results support the concept that obesity is detrimental in high risk 
patients as in the general population. 
9:00 a.m.
1004-151	 Warm-Dry	Clinical	Profile	at	1	Month	after	Heart	Failure	
Hospitalization	Can	Be	Used	for	Triage	in	Advanced	
Heart	Failure:	An	Analysis	from	the	Evaluation	
Study	of	CHF	and	Pulmonary	Artery	Catheterization	
Effectiveness	(ESCAPE)	Trial
Joseph G. Rogers, Anju Norhia, Anne S. Hellkamp, James A. Hill, Lynne E. Wagoner, 
Ileana L. Pina, William T. Abraham, Lynne W. Stevenson, Christopher M. O’Connor, for 
the ESCAPE Investigators and Coordinators, Duke University, Durham, NC, Brigham 
and Women’s Hospital, Boston, MA
Background:	Heart failure (HF) hospitalization identifies patients (pts) at high risk for 
rehospitalization and death. Therapy in hospital is targeted to reduce congestion and 
improve perfusion, but the relationship between a clinically-assessed hemodynamic 
profile at 1 month after discharge and 6 month outcomes has not been established.
Methods:	In the ESCAPE trial, 319 pts were assessed for congestion (“wet” or “dry”) and 
perfusion (“warm” or “cool”)	1 month after discharge. Rehospitalizations and death over 
the next 5 months were combined with change in Minnesota Living with Heart Failure 
score to assemble the A-HeFT composite endpoint (range: -6 to 2; highest score is 
improved quality of life (QoL) without rehospitalization or death).
Results:	At 1 month 217 pts were deemed warm+dry (WD) and 102 were cold or wet (CW). 
The CW pts were more likely to be rehospitalized (68% vs. 38%, p=0.001) or die (25% vs. 
8%, p=0.001), and had less improved QoL at 6 months. The A-HeFT outcome was negative 
in >50% of CW pts compared to only 25% of the WD pts (Fig, p=0.001 for trend).
Conclusions:	The A-HeFT endpoint integrates death and hospitalization with meaningful 
QoL change for this advanced HF population. The WD profile at 1 month after HF 
hospitalization identifies pts at lowest risk, while the CW profile confers an increased 
relative risk for hospitalization (3.4, CI=2.1-5.5) and death (3.8, CI=2.0-7.5) at 6 months, 
and should trigger closer monitoring and additional intervention. 
9:00 a.m.
1004-152	 Beneficial	Effect	Of	Celecade	Immunotherapy	Among	
Patients	With	No	History	Of	Prior	Myocardial	Infarction:	
Data	from	The	Acclaim	Trial.
James B. Young, Wilson S. Colucci, Francois Sestier, Jan E. Otterstad, Jean L. Rouleau, 
James Young, Guillermo Torre-Amione, On Behald of the ACCLAIM Steering Committee 
and Investigators, The Cleveland Clinic, Cleveland, TX, The Methodist DeBakey Heart 
Center, Houston, TX
Background: While the natural history of heart failure (HF) due to non-ischemic 
cardiomyopathy is different from HF with ischemic etiology, current treatment strategies 
are similar for these two distinct subsets. Furthermore, increasing experimental and 
clinical evidence suggests greater participation of the inflammatory cascade in the 
progression of HF in patients with non-ischemic disease.
Methods: We evaluated the effect of immunotherapy (IMT using the Celacade system; 
Vasogen Inc.) in patients with no history of prior myocardial infarction (MI), a surrogate 
for non-ischemic cardiomyopathy. Of the 2,408 subjects evaluated in ACCLAIM (NYHA 
class II-IV, LVEF≤30%), a pre-specified subgroup of 919 (460 IMT; 459 placebo) reported 
no history of prior MI.
Results: There were no between-group differences in baseline characteristics including 
NYHA class, mean LVEF, or medication use. In this subgroup of subjects with no history 
of prior MI, IMT significantly reduced the risk of the primary composite endpoint of time 
to death from all causes or first cardiovascular hospitalization (105 vs. 138 events; hazard 
ratio 0.74, CI: 0.57 - 0.95, P=0.02). In contrast, among subjects with a prior history of MI, 
there was no difference between IMT and placebo groups (294 vs. 291 events; hazard 
ratio 1.01, CI: 0.86 - 1.19, P=0.89). In addition, in the subgroup with no history of prior MI, 
there was a trend to reduced number of days in hospital for any cause which favoured 
the IMT group over placebo (4.6 vs. 5.7 days; P=0.15). Conclusion: These observations 
suggest a beneficial effect of immunotherapy in NYHA class II-IV systolic HF patients 
without prior history of MI. 
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1201-244	 Combined	Measurements	of	Cardiac	Troponin	T	and	
Brain	Natriuretic	Peptide	in	Patients	With	Congestive	
Heart	Failure	From	Various	Etiology
Ryoji Taniguchi, Yukihito Sato, Toru Kita, Takeshi Kimura, Hyogo Prefectural Amagasaki 
Hospital, Hyogo, Japan, Kyoto University, Kyoto, Japan
Background: Since chronic heart failure (CHF) is a complex clinical syndrome, a single 
biomarker may not reflect all of its characteristics. In this study, the clinical significance 
of combination and serial measurement of biochemical markers of myocyte injury and 
myocardial load in patients with CHF from various etiologies, was examined.
Methods	and	Results:	Serum concentrations of cardiac troponin T (cTnT) and plasma 
concentrations of brain natriuretic peptide (BNP) were measured simultaneously in 190 
patients with CHF including dilated cardiomyopathy (DCM) (n=41), ischemic heart disease 
(IHD) (n=40), valvular or congenital disease (n=53), hypertensive heart disease (HHD) 
(n=16), and hypertrophic cardiomyopathy (HCM) (n=22). No patient had suffered from 
acute coronary syndrome. Serum cTnT concentrations >0.01 ng/ml were found in 46/190 
patients (24%) at baseline (20% in DCM, 42% in IHD, 21% in valvular or congenital 
disease, 43% in HHD, and 9% in HCM). Follow-up samples were obtained in 137 patients 
after a mean treatment period of 31.8 days. Although BNP decreased significantly in 
each disease categories (p<0.0001: DCM, p<0.005: IHD, p<0.05: valvular or congenital 
disease, p<0.005: HHD, and p<0.05: HCM), cTnT remained high in 36/137 patients (26%) 
(19% in DCM, 39% in IHD, 25% in valvular or congenital disease, 38% in HHD, and 19% 
in HCM). The rate of adverse cardiac events was significantly higher in patients with high 
cTnT than in patients with low cTnT concentrations (P <0.0001) (p<0.05: DCM, p<0.05: 
IHD, and p<0.01: valvular or congenital disease). Multivariate analysis (this analysis was 
adjusted for age, LVEF, NYHA functional classification, renal function, BNP) showed that 
both cTnT( Hazard Ratio(HR) 3.48, 95%C.I. 1.50-8.10 ) and BNP ( HR 3.10, 95%C.I. 
1.11-8.66 ) are independent prognostic factors and patients with elevations of both cTnT 
and BNP had the poorest prognosis (p <0.0001).
Conclusions: In patients with CHF, the evolution and prognostic value of cTnT and 
BNP are different. The combined measurements of these markers should refine our 
understanding of the state and evolution of CHF.
Noon
1201-245	 Diverse	Cardiac	Geometry	and	Cardiorenal	Interaction	
in	Diastolic	Heart	Failure
Carolyn S.p. Lam, Veronique L. Roger, Richard J. Rodeheffer, Margaret M. Redfield, 
Mayo Clinic and Foundation, Rochester, MN
Background: While left ventricular (LV) hypertrophy (LVH) is considered sine qua non of 
diastolic heart failure (DHF), recent studies suggest otherwise. 
Methods: Consecutive DHF patients (pts, n=207) and randomly selected controls 
without HF (CON, n=1523) were studied. All were Olmsted County, MN, residents with 
EF>50%. Based on relative wall thickness and sex-specific LV mass index, LV geometry 
was: normal (NL); concentric remodeling (CR); concentric (CH) or eccentric (EH) LVH. 
LV structural and functional parameters were determined by validated echo Doppler 
methods and compared between DHF and geometry-matched CON. 
Results: (Table) LVH was absent in 59% of DHF pts (NL, CR) who had higher end-diastolic 
(ED) pressure (P), smaller ED volume (V) and higher diastolic stiffness coefficient (β) than 
CON but similar renal function. DHF pts with LVH (CH, EH) had higher EDP despite 
similar EDV and β but more impaired relaxation (↑Tau) and renal dysfunction than CON.
Conclusions: LV geometry varies in DHF. Many have a “restrictive cardiomyopathy” 
picture with diastolic dysfunction in the absence of LVH or renal dysfunction. In DHF 
with LVH, elevated EDP without LV dilatation or increased β compared to CON suggests 
a parallel upward shift of the EDP-V curve which may be due to an effect of relaxation 
on LV diastolic pressures, decreased myocardial distensibility or extrinsic forces. The 
renal impairment in DHF with LVH suggests an important cardiorenal connection with 
concomitant cardiac and renal end organ damage. 
Normal	(NL) Concentric	Remodeling	(CR)
Concentric	Hypertrophy	
(CH)
Eccentric	Hypertrophy	
(EH)
CON DHF CON DHF CON DHF CON DHF
N	(%	CON	or	
DHF)
812 
(53%) 64 (31%) 286 (19%) 57 (28%) 191 (13%) 54 (26%) 234 (15%) 32 (15%)
Glomerular	
filtration	
rate	(ml/
min/1.73m2)
77.8±33.7 72.4±26.1 75.0±17.2 67.7±30.6 70.9±18.8 57.4±26.3†* 73.0±18.3 56.7±28.8†*
LV	mass	
index	(g/m2) 85.1±13.0 84.5±16.8 87.5±13.0 84.1±14.8 119.2±20.3 131.6±27.1† 114.7±16.8 119.4±17.0
Relative	wall	
thickness 0.36±0.04 0.38±0.04† 0.47±0.05 0.50±0.09† 0.48±0.06 0.52±0.08† 0.37±0.03 0.38±0.04
End	diastolic	
pressure	
(mmHg)
16.9±1.7 20.6±5.1†* 17.0±1.9 22.6±5.3†* 17.9±2.2 25.7±5.8†* 17.2±1.6 23.9±4.8†*
Indexed	left	
atrial	volume	
(ml/m2)
23.3±6.6 31.8±12.2†* 22.6±6.6 34.1±14.3†* 26.6±9.1 39.4±12.8†* 26.2±8.3 41.8±16.1†*
Log	BNP	
(Shionogi) 1.09±0.41 1.91±0.63†* 1.12±0.42 2.19±0.43†* 1.30±0.49 2.25±0.49†* 1.26±0.45 2.34±0.47†*
Indexed	LV	
end	diastolic	
volume	
(ml/m2)
60.2±8.7 56.0±10.3†* 47.6±7.7 43.5±8.4† 57.4±10.0 59.9±11.0 72.4±9.7 74.1±11.1
Stroke	
volume	index	
(ml/m2)
45.2±8.0 42.5±9.2†* 44.0±8.5 41.0±8.8†* 47.8±9.9 44.4±11.6†* 48.5±8.9 44.0±10.3†*
Time	
constant	of	
isovolumic	
relaxation,	
Tau	(ms)
38.6±18.9 52.4±14.9† 38.6±47.4 56.8±13.3† 48.2±15.5 64.7±10.6†* 43.2±23.4 60.9±16.3†
Diastolic	
stiffness	
constant,	ß
6.13±0.55 6.35±1.08†* 6.13±0.34 8.08±4.35†* 6.23±0.44 6.99±3.87 6.12±0.14 6.55±1.40
†p<0.05 vs CON, * P<0.05 vs CON adjusting for age, sex +BSA
Noon
1201-246	 Central	Sleep	Apnea	Promotes	Increased	Endothelin-
1	and	Norepinephrine	Serum	Concentration	and	
Pulmonary	Hypertension	in	Patients	With	Congestive	
Heart	Failure
Alfred G. Valles, Virend K. Somers, Tomas Kara, Jennifer M. Miller, Michal Hoffmann, 
Lyle J. Olson, Mayo Clinic College of Medicine, Rochester, MN
Background:	 Patients with congestive heart failure (CHF) frequently have central 
sleep apnea (CSA) with episodic nocturnal hypoxia which is an independent risk for 
increased mortality. Hypoxia is a potent stimulus of pulmonary vasoconstriction and 
promotes release of vasoconstrictor peptides including norepinephrine (NE) and 
endothelin-1 (ET-1). We hypothesized that patients with CHF and co-existent CSA 
have higher circulating concentrations of NE and ET-1 and elevated pulmonary artery 
pressure (PAP). Accordingly, the aims of this study were to: 1) compare NE and ET-1 
concentrations of subjects with CHF and CSA (CHF/CSA) to subjects with CHF only and 
2) evaluate the relationship between ET-1 concentration and pulmonary hypertension. 
Methods: All subjects had a prior diagnosis of CHF; inclusion required left ventricular 
ejection fraction (LVEF) <35%. Doppler measurement of right ventricular systolic pressure 
(RVSP) was used for estimation of PAP. All subjects had measurement of serum NE 
and ET-1 concentration and laboratory-based overnight polysomnography (PSG). 
Subjects with obstructive sleep apnea were excluded. CSA was defined by apnea-
hypopnea index > 10/hr. Subjects were grouped as either CHF alone (n=16) or CHF/CSA 
(n=12) by PSG. Characteristics for the groups were compared by unpaired t-test and 
linear regression was performed to evaluate the relationship between RVSP and ET-1.	
Results: Data summarized as mean ± SD; CHF/CSA vs CHF only. RVSP (mmHg) 
56.6±14.0 vs 37.7±13.1 (p=.002); NE (pg/ml) 419.1±233.1 vs 283.7±115.7 (p=0.03) 
and ET-1 (pg/ml) 2.2±1.3 vs 1.2±0.4 (p= 0.03) concentrations were higher in CHF/CSA 
compared to CHF alone while LVEF 23±10 vs 28±7 (p= 0.06) was similar. For all CHF 
subjects NE concentration was significantly correlated with ET-1 concentration (r=0.36, 
p=0.001) and ET-1 concentration was highly correlated with RVSP (r=0.57, p=0.003). 
Conclusion: Daytime pulmonary artery pressure is higher in CHF/CSA subjects 
compared to CHF alone associated with greater concentrations of NE and ET-1 which 
may be implicated in the worse prognosis of patients with CHF and CSA.
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1201-247	 Are	Angiotensin	Receptor	Blockers	as	Safe	as	
Angiotensin	Converting	Enzyme	Inhibitors	in	Patients	
With	Heart	Failure?	A	Systematic	Review	and	Meta-
Analysis	of	Randomized	Controlled	Trials
Rachid Lakhdar, Mouaz H. Al Mallah, David E. Lanfear, Henry Ford Hospital System, Detroit, MI
Background: Angiotensin receptor blockers (ARB) and Angiotensin converting enzyme inhibitors 
(ACE-I) have similar efficacy in heart failure patients. The most recent heart failure guidelines 
recommend that ARB may be used as alternatives to ACE-I as first line therapy for patients with mild 
to moderate heart failure and reduced left ventricular ejection fraction (class IIA recommendation). 
However, it is not clear whether these agents have the same safety profile. We sought to conduct a 
systematic review and meta-analysis of randomized controlled trials to test the hypothesis that ACE-
Is and ARBs have the same tolerability and safety profile in patients with heart failure.
Methods: MEDLINE, EMBASE, BIOSIS, Cochrane databases from inception until 
January 2006, abstract books from major cardiology meetings and bibliographic review of 
secondary sources were searched. Eligible studies were randomized, placebo-controlled 
trials of ACE-Is versus ARBs in patients with heart failure, and which reported side effects. 
We performed random-effect model meta-analyses and quantified between-studies 
heterogeneity with I2 (I2<50% indicates no heterogeneity).
Results: Six trials met the inclusion criteria. 8,730 patients received ARB therapy while 
8,267 patients received ACE-Is. Patients on ARBs had an increased risk of developing 
worsening renal function (RR=1.57, 95% CI=1.29 1.92, p<0.00001, I2 =0%). Expectedly, 
Patients on ACE-I therapy had an increased risk of developing cough (RR=0.44, 95% 
CI= 0.31 0.62, p< 0.00001, I2 =63.3%) and angioedema (RR=0.48, 95% CI=0.28 0.80, 
p=0.005, I2 =0%). There was no difference in the incidence of total side effects (RR=0.95, 
95% CI= 0.68 1.34, p= 0.78, I2 =85.2%) hyperkalemia (RR=0.89, 95% CI=0.24 3.31, p= 
0.86, I2 =65.1%), or hypotension (RR=1.06, 95% CI= 0.74 1.52, p< 0.0001, I2 = 85.6%).
Conclusion: The current cumulative evidence suggests that ARBs and ACE-Is have 
similar overall rate of adverse events. ARBs are associated with an increased risk of 
worsening renal function. The clinical relevance of this finding requires further study, until 
which ARBs should remain 2nd line therapy except for patients that are known to have 
ACE-I related cough or angioedema
Noon
1201-248	 Differences	in	Left	Ventricular	Hypertrophy	Between	
Highly	Trained	Caucasian	and	Black	(African/Afro-
Caribbean	Origin)	Athletes	Engaging	in	Similar	
Sporting	Disciplines
Sandeep Basavarajaiah, Mathew Wilson, Greg Whyte, Ajay Shah, Sanjay Sharma, 
University hospital Lewisham, London, United Kingdom, Kings College hospital, 
London, United Kingdom
Background: Upper limits for physiologic left ventricular hypertrophy (LVH) for the purposes of 
differentiation from hypertrophic cardiomyopathy (HCM) are well established in Caucasian athletes. 
However, there are few data regarding physiologic left ventricular remodelling in black athletes 
in whom deaths from HCM are more common. This study compared ethnic differences in left 
ventricular remodelling between Caucasian and black (African/Afro Caribbean origin) athletes.
Methods:	Between 2005 and 2006, 80 asymptomatic and normotensive black male athletes (mean 
age: 20.5 ± 5.80; range 14-35 years and a mean body surface area: 1.94 ± 0.16 m2; range1.36-
2.29) underwent 12-lead EKG and 2-D echocardiography. The results were compared to those of 
80 sedentary black males and 160 highly trained white male athletes matched for age, size, sport 
and training programs. None of them had a family history of HCM. End diastolic left ventricular 
dimensions and indices of cardiac function were measured in accordance with American Society 
of Echocardiography guidelines.
Results:Both black athletes (BA) and white athletes (WA) had a greater left ventricular wall thickness 
(LVWT) than black controls [10.81 ± 1.73mm; (8-15) and 10.01 ± 1.46mm (7-14) respectively vs 
8.96 ± 1.21mm (6-12); p<0.001]. No control subject had a LVWT > 12 mm.
The BA had greater LVWT than WA [10.81 ± 1.73mm; (8-15) vs10.01 ± 1.46mm; (7-14); p<0.001] 
amounting to 7.4% difference. In absolute terms 14 (17.5%) BA had a LVWT > 12 mm compared 
with 7 (4.4%) WA. There were no significant differences in the left ventricular cavity size or indices of 
diastolic function between BA and WA.
All BA with a LVWT > 12 mm had an enlarged left ventricular cavity size [54.92 ± 4.35mm 
(52-60)] and normal indices of diastolic function (E wave, A wave, E/A) indicating physiologic 
LVH rather than HCM.
Conclusion:	Black athletes develop modest LVH compared with non-athletes. The magnitude 
of LVH in BA is slightly greater than in WA, however, more BA have absolute LVWT values in the 
region compatible with HCM. These ethnic differences warrant a larger study in BA to define upper 
limits of LVH in order to minimise the risk of an erroneous false positive diagnosis of HCM.
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1010-55	 Dual-Specific	A	Kinase-Anchoring	Protein	2	
Polymorphism	is	Associated	with	Increased	Left	
Ventricular	End-Systolic	Elastance	in	Caucasians:	Data	
from	the	Heart	and	Soul	Study
Sanjiv J. Shah, Whittemore G. Tingley, Jonathan G. Zaroff, Ludmila Pawlikowska, Pui-
Yan Kwok, Mary A. Whooley, University of Chicago, Chicago, IL, University of California, 
San Francisco, San Francisco, CA
Background:	An amino-acid variant (Ile646Val) in the kinase binding domain of dual-
specific A kinase anchoring protein (D-AKAP2) has been identified as a disease 
susceptibility polymorphism in Caucasians. Little is known about this single-nucleotide 
polymorphism (SNP) except its association with decreased PR interval. Since modulation 
of the interaction between AKAPs and protein kinase A has been shown to increase 
contractility in animal models, we hypothesized that the D-AKAP2 SNP would be 
associated with increased contractility, as measured by end-systolic elastance (E
es
) on 
pressure-volume analysis.
Methods:	 In a cross-sectional study of 493 Caucasians, we determined D-AKAP2 
genotype and examined its association with clinical, laboratory, and echo data. We 
used multivariable linear regression to determine the independent association between 
genotype and E
es
 (defined as end-systolic pressure / end-systolic volume index).
Results:	Genotype frequencies observed were in Hardy-Weinberg equilibrium: AA (Ile/
Ile): 222/493, 45%; AG (Ile/Val): 217/493, 44%; and GG (Val/Val) 54/493, 11%; p=0.93 
for χ2 test of observed vs. expected frequencies. There were no demographic, clinical, or 
laboratory differences between SNP groups. Patients in all three SNP groups had similar 
blood pressure, ventricular volumes, ejection fraction, and diastolic function. However, 
there was a linear, dose-effect relationship between genotype and E
es
 phenotype. With each 
abnormal allele, E
es
 (mmHg/ml/m2) increased linearly: 6.56 ± 2.94 (AA), 7.25 ± 3.15 (AG), 
8.04 ± 4.07 (GG); p=0.005 On multivariable analysis, the G allele remained independently 
associated with Ees (β-coefficient=0.31, p=0.001), after adjusting for age, sex; history of 
heart failure, myocardial infarction, or hypertension; BNP, creatinine clearance; diastolic 
function, ejection fraction, LV mass index, and end-diastolic volume index
Conclusions:	 The I646V D-AKAP2 polymorphism is independently and linearly 
associated with elevated LV end-systolic elastance in Caucasians in a dose-effect fashion. 
This finding may provide insight into the function of the D-AKAP2 protein and its possible 
role in regulating cardiac contractility.
1:30 p.m.
1010-56	 The	Novel	Cytokine	Interleukin-17	Stimulates	MMP-1	
Expression	In	Primary	Human	Cardiac	Fibroblasts	Via	
p38	MAPK	And	ERK-dependent	C/EBPβ,	NF-κB,	And	
AP-1	Activation
Maria Dolores Cortez, Marc D. Feldman, Srinivas Mummidi, Anthony J. Valente, Matthew 
Vincenti, Jeffrey L. Barnes, Bysani Chandrasekar, Dept. of Veterans Affairs South Texas 
Veterans Health Care System, San Antonio, TX, Univ. of Texas Health Science Center at 
San Antonio, San Antonio, TX
Background: Matrix metalloproteinase-1 (MMP-1) is expressed by cardiac fibroblasts, 
degrades collagen, and plays a role in myocardial remodeling and failure. Interleukin-17 
(IL-17) is a novel proinflammatory cytokine whose effects on MMP-1 induction in the 
heart are not known.
Methods:	  Human primary cardiac fibroblasts (HCF) were treated IL-17. MMP-1 
expression was analyzed by RT-qPCR, Western blotting, gelatin zymography, and type 
I collagenase activity, transcriptional induction and transcription factor (TF) binding by 
reporter assays, ELISA and mobility shift assays, and p38 MAPK and ERK activation by 
immunecomplex kinase assays and immunoblotting using activation-specific antibodies 
(Abs). Signal transduction pathways involved in IL-17-mediated MMP-1 induction 
were determined using pharmacological inhibitors, RNA interference, and adenoviral 
transduction of dominant negative expression vectors.
Results:	  IL-17 stimulated MMP-1 mRNA expression, protein levels, and promoter-
reporter activity in HCF in a time- and dose-dependent manner. These effects were 
blocked by IL-17R/Fc chimera, IL-17 and IL-17R neutralizing Abs, but not by IL-6, TNF-α 
or IL-1β neutralizing Abs. IL-17 stimulated type I collagenase activity, an effect that was 
attenuated by the MMP inhibitor GM6001 or siRNA-mediated MMP-1 knockdown. IL-17 
stimulated AP-1 (c-Fos, c-Jun, Fra-1), NF-κB (p50, p65) and C/EBPβ DNA binding and 
reporter gene activities, effects that were attenuated by antisense oligonucleotides, RNAi-
mediated knockdown, and adenoviral transduction of dominant negative expression 
vectors. Inhibition of these TFs attenuated IL-17-mediated MMP-1 expression. IL-17 
stimulated p38 MAPK and ERK activation, effects that were blocked by SB203580 and 
PD98059. Furthermore, inhibition of p38 MAPK and ERK blocked IL-17-mediated TF 
activation and MMP-1 induction.
Conclusions:	 These data show for the first time that IL-17 potently induces MMP-1 
expression in HCF independent of IL-1β, IL-6, and TNF-α, but dependent on p38 MAPK- 
and ERK-mediated AP-1, NF-κB and C/EBPβ activation, and suggest that IL-17 may play 
a role in myocardial remodeling and failure.
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1010-57	 Angiotensin	II-induced	Increase	In	Myocardial	
Distensibility	Is	Modulated	By	The	Endocardial	
Endothelium,	Endothelin-1	And	Nitric	Oxide
Paulo M. Castro-Chaves, Pedro Pimentel-Nunes, Ricardo Fontes-Carvalho, João 
B. Soares, João Martins, Adelino Leite-Moreira, Physiology Department, Faculty of 
Medicine, Porto, Portugal, Portugal
As recently described, angiotensin II (AngII) acutely increases myocardial distensibility. 
Although endothelin-1 (ET-1) and the endocardial endothelium (EE) also modulate 
myocardial diastolic properties, their interaction with AngII at this level has not yet been 
investigated.
The effects of increasing concentrations of AngII (10-8, 10-7, 10-6, 10-5 M) were studied 
in rabbit right papillary muscles immersed in a modified Krebs solution (0.6Hz; 1.8mM 
Ca2+; 35ºC) in the following conditions: (1) with intact EE (Protocol A; n=11); (2) after 
selective removal of EE with Triton X-100 (0.5%; Protocol B; n=8); and (3) with intact EE 
in presence of PD-145065, a nonselective endothelin receptor antagonist (Protocol C; 10-
7M; n=8), or BQ-123 (Protocol D; 10-7M; n=8), a selective ET-A receptor antagonist, or NG-
nitro-L-arginine, an inhibitor of nitric oxide synthesis (Protocol E; 10-5M; n=8). Calculated 
parameters: active tension (AT), maximum velocity of tension rise (dT/dtmax), passive 
tension and muscle length. Results presented as mean±SE (p<0.05).
In Protocol A, Ang II induced a concentration dependent positive inotropic effect, increasing 
at 10-5M 43.3±6.3% AT and 58.6±9.6% dT/dtmax. With regard to the diastolic properties, 
the same concentration of AngII induced an increase in passive muscle length up to 
1.020±0.004 L/Lmax. Restoring muscle length to Lmax decreased 46.1±4.0% passive 
tension, indicating an increase in myocardial distensibility. When the EE was damaged 
(Protocol B) this effect was abolished. In Protocols C, D and E the effects of AngII 10-5 M 
were only attenuated inducing an increase in passive muscle length which corresponded to 
a decrease in passive tension of 24.5±3.6%, 16.1±6.0% and 19.3±6.2%, respectively.
In conclusion, Ang II induces a concentration-dependent acute increase in myocardial 
distensibility. This effect is abolished by the selective removal of EE and attenuated in the 
presence of the ET-1 receptor antagonists and an inhibitor of nitric oxide synthesis. The 
interaction between AngII, ET-1 and the EE in the modulation of the diastolic myocardial 
properties is a novel finding with potential pathophysiologic and therapeutic implications 
in heart failure.
1:30 p.m.
1010-58	 Opening	of	Mitochondria	Permeability	Transition	Pores	is	
a	Key	Factor	in	Increased	Hypoxia-Induced	Susceptibility	
of	Failing	Cardiomyocytes	to	Undergo	Apoptosis
Anastassia V. Todor, Victor G. Sharov, Hani N. Sabbah, Saint Joseph Mercy Oakland 
Hospital, Pontiac, MI, Henry Ford Health System, Detroit, MI
Background: We previously showed that failing LV cardiomyocytes exhibit increased 
hypoxia-induced susceptibility to undergo programmed cell death or apoptosis. The 
underlying mechanism(s) responsible for this enhanced susceptibility, however, is not 
known. Cardiomyocytes isolated from dogs with heart failure (HF) exhibit decreased 
mitochondrial membrane potential and increased opening of mitochondria permeability 
transition pores (mPTP). In this study, we tested the hypothesis that increased opening 
of mPTP may be the cause of increased hypoxia-induced susceptibility of failing 
cardiomyocytes to undergo apoptosis.
Methods: Cardiomyocytes were isolated from 5 dogs with HF produced by intracoronary 
microembolizations. Cardiomyocytes were subjected to either 30 minutes of hypoxia 
(95% N2 - 5%CO2) followed by 30 min of reoxygenation or to 1 hour of normoxia (95% air 
- 5%CO2). Cardiomyocytes were incubated in the presence and absence of 0.2 μM of the 
mPTP inhibitor cyclosporine-A (CsA). Cardiomyocytes were tested for yield of viable cells; 
state-3 respiration expressed in ng O2/min/1X106 cardiomyocytes, mPTP opening with 
calcein AM and expression of active caspase-3. Cardiomyocytes isolated from 5 normal 
dogs were used as control.
Results: The yield of viable cardiomyocytes was not altered in any of the experiments. 
Hypoxia increased mPTP opening by nearly 30 ± 7%. This was accompanied by a 
decrease in state-3 respiration (77 ± 8 vs. 62 ± 7, p<0.05) and activation of caspase-
3 through partial cleavage of its 32 kDa inactive form into the 17 kDa form. In hypoxic 
cardiomyocytes, inhibition of mPTP with CsA attenuated mPTP opening, restored state-
3 respiration (75 ± 8) and preventated activation of caspase-3. Exposure of normal 
cardiomyocytes to hypoxia had no effect on mPTP opening, mitochondria state-3 
respiration or activation of caspase-3.
Conclusions:	 The results indicate that hypoxia-induced activation of caspase-3 and 
hence, apoptosis, was triggered in failing cardiomyocytes by mPTP opening. Inhibition of 
mPTP opening may represent a viable novel target for treatment of chronic HF.
1:30 p.m.
1010-59	 AKT	Kinase	Overexpression	Prevents	Heart	Failure	
Development	Modulating	Cardiac	Contractility	in	
Pressure	Overload	Animal	Model
Paolo Gallo, Marcello Ceci, Marco Santonastasi, Germano Di Sciascio, Gianluigi Condorelli, 
Department of Cardiovascular Science-Campus Bio-Medico University, Rome, Italy, 
Molecular Cardiology Department-San Raffaele Biomedical Science Park, Rome, Italy
Background: Cardiomyocytes (CMC) adapt to physical stress by increasing cell size 
while maintaining cell function, (physiological hypertrophy), in contrast to maladaptation, 
in which cell size and function do not increase accordingly. As shown previously, 
overexpression of the E40K Akt mutant increases CMC size and improves cardiac 
function in transgenic mice and increases inotropism and lusitropism at cellular level. We 
further investigated the role of Akt on cardiac hypertrophy and its effect on modulating 
contractility in the pressure overload model of heart failure.
Methods: Quantitative real time PCR (qRT-PCR) and Western Blots were performed on 
tissue extracts from Akt-Tg and wild type (Wt) mouse hearts for evaluating embryonic 
gene activation and VEGF levels. Histological analysis was performed to quantify tissue 
apoptosis, fibrosis and angiogenesis. Moreover, Wt and Akt mice underwent transverse 
aortic costriction (TAC) and echocardiographic study performed at 1, 4, and 8 weeks after 
TAC while hemodynamic study at 8 weeks and right before heart explantation
Results: mRNA levels of the embryonic genes β-isoform of myosin heavy chain (β-MHC), 
atrial natriuretic factor (ANF) and skeletal actin (SA) were increased after 1 week of TAC 
and totally depressed after 8 weeks of TAC in Wt mice. In contrast, in E40K-AKT mice, 
activation of embryonic genes was dramatically decreased after 1 week of TAC while 
a significant gene activation after 8 weeks was observed. In vivo, the effects of Akt on 
cardiac contractility were evident as compared to Wt: fractional shortening (FS %) and dP/
DtMAX were significantly higher in E40K vs WT mice, which also revealed severe systolic 
dysfunction (at 8 weeks TAC: FS%: 41,5 vs 26,6, p<0.0002; Max dP/dT: 6851+1972 vs 
2442+536 mmHg, p<0.02).
Histological analysis showed a significantly smaller amount of apoptosis, decreased 
stromal tissue accumulation and increased capillary density in Akt-Tg vs WT mice; VEGF 
levels were increased accordingly.
Conclusions: our study suggests that E40K Akt overexpression induces compensatory 
hypertrophy which protects CMCs against the transition toward cardiac dilatation and 
failure in response to hemodynamic overload.
1:30 p.m.
1010-60	 Human	Mesenchymal	Stem	Cell	From	Human	Chorionic	
Villi	is	a	New	Cell	Source	for	Autologous	Cardiac	Stem	
Cell	Therapy.
Kazuma Okamoto, Naoko Hida, Shunichiro Miyoshi, Nobuhiro Nishiyama, Yukinori 
Ikegami, Daiske Kami, Taro Uyama, Kenji Miyado, Kaoru Segawa, Hironori Asada, 
Yasunori Yoshimura, Ryo Aeba, Satoshi Ogawa, Akihiro Umezawa, Ryohei Yozu, Keio 
University School of Medicine, Tokyo, Japan, National Research Institute for Child 
Health and Development, Tokyo, Japan
Background: Marrow-derived mesenchymal stem cell (MSC) is a cell source for cardiac 
stem cell therapy. However, those cells may not function well because of patient’s 
disease background, age, and the ability of stem cell transdifferentiation that may be 
impaired. Placental chorionic villi are a good cell source for MSC since the young and 
fresh MSC can be obtained from them without any ethical problem. We hypothesized that 
placental chorionic villi cells (CVCs) can transdifferentiate into physiologically functioning 
cardiomyocytes in vitro.
Methods	 and	 results:	Human placental CVCs were isolated at male infant delivery, 
and confirmed them as infant-derived cells by sex chromosomal analysis (to exclude the 
contamination of maternal endometrial cells). Before cardiomyogenic induction, mRNA 
of Nkx-2.5, GATA-4, hBNP, and cardiac tropnonin-I (Trop-I) were detected by RT-PCR 
in the CVCs. The GFP-labeled CVCs were co-cultured with murine fetal cardiomyocytes 
to induce cardiomyogenic differentiation. A week after the induction, GFP-positive 
CVCs rhythmically and synchronously contracted, suggesting the presence of electrical 
communication between CVCs. The cardiomyocyte-specific action potential was obtained 
from spontaneous beating CVCs that showed the specific cardiac action potential plateau 
(duration; 209 +- 48 msec, amplitude 63.9 +- 8.4 mV, n=14). Immunocytochemical analysis 
with confocal laser microscopy revealed differentiated CVCs which were stained positive 
for anti-Trop-I, sarcomeric α-actinin (clearly stained striation pattern) and connexin 43 
(diffused dot-like shapes at the margin of CVCs). The percentage of Trop-I positive cells 
in the GFP-positive cells was 14 +- 5%. The fractional shortening of the beating CVCs 
was 5.5 +- 0.4% (n=10).
Conclusions: In CVCs, MSC with cardiomyogenic ability accounted for 14%. Although 
CVCs are usually considered as medical waste at delivery, we can obtain young stem 
cells from them without any ethical problem. We can utilize our own CVCs to repair our 
own heart disease in the future if they are stored at birth. CVCs are superior to marrow-
derived MSC because they can be obtained from younger people and have a higher 
cardiomyogenic potential.
1:30 p.m.
1010-61	 The	Protein	Synthesis	and	T-CAP	Translational	
Control	by	AKT/mTOR/4E-BP1	Signal	Prevent	Dilated	
Cardiomyopathy	in	MLP-/-	Mice
Paolo Gallo, Marcello Ceci, Marco Santonastasi, Germano Di Sciascio, Gianluigi 
Condorelli, Department of Cardiovascular Science-Campus Bio-Medico University, 
Rome, Italy, Molecular Cardiology Department- San Raffaele Biomedical Science Park, 
Rome, Italy
Background: “Idiopathic” dilated cardiomyopathies (DCM) are caused by single gene 
mutations in approximately 40% of cases. Frequently, the affected gene is a component 
of the mechanotransduction machinery. Muscle LIM protein (MLP), is a component of 
the Z disk, the cytoskeletal structure of the cardiomyocyte (CMC) which constitutes an 
anchoring site for actin, titin and nebulin filaments. Recent studies suggest a role of the 
IGF-1/PI-3K/Akt pathway in myocardial adaptation to physical stress. To identify the 
role AKT/mTOR signal, the MLP-/- mice, model for DCM, are crossed with E40K-AKT 
transgenic mice, overexpressing in cardiac tissue an active form of AKT
Methods: Cardiac function was evaluated by echocardiography and hemodynamic assessment. 
Immunofluorescence, electrophoresis and immunoblotting were used for assessing the 
distribution and amount of T-CAP protein and for measuring Akt and mTOR activities.
Results: Fractional shortening (FS) was dramatically increased in Akt E40K/MLP-/- mice 
54A    ABSTRACTS - Cardiac Function and Heart Failure  JACC  March 6, 2007 
C
ar
di
ac
 F
un
ct
io
n 
an
d 
H
ea
rt
 F
ai
lu
re
as compared to MLP KO mice, which show severe contractile impairment. The inotropic 
function was markedly depressed in MLP KO in basal condition and after inotropic stimuli 
(FS% 42,04 in Akt E40K/MLP-/-, vs 22,85 in MLPKO, p<0.0001; Max dP/dT at rest: 8353 
Akt E40K/MLP-/- vs 2800 mmHg in MLPKO, p<0.05). HW/BW ratio was increased in Akt 
E40K/MLP-/- mice compared to WT and MLP KO mice. The expression levels of embryonic 
cardiac genes were dramatically decreased in E40K/MLP-/- mice compared to MLPKO 
mice. Myocardial tissue from E40K/MLP-/- mice showed a decreased accumulation of 
collagen, increased cellularity and increased cell size; electron microscopy analysis of 
myocardial tissue showed the normalization of the Z disk structure, remarkably altered 
in MLP-/-myocytes 
Conclusions:	 In MLP-/-/E40K-AKT mice, the mTOR signal activated by E40K-AKT 
induced the increase T-CAP protein, which is profoundly decreased in MLP-/- mice. 
Moreover, the cardiac hypertrophy, reduced the diastolic wall, maintaining T-CAP protein 
in the myofilament fraction and associated it with Titin. This molecular mechanism 
favoured the Z disks reorganization and prevented the onset of the cardiomyopathy in 
MLP KO mice.
1:30 p.m.
1010-62	 Successful	In	Vivo	Imaging	of	the	Enhanced	
Transcriptional	Activity	of	GATA	in	the	Heart	
during	the	Progression	of	Angiotensin	II-Induced	
Hypertrophy	in	Mice
Masaharu Nakayama, Tatsuya Komaru, Hiroaki Shimokawa, Tohoku University Hospital, 
Sendai, Japan
Background:	Pathological hypertrophy and heart failure are associated with activation 
of transcription factors, resulting in cardiac gene expression and remodeling. However, 
the activity of transcription factors during the progression of hypertrophy is not entirely 
understood in living animals. This study aims to visualize the transcriptional activity in the 
in vivo heart using bioluminescence in vivo imaging system.
Methods: We directly injected a firefly luciferase vector plasmid containing 6x GATA 
binding site into the heart in a 6-week-old mouse. Two days after the injection (day0), 
we measured the intensity of light emitting from the heart with a CCD camera detection 
system with intraperitoneal administration of luciferin, the substrate for luciferase, and 
implanted an osmotic minipump with either a pressor dose of angiotensin II (2.0 mg/kg/
day) or vehicle (control) (n=11 each). Light intensity emitting from the heart of the same 
animal was serially measured every 2 days from day 1 to day 15.
Results: The ratio of light intensity emitting from the heart on day 1 to day 0 was 
significantly enhanced in mice administered with angiotensin II as compared with the 
controls (2.2+0.4 vs. 0.7+0.2, P<0.01). The bioluminescence was also kept augmented 
in mice administered with angiotensin II between day 3 and day15 although no induction 
was observed in the controls. The heart was harvested from a mouse at day 15 after 
the minipump implantation. The heart-to-body weight ratio was significantly increased 
in the animals administered with angiotensin II as compared with the controls (5.5+0.3 
vs. 4.2+0.2 mg/g, P<0.01). Coadministration of angiotensin II type 1 receptor antagonist 
olmesaltan abolished the fold induction of GATA reporter gene in the in vivo heart and 
caused no hypertrophy in mice administered with angiotensin II.
Conclusions: We were able to demonstrate the enhanced transcriptional activity of 
GATA in the in vivo heart during the progression of angiotensin II-induced hypertrophy in 
mice. The present bioluminescence in vivo imaging system may be a useful method for 
monitoring transcriptional activity in the heart prior to any morphological changes (e.g. 
hypertrophy) in the living animal.
1:30 p.m.
1010-63	 N-	Terminal	pro	BNP	is	Associated	with	Cardiac	
Structure	and	Function	in	Elderly	Patients	with	
Heart	Failure	and	Preserved	Systolic	Function;	the	
iPRESERVE	Study
John S. Gottdiener, Barrie M. Massie, Peter E. Carson, Amithaba Bhaumik, Agata 
Ptaszynska, Michel Komajda, Robert McKelvie, John McMurray, Michael Zile, University 
of Maryland Hospital, Baltimore, MD
Background: This study was done to determine relationships between NT pro B type 
natriuretic peptide (NT -BNP) and cardiac structure and function in elderly pts with heart 
failure (HF) and preserved systolic function (HF-PSF) in the Irbesartan in Heart Failure 
with Preserved Systolic Function trial (I-PRESERVE) .
Methods: 4128 pts, ≥60 yrs old and with ejection fraction (EF)≥45%, with either NYHA 
II-IV symptoms and HF hospitalization within 6 months, or NYHA III-IV symptoms with 
ECG, radiologic or echo evidence of cardiac disease were randomized. NT-BNP was 
measured using the Elecsys proBNP assay (Roche). 2D echo as well as mitral inflow 
and tissue Doppler was done at baseline in 631 pts (av age 72 ± 7 yrs, av BP 136 ± 
15/79 ± 9 mmHg, 38% men) in sinus rhythm and used to determine diastolic dysfunction 
(DD), LV diastolic volume (LVEDV), EF, LV mass, and RV systolic pressure (RVP). LVH 
and LA enlargement were defined by Cornell-Naples criteria and American Society of 
Echocardiography (ASE) criteria respectively.
Results: NT -BNP (age adjusted m±se) was> in pts with ↑ LA volume (322± 23, vs 149 
±25 pg/ml, p <0.0001), worse DD (Grade 1; 210± 16, grade 2; 724 ±138pg/ml, p<0.0001), 
LVH on echo (LVH 389 ±40, no LVH 226±14 pg/ml, p<0.0001), and LV EF < median 
value 65% (<65%; 429± 34, ≥ 65%; 239± 19 pg/ml, p<0.0001). Echo findings according 
to tertiIe distribution of BNP shown in table.
Conclusion: In pts with clinical evidence of HF-PSF higher BNP levels are associated 
with more severe cardiac structural and functional changes.
NT-BNP (pg/ml) LA vol (ml/m2) LVMg LVEDV (ml) RVP (mmHg) LVEF(%)
<172 (a) 36+2 150+3 89+3 30+2 67+1
172 -587 (b) 42+2 162+3 94+3 34+1 65+1
≥ 588 (c) 53+5 183+1 106+3 41+1 61+1
p a vs b 0.0021 0.001 0.16 0.051 0.13
p b vs c <0.0001 <0.0001 0.0048 0.0006 <0.0001
p c vs a <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
1:30 p.m.
1010-65	 Sleep	Apnea	Predicts	Lethal	Arrhythmic	Events	in	
Patients	with	Chronic	Heart	Failure
Tsuyoshi Shinozaki, Koichiro Sugimura, Shigefumi Fukui, Hiromasa Ogawa, Hiroaki 
Shimokawa, Sendai Medical Center, Department of Cardiovascular Medicine, Sendai, 
Japan, Tohoku University, Department of Cardiovascular Medicine, Sendai, Japan
Background: Sleep apnea (SA) predicts mortality of patients with chronic heart failure 
(CHF). Predictive power of SA, however, remains unclear for sudden death. We thus 
aimed to examine whether SA predicts lethal arrhythmic events in patients with CHF.
Methods: Sleep study was performed in 95 consecutive patients with stable CHF (LV 
ejection fraction, 36±13%). Nocturnal oxygen therapy and continuous positive airway 
pressure therapy were introduced to 18 among the 27 patients with central SA and 6 
among the 9 patients with obstructive SA. Cox-proportional analysis was performed 
using covariates of age, gender, etiology, BNP, LV ejection fraction, LV diameter, left 
atrial diameter, medications and apnea-hypopnea index (AHI)>5/h (after nocturnal 
respiratory therapy, if introduced). Endpoints included lethal events (overall death or 
ventricular tachyarrhythmia) and lethal arrhythmic events (sudden death or ventricular 
tachyarrhythmia).
Results: During 29±17 months of follow-up, 18 patients died and 10 ventricular 
tachyarrhythmia occurred. Predictors of lethal events were AHI>5/h (hazard ratio, 
HR:4.1, 95%CI:1.2-13.5) and left atrial diameter (HR:1.07, 95%CI:1.01-1.13). Predictors 
of lethal arrhythmic events were AHI>5/h (HR:17.5, 95%CI:1.5-197.3), left atrial diameter 
(HR:1.20, 95%CI:1.07-1.34) and LV ejection fraction (HR:0.91, 95%CI:0.85-0.98). The 
frequency of lethal events and lethal arrhythmic events increased with AHI (lethal 
events: 10%, 19% and 35%, lethal arrhythmic events: 3%, 14% and 20% in patients 
with AHI<5/h, 5/h≤AHI<15/h and 15/h≤AHI, respectively). The rate of occurrence of 
lethal arrhythmic events during sleep were 0% and 44% in patients with AHI<5/h and 
5/h≤AHI, respectively.
Conclusions: SA predicts lethal arrhythmic events independently of hemodynamic 
parameters in patients with CHF, providing a rationale for management of SA.
1:30 p.m.
1010-66	 Subclinical	Hypothyroidism	as	a	Risk	Factor	for	
Poor	Outcome	in	Patients	With	Chronic	Heart	
Failure	-	A	Prospective	Study	-
Takahisa Yamada, Takanao Mine, Takashi Morita, Yasumasa Tsukamoto, Shunsuke 
Tamaki, Masaharu Masuda, Keiji Okuda, Yuusuke Iwasaki, Masatake Fukunami, Osaka 
General Medical Center, Osaka, Japan
Background: The association of overt hypothyroidism with cardiovascular disease is 
widely accepted, but the cardiac effect of subclinical hypothyroidism is less documented. 
Subclinical hypothyroidism has been associated with systolic and diastolic cardiac 
dysfunction, but limited information is available on the effect of subclinical hypothyroidism 
on cardiac outcome in patients with chronic heart failure (CHF). 
Methods	 and	 Results: We prospectively studied 130 CHF patients (NYHA 2.0±0.7, 
ischemic origin 49.6%) without overt thyroid dysfunction, with radionuclide left ventricular 
(LV) ejection fraction less than 40% (29±7%). At the entry, subclinical hypothyroidism 
(defined as an elevated thyroid stimulating hormones (TSH) and a normal free thyoxine 
level) was observed in 22 (17%) of 130 CHF patients. There were no significant 
differences in age, gender, etiology of CHF, NYHA class, LV dimensions assessed by 
echocardiography, radionuclide LV ejection fraction or the content of ant-heart failure 
therapy between patients with and without subclinical hypothyroidism, except for six 
minute walk distance (326±108 vs 377±86 m, p<0.05). For a mean follow-up period of 
5.1±3.2 yrs, patients with subclinical hypothyroidism had 11 (50%) cardiac death and 
7 (32%) hospitalization for worsening heart failure, while patients without subclinical 
hypothyroidism had 22 (20%) cardiac death and 18 (17%) hospitalization for heart failure. 
Kaplan-Meier analysis revealed that cardiac death and combined endpoint (cardiac death 
plus hospitalization for heart failure) were significantly frequently observed in patients 
with than without subclinical hypothyroidism (log-rank test, p=0.02 and p=0.0002, 
respectively). Relative risk for cardiac death and combined endpoint in patients with 
subclinical hypothyroidism were 2.43 (95% confidence interval, 1.39-4.25) and 2.19 (95% 
confidence interval, 1.60-3.00), respectively. By mutivarite Cox analysis, TSH level was 
independently associated with combined endpoint (p=0.004, hazard ratio 1.148 (95% 
confidence interval, 1.045-1.262)). 
Conclusions: Subclinical hypothyroidism may be an independent risk factor for poor 
outcome in patients with CHF.
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1010-67	 Patients	With	Heart	Failure	And	Chronic	Obstructive	
Pulmonary	Disease	May	Be	Inappropriately	Denied	
Beta-Blockers
Nathaniel M. Hawkins, Shona M. M. Jenkins, Michael R. MacDonald, John J. V. 
McMurray, Francis G. Dunn, Stobhill Hospital, Glasgow, United Kingdom
Background: Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity 
in heart failure (HF) and a perceived contraindication to β-blockade. We examined the 
prevalence of severe COPD, and the extent to which β-blockade is inappropriately 
withheld.
Methods: We reviewed discharge summaries, pulmonary function tests (PFTs) and 
echocardiograms of 449 consecutive ICD10 coded HF admissions to a large urban 
hospital. Miscoding, re-admissions, and patients with preserved systolic function were 
excluded (n=24, 108 and 55 respectively). COPD severity was classified using Global 
Initiative for Chronic Obstructive Lung Disease guidelines.
Results: 75 of 262 patients (29%) had a physician diagnosis of COPD; PFTs were 
measured in 53 (71%). 41% of the 75 patients with COPD received β-blockers. In 
19%, β-blockers were contraindicated or considered inappropriate for reasons other 
than COPD - these included bradycardia, conduction disturbance, hypotension, severe 
peripheral arterial disease or advanced malignancy and dementia. The remaining 40% 
did not receive β-blockers. 13% had severe airflow obstruction (figure). 27% had milder 
obstruction or no documented PFTs and may have been inappropriately denied treatment 
with a β-blocker.
Conclusions: Patients with HF and COPD often tolerate or have alternative reasons 
precluding β-blockade. Only a minority have severe airflow obstruction. Many of the 
remainder have β-blocker therapy inappropriately withheld.
1:30 p.m.
1010-68	 Brain	Natruretic	Peptide	and	Severity	of	Diastolic	
Dysfunction:	Interaction	With	LV	Geometry	and	
Function	in	Mild-Moderate	Heart	Failure.	The	AREA-IN-
CHF	Study
Gian F. Mureddu, Giovanni de Simone, Roberto Latini, Lucio Gonzini, Giuseppe 
Cacciatore, Serge Masson, Marcello Chinali, Antonio Nicolino, Aldo P. Maggioni, 
Alessandro Boccanelli, S. Giovanni-Addolorata Hospital, Roma, Italy
Background: to verify whether the severity of diastolic dysfunction is related to the 
level of neurohormonal activation in mild heart failure we studied patients enrolled in the 
AREA-in-CHF (AntiRemodeling Effect of Aldosterone receptors blockade with canrenone 
IN mild Chronic Heart Failure) study, a prospective, randomized, double blind study on 
anti-aldosterone treatment with canrenone, a metabolite of spironolactone, in patients 
with class 2 NYHA chronic heart failure (CHF) and ejection fraction≤45%. 
Methods: Among 505 participants enrolled at baseline, 495 underwent Doppler 
echocardiography and 454 serum aldosterone and Brain Natriuretic Peptide (BNP) 
determinations. End diastolic (ED), end systolic (ES) volumes and ejection fraction (EF) 
were assessed by Simpson’s rule. LV mass and relative diastolic wall thickness (RWT) 
were calculated by standard methods. Diastolic function was assessed by transmitral and 
pulmonary vein Doppler interrogations. A delayed relaxation was defined for values of 
E/A<0.75, E deceleration time [DTE]>=140 ms and pulmonary Systolic/Diastolic velocity 
[S/D]>1, whereas a restrictive pattern for values of E/A>1.5, DTE<140 and S/D<=1. All 
diastolic patterns not included in the previous ones were defined as pseudonormalized. 
Results: Most patients (84%) exhibited a pseudonormalized pattern, 12% had delayed 
relaxation and 4% a restrictive pattern. Degree of diastolic dysfunction severity was 
associated with increasing values of ES volume (p<0.05) and decreasing tertiles of RWT 
(p<0.02) and EF (p<0.0003) grouped in tertiles The highest tertile of BNP (>138 pg/ml) 
was associated with a shorter DTE (<140), an higher E/A (>1.5) and a lower S/D ratio but 
also strongly related to both a shorter isovolumic relaxation time (<60 ms) and an higher 
difference between durations of pulmonary and atrial velocities at atrial contraction (PVa-
A dur) (all p<0.0001).
Conclusions: In mild CHF with systolic dysfunction, severity of diastolic dysfunction was 
associated with high values of BNP and more severe LV remodeling and dysfunction. 
Combination of Doppler analysis of transmitral and pulmonary vein is helpful to better 
stratify the severity of diastolic dysfunction.
1:30 p.m.
1010-97	 Candesartan	Benefits	and	Safety	Observed	Regardless	
of	Age.	Insights	from	the	Candesartan	in	Heart	Failure:	
Assessment	of	Reduction	in	Mortality	and	morbidity	
(CHARM)	Program.
Alain Cohen-Solal, Karl Swedberg, John Mc Murray, Marc Pfeffer, Bertil Olofsson, Eric 
Michelson, Salim Yusuf, Christopher Granger, Lariboisiere Hospital, Paris, France
Background: Aging may affect drug efficacy and safety in patients with heart failure 
(HF). The CHARM program offered an opportunity to study the relationship between age 
and the efficacy and safety of treatment in a uniquely broad spectrum of patients with 
symptomatic HF.
Methods: In CHARM, 7599 patients in NYHA class II-IV HF were randomized to 
candesartan (target dose 32 mg, mean dose 24 mg) or placebo. Mean follow-up was 
37.7 months. The proportional hazards model was used to estimate the treatment effect 
and safety within five age groups.
Results: Cardiovascular (CV) deaths or HF hospitalizations (primary outcome) increased 
from 24% in the lowest age group to 46% in the upper age group (and mortality from 13% 
to 41%). Hazard ratios (HR) and 95% confidence intervals (CI) for candesartan versus 
placebo, by age groups, for both outcomes, are shown in the table. 
Age group (yrs) N
CV 
death/HF 
hosp (%)
HR (95% CI) Mortality (%) HR (95% CI)
< 50 658 23.8 1.021 (0.736, 1.416) 12.9 1.067 (0.684, 1.665)
50-59 1,527 22.7 0.868 (0.701, 1.076) 13.9 0.839 (0.637, 1.104)
60-69 2,395 30.2 0.849 (0.733, 0.984) 21.1 0.953 (0.799, 1.137)
70-79 2,409 38.4 0.806 (0.709, 0.916) 30.8 0.929 (0.805, 1.071)
> 80 610 46.3 0.788 (0.633, 0.982) 41.0 0.863 (0.685, 1.087)
Adverse events leading to drug discontinuation increased with age in both treatment 
groups (%, placebo/candesartan, lower to upper quintile): hyperkalaemia (0.3/1.8 to 
0.9/3.4), renal dysfunction (1.5/4.9 to 5.0/6.9), hypotension (2.1/2.8 to 4.7/7.4). However, 
there was no interaction between drug assignment and age categories regarding safety.
Conclusion:	Although both adverse events and the risk of morbidity and mortality increase 
steeply with age, the safety and the benefit of candesartan on outcomes was apparent 
irrespective of age. The absolute benefit therefore increases with increasing age.
1:30 p.m.
1010-98	 The	Effect	Of	Nesiritide	On	Left	Ventricular	Diastolic	
Function
Douglas L. Kosmicki, Mia Shapiro, Sarah G. Weeks, Elyse Foster, Andrew D. Michaels, 
University of Utah, Salt Lake City, UT, University of California San Francisco, San 
Francisco, CA
Background: Nesiritide is a recombinant form of human B-type natriuretic peptide that 
has been shown to be beneficial in patients with decompensated congestive heart failure. 
This study evaluated the effects of nesiritide on left ventricular diastolic function.
Methods: 25 patients with symptomatic heart failure (15 with LVEF<40% and 10 with 
LVEF>50%) underwent right and left heart catheterization using a pressure-volume 
catheter (CD Leycom, Zoetermeer, Netherlands) and echocardiography at baseline and 
after a 30 min IV infusion of nesiritide (Natrecor®, Scios Inc., Fremont, CA; 2 mcg/kg bolus 
and 0.01 mcg/kg/min). We calculated α and β coefficients to define the non-linear slope 
of the end-diastolic pressure volume relationship (EDPVR) using the single-beat method 
for measuring LV end-diastolic elastance.
Results:	The mean age was 60±11 years, 48% were male, 56% had CAD, and 64% 
had hypertension. The pulmonary capillary wedge pressure decreased from 17.1±7.8 
to 9.6±6.2 mmHg (p<0.001), systemic vascular resistance decreased from 1521±426 
to 1246±344 dynes*sec/cm5 (p<0.001), and aortic systolic pressure decreased from 
131±31 to 111±29 mmHg (p<0.001). LV end-diastolic pressure decreased from 20.6±9.3 
to 13.3±8.0 mmHg (p<0.001), LV tau decreased from 42.6±8.5 to 40.2±9.9 ms (p=0.04), 
and LV negative dP/dt decreased from -1053±321 to -962±307 mmHg/s (p=0.03). 
Echocardiographic E peak velocity increased from 0.60±0.30 to 0.76±0.28 m/s (p<0.001), 
the A peak velocity trended from 0.76±.32 to 0.67±0.35 m/s (p=0.09), E/E’ decreased 
from 9.3±4.0 to 7.0±3.5 (p=0.01), LV end-systolic and diastolic volumes decreased 
(p=0.04), and left ventricular wall stress decreased (p=0.002). Deceleration time, the 
diastolic stiffness index (E/E’/SV), and the diastolic filling pattern classification did not 
change. There was no change in the α or β EDPVR coefficients.
Conclusions: While nesiritide is an effective vasodilator acutely resulting in decreased 
left ventricular preload and afterload in heart failure patients, intrinsic LV diastolic function 
showed only a modest 6% improvement in the time constant tau. The EDPVR did not 
change, suggesting that nesiritide has no significant lusitropic effect.
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1:30 p.m.
1010-99	 Does	Thiazolidinediones	Worsen	Heart	Failure	In	
Patients	Type	2	Diabetes	Mellitus	And	Structural	Heart	
Disease	?	Study	With	Doppler	Echocardiography.
Hiroyuki Nagai, Hiroshi Ito, Katsuomi Iwakura, Shigeo Kawano, Atsunori Okamura, 
Toshiya Kurotobi, Yasushi Koyama, Motoo Date, Koichi Inoue, Kenshi Fujii, Sakurabashi 
Watanabe Hospital, Osaka, Japan
Background: Recent mega-trial shows that thiazolidinediones(TZDs), new class of insulin-
sensitizaing drugs, reduce cardiovascular events in high-risk patients with type 2 diabetes 
mellitus (DM). Although TZDs induces edema in 10-15% of patients, it remains unknown 
it actually is associated with heart failure (HF). In this study, we investigated the impact of 
TZDs on LV filling pressure and diastolic performance in patients with heart disease.
Method:	Study population consisted of 120 patients with type 2 DM and coronary heart 
disease or cardiomyopathy. All patients underwent echo-Doppler study before and average 
of 16 (range: 1-76) months after pioglitazone treatment. We measured chamber dimensions, 
transmitral flow velocity and mitral annulus velocity. To assess LV diastolic performance, we 
measured peak-E (cm/s), deceleration time of E wave (DT, ms), early peak mitral annulus 
velocity (e’, cm/s). E/e’ was calculated as an estimate of LV filling pressure.
Results:	 HbA1c decreased (7.8 vs. 7.2 %, p<0.0001) after TZDs. NYHA class was 
comparable before and after treatment (1.3 vs. 1.3). No hospitalization due to worsening 
of HF was observed. LV dimensions and LVEF were comparable before and after TZDs. 
There were no changes in left atrial dimension (before vs. after; 34 vs. 35 mm), right 
ventricular dimension (27 vs. 28 mm), dimension of inferior vena cava (12 vs. post 12 mm) 
after TZDs. There were also no changes in E/A (0.92 vs. 0.90), DT (218 vs. 220 ms) and 
E/e’ (11 vs. 12) after treatment.
Conclusion:	Treatment with	TZDs is not associated with an increase in LV filling pressure or 
worsening of LV diastolic performance in patients with structural heart disease. This observation 
is important to decide the strategy of treating DM in patients with diseased heart.
1:30 p.m.
1010-100	 Association	Between	an	Angiotensin	II	Receptor	
Gene	Polymorphism	and	Left	Ventricular	Systolic	
Dysfunction	in	Sarcomere	Gene	Mutation-induced	
Hypertrophic	Cardiomyopathy
Toshinari Tsubokawa, Hidekazu Ino, Noboru Fujino, Katsuharu Uchiyama, Kenshi 
Hayashi, Tetsuo Konno, Takashi Fujita, Hiromasa Katoh, Yuichiro Sakamoto, Masakazu 
Yamagishi, Division of Cardiovascular Medicine, Graduate School of Medical Science, 
Kanazawa University, kanazawa, Japan
Background: In hypertrophic cardiomyopathy (HCM), some patients develop a left 
ventricular (LV) systolic dysfunction and dilatation. Genetic variation in the renin-
angiotensin-aldosterone system is thought to play a role in LV remodeling with congestive 
heart failure and cardiac hypertrophy.
Objectives: To evaluate the influence of angiotensin II receptor gene polymorphisms on the 
development of LV systolic dysfunction in patients with HCM and sarcomere gene mutations.
Methods: The polymorphisms of angiotensinII type1 receptor and type2 receptor genes, 
(AT1-R)/A1166C and (AT2-R) /A1332G, were identified using polymerase chain reaction 
- restriction fragment length polymorphism (PCR-RFLP) in 84 genotyped HCM patients 
(age 58 ± 13 years, 38 males). LV wall thickness, LV dimensions, fractional shortening, 
ejection fraction and LV mass were measured with echocardiography. The association 
between these polymorphisms and LV systolic function was analyzed.
Results: LV systolic dysfunction was found more frequently (P<0.05) in patients with the 
AT1-R A/C genotype than in those with the A/A genotype. In particular, (AT1-R)/A1166C 
was associated significantly with an increased risk for LV systolic dysfunction in female 
patients (P<0.01), but not in male patients (NS). In contrast, no significant association 
between LV systolic dysfunction and the (AT2-R) /A1332G polymorphism were observed.
Conclusions:	 The polymorphisms of AT1-R (A1166C), but not AT2-R (A1332G) may 
influence the development of LV systolic dysfunction in patients with HCM caused by 
sarcomere gene mutations.
1:30 p.m.
1010-101	 Incremental	Value	of	Measuring	Systolic	Mitral	Annular	
Velocity	and	Time	Difference	Between	Onset	of	Mitral	
Inflow	and	Onset	of	Early	Diastolic	Mitral	Annular	
Velocity	for	Differentiating	Constrictive	Pericarditis	
from	Restrictive	Cardiomyopathy
Eui-Young Choi, Jong-Won Ha, Jin-Mi Kim, Jee-Hyun Lee, Se-Joong Rim, Namsik 
Chung, Yonsei University College of Medicine, Seoul, South Korea
Background: Although, normal or exaggerated early diastolic mitral annular velocity 
(E’) provides an excellent specificity for differentiating CP from RCM, its sensitivity has 
been shown to be lower, especially in patients with CP who had underlying myocardial 
abnormality. This study sought to evaluate the incremental value of systolic mitral annular 
velocity (S’) and time difference between onset of mitral inflow and onset of early diastolic 
mitral annular velocity (T(E’-E)) for differentiation between constrictive pericarditis (CP) and 
restrictive cardiomyopathy (RCM).	
Methods:This study consisted of 44 subjects (28 men, 16 women; mean age 47 years, 
range 10 - 76); 17 patients with CP, 12 with RCM, and 15 controls. Standard mitral inflow 
Doppler and tissue Doppler echocardiography were performed. 
Results: E’ (9.5±1.7 cm/s vs. 4.7±1.6 cm/s, p <0.001) and S’ (7.7±1.3 cm/s vs.4.6±1.9 
cm/s, p<0.001) were significantly higher, whereas T(E’-E) (21.0±32.0 ms vs. 53.1±30.4 
ms, p=0.02) was significantly shorter in patients with CP than that of RCM. Diagnostic 
accuracy of E’ for differentiation of CP from RCM was higher than S’ or T(E’-E) (area under 
curve 0.99 vs. 0.87 vs. 0.74, respectively). E’ of 8cm/s has excellent specificity (100%) for 
differentiation of CP from RCM but sensitivity (70%) was relatively low. However, when 
combining E’ with S’ and T(E’-E), the sensitivity could be increased when compared with E’ 
alone (70% with E’, 88% with E’+S’ and 94% with E’+S’+T(E’-E), p=0.001). 
Conclusions: The measurement of	S’ and	T(E’-E) can be helpful for differentiating between 
CP and RCM by providing incremental diagnostic information to E’
1:30 p.m.
1010-102	 High	Frequency	of	Intracardiac	Thrombosis	and	
Embolic	Events	in	116	Autopsy	or	Explant	Cases	of	
Cardiac	Amyloidosis
DaLi Feng, William W. Edwards, Jae K. Oh, Krishnaswamy Chandrasekaran, Martha 
Grogan, John A. Lust, Morie A. Gertz, Kyle W. Klarich, Divisions of Cardiovascular 
Diseases, Anatomic Pathology and Hematology, Mayo Clinic, Rochester, MN
Background: Patients with primary amyloidosis have a poor prognosis in part due to 
frequent cardiac involvement. Although intracardiac thrombus has been reported in 
several anecdotal cases, neither its frequency nor its role in causing mortality is known.
Methods: 116 autopsy or explanted cases of cardiac amyloidosis (55 primary amyloidosis and 
61 non-primary amyloidosis cases) were identified in the Mayo Clinic Tissue Registry (1996 
to 2005); 46 fatal non-amyloid trauma cases served as controls. Each heart was examined 
for intracardiac thrombus. The cause of death was determined from autopsy and clinical notes.
Results: Intracardiac thrombosis was identified in 38 (33%) of 116 amyloid hearts. Of these, 
23 had only 1 thrombus, and 15 had 2-5 thrombi. For all 63 thrombi, 36 had right atrial 
origin, 19 left atrial, 4 coronary sinus valve, and 4 ventricular. Although primary amyloidosis 
patients had less atrial fibrillation (AF) (22% vs. 45%, p=0.008) and were younger (60±11 
vs. 83±11, p<0.0001) than the non-primary amyloidosis, primary amyloidosis patients had 
a significantly higher frequency of intracardiac thrombus (51% vs. 16%, p<0.001) and more 
fatal embolic events (26% vs. 8%, p<0.03) than non-primary amyloidosis patients. Controls 
had no intracardiac thrombus. By multivariate analysis, primary amyloidosis type (odds ratio 
7.7 with 95% CI 1.5-54.2, p=0.02) and atrial fibrillation (odds ratio 6.8 with 95% CI 1.8-32.4, 
p=0.009) were independently associated with intracardiac thrombosis while female gender 
(odds ratio 7.1; 95% CI 2.0-31.6, p=0.004) and the presence of intracardiac thrombus (odds 
ratio 5.5; 95% CI 1.3-26.7, p=0.02) were statistically associated with embolic events. There 
was a trend toward primary amyloidosis being associated with embolism as well (odds ratio 
4.8; CI 0.9-32.6, p=0.06) .
Conclusions: There was a high frequency of intracardiac thrombosis in patients with cardiac 
amyloidosis, especially primary amyloidosis type. Furthermore, intracardiac thrombosis 
frequently led to fatal embolic events. Early screening for intracardiac thrombosis and 
anticoagulation therapy could potentially reduce morbidity and mortality in such patients.
1:30 p.m.
1010-103	 A	new	Familial	Syndrome	Induced	by	the	Interaction	of	
Trypanosoma	Cruzi	With	the	Cardiac	Sodium	Channel	
Gene	SCN5A
Ivan Mendoza, Juan Marques, Igor Palacios, Domenico Corrado, Ivan Mendoza B, Silvia 
G. Priori, Luis Pulpon, Federico Moleiro, Francesca Misticchio, Alvaro Matheus, Central 
University of Venezuela, Caracas, Venezuela, Massachusetts General Hospital, Boston, MA
Background: Chagas´ disease is one of the leading causes of sudden death. Around 18 million, 
almost all poor people, are infected with Trypanosoma Cruzi. Literature reports the presence of 
ST-elevation most frequently in inferior and lateral leads, between 1-14 %, in Chagas disease. 
SCN5A mutations can produce: 1.- Brugada Syndrome, 2.- Long QT-3 Syndrome, 3.- cardiac 
conduction defects (Lenegre syndrome) 4.- LQT-Brugada combination
Methods: Analysis of family’s members: 1.- with and without Chagas´ disease; 2.- 
ST-elevations in V1 to V3; 3.- Right bundle branch block (RBBB) and advanced AV 
block. Thirteen family’s members (12 brothers and mother), 8 with positive serologic 
test for Chagas (STCH) (+), 5 STCH (-), were studied by clinical history, ECG, Holter, 
echocardiogram and stress test. The results were compared with the reported series of 
chagasic patients in literature.
Results: 7/8 with STCH (+) had ST-elevation on right precordials + RBBB (87% vs. 1 % 
in literature in V1-V3), whereas none (0/5) with STCH (-) presented these alterations. Two 
brothers with STCH (+) and their mother STCH (+) have pacemakers due to a high-degree 
Atrio-Ventricular block. None of the cases studied displayed serious ventricular arrhythmias. 
None of the five brothers without Chagas´disease expressed the described alteration.
Conclusions:	 To the best of our knowledge, a familial syndrome characterized by 
Chagas´ disease, ST-elevation on right precordials with RBBB, severe Atrio- ventricular 
conduction disorders, in the absence of malignant arrhythmias, is presented for the first 
time. The family’s members with Chagas´ disease expressed the syndrome, suggesting 
as a possible mechanism the interaction of Trypanosoma Cruzi and the immunological 
modifications that it causes with the SCN5A-dependent sodium channel gene, mediated 
through mechanisms still to be determined.
1:30 p.m.
1010-104	 Late	Mortality	of	Patients	with	Takotsubo-like	
Cardiomyopathy.
Yoshimitsu Soga, Daisuke Kamoi, Kenji Ando, Masashi Iwabuchi, Hiroyoshi Yokoi, 
Hitoshi Yasumoto, Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, 
Kitakyushu, Japan
Objectives: Although several cases about Takotsubo-like cardiomyopathy have been 
reported, a little is known about long-term outcomes of the patients. We tried to evaluate 
its impact on survival.
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Methods: To examine long-term clinical outcomes, clinical follow-up information was analyzed 
in 58 consecutive patients with Takotsubo-like cardiomyopathy in our hospital from Dec.1995 to 
Jun.2006. We analyzed all patients (20 men and 38 women), aged 64 ± 17 years, who fulfilled the 
following criteria: 1) transient LV apical ballooning in left ventriculography (LVG) 2) no significant 
angiographic coronary stenosis and 3) no history of myocardial infarction and cardiomyopathy.
Results: Emotional and physical stress observed in 34 patients (60%). Coronary 
angiography and LVG were performed in all patients during the acute phase. Of all 
patients, 2 patients (5%) died during the hospitalization. The reasons of in-hospital death 
were pneumonia and cardiogenic shock. A total of 56 patients who were discharged alive 
constituted the study population for long-term outcomes. Clinical follow-up information 
was obtained in all patients. During the follow-up period, 12 patients (21%) died, 3 
patients (5%) were re-hospitalized by heart failure. Of the 3 patients with heart failure, 
1 patient (3%) recognized the recurrence of Takotsubo-like cardiomyopathy. The causes 
of death were malignancy (3 patients), pneumonia (3 patients), aging (2 patients) stroke 
(1 patient) and unknown (3 patients). Kaplan-Meyer survival curve showed that freedom 
from all death was 97% (1 year), 91% (3 years), 85% (5 years) and 81% (8 years). Using 
multivariate analysis of various factors that may have affected mortality, age (Hazard ratio 
1.2, 95% confidence interval 1.1 to 1.4, p=0.005) and cardiogenic shock (Hazard ratio 
7.1, 95% confidence interval 5 to 90, p=0.005) were identified as predictors.
Conclusions: The survival of patients with transient LV apical ballooning was favorable 
except for patients with cardiogenic shock during the acute phase. Age and cardiogenic 
shock were identified as independent predictors in overall survival. It was thought that the 
prognosis was determined greatly by primary disease.
1:30 p.m.
1010-105	 Time	Course	of	Gradient	Reduction	During	Septal	Ethanol	
Ablation	for	Obstructive	Hypertrophic	Cardiomyopathy	is	
Related	to	Changes	in	Myocardial	Mechanics
Shemy Carasso, Anna Woo, Hua Yang, Leonard Schwartz, Michal Jamorski, Mani A. 
Vannan, Harry Rakowski, Toronto General Hospital, Toronto, Canada, University Of 
Toronto, Toronto, Canada
Background: Septal ethanol ablation (SEA) alleviates left ventricular outflow (LVOT) 
obstruction in symptomatic patients with hypertrophic obstructive cardiomyopathy 
(HOCM) by controlled basal septal infarction. We hypothesized that the time course of 
LVOT gradient reduction is related to changes in myocardial mechanics.
Methods: 18 HOCM patients (62±13 years old, 8 women) undergoing SEA were analyzed. 
LV and aortic pressures were monitored throughout the procedure. Echocardiographic 
long axis (2,3,4 chambers) and short axis (base, mid, apex) scanning was done at 
baseline, 5 min after balloon occlusion of the septal perforator, after injection of alcohol 
and prior to discharge. Longitudinal and circumferential strains were calculated by 
velocity vector imaging (VVI).
Results: LVOT gradient decreased from 103±30mmHg to 56±32 (occlusion), further 
dropped to 21±13 (post alcohol) and rose to 30±22 at discharge (5-6 days post 
procedure). Figure demonstrates segmental longitudinal strain during various stages of 
SEA. Circumferential strain demonstrated the same pattern of change.
Conclusions: Myocardial mechanics suggest that the decrease in LVOT gradient during SEA 
coincides with global LV dysfunction despite only local ischemia during septal balloon occlusion. 
The likely etiology is cytokine release rather than the toxic effect of alcohol. Global dysfunction is 
transient and the gradient rebounds when dysfunction is limied to the basal septum. 
1:30 p.m.
1010-106	 Clinical	Relevance	of	Fat	Replacement	of	the	Right	
Ventricular	Myocardium	Determined	by	Multislice	CT:	
Relationship	with	Aging,	Obesity,	and	the	Occurrence	
of	Ventricular	Arrhythmia
Nobusada Funabashi, Yasuhiko Hori, Masae Uehara, Marehiko Ueda, Koki Nakamura, 
Yoko Mikami, Taichi Murayama, Issei Komuro, Chiba University Graduate School of 
Medicine, Chiba, Japan
Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) has been 
diagnosed by presence of fat deposits in the right ventricular myocardium (RVM). But fat 
replacement (FR) of the anterior wall of the RVM is frequently observed. We therefore 
evaluated the relationship of FR of the RVM determined by multislice CT (MSCT) with 
ventricular premature beats (VPB).
Methods: One hundred three consecutive subjects (66 males, 11 - 85 years old) who 
underwent ECG-gated MSCT (Light Speed Ultra 16, GE) and Holter ECG at the same 
time were retrospectively analyzed for FR of the RVM. Presence of FR of the RVM was 
defined as the presence of low CT area of less than 0HU in the RVM. We evaluated the 
relationship of presence of FR of the RVM with aging, body mass index (BMI) suggesting 
obesity, and occurrence of VPB.
Results: Thirty-nine of 103 subjects evaluated with MSCT and Holter ECG, exhibited 
FR of the RVM; 23% of the 39 subjects with FR and 19% of the 64 subjects without FR 
received anti arrhythmia drugs for VPB. Among 82 untreated subjects, 30 subjects (22 
males) had FR of RVM and their median age was 66 years (range 11-79 years, mean 
60.4 years) whereas in 52 subjects (30 males) without FR the median age was 58.5 years 
(range 15-83 years, mean 56.4 years). Median age was significantly higher in subjects 
with FR of RVM than those without FR (P < 0.01). The median BMI was 22.1 (range 
17.5 to 34.9, mean 23.15) in 30 subjects with FR and 21.95 (range 13.6 to 36.1; mean 
22.59) in 52 subjects without FR; the difference was not significant (P=0.99). Holter ECG 
recordings showed that in 30 subjects with FR the average number of VPBs was 1038 
(range: 0~26169, median 29) and ventricular tachycardia (more than 3 consecutive VPB) 
was observed in 2 subjects. Among 52 subjects without FR, the average number of VPBs, 
by Holter ECG, was 207 (range; 0-1696, median 4.5) and ventricular tachycardia was 
observed in 1 subject. The numbers of VPBs tended to be higher in subjects with FR than 
those without FR but the difference was not significant (P = 0.28).
Conclusions: There was a significant relationship between the presence of FR in 
the RVM and aging but not with BMI. Presence of FR of the RVM may influence the 
occurrence of VPB.
1:30 p.m.
1010-107	 Strain	And	Strain	Rate	By	Velocity	Vector	Imaging	In	
Diagnosing	Acute	Rejection	After	Heart	Transplantation	
Francesco Tona, Alida LP Caforio, Roberta Montisci, Antonio Gambino, Annalisa 
Angelini, Massimo Ruscazio, Giuseppe Toscano, Andrea Bortolami, Gaetano Thiene, 
Gino Gerosa, Sabino Iliceto, Cardiology, University of Padova, Padova, Italy
Background: A new method for estimation of Strain (S) and strain rate (SR) - Axiustm 2D 
Velocity Vector Imaging (2D VVI) (Siemens Medical Solutions, Mountain-View, California)-
, independent of angle of insonation, has been developed. We aimed to assess the use 
of S and SR by 2D VVI as a non-invasive method for monitoring and diagnosing acute 
rejection (AR) in heart transplant (HT) recipients.
Methods: A prospective preliminary study was carried out involving 17 consecutive HT 
recipients (10 male, aged 52 ± 10 years) who underwent a routine follow up endomyocardial 
biopsy with correlative 2D VVI data. To assess longitudinal (long) and radial (rad) 
deformations, 2D VVI-derived S and SR data were acquired from interventricular septum 
and left ventricular lateral wall. For circumferential (circ) deformation data were obtained 
from anterior-lateral and anterior walls, anterior and inferior septum, inferior and inferior-
lateral walls. Patients were subdivided according a rejection grade cutoff ≥ 1B and then 
≥ 3A (ISHLT classification).
Results: In all segments (seg), it was possible to obtain adequate 2D VVI analysis. Long 
and rad peak systolic S and SR were decreased in patients with rejection ≥ 1B and also ≥ 
3A in the basal (P<0.05), mid (P<0.005), and apical (P<0.05) interventricular septum and 
in basal (P<0.005), mid (P<0.01), and apical (P<0.05) lateral wall; rad peak systolic S and 
SR were lower in anterior-lateral (P<0.01) and anterior walls (P<0.01), anterior (P<0.01) 
and inferior (P<0.05) septum, inferior (P<0.01) and inferior-lateral (P<0.01) walls. There 
was also a progressive reduction of longitudinal, radial and circumferential systolic S and 
SR depending on the different rejections grades (P ranged from 0.04 to 0.005). For some 
myocardial seg sensitivity and specificity in detecting acute rejection reached 100%.
Conclusions: S and SR by 2D VVI might be a promising new noninvasive tool for 
detecting AR. Myocardial deformation, as assessed by 2D VVI, could be of clinical value 
in monitoring and diagnosing acute rejection in HT recipients and could improve patients’ 
management by reducing the number of biopsies performed
1:30 p.m.
1010-108	 Relationship	Between	Insulin	Resistance	Features	and	
Progression	of	Cardiac	Allograft	Vasculopathy
Shahnawaz A. Virani, Andrew M. Wilson, Michael X. Pham, Hannah A. Valantine, John P. 
Cooke, William F. Fearon, Stanford University, Stanford, CA
Background: Cardiac allograft vasculopathy (CAV) is a major cause of both late graft 
failure and mortality after orthotopic heart transplantation (OHT). The relationship between 
features of insulin resistance in both the donor and the recipient and the subsequent 
progression of CAV has not been studied.
Methods: We prospectively monitored 25 OHT recipients for CAV by measuring 
intimal thickness (IT) and % plaque volume in the left anterior descending artery with 
intravascular ultrasound (IVUS) at 1 month, 1 year and 2 years after heart transplantation. 
Clinical and laboratory measures, including features suggestive of insulin resistance, 
were concomitantly recorded and correlated with the IVUS parameters using stepwise 
regression analysis.
Results: IT increased (0.26 ± 0.10mm to 0.80 ± 0.10mm, median, p<0.001), and % 
plaque volume increased (12.1± 8.2% to 22.7 ± 13.5%, median, p = 0.003). Using 
stepwise regression analysis, change in IT at 2 years was associated independently 
with donor BMI (p = 0.001), donor diabetes (p<0.001), recipient BMI (p = 0.012), LDL 
cholesterol (p = 0.010) and diastolic blood pressure at first clinic visit (p = 0.006). Therapy 
with angiotensin converting enzyme inhibitors (ACE-I) was protective (p = 0.006) (Model 
R2 = 88%). Change in %plaque volume was associated independently with donor age 
(p<0.001), recipient age (p = 0.05), triglyceride/ HDL ratio (an established marker of 
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insulin resistance) (p = <0.001), treated rejection in the first year after OHT (p <0.001) 
(Model R2 = 79%). Use of rapamycin was inversely correlated with % plaque volume 
increase (p = 0.002).
Conclusions: Features of insulin resistance in both the donor and the recipient are 
independently associated with CAV progression. ACE-I therapy, which might counteract 
insulin resistance, is associated with decreased CAV progression.
1:30 p.m.
1010-109	 Normalization	of	Fixed	Pulmonary	Hypertension	in	
Severe	Heart	Failure	Patients	With	Placement	of	Left	
Ventricular	Assist	Device
Ronald Zolty, Simon Shakar, Eugene Wolfel, Anne Cannon, Joseph Cleveland, Jr., Brian 
D. Lowes, UCHSC, Denver, CO
Background:	 Fixed pulmonary hypertension in severe heart failure patients is an 
absolute contraindication to cardiac transplantation. The purpose of this study was to 
evaluate the effect of left ventricular assist device (LVAD) on pulmonary artery (PA) 
pressures and pulmonary vascular resistance (PVR) in patients with severe heart failure 
and fixed pulmonary hypertension. Fixed pulmonary hypertension is defined as elevated 
PA pressures, with a trans-pulmonary gradient >15mmHg, PVR > 5mmHg, PA diastolic-
wedge gradient > 7mmHg, and not reversible with pharmacologic agents.
Methods: 8 severe heart failure patients (6 with idiopathic dilated cardiomyopathy and 2 
with ischemic heart disease), left ventricular ejection fraction <25% and fixed pulmonary 
hypertension (PA systolic 66±7 mmHg and PVR 7.6±0.7 WU) underwent placement of 
LVAD. These patients were prospectively studied for reassessment of their PA pressures 
at 1 to 3 months post LVAD implantation.
Results: The placement of LVAD (Heartmate device) resulted in statistically significant 
improvement of their PA pressures and PVR . The PA pressures as well as the cardiac 
output, wedge and PVR are shown in table. Subsequently, all these patients were 
successfully transplanted with no development of RV failure after transplantation.
Conclusions: Patients with severe heart failure and fixed pulmonary hypertension 
may benefit from LVAD implantation with normalization of their PA pressures and may 
subsequently be listed for heart transplantation.
PA 
systolic 
(mmHg)
PA 
diatolic 
(mmHg)
PA 
mean 
(mmHg)
Wedge mean 
Pressure 
(mmHg)
Cardiac Output 
(L/min by 
thermodilution 
method )
PVR 
(Wood 
Unit)
Baseline 66 ± 7 36 ± 1 48 ± 2 24 ± 1 3.1 ± 0.1 7.6 ± 0.7
Post LVAD 
placement 36 ± 2 14 ± 4 24 ± 2 13 ± 2 5.0 ± 0.6
2.2 ± 
0.2
p-value 
(compared to 
baseline)
0.0187* 0.0035* 0.0023* 0.0155* 0.028* 0.0023*
1:30 p.m.
1010-110	 Use	of	the	Percutaneous	Left	Ventricular	Assist	
Device	to	Reverse	Cardiogenic	Shock	in	Non-Ischemic	
Cardiomyopathy	Patients	Failing	Intra-Aortic	Balloon	
Pump	Support.
Gary M. Idelchik, Leo Simpson, Igor Gregoric, Pranav Loyalka, Biswajit Kar, Texas 
Heart Institute, Houston, TX
Background: Cardiogenic shock in non-ischemic cardiomyopathy (NICM) patients 
is associated with significant mortality and often requires left ventricular assist device 
(LVAD) placement. Due to the morbidity and mortality associated with surgically placed 
devices, we sought to determine the efficacy of the TandemHeart™, a percutaneously 
placed continuous-flow left ventricular assist device (PVAD) in NICM patients presenting 
with cardiogenic shock refractory to IABP and pressor support.
Methods:	From May 2003 to April 2006, devices were placed in 20 NICM patients in 
severe refractory cardiogenic shock. The mean age was 45.5 ± 16.1 years; 13 were 
male. Etiologies included: idiopathic dilated cardiomyopathy (12), viral myocarditis 
(4), peripartum cardiomyopathy (1), sarcoid cardiomyopathy (1), and Grade 3A heart 
transplant rejection (2). Eighteen patients were on IABP support and 10 were actively 
undergoing cardiopulmonary resuscitation during PVAD placement. The mean number of 
pressors used was 2.7 ± 1.3. The mean duration of support was 4.8 ± 2.7 days.
Results: 
Pre-PVAD With	PVAD
Table of Contents  o	 P-values
P-values
C.I.	-L/min/m2 0.86	±	0.68 2.70	±	0.95 <0.001
SBP	-	mmHg 70.4	±	12.9 101.6	±	13.3 <0.001
SVO2	-	mmHg 37.3	±	11.8 64.7	±	6.9 <0.001
PCWP	-	mmHg 29.0	±	9.1 13.3	±	4.6 <0.001
Lactic	-	mg/dL	 50.8	±	32.2 23.1	±	34.3 0.36
Cr	-	mg/dL 2.2	±	1.4 1.2	±	0.5 0.06
One patient received a heart transplant and 9 were bridged to LVAD. Ten recovered 
myocardial function during PVAD support. Survival at 30 days and 6 months was 70% 
and 65%, respectively. There were no device-related complications.
Conclusion:	Percutaneous left ventricular assist devices safely reverses severe refractory 
cardiogenic shock in NICM patients in whom IABP and pressors failed; 6 month survival 
was 65% in this high-risk group.
1:30 p.m.
1010-140	 Relationship	of	Increasing	QRS	Duration	to	Worsening	
Systolic	Function	in	Hypertensive	Patients	with	ECG	
Left	Ventricular	Hypertrophy:	the	LIFE	Study
Silvana Cicala, Richard B. Devereux, Giovanni de Simone, Rakesh K. Mishra, Eva 
Gerdts, Kristian Wachtell, Kurt Boman, Markku S. Nieminen, Björn Dahlöf, Peter M. 
Okin, Cornell Medical Center, New York, NY
Background: Increased QRS duration (QRSd) is associated with reduced left ventricular 
(LV) function. Although persistence or development of increased QRSd has been 
associated with an increased risk of new heart failure in hypertensive patients (pts), 
whether development of abnormal QRSd over time is associated with decreased LV 
systolic function is unclear.
Methods: QRSd, midwall fractional shortening (MWS) and stress-corrected (SC) MWS 
were examined at baseline and after 4 years in 684 hypertensive pts. QRSd ≥110 ms, 
MWS<14.2% and SC-MWS <89.2% were considered abnormal.
Results: At follow-up, compared with pts with persistently normal QRSd, pts with 
persistent or new abnormal QRSd had lower values of MWS and SC-MWS, and higher 
odds of subnormal MWS and SC-MWS (Table). After controlling for baseline QRSd, age, 
race, history of coronary artery disease and diabetes, albumin-creatinine ratio and Cornell 
voltage, pts with new abnormal QRSd had >3.5-fold higher risk of abnormal midwall 
function at follow-up; persistence of abnormal QRSd was not independently associated 
with abnormal wall mechanics. In pts with normalization of QRSd, the risk of abnormal 
midwall function was similar to pts with persistent normal QRSd.
Conclusions: Among hypertensive pts with ECG LV hypertrophy, prolongation of 
QRSd during antihypertensive treatment predicts an increased risk of abnormal LV 
midwall function, suggesting a link between electric and mechanical manifestations of 
hypertensive cardiomyopathy. 
Relationship of Left Ventricular Function to Normal vs Abnormal QRS 
Duration Over Time
Variable at 4-Year 
Follow-Up
QRS<110 
Baseline/ QRS 
<110 Year 4:
Normal QRS
(n=503)
QRS ≥110 
Baseline/QRS 
<110 Year 4:
Normalization 
of QRS
(n=30)
QRS ≥110 
Baseline/QRS 
≥110 Year 4:
Persistent 
Abnormal QRS
(n=93)
QRS <110 
Baseline/ QRS 
≥110 Year 4:
New Abnormal 
QRS
(n=58)
p value
MWS (%) 17.2±2.0 16.7±2.6 16.2±3.0 16.1±2.7 <0.0001
Stress-Corrected MWS (%) 108±11 107±13 105±16 104±15 0.020
Univariate Odds Ratio of 
Abnormal MWS (95% CI) 1
3.2
(1.1-8.8)
3.8
(2.0-7.1)
4.1
(2.0-8.6) <0.0001
Univariate Odds Ratio of 
Abnormal Stress-Corrected 
MSW (95% CI)
1 2.7(0.8-9.7)
4.2
(2.1-8.8)
4.9
(2.2-11.0) <0.0001
Adjusted Odds Ratio of 
Abnormal MWS (95% CI) 1
2.3
(0.6-8.5)
1.1
(0.3-4.1)
3.6
(1.5-8.2) 0.003
Adjusted Odds Ratio of 
Abnormal Stress-Corrected 
MWS (95% CI)
1 2.1(0.4-10.4)
1.1
(0.2-5.1)
4.1
(1.5-10.7) 0.005
1:30 p.m.
1010-141	 Electromechanical	Property	In	Heart	Failure	And	Its	
Implication	To	Cardiac	Resynchronization	Therapy
Jeffery WH Fung, Joseph YS Chan, Gabriel WK Yip, Winnie WL Chan, Anna KY Chan, 
Leo CC Kum, Yat-yin Lam, Qing Zhang, Cheuk-man Yu, The Chinese University of Hong 
Kong, Hong Kong, Hong Kong
Objective: We explore the left ventricular (LV) electromechanical property and its 
implication to cardiac resynchronization therapy (CRT).
Background: The relationship between LV electrical activation and mechanical 
dyssynchrony in CRT candidates is unclear.
Methods: The baseline LV endocardial activation pattern and total activation time (Tat) 
was determined by non-contact mapping in 23 patients receiving CRT with NYHA class 
III, QRS duration > 120ms and LV ejection fraction <35%. LV mechanical dyssynchrony 
was determined by the standard deviation (Ts-SD) and maximal difference (Ts-diff) of time 
to peak systolic contraction (Ts) among 12 LV segments using tissue Doppler imaging.
Results: Two activation patterns, homogenous (Type I, N= 8) and presence of line of 
block (Type II, N=15), were identified. Significant correlation between Tat and Ts-SD/Ts-
diff was noted in Type II pattern (r = 0.73/0.56, p = 0.002/0.03) but not in Type I (r =0.19/-
0.16, p = NS/NS). Ts-SD (42.6 ± 8.6 Vs 30.6 ± 7.8 ms, p = 0.003) and Ts-diff (112.5 ± 
11.9 Vs 89.5 ± 30.0ms, p = 0.01) in Type II were significantly longer than Type I. Twelve 
patients (80%) in Type II and 2 (25%) in Type I were volumetric	 responders after CRT 
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(p=0.01). After 487 ± 447 days, patients with Type II pattern had a significantly lower risk 
of heart failure hospitalization or death (Log rankχ2= 5.25; p=0.02).
Conclusion: Despite similar QRS duration, patients with Type II pattern were associated 
with more severe mechanical dyssynchrony and had a more favorable response to CRT 
than Type I.
1:30 p.m.
1010-142	 Improvement	of	Short-axis	Myocardial	Function	but	
not	Long-axis	Function	or	Left	Ventricular	Torsion	After	
Cardiac	Resynchronization	Therapy	-	An	Assessment	
by	2D	Speckle	Tracking
Qing Zhang, Jeffery WH Fung, Gabriel WK Yip, Joseph Yat-sun Chan, Leo CC Kum, 
Alex Pui-wai Lee, Yat-yin Lam, Li-wen Wu, Cheuk-man Yu, The Chinese University of 
Hong Kong, Hong Kong, Hong Kong
Background:	This study evaluated the changes of LV short-axis and long-axis myocardial 
function as well as torsion after CRT; and their relation with global LV function and geometry.
Methods:	2D speckle tracking echocardiography was performed in 39 patients at baseline 
and 3-month to assess mean systolic circumferential (ε-circum), radial (ε-radial), longitudinal 
(ε-long) strain and torsion from base to apex, and compared with global LV indices.
Results: 21 responders of reverse remodeling (reduction of LVESV ≥ 15%) had higher 
baseline mean ε-circum than non-responders, while both mean ε-circum and mean 
ε-radial were only improved in responders (Table). Improvement of mean ε-circum 
correlated with increase in ejection fraction (r=0.57, p<0.001) and decrease in mid-cavity 
width (r=-0.52, p=0.001). A cutoff value of mean ε-circum of ≥ 6.5% predicted a gain in 
ejection fraction ≥ 5%, with a sensitivity of 73% and a specificity of 71%. The baseline 
ε-long was not different between the 2 groups, and remained unchanged after CRT. The 
torsion did not improve in responders, but was worsened in non-responders (Table).
Conclusions:	 The improvement of LV short-axis function but not long-axis function 
or torsion contributes to the changes in LV global function and geometry after CRT. 
A relatively preserved mean ε-circum of ≥ 6.5% might be useful to predict favorable 
responses after CRT. 
Parameters Responders	(n=21) Non-responders	(n=18)
Baseline 3-month Baseline 3-month
LVESV, cm3 121±37 85±34* 143±71 138±70†
LV ejection fraction, % 29.5±6.0 40.1±7.7* 26.4±7.2 29.0±7.5‡
Mean ε-circum, % -7.9±2.4 -10.0±2.9‡ -6.1±2.6§ -6.8±2.6
Mean ε-radial, % 11.6±6.2 18.8±9.1† 9.4±6.4 8.7±5.9
Torsion, degree 6.8±4.5 5.6±5.6 6.9±4.1 4.2±3.7†
Mean ε-long, % -8.0±2.9 -9.0±3.5 -7.1±3.8 -6.2±2.7
*p<0.001, †p<0.05, ‡p≤ 0.005 vs baseline
§p<0.05 vs responders at baseline
1:30 p.m.
1010-143	 Intraoperative	Optimization	of	Cardiac	
Resynchynchronization	Therapy	using	Intracardiac	
Echocardiography	Can	Enhance	Response	and	
Outcomes	in	Refractory	Heart	Failure
Sanjeev Saksena, Marc Rahme, Mary A. Viggiano, Praveen Dala, Philip Mathew, 
Electrophysiology Research Foundation, Warren, NJ, RWJ Medical School, New 
Brunswick, NJ
Background: Cardiac resynchronization therapy (CRT) is used for refractory heart 
failure (HF) but non-responders & an unpredictable degree of benefits make its outcome 
uncertain. Intraoperative assessment of resynchronization and its optimization has not 
routinely performed.
Methods: We examined the outcomes of CRT based on intraoperative optimization 
using intracardiac echocardiography (ICE) to reliably visualize LV function & aortic flow 
(AO) intraoperatively during CRT device implant. Phased array imaging at 7-8.5 Hz was 
performed using an ICE catheter placed in the RV and/or RA. LV ejection fraction (EF), 
septal-to-posterior wall motion delay, LV regional wall motion abnormality (RWMA) & 
aortic flow velocity/ejection indices (AO) were measured. Acute optimization of CRT was 
done by varying rate, AV interval & V-V timing and clinical outcomes assessed.
Results: 21 pts (18 men), mean age 72 yrs, mean QRS duration 162 ms, underwent 
ICE imaging. ICE showed global hypokinesis in 6 pts, RWMA in 10 pts & both in 5 pts. 
Optimization resulted in an increment in M-mode LVEF by CRT in all pts (range 5 to 25%). 
Optimized CRT modes included AV intervals ranging from 150 to 200 ms & V-V timing 
using simultaneous RV-LV pacing (2 pts), LV only (1 pt), & sequential LV to RV stimulation 
(18 pts). ICE guided CRT programming resulted in improvement in mean LVEF from 
23+8% to 40+13% (p<.00001). During a follow-up period of 1-24 (mean 10.4 months), 
NYHA heart failure class improved in all pts from a mean of 3.1 + 0.2 at implant to 1.7+ 0.6 
(p <.0001) with 20 pts (95%) showing improvement to class 2 or 1. Actuarial total survival 
was 94% at 6 months and 92% at 12 monthsof follow up.
Conclusions: 1. Intraoperative	 ICE guided CRT optimization provides a more uniform 
response to CRT therapy in heart failure and may be associated with a more consistent 
improvement in heart failure status. 2. Sequential biventricular pacing and longer AV interval 
programming are more often necessary to obtain maximal optimization with CRT therapy. 3. 
Systematic optimization of CRT guided by ICE could further enhance CRT benefit.
1:30 p.m.
1010-144	 Evaluation	of	Left	Ventricular	Dyssynchrony	
Indices	in	Heart	Failure	Patients	with	Narrow	and	
Wide	QRS	Durations
Jing Ping Sun, William J. Stewart, Xing Sheng Yang, Angel R. Leon, James D. Thomas, 
John D. Merlino, Emory University School of Medicine, Atlanta, GA, The Cleveland 
Clinic Foundation, Cleveland, OH
Background: Quantification of left ventricular (LV) dyssynchrony during screening 
for cardiac resynchronization therapy (CRT) may be important. It is hypothesized that 
dysynchrony may not depend on QRS prolongation.
Methods: We correlated previously-reported parameters of LV dyssynchrony in 34 
heart failure (HF)	pts	with narrow	QRS	(NQRS) [54 ± 18 yrs, 18 male] and 48 HF	pts	
with	wide	QRS	>130 ms (WQRS) [56 ± 18 yrs, 30 male], and 70 controls	[age 40±13 
yrs, 50 male] with normal EKGs, Echos, and no clinical disease. Measured parameters 
included the aortic pre-ejection (Ao preET) and pulmonary pre-ejection (Pul preET) times 
from PW Doppler, the time from the begining of QRS to peak velocity (Ts), and to peak 
displacement (Td) of 12 basal and mid LV segments by tissue Doppler imaging, and the 
time between peak contraction of the septum and posterior wall using M-mode (Tsep-
post). The present values were mean ± standard deviations.
Results: Results listed in table.
unit=msec QRS preET(AO-Pul) Ts-SD Td-SD TSep-Post
Ts
(sepB-latB)
Normal 90 ± 20 8± 8 20 ± 10 16 ± 8 28 ± 35 31 ± 25
NQRS 100 ± 12 20± 19 46 ± 13 69 ± 29 95 ± 82 41 ± 30
WQRS 168 ± 29 29 ± 24 49 ± 20 80 ± 35 133 ± 82 43± 40
p (normal vs all HF pts) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.03
p (NQRS vs WQRS) <0.0001 ns ns ns ns ns
Conclusions: Heart failure pts showed dyssynchrony compared to control independent 
of QRS duration < or > 130 ms, as measured by TSep-Post, Ts-SD, and Td-SD. There is a 
substantial prevalence of LV dyssynchrony, even in pts with normal QRS interval, who 
may also benefit from CRT.
1:30 p.m.
1010-145	 Clinical	and	Echocardiographic	Predictors	of	
Significant	Improvement	in	Ejection	Fraction	After	
Cardiac	Resynchronization	Therapy
Matthew S. Suffoletto, Masaki Tanabe, Glen Miske, Randolph P. Martin, John Merlino, 
David Schwartzman, Angel R. Leon, John Gorcsan, III, University of Pittsburgh, 
Pittsburgh, PA, Emory University, Atlanta, GA
Background: Degree of response to resynchronization therapy (CRT) is heterogeneous. 
Our aim was to test the hypothesis that clinical and echo features are predictive of reverse 
remodeling response after CRT.
Methods: 94 NYHA III-IV heart failure (HF) patients (64±13 yrs, EF 25±7%, QRS 163±29 
ms) were studied before and 6±4 mo after CRT. Dyssynchrony was assessed by tissue 
Doppler (opposing wall delay from 3 apical views). Response was defined by ejection 
fraction (EF) units: Non-Responder (<4% increase), Moderate Responder (4-10% 
increase), and Large Responder (> 10% increase). Age, gender, dyssynchrony, EF, QRS 
duration, volumes and etiology of HF were examined as predictors.
Results: Overall, EF improved from	 25±7% to 33±10% (p < 0.001) and end-systolic 
volume (ESV) decreased 166±77 ml to 139±75 ml (p<0.05). Non-Responders had less 
dyssynchrony (57±23 ms) than Responders (157±23 ms), (p<0.01 vs. responders). Large 
Responders had smaller baseline ESV compared to Moderate Responders (141 ± 58 
vs. 187 ± 82 ml, p<0.01). Large Responders were more frequently non-ischemic HF 
in etiology than moderate EF responders or non-responders (55%* vs. 35% vs. 25%, 
respectively, *p< 0.05).
Conclusions: Baseline tissue Doppler dyssynchrony predicted response to CRT, but 
not the degree of EF response. Large EF responders were associated with non-ischemic 
etiology, relatively less dilated LVs and less depressed baseline EF. These observations 
have potential clinical implications. 
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1010-150	 Left	Ventricular	Reverse	Remodelling	after	Cardiac	
Resynchronisation	Therapy	in	Heart	Failure	Patients	
with	a	Narrow	QRS	Duration
Lynne K. Williams, Susan Ellery, Berthold Stegemann, Kiran Patel, Francisco Leyva, 
Vince Paul, Michael Frenneaux, University of Birmingham, Birmingham, United Kingdom
Background: Cardiac resynchronisation therapy (CRT) is currently restricted to those 
patients with a QRS duration >120ms. We hypothesized that CRT would result in left 
ventricular reverse remodelling in patients with left ventricular systolic dysfunction, a 
normal QRS duration, and no evidence of significant inter- or intra-ventricular dysynchrony 
according to current echocardiographic criteria.
Methods: Eighteen patients with a left ventricular ejection fraction (LVEF) ≤ 35% (6 with 
non-ischaemic dilated cardiomyopathy (DCM) and 12 with ischaemic cardiomyopathy), 
in sinus rhythm, and with no evidence of inter or intraventricular conduction delay on 
both ECG (QRS duration < 120ms) and echocardiography (12-segment standard 
deviation dysynchrony index < 32 and Qp-Qa duration < 40ms) were randomised to 
active biventricular pacing (n=10) versus inactive pacing (VVI at 40 beats/min) (n=8). 
Echocardiographic measures were compared before implantation and after 3 months of 
active biventricular pacing.
Results: At baseline there were no significant differences between the active and inactive 
pacing groups with regard to LVEF (26.5 ± 5.52 vs. 26.5 ± 4.75%; p=1.00), left ventricular 
end-diastolic diameter (3.47 ± 0.36 vs. 3.14 ± 0.48cm; p=0.11), or MR jet area (5.72 ± 7.04 vs. 
2.90 ± 4.87; p=0.33). LVEF was significantly increased in the active pacing group compared 
with a decrease in the inactive pacing group after three months (+4.6 ± 7.08 vs. -4.38 ± 6.82; 
p=0.002). A decrease in LVEDd (corrected for body surface area) was seen in the active 
group compared with the inactive group (-0.29 ± 0.25 vs. +0.121 ± 0.26; p=0.004), associated 
with a decrease in the MR jet area (-2.45 ± 3.14 vs. +0.56 ± 1.36; p=0.02).
Conclusions: Cardiac resynchronisation therapy in patients without significant 
dysynchrony results in left ventricular reverse remodelling after 3 months of active 
pacing. It appears that resynchronisation is not the only mechanism by which remodelling 
may occur with CRT. ECG and echocardiographic indices of dysynchrony are therefore 
potentially inaccurate tools upon which to select patients for CRT.
ACC.ORAL CONTRIBUTIONS
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801-3	 Serum	Proteomic	Profiles	in	Giant	Cell	Myocarditis:	
Altered	Expression	of	Immune	Response	and	Lipid	
Metabolism	Proteins
Oyere K. Onuma, Sreekumar Raghavakaimal, Peter L. Elkin, Leslie T. Cooper, Mayo 
Clinic and Foundation, Rochester, MN
Background: Giant Cell Myocarditis (GCM) is a highly lethal disease of unknown cause. 
Using liquid chromatography and tandem mass spectroscopy (LC/MS/MS), we analyzed 
serum in acute (day 1) and convalescent (day 30) samples of GCM in order to identify 
mechanistic pathways and potential biomarkers. 
Methods: Serum from 8 patients with histopathologic diagnosis of GCM were separately 
filtered through an antibody-affinity microbead separation column, trypsinized, isotope 
labeled, combined and analyzed by tandem mass spectrometry. Protein identification 
and quantification was done with the ProQuant software and pathway analysis with the 
Ingenuity software. Proteins with a fold change of 20% i.e. ratios >1.2 or <0.8, were 
defined as differentially expressed. 
Results: Of more than 600 differentially regulated proteins, there was marked up regulation 
in acute GCM of immune and defense proteins (n=217) such as CRP, immunoglobulins 
and the complement proteins. Proteins involved in lipid, fatty acid and steroid metabolism, 
such as the apolipoproteins were down regulated in acute GCM as shown in Figure 1. 
Pathway analysis of 43 common differentially expressed proteins identified activation of 
the immune response and lipid metabolism molecular pathways in acute GCM. 
Conclusions: Acute GCM is associated with altered expression of serum proteins 
involved in immune response and lipid metabolism. This proteomic strategy may ultimately 
allow for noninvasive identification of disease-specific biomarkers. 
7:15 a.m.
801-4	 Natural	History	of	Patients	With	Biopsy-Proved	
Myocarditis	According	to	Different	Clinical	
Presentations
Andrea Di Lenarda, Adriana Magagnin, Marco Merlo, Stylianos Pyxaras, Rossana 
Bussani, Alberto Pivetta, Aneta Aleksova, Gianfranco Sinagra, Department of 
Cardiology, University of Trieste, Trieste, Italy
Background: Patients (pts) with acute myocarditis may have different clinical presentation. 
Whether the differeces in the clinical manifestations entail different prognosis of pts with 
myocarditis has not been extensively evaluated.
Methods: We analysed 74 pts with biopsy-proved myocarditis enrolled in the Trieste 
Heart Muscle Disease Registry from 1981 to 2006. Study population was divided in 
three groups according to their clinical presentation: heart failure (HF) (47 pts, group A); 
major ventricular arrhythmias (16 pts, group B) and pseudo-infarction pattern (11 pts, 
group C). Improvement was defined as increase of LV ejection fraction (LVEF) >10 points, 
10% decrease of LV end-diastolic diameter (LVEDD) and one stage recovery in NYHA 
class, while normalization was considered as recovery of LVEF >50% and absence of 
symptoms (NYHA I). The evolution to dilated cardiomyopathy was defined as LVEF<45% 
and LVEDD >117% of value predicted by Henry formula.
Results: Pts from group A, compared to group B and C, had more severe symptoms 
(NYHA III-IV: 49%, 13%, 9% respectively, p=0.004) and lower LVEF (32±16%, 46±16%, 
56±12% respectively, p<0.001). During a mean follow-up of 114±91 months died or 
underwent heart transplantation 25 pts. Mortality or cardiac transplant (D/HTx) rate at 
two, five and 10 years was 21%, 32%, 40% in group A, 0%, 0%, 27% in group B and 0%, 
0%, 0% in group C (p=0.007). Among pts of group A improvement and/or normalization 
six months after the diagnosis was associated to a lower rate of D/HTx or cardiovascular 
hospitalisations at two, five and 10 years of follow-up (respectively 11, 24 and 49% vs 
43, 60 and 60%, p=0.026). In group A 48% of patients developed a phenotype of dilated 
cardiomyopathy or died after 24 months from diagnosis. 
Conclusions: Clinical presentation of acute myocarditis is significantly related to long-
term prognosis. Clinical improvement and/or normalization six months after diagnosis 
may allow an accurate stratification of short and long term cardiovascular risk.
7:30 a.m.
801-5	 Prevalence	of	Organ-Specific	Autoantibodies	and	
Coeliac	Disease	in	Patients	With	Sporadic	and	Inherited	
Dilated	Cardiomyopathy	and	Their	Relatives
Andrea Di Lenarda, Daniela Chicco, Michele Moretti, Taddio Andrea, Baldas Valentina, 
Not Tarcisio, Gianfranco Sinagra, Department of Cardiology, University of Trieste, 
Trieste, Italy, Department of Pediatrics, University of Trieste, Trieste, Italy
Background:	 Idiopathic dilated cardiomyopathy (DCM) is a relevant cause of heart 
failure. The presence of several autoantibodies or other immune factors in some patients 
and in their first degree relatives (FDR) supports the hypothesis that multiple autoimmune 
mechanisms are involved in DCM. Coeliac disease (CD) is a permanent intolerance to 
gluten and it’s often associated with autoimmune extra-intestinal disorders. It has recently 
been shown an increased incidence of CD in patients with DCM as compared to the 
general population. The aim of this study was to establish the prevalence of some organ 
specific autoantibodies in DCM patients and their FDR.
Methods:	 We screened for anti-human-tissue-transglutaminase antibodies (IgA and 
IgG anti-h-tTG), anti-endomysial antibodies (AEAs), anti-actin antibodies and anti-
thyreoperoxidasis antibodies 55 consecutive adult patients with inherited or sporadic 
DCM, 78 FDR and 200 healthy blood donors enrolled as control population. CD related 
HLADQ2-DQ8 was searched in tTG-positive subjects.
Results:	 Three subjects were tTG-positive: two DCM patients (3,6%) and one FDR 
(1,3%). All the three subjects were AEA, and HLA-positive. Both of the tTG-positive 
subjects affected by DCM underwent duodenal biopsy, that showed characteristic coeliac 
mucosal atrophy. 32/55 (58,2%) patients with DCM and 24/78 (31%) of FDR were tested 
positive for anti-actin antibodies. 18/55 (33%) patients with DCM and 20/78 (25%) FDR 
were tested positive for anti-thyreoperoxidasis antibodies. 2/200 (1%) of control population 
were tested positive for anti-thyreoperoxidasis antibodies, whereas 28/200 (14%) were 
tested positive for anti-actin antibodies. No one patient resulted positive for anti-human-
tissue-transglutaminase and for anti-endomysial antibodies screening.
Conclusions:	High prevalence of CD in patients with DCM is confirmed. Moreover, a 
high presence of anti-actin and anti-thyreoperoxidasis antibodies was demonstrated both 
in patients with DCM and in their relatives as compared with controls. These preliminary 
data support the hypotesis that DCM could be an autoimmune disorder in a context of 
unknown genetic predisposition.
7:45 a.m.
801-6	 Peripartum	Cardiomyopathy:	Incidence,	Mortality,	and	
Race	in	a	Large	Community-Based	Cohort
Somjot S. Brar, Neil Parikh, Gagandeep K. Sandhu, Michael B. Jorgensen, Steven S. 
Khan, Jin-Wen Y. Hsu, Albert Yuh-Jer Shen, Kaiser Permanente, Los Angeles, CA, 
UCLA School of Medicine, Los Angeles, CA
Background: The reported incidence of and prognosis after peripartum cardiomyopathy 
(PPCM) varies widely. Many such estimates suffer from referral and other biases. 
Furthermore, the influence of ethnicity/race on the incidence of PPCM has not been 
studied in a large cohort under a single healthcare delivery system.
Methods: Between 2000 and 2005, 248,481 unique women delivered live births within the 
Southern California Kaiser healthcare system. By searching ICD-9 codes for heart failure 
(HF), we identified patients who were hospitalized with HF 6 months before to 12 months 
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after delivery. The cases thus identified underwent chart review. Patients were considered 
to have PPCM if they satisfied all the following criteria: (1) LV ejection fraction <0.50 (2) 
met the Framingham criteria for HF (3) new symptoms of HF or initial echocardiographic 
diagnosis of LV dysfunction occurred in the month before or in the 5 months after delivery 
(4) no alternative cause of HF could be identified.
Results: Our initial screening identified 240 women, of which 60 met criteria for PPCM 
by detailed chart review. Their mean age was 33 ± 7 years. The mean EF at diagnosis 
was 0.32 ± 0.10. By self reported race/ethnicity, the full cohort consisted of 49% Hispanic, 
27% White, 11% Asian, 10% Black, and 3% other races. Among the PPCM cohort, 28% 
were Black, 27% White, 20% Hispanic, 17% Asian and 8% other. The incidence of PPCM 
per live birth was 1/1,462 in Blacks, 1/2,733 in Asians, 1/4,193 in Whites and 1/10,146 in 
Hispanics. After a mean follow up of 4.7yrs, a Kaplan-Meier analysis censoring for loss of 
membership and study termination showed 95% survival in the PPCM cohort. No patients 
underwent cardiac transplantation during the study period.
Conclusion: In this large, community based population the overall incidence of PPCM 
was 1 in 4,142 live births, but there was substantial variability between races. The 
incidence in Blacks was nearly 7 fold that of Hispanics. Furthermore, our data suggest 
that PPCM prognosis is more favorable than previously reported.
8:00 a.m.
801-7	 Peripartum	Cardiomyopathy:	Differences	in	Clinical	
Profile	and	Presentation	in	African	Americans
Uri Elkayam, Sorel Goland, Parta Hatamizadeh, Munir Janmohamed, Kalgi Modi, 
University of Southern California, Los Angeles, CA
Background: Peripartum cardiomyopathy (PPCM) is rare and heterogeneous disease 
whose clinical presentation has not been completely defined. We aimed to evaluate 
whether there are differences in the clinical profile between African American (AA) and 
Non-African American (NAA) patients with PPCM.
Methods: We studied 178 patients with PPCM and compared clinical characteristics and 
outcomes between 52 AA and 126 NAA (101 Caucasian, 19 Hispanic & 6 Asian).
Results: AA were significantly younger and had higher prevalence of gestational 
hypertension and onset of symptoms postpartum rather than antepartum compared with 
NAA. No differences were observed in terms of index pregnancy, twin pregnancies and 
use of tocolytic therapy. Baseline left ventricular (LV) function was similar in the two groups; 
however AA women had larger LV size. The LV ejection fraction (EF) was significantly 
lower and LV diastolic diameter (DD) larger at the last follow up (21±28 months) in AA. 
Moreover, rate of LV recovery (LVEF≥ 50%) was significantly lower in AA. No significant 
differences were observed in complications and rate of mortality/transplantation between 
NAA and AA (23% vs 31%, p=0.3 & 17% vs 19%, p=0.3).
Conclusions: PPCM in AA patients occurred in younger age, was strongly associated 
with gestational hypertension and presented more commonly postpartum rather than 
antepartum. Although LVEF at diagnosis was similar in both groups, incidence of LV 
recovery was significantly lower in AAs.
8:15 a.m.
801-8	 Effects	of	SIV	Infection	and	Immunostimulation	on	
the	Development	of	Myocarditis	and	Contractile	
Dysfunction	in	Rhesus	Macaques
George G. Sokos, Jennifer H. Yearley, Angela A L Carville, Srinivas Vengala, Keith G. 
Mansfield, Richard P. Shannon, Allegheny General Hospital, Pittsburgh, PA, Department 
of Pathology, Harvard Medical School, Southborough, MA
Background: Controversy remains as to whether lentiviruses, either HTLV-1 or 
HTLV-2, can directly infect cardiomyocytes or whether the endothelium needs to be 
primed immunologically in order to facilitate viral injury. We studied cardiac functional 
and pathological consequences of acute simian immunodeficiency virus (SIV) infection 
alone or in combination with heat inactivated mycobacterium avium (MAI) as an 
immunostimulant in juvenile rhesus macaques.
Methods: Twenty-two rhesus macaques (age 2-4 years) were randomly assigned to 
four groups: SIV
mac
 251 infection (SIV n=6); MA immunostimulation (MAI, n=6); SIV 
infection +MAI; (SIV+MAI, n=8) and SIV+MAI + enterecept (n=4). Echocardiograms were 
performed prior to, on the day of infection, and weekly for 5 weeks. MAI was injected on 
days 4 and 8 and enterecept (5 mg/m2, IV) was given weekly. Myocardium was examined 
for pathological evidence of myocarditis using NERPRC inflammatory score and for 
cardiomyocyte expression of TNFα using Western blots.
Results: There was a significant decline in LVEF in the SIV+MAI group (Base: 74±2%; 
5wks: 58±3%, p<0.01). LV function in the SIV alone (Base: 71±6%; 5 weeks: 70±5%) 
and MAI groups (Base: 82±1%; 5 wks: 80±4%) did not change significantly. Treatment 
with enterecept prevented the adverse effects of SIV+MAI on LVEF (Base: 76±3%; 5 
wks: 77±2%). All samples had similar inflammatory scores with active, but focal infiltrates 
comprised of T cell and macrophage infiltrates. However, myocardial expression of 
TNFα was highest (p<0.02) in SIV+MAI (783±14 DU) and was suppressed (p<0.001) by 
enterecept (188±40 DU).
Conclusions: SIV infection alone is insufficient to explain cardiac functional involvement 
in AIDS and immunological priming with MAI appears to be necessary for decline in 
cardiac function. Furthermore, myocardial TNFα expression correlates most closely with 
functional abnormalities while enterecept mitigates the decline in LV function.
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614-5	 Comparison	of	the	Risk	Associated	With	Diabetes	
Mellitus	in	Patients	With	Preserved	and	Low	Ejection	
Fraction	Heart	Failure:	An	Analysis	of	the	Candesartan	
in	Heart	Failure	Assessment	of	Reduction	in	Mortality	
and	Morbidity	(CHARM)	Program
Michael R. MacDonald, Fumi Varyani, Jonas Carlsson, Mark Petrie, Jan Ostergren, Eric 
L. Michelson, Scott D. Solomon, Christopher B. Granger, Karl Swedberg, Marc A. Pfeffer, 
Salim Yusuf, John J. McMurray, on behalf of the CHARM investigators, University of 
Glasgow, Glasgow, United Kingdom
Background:	 In prior trials, diabetic patients with low ejection fraction (EF) heart 
failure (HF) had an increased risk of death compared to non-diabetic patients. The risk 
associated with diabetes in patients with HF and a preserved EF (PEF), compared to 
low EF, HF is unknown and has now been examined in the Candesartan in Heart failure: 
Assessment of Reduction in Mortality and morbidity (CHARM) program.
Methods:	The program had 3 component trials: CHARM-Alternative (EF <40%, ACE-I 
intolerant, n=2028), -Added (EF <40%, ACE-I treated, n=2548) and -Preserved (EF >40%, 
n=3023). The primary outcomes of the component trials (cardiovascular [CV] death or HF 
hospitalization) and overall program (all-cause mortality), were evaluated in diabetic and 
non-diabetic patients. Comparison of the outcomes in these two groups is expressed as a 
hazard ratio (HR) adjusted for the 33 most important prognostic co-variates.
Results: 1306/4576 (29%) low EF and 857/3023 (28%) PEF patients had diabetes at 
baseline. Diabetes was an important independent predictor of outcome in both types of 
HF. In low EF patients, CV death or HF hospitalization occurred in 50% diabetics and 
34% of non-diabetics - adjusted HR 1.6 (1.44, 1.77). In PEF patients, these proportions 
were 36% and 18%, respectively - HR 2.0 (1.70, 2.36). For death, the proportions in 
low EF patients were 38% and 26%, respectively adjusted HR 1.55 (1.38, 1.74) and 
in PEF patients they were 22% and 14% HR 1.84 (1.51, 2.26). For the outcome of CV 
death or HF hospitalization, the patient group-diabetes interaction p value was 0.0009 (i.e. 
diabetes was associated with a significantly greater relative risk in PEF patients than in 
low EF patients). The interaction p value for death alone was 0.51.
Conclusions:	Diabetes is associated with a higher relative risk of adverse outcomes 
in patients with both low and preserved EF HF. The magnitude of the increase in risk 
associated with diabetes is at least as great in patients with PEF.
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807-3	 A	Novel	Clinical	Indicator	Using	Tc-99m	Sestamibi	for	
Evaluating	Cardiac	Mitochondrial	Function	in	Patients	
With	Cardiomyopathies
Shinro Matsuo, Ichiro Nakae, Takayoshi Tsutamoto, Daisuke Masuda, Noriake Okamoto, 
Tetsuya Matsumoto, Minoru Horie, Shiga University of Medical Science, Otsu, Japan, 
Bristol-Myers Squibb Y.K., Tokyo, Japan
Background: Technetium-99m sestamibi (MIBI) is a technetium labeled myocardial 
perfusion agent. Previous studies suggest MIBI shows very slow myocardial clearance 
after its initial uptake in animal model, which is related with mitochondrial function. This 
study was designed to test the hypothesis that the use of MIBI washout can be used 
as evaluating the severity of congestive heart failure in comparison to other clinical 
parameters in patients with cardiomyopathies. 
Methods: After administration of MIBI, 61 patients with non-ischemic congestive heart 
failure (49 dilated cardiomyopathies and 12 other cardiomyopathies) and 7 normal controls 
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were examined by ECG-gated myocardial perfusion SPECT and planar data acquisition 
in the early and delayed (interval of 3 hours) phase. Myocardial MIBI washout rates were 
calculated from the early and delayed planar images. Left ventricular functions (systolic 
and diastolic) were analyzed using QGS data. Plasma levels of B-type natriuretic peptide 
(BNP) and iodine-123 iodobenzylguanidine (MIBG) parameters were also measured. 
Patients were followed up for 12 months (1-19 months). 
Results: As the severity of NYHA functional class advanced, the washout rate of MIBI 
increased (NYHA I (n=23), II (n=27), III and IV (n=10): 21.6±2.4, 28±4, 35±5, respectively, 
p<0.05, ANOVA). The washout rate of MIBI was positively correlated with the level of BNP 
(r=0.31, p<0.05), end-diastolic volume (r=0.396, p<0.01), end-systolic volume (r= 0.496, 
p<0.01), and was negatively correlated with left ventricular ejection fraction (r=0.523, 
p<0.01), peak filling rate (r=0.444, p<0.01), and first third ejection fraction (r=0.414, 
p<0.01). The parameters of MIBG scintigraphy were calculated as H/M (1.9±3), and the 
washout rate (38±4 %). We found significant relation between the washout rate of MIBI 
and H/M of MIBG (r=0.51, p<0.01). Patients with higher washout rate of MIBI had higher 
cardiac event rate (> 28 %) than those with lower washout rate (< 28%)(p<0.05). 
Conclusions: The myocardial washout rate of MIBI is thought to be a novel marker for 
the diagnosis of myocardial damage or dysfunction, providing prognostic information in 
patients with congestive heart failure.
9:15 a.m.
807-4	 mRNA	Expression	of	Peroxisome	Proliferator-
Activated	Receptor	Gamma	Coactivator-1	Alpha	Is	
Increased	in	Left	Ventricular	Myocardium	of	Patients	
With	Heart	Failure
Sharad Rastogi, Sidney Goldstein, Robert Brewer, Hani N. Sabbah, Henry Ford Health 
System, Detroit, MI
Background: We previously showed that in explanted failed human hearts and in 
hearts from dogs with heart failure (HF) constituent cardiomyocytes of the failing left 
ventricle (LV) manifest structural and functional abnormalities of mitochondria evidenced 
by mitochondrial ultrastructural abnormalities, hyperplasia and reduced organelle size 
and by abnormal mitochondrial oxidative capacity, conditions that facilitate progressive 
worsening of the HF state. Peroxisome proliferator-activated receptor gamma coactivator-
1 alpha (PGC-1α) is a regulator of mitochondrial biogenesis and function. Forced 
cardiac specific overexpression of PGC-1α in transgenic mice results in uncontrolled 
mitochondrial biogenesis, loss of sarcomeric structure and dilated cardiomyopathy. In 
this study, we examined mRNA expression of PGC-1α in LV myocardium of patients with 
ischemic and idiopathic dilated cardiomyopathy.
Methods: mRNA gene expression for PGC-1α was measured in LV myocardium of 
explanted failed human hearts due to ischemic cardiomyopathy (ICM, n=6), idiopathic 
dilated cardiomyopathy (IDC, n=6) and normal donor human hearts which were deemed 
not suitable for transplantation (NL, n=6). Tissue samples from all 3 groups were used to 
extract RNA. mRNA expression for PGC-1α was measured using reverse transcriptase 
polymerase chain reaction (RT-PCR) and bands, obtained after ethidium bromide gel 
electrophoresis, were quantified in densitometric units.
Results: mRNA expression for PGC-1α was significantly increased in LV myocardium of 
patients with ICM compared to LV myocardium from NL donor hearts (1179 ± 31 vs. 613 
± 40 ). mRNA expression for PGC-1α was also significantly increased in LV myocardium 
of patients with IDC compared to LV myocardium from NL donor hearts (1062 ± 28 vs. 
613 ± 40).
Conclusions: The results of this study indicate that in LV myocardium of explanted failed 
human hearts, mRNA expression for PGC-1α is upregulated regardless of HF etiology. 
This finding may explain observed abnormalities in mitochondrial structure and function 
seen in LV myocardium of patients with advanced HF.
9:30 a.m.
807-5	 Transplantation	of	Bone	Marrow	Mesenchymal	Stem	
Cells	Induces	Angiogenesis	and	Attenuates	the	
Remodeling	of	Diabetic	Cardiomyopathy
Wang Jian an, Li Jia hui, Zhang Nan, Luo Rong hua, Jiang Jun, No.2 affiliated hospital, 
College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Background:	 Diabetic cardiomyopathy (DCM), an important cause of heart failure, is 
characterized by microvascular pathologies and interstitial fibrosis. Bone marrow mesenchymal 
stem cells (MSCs) are pluripotent, which can differentiate into cardiomyocytes and vascular 
endothelial cells. They also secrete angiogenic and antiapoptotic factors. However, little 
information is available about the effect of MSC transplantation on diabetic heart.
Methods:	MSCs were isolated from bone marrow of isogenic adults and cultured ex vivo. 
Diabetic rat was induced with streptozotocin and exogenous MSCs labelled with 4’6-Diamidino-
2-Phenylindole were injected into the femoral vein 8 weeks later. 4 weeks after transplantation, 
we evaluated the cardiac conditions in control, DCM and DCM+MSC group by echocardiography, 
histopathologic analysis, reverse transcription polymerase chain reaction analysis for matrix 
metalloproteinase(MMP)-2, MMP-9 and tissue inhibitor of matrix metalloproteinase(TIMP)-1, 
zymography analysis for activites of MMP-2 and western blot analysis for Troponin T(TnT).
Results: Left ventricular posterior wall thickness and myocardial arteriolar density were 
decresed in DCM group ( P<0.01 versus control respectively ), which were both improved by 
MSC transplantation (p<0.05 versus DCM respectively). MSC transplantation also decreased 
elevated fibrosis fraction and elevated transcriptional level of MMP-9 in diabetic myocardium, 
while only the latter reached statistical significance (p<0.01 versus DCM). The transcriptional 
level of TIMP-1 mRNA and MMP-2 activity were decreased in DCM group (p<0.01 versus 
control group respectively), which were both increased by MSC transplantation, although only 
the change in MMP-2 activity reached statistical significance (p<0.01 versus DCM group).
Conclusion	Intravenous MSC transplantation induces angiogenesis and attenuates the 
remodeling of DCM.
9:45 a.m.
807-6	 Effect	of	Glycemic	Control	in	a	Canine	Model	of	
Diabetes	and	Left	Ventricular	Dysfunction	on	Left	
Ventricular	Performance:	Utility	of	the	Index	of	
Myocardial	Performance
Steven J. Lavine, Petar Prcevski, University of Florida, Jacksonville, FL, Wayne State 
University, Detroit, MI
Background: Although diabetic cardiomyopathy may cause LV dysfunction, the influence of 
glycemic control on LV systolic and diastolic function with pre-existing LV dysfunction is not 
well described. The index of myocardial performance (IMP) has been useful in characterizing 
prognosis post myocardial infarction and with cardiomyopathy. We hypothesized that IMP 
may reflect both systolic and diastolic abnormalities and be useful in assessing the effect of 
glycemic control on LV function with pre-existing LV dysfunction.
Methods:	Chronic	 LV dysfunction was induced in 11 dogs using coronary microsphere 
embolization to produce an ejection fraction (EF) between 35-40%. Following stabilization, 
diabetes was induced with sequential injections of alloxan tetrahydrate and randomized to 
either good control (GC) (fasting blood glucose: 100-150 mg%) or poor control (PC) (fasting 
blood glucose between 250-350 mg%) for 3 months using insulin. After 3 months, each dog 
was crossed over to the opposite glycemic control group. LV size and function was assessed 
with LV pressures, echo and Doppler prior to diabetes induction and with PC and GC.
Results:	With PC (hemoglobin A1c: 8.7+3.2%), EF declined as compared to baseline LV 
dysfunction (38+6% vs 34+5%, p=0.04). Both septal (p<0.05) and posterior wall thickness 
declined (10.2+0.6 vs 8.3+1.8 mm, p<0.01). LV end diastolic pressure increased 3 mm Hg, 
P<0.05 and deceleration time declined (195+30 vs 151+28 msec, p<0.01). IMP increased 
(0.63+0.24 to 0.81+0.22, p<0.01) due to an increase in isovolumic contraction time (52+25 
to 108+36 msec, P<0.001) despite a shortening of the isovolumic relaxation time (67+23 vs 
39+20 msec, p<0.01). The diastolic filling period was also shortened (409+107 vs 512+157 
msec, P<0.01) due to earlier end of mitral flow (85 msec earlier, p<0.001). The above 
parameters with GC (Hemoglobin A1c: 4.0+0.9) were similar to baseline LV dysfunction. 
Forward stepwise regression revealed that posterior wall thickness (p<0.0001) and isovolumic 
contraction time (p=0.03) were related to glycemic control (r=0.7623, p<0.0001).
Conclusion:	Glycemic control has a modulating effect of LV systolic and diastolic function 
and LV wall thickness.
10:00 a.m.
807-7	 Long-Term	Therapy	With	Metoprolol	Succinate	
Up-Regulates	mRNA	Gene	Expression	of	Glucose	
Transporter-1	and	-4	in	Left	Ventricular	Myocardium	of	
Dogs	With	Chronic	Heart	Failure
Issa Alesh, Sharad Rastogi, Sidney Goldstein, Hani N. Sabbah, Henry Ford Health 
System, Detroit, MI
Background: The typical response of the heart to increased energetic stress is to 
increase utilization of glucose. Recruitment of glucose transport proteins GLUT-1 
and GLUT-4 is a cellular mechanism by which the heart increases glucose transport 
for subsequent metabolism. Instead, the energy stress imposed by heart failure (HF) 
appears to increase dependence on fatty acid oxidation rather than glucose utilization. 
To further explore this maladaptation, we examined mRNA expression of GLUT-1 and 
GLUT-4 in LV myocardium of normal (NL) dogs and dogs with heart failure (HF) that were 
untreated or treated with beta-blockade.
Methods: RNA was isolated from LV tissue of 6 NL dogs, 6 dogs with HF that were not 
treated and 6 dogs with HF treated with extended release metoprolol succinate (MET, 100 
mg once daily). mRNA expression of GLUT-1 and GLUT-4 was measured using RT-PCR 
and bands quantified in densitometric units (du) and normalized to GAPDH, a house 
keeping gene.
Results: mRNA expression of GLUT-1 and GLUT-4 decreased significantly in untreated 
HF dogs compared to NL dogs. Treatment with MET normalized expression of GLUT-1 
and GLUT-4.
Conclusions: The decrease in mRNA expression of GLUT-1 and GLUT-4 in HF may be 
one reason for increased reliance on fatty acid oxidation. Normalization of GLUT-1 and 
GLUT-4 expression with MET may have contributed to a more efficient energy utilization 
in HF and can account, in part, for the improved LV ejection fraction seen following 
therapy with beta-blockers.
NL HF-Untreated HF + MET
GLUT-1 (du) 28.9 ± 0.9 15.8 ± 1.3* 29.6 ± 1.0**
GLUT-4 (du) 30.8 ± 1.2 15.1 ± 0.8* 23.3 ± 1.4**
*=p<0.05 vs. NL; **=p<0.05 vs. HF-Untreated
10:15 a.m.
807-8	 Safety	and	Efficacy	of	Bariatric	Surgery	in	Morbid	
Obese	Patients	With	Severe	Heart	Failure
Gautam V. Ramani, Michael Mathier, University of Pittsburgh, Pittsburgh, PA
Background: Morbid obesity (MO) is an increasingly prevalent chronic metabolic disorder that 
is well established as a risk factor for heart failure. Longstanding MO results in cardiac structural 
changes and reduced LV systolic performance, and impairs functional status in patients with 
established CHF. Bariatric surgery (BAS) has emerged as a viable treatment for MO, yet the 
safety and efficacy of this procedure in severe systolic CHF has not been reported.
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Methods: We performed BAS (10 laparoscopic/ 2 open) on 12 patients with MO (BMI 53 
± 7 kg/m2) and severe systolic CHF (LVEF 22 ± 7%, NYHA 2.9 ± 0.7, 2 ischemic). We 
compared outcomes to 10 matched controls (LVEF 24 ± 7%, p = NS, NYHA class 2.4 
± 0.7; p = NS, 2 ischemic). BMI was modestly, though significantly lower in the control 
group (47.2 ± 3.6 kg/m2; p = 0.02). Controls were counseled regarding diet and exercise 
but did not undergo BAS. Perioperative care was optimized using a cooperative approach 
between surgeons and cardiologists. We assessed operative complications, hospital 
length of stay, hospital readmissions, weight loss, LVEF and NYHA class at 12 months.
Results: BAS was safe, with a mean postoperative hospital length of stay of 3 ± 1 days 
and only two minor post-operative complications. At one year, BAS resulted in a marked 
reduction in BMI (38.19 ± 7.80 kg/m2) with no change in controls (48.2± 2.93 kg/m2, p < 
0.001). Frequency of hospitalization following BAS was significantly lower than controls 
(0.42 ± 0.76 vs. 2.46 ± 2.6, p = 0.04). LVEF (35 ± 15 %, p = 0.005) and NYHA class (2.3 ± 
0.5, p = 0.02) improved significantly in the surgical cohort, but not in controls (29 ± 14%, p 
= NS and 3.3 ± 0.9, p = 0.02, respectively). Overall, 5 controls, but only 1 surgical patient, 
had worsening of NYHA class. Finally, 1 surgical patient was successfully transplanted, 
and another listed for transplantation, compared to zero controls.
Conclusions: This study suggests that BAS can be safe and effective in patients with 
severe systolic CHF and MO. BAS should be considered for such patients who have 
failed diet and medical therapy, and especially for patients who would qualify for cardiac 
transplantation if not for MO. A meticulous perioperative approach is mandatory.
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808-3	 Effect	of	Spironolactone	Use	on	the	Benefit	of	Fixed-
Dose	Combination	of	Isosorbide	Dinitrate/Hydralazine	
in	the	African-American	Heart	Failure	Trial
Jalal K. Ghali, S. William Tam, Anne L. Taylor, Jay N. Cohn, Manuel Worcel, Michael L. 
Sabolinski, Wayne State University, Detroit, MI, NitroMed, Inc., Lexington, MA
Introduction: In A-HeFT, fixed-dose combination of isosorbide dinitrate/hydralazine (I/H) 
reduced mortality and morbidity in African American (AA) patients with HF on standard 
therapy. Spironolactone (SP) added to standard HF therapy may enhance the benefit of 
I/H in AA patients.
Methods: Kaplan-Meier survival analyses were used for comparing between and within 
groups for outcomes in 1,050 A-HeFT patients.
Results: In A-HeFT at baseline, patients receiving SP were significantly younger, heavier, 
with lower LVEF, systolic and diastolic BP, and higher use of beta blockers and digoxin. 
There was no significant difference in patient demographics, baseline characteristics and 
medications between I/H and placebo groups within subgroup of SP use or no SP use. 
In the whole A-HeFT population, I/H, compared to placebo, was effective in reducing 
mortality and morbidity. Subgroup analysis by baseline SP use showed that I/H, compared 
to placebo, significantly decreased all-cause mortality and morbidity regardless of SP or 
other standard heart failure medication usage. Within the I/H group, SP use significantly 
enhanced the survival benefit of I/H. In contrast, within the placebo group, SP use had no 
impact on mortality or morbidity. 
Outcome Group Comparison(n)
Hazard	
Ratio
%	Risk	
Reduction P
Death All Patients I/H (518)) vs. Placebo (532) 0.57 43 0.012
Death I/H Patients 
only
SP Use (208) vs. No SP 
Use (310) 0.41 59 0.034
Death Placebo Patients only
SP Use (201) vs. No SP 
Use (331) 1.13 0 0.668
Death or 1st 
HF Hosp All Patients
I/H (518)) vs. Placebo 
(532) 0.63 37 0.0002
Death or 1st 
HF Hosp
SP Use 
Patients
I/H (208) vs. Placebo 
(201) 0.49 51 0.0004
Death or 1st 
HF Hosp
No SP Use 
Patients
I/H (310) vs. Placebo 
(331) 0.73 27 0.049
Death or 1st 
HF Hosp
Placebo 
Patients only
SP Use (201) vs. No SP 
Use (331) 1.07 0 0.699
Conclusion: In A-HeFT, I/H significantly decreased the risk of mortality and morbidity in 
AA patients with HF regardless of SP use. Within the limitations of sub-group analysis, 
the use of SP appears to potentiate the effect of I/H while no benefit was noted in patients 
not receiving I/H.
9:15 a.m.
808-4	 Nesiritide	Does	Not	Cause	Renal	Dysfunction	in	Acute	
Decompensated	Heart	Failure:	A	Randomized,	Double-
Blind,	Placebo-Controlled	Clinical	Trial
Ronald M. Witteles, David Kao, Randall Vagelos, Dianne Christopherson, Kelly Matsuda, 
Donald Schreiber, Michael B. Fowler, Stanford University School of Medicine, Stanford, CA
Background: Nesiritide (human B-type natriuretic peptide) is approved for the treatment 
of acute decompensated heart failure. Subsequent retrospective analyses have raised 
concerns that it may cause worsened renal function. To date, no randomized clinical trials 
have prospectively evaluated this issue.
Methods: The B-Type Natriuretic Peptide in Cardiorenal Decompensation Syndrome 
(BNP-CARDS) trial was a randomized, double-blind, placebo-controlled clinical trial 
performed at two sites from March, 2004-August, 2006. Consecutive patients with acute 
decompensated heart failure and moderate-severe baseline renal dysfunction (calculated 
creatinine clearance 15-60 cc/min) were enrolled within 12 hours of hospital admission 
after informed consent. Subjects were randomized to receive nesiritide (0.01 mcg/kg/min 
with or without a 2 mcg/kg bolus) or placebo (5% dextrose in water) for 48 hours in 
addition to their usual care. The predefined primary endpoints of the trial were a rise in 
serum creatinine by ≥ 20%, and change in serum creatinine from baseline to discharge.
Results: Seventy-five patients were enrolled in the trial (39 nesiritide, 36 placebo). The 
groups had similar baseline age (74.9 vs. 75.5 years, respectively), blood pressure (123/64 
vs. 125/64 mmHg) and serum creatinine (1.82 vs. 1.86 mg/dl). There were no significant 
differences in the incidence of a 20% creatinine rise (23% vs. 25%, p=NS) or in the absolute 
change in creatinine (-0.05 vs. +0.05 mg/dl, p=NS). There were no significant differences 
in the predefined secondary endpoints of change in weight (-2.19 vs. -1.58 kg, p=NS), net 
diuresis of at least one liter for each 24 hours on the infusion (49% vs. 48%, p=NS), total 
furosemide dose during the infusion (125 vs. 107 mg, p=NS), median length of hospitalization 
(4 vs. 4 days, p=NS), need to have the infusion discontinued due to hypotension (13% vs. 
6%, p=NS), or 30-day death/hospital readmission (33% vs. 25%, p=NS).
Conclusion: In this randomized, double-blind, placebo-controlled clinical trial which 
prospectively evaluated the effects of nesiritide on renal function in acute decompensated 
heart failure, there was no evidence of a negative impact on renal function.
9:30 a.m.
808-5	 Ultrafiltration	Is	Associated	With	Fewer	Re-
Hospitalizations	Than	Continuous	Diuretic	Infusion	in	
Patients	With	Decompensated	Heart	Failure:	Results	
From	UNLOAD
Maria Rosa Costanzo, Mitchell T. Saltzberg, Mariell L. Jessup, John R. Teerlink, Paul A. 
Sobotka, Midwest Heart Foundation, Lombard, IL
Background: In the Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized 
for Acute Decompensated Heart Failure (UNLOAD), ultrafiltration (UF) was associated 
with greater fluid reduction at 48 hours after randomization and fewer heart failure (HF) 
re-hospitalizations in 90 days than intravenous (IV) diuretics in 200 pts hospitalized for 
HF and volume overload (63±15 years, 69% male, 71% LVEF ≤ 40%). While the reduced 
hospitalizations may have been due to more effective volume removal by UF, UF also 
removes more sodium per unit volume than diuretics. We hypothesized that, compared 
to continuous IV diuretic infusion (inf), UF is associated with similar fluid loss but fewer 
re-hospitalizations in 90 days.
Methods: The outcomes of 100 pts randomized to UF (veno-venous UF≤500 cc/h) were 
compared with those of 32 pts randomized to standard care given as diuretic inf ( ≥ twice 
daily PO dose in the 48 hours post-randomization) using the Wilcoxon’s rank sum testa	
and	Fisher’s exact testb.
Results: At 48 hours weight (5.0±3.1 vs. 3.6±3.5 Kg; p=0.145)a and net fluid loss (4.6 vs. 
3.9 L; p=0.232)a were similar in the UF and diuretic inf groups. At 90 days the UF group 
had fewer: pts re-hospitalized for HF [16/89 (18%) vs.11/28 (39%); p=0.037]a; mean HF re-
hospitalizations (0.22±0.54 vs. 0.54±0.79; p=0.018)a; re-hospitalization days/pt (1.4±4.1 
vs. 4.9±10.5; p=0.016)a; and pts presenting for unscheduled visits [14/65 (21.5%) vs. 
11/29 (52.4%); p=0.012]b. No serum creatinine differences occurred between groupsa. 
Deaths: 9/94 (9.6%) in UF and 6/31 (19.4%) in diuretic inf group: p=0.200.
Conclusions: Despite similar fluid loss by UF vs. diuretic inf, sustained clinical benefit, as 
indicated by fewer re-hospitalizations for HF and unscheduled visits, occurred only with UF. 
These findings suggest that removal of isotonic fluid by UF vs. hypotonic urine by diuretic inf 
may be a superior strategy for pts with decompensated HF and volume overload.
9:45 a.m.
808-6	 Mechanical	Stretch	Enhances	the	Expression	of	Resistin	
Gene	in	Cultured	Rat	Cardiomyocytes	via	TNF-α
Kou-Gi Shyu, Bao-Wei Wang, Peiliang Kuan, Hang Chang, Shin Kong Wu Ho-Su 
Memorial Hospital, Taipei, Taiwan,ROC
Background:	Heart is a resistin target tissue and heart can function as an autocrine organ. 
Cardiac myocytes have been identified as a principal target of the pro-inflammatory actions of 
tumor necrosis factor-α (TNF-α). TNF-α can modulate the expression of resistin in adipocytes 
and peripheral blood mononuclear cells. The link between TNF-α and resistin in cardiomyocytes 
has not been previously reported. The present study was designed to investigate whether cyclic 
mechanical stretch could induce resistin expression in cardiac myocytes and to test whether there 
is a linkage between the stretch-induced TNF-α and resistin.
Methods:	 Neonatal Wistar rat cardiomyocytes grown on a flexible membrane base were 
stretched by vacuum to 20% of maximum elongation at 60 cycles/min.
Results:	 RT-PCR confirmed the expression of mRNA in cardiomyocytes. Cyclic stretch 
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significantly increased resistin protein and mRNA expression after 2 h to 18 h of stretch. Addition 
of PD98059, TNF-α monoclonal antibody, and ERK MAP kinase siRNA 30 min before stretch 
inhibited the induction of resistin protein. Cyclic stretch increased, while PD98059 abolished the 
phosphorylated ERK protein. Gel shifting assay showed significant increase of DNA-protein 
binding activity of NF-κB after stretch and PD98059 abolished the DNA-protein binding activity 
induced by cyclic stretch. DNA-binding complexes induced by cyclic stretch could be supershifted 
by p65 monoclonal antibody. Chromatin immunoprecipitation assays also demonstrated the 
acetylation of histones with resistin promoter in cardiomyocytes after stretch. Cyclic stretch 
significantly increased the TNF-α secretion from myocytes. Recombinant resistin protein and 
conditioned medium from stretched cardiomyocytes reduced glucose uptake in cardiomyocytes 
and recombinant siRNA of resistin or TNF-α antibody reversed the glucose uptake.
Conclusions: Cyclic mechanical stretch enhances resistin expression in cultured rat neonatal 
cardiomyocytes. The stretch-induced resistin is mediated by TNF-α at least in part, through ERK 
MAP kinase and NF-κB pathways. This study confirms that heart is not only a resistin target tissue 
but also a resistin autocrine organ.
10:00 a.m.
808-7	 Hemodynamic	Effects	of	Bosentan	on	Patients	With	
Severe	Heart	Failure	and	Left	Ventricular	Systolic	
Dysfunction	Associated	With	Pulmonary	Hypertension:	
A	Multicenter	Randomized	Trial
Edo Kaluski, Gad Cotter, Marina Leitman, Olga Milo Cotter, Isaac Kobrin, Tina Moriconi, 
Maruizio Rainisio, Avraham Caspi, Leonardo Reizin, Reuven Zimlichman, Zvi Vered, 
Department of Cardiology, University of Medicine and Dentistry of New Jersey, Newark, NJ, 
Department of Cardiology, Assaf Harofeh Medical Center, University of Tel Aviv, Zrifin, Israel
Background: Studies employing intravenous endothelin blockers for treatment of 
symptomatic heart failure (HF), were able to demonstrate significant short term improvement 
in both cardiac output and pulmonary wedge pressure. The studys’ objective was to assess 
the effects of bosentan, on hemodynamic, morphologic, and functional parameters, over a 
therapeutic period of 20 weeks.
Methods: Multi-center, double-blind, randomized, placebo controlled study, comparing bosentan 
gradual up-titration protocol (starting at 8 mg BID, with up-titration every 4 weeks to 16, 32, 62.5 
and 125 mg BID) to placebo (2:1) in patients with NYHA IIIb-IV HF, and left ventricular ejection 
fraction <35%, associated with pulmonary hypertension >40 mmHg. Echo-doppler interoggation 
was performed every 4 weeks, and was read by central core lab. Primary and secondary endpoints 
were the change from baseline in systolic pulmonary artery pressure (SPAP) and cardiac index 
(CI) respectively. Exploratory endpoints were 25 hemodynamic, morphological, and functional 
measurements obtained every 4 weeks during echo-Doppler interrogation.
Results: 94 patients enrolled, 60 to bosentan 34 to placebo. There was no significant difference 
in SPAP change (0.1 ± 11.5 mmHg , 95% CL -5.4-5.2, p=0.97) or CI shift (0.12 ± 0.45, 95% CL 
-0.09-0.33 , p = 0.24 ) between the 2 arms. The other 25 parameters measured every 4 weeks did 
demonstrate any favorable effect of therapy.
Conclusions: Bosentan therapy did not yield any sustained measurable hemodynamic, 
morphologic, or functional benefits, in patients with severe heart failure.
10:15 a.m.
808-8	 The	V-HeFT	Paradox,	Identical	Doses	of	Different	
Formulations	of	Isosorbide	Dinitrate	and	Hydralazine	
Are	Not	Bioequivalent	and	Neither	Is	Bioequivalent	to	
the	Fixed-Dose	Combination	of	ISDN/Hydralazine	Used	
in	A-HeFT
Michael L. Sabolinski, Milton Packer, S. William Tam, Manuel Worcel, Jay N. Cohn, 
NitroMed, Inc., Lexington, MA, University of Minnesota, Minneapolis, MN
Introduction: In the V-HeFT I trial, a combination of isosorbide dinitrate (ISDN) and 
hydralazine HCl (HYD), increased survival of black heart failure (HF) patients by 47% 
(p<0.04) when compared to placebo in a retrospective analysis. The V-HeFT II trial used 
a different HYD formulation and found ISDN + HYD to be comparable to enalapril in 
blacks in a retrospective analysis of mortality (HR 1.01, p=0.96). The apparent difference 
in the annual mortality rates for ISDN + HYD treatment of black patients in V-HeFT I 
(9.7%) and V-HeFT II (12.9%) has not been addressed previously. We investigate whether 
this apparent lower efficacy of ISDN + HYD in V-HeFT II could be due to differences in 
bioequivalence of the study drug materials.
Methods: A bioequivalence study was performed (n=19-20 per group) comparing 
the V-HeFT I and V-HeFT II ISDN and HYD formulations. The proprietary fixed-dose 
combination of ISDN/HYD (I/H) was tested as a third arm.
Results: V-HeFT I used a HYD capsule (37.5 mg) and an ISDN tablet and V-HeFT II used 
a HYD tablet (37.5 mg) and the same ISDN formulation as in V-HeFT I. I/H tablets used 
in A-HeFT also contained 37.5 mg HYD. Even thought all 3 arms of the bioequivalence 
study used identical amounts of active drugs, neither V-HeFT I nor V-HeFT II study drug 
materials were bioequivalent to each other based on the ratios of C
max
, AUC, t1/2, and Tmax. 
Compared to the V-HeFT II HYD tablets, the HYD capsules of V-HeFT I had significantly 
higher bioavailability (tablet/capsule: C
max
 ratio=0.46, AUC ratio=0.62). The 90% CI 
exceeded the FDA requirements of 0.80 - 1.25 required for bioequivalence. These results 
may explain the lower mortality benefit of ISDN+HYD in blacks shown in V-HeFT II 
compared to ISDN+HYD in V-HeFT I. The formulations of ISDN and HYD used in V-HeFT 
I and V-HeFT II were not bioequivalent, and neither were bioequivalent to the formulation 
of fixed-dose combination of I/H.
Conclusion:	The ISDN and HYD formulations used in V-HeFT I and II and the fixed-
dose combination of I/H formulation were not bioequivalent. The strength of evidence for 
improving survival in black HF patients in each of these studies may have been affected 
by the pharmacokinetic properties of formulations tested.
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1016-55	 Glucagon-Like	Peptide-1	(GLP-1)	Decreases	Myocardial	
Contractility	and	Stimulates	Myocardial	Glucose	
Uptake	by	Opening	Sarcolemmal	K+ATP	Channels
Siva Bhashyam, Pratik Parikh, Alexander H. Shannon, James H. Porter, Richard P. 
Shannon, Allegheny General Hospital, Pittsburgh, PA
Background: GLP-1 is an incretin hormone shown to be cardio protective. GLP-1[7-36] 
amide and its active metabolite GLP-1[9-36] amide stimulate glucose uptake and improve 
LV systolic function in cardiomyopathy. It is unclear if the effects are direct on myocardium 
and if both GLP-1[7-36] and its metabolite GLP-1[9-36] act through the GLP-1 receptor.
Methods: We studied 3 month old Sprague Dawley rats (n=80) using isolated, isovolumic 
heart preparations perfused with KH solution containing 5mM glucose and 40 µU/L 
insulin. At 30 min, GLP-1[7-36] or GLP-1[9-36] was added. Contractility and glucose 
uptake (MGU) were assessed, and compared to control in the presence and absence 
of the GLP-1 R antagonist, exendin 9-39 (EX), the K+ATP channel closer, glybenclamide 
(GLIB) and a DPP-IV inhibitor (Diprotin A).
Results: In normal hearts, GLP-1[7-36] decreased LV contractility by 29%, but increased 
MGU by 56%. Effects on contractility but not the effects on MGU were blocked by EX. 
DPPI did not affect contractility but blocked the increase in MGU with GLP-1[7-36]. In 
contrast, the active metabolite GLP-1[9-36] had no effect on contractility, but increased 
MGU. The effects of GLP-1[9-36] were unaffected by EX, but were abolished by GLIB.
Conclusion: GLP-1 acts directly on the normal myocardium. Effects on contractility are 
mediated through the GLP-1 receptor, but MGU is mediated through the K+ATP channel. 
Importantly, while GLP-1[7-36] alters contractility, GLP-1[9-36] stimulates MGU acting 
though the K+ATP channel. 
GLP-1	(7-36)
Δ FROM BASE LINE
CONTROL
GLP-1
(400-800  
pmol/L)
EX
(3 nmol) 
+
GLP-1
GLIB
(10 nmol) 
+
GLP-1
DPP -IV I
(0.1 mmol) 
+
GLP-1
LV	dev	P	
(110±2	mmHg) -3±4 -32±7* -4±5 -29±3* -21±4*
HR	
(267±26	beats/min) -15±7 -10±6 -9±10 -7±6 -7±8
CBF	
(21±4	ml/min) -2±0.5 -3±0.5 -4±0.6 -4±0.4 -4±0.2
MGU	
(1.78±0.3	µmol/min) 0.03±0.3 1±0.1* 0.9±0.2* -0.2±0.3 -0.5±0.4
GLP-1	(9-36)
Δ FROM BASE LINE
CONTROL
GLP-1
(400-800  
pmol/L)
EX
(3 nmol) 
+
GLP-1
GLIB
(10 nmol)
+
GLP-1
LV	dev	P	
(110±2	mmHg) -3±4 4±9 2±7 0.5±5
HR	
(267±26	beats/min) -15±7 -9±13 -8±10 -13±13
CBF	
(21±4	ml/min) -2±0.5 -3±0.6 -4±0.6 -3±0.5
MGU	
(1.78±0.3	µmol/min) 0.03±0.3 1.9±0.2* 2.3±0.4* -0.02±0.3
*	p<0.05	compared	to	Control
9:00 a.m.
1016-56	 Improvement	in	Cardiac	Function	with	Parecoxib,	
a	Cyclo-oxygenase-2	Inhibitor,	in	aA	Rat	Model	of	
Ischemic	Heart	Failure
Antonio Abbate, Fadi N. Salloum, Ramzi Ockaili, Evan Ownby, Giuseppe Biondi-Zoccai, 
Stefania Straino, Michael Lipinski, Rakesh C. Kukreja, George W. Vetrovec, Virginia 
Commonwealth University, Richmond, VA
Background. Cyclooxygenase-2 (COX-2) expression has been found in patients with 
congestive heart failure (CHF) and associated with worsening failure. However, direct 
evidence of functional effects of COX-2 inhibition in ischemic CHF is lacking. The aim of 
this study was to assess changes in cardiac function in rats with ischemic CHF treated 
with parecoxib, a selective COX-2 inhibition.
Methods. Thirty male Wistar rats (10 weeks of age, 350-500 g of weight) underwent 
coronary ligation. Five sham-operated rats were also available for comparison. Of the 
30 animals, only 6 (20%) survived up to 12 months. All animals underwent transthoracic 
echocardiography for the measurement of dimensional and functional parameters. The 
animals were thereafter treated with a soluble COX-2 inhibitor, parecoxib (0.75 mg/Kg 
intraperitoneal) daily for 7 days. On day 7, 1 hour after treatment, a repeat echocardiogram 
was obtained. Continuous variables are expressed as mean and standard error.
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Results.	 All 6 animals survived the 7-day treatment. Echocardiography after 7 days 
of parecoxib treatment showed no changes in the EDD (9.4±0.4 mm vs 9.4±0.3 mm, 
P=0.9), a significant reduction of ESD (5.5±0.8 mm vs 6.4±0.3 mm, P=0.028), and a 
significant improvement in the FS (43±0.3% vs 32±5%, P=0.027). Improvement of FS 
was associated with a significant change in systolic thickness in the infarct-zone (3.6±0.4 
mm vs 3.0±0.1 mm, P=0.046), while no significant changes in systolic thickness in the 
remote area were observed (3.8±0.3 mm vs 3.9±0.3 mm, P=0.62). 
Conclusions. These preliminary data show that inhibition of COX-2 with parecoxib in 
the setting of ischemic CHF in the rat model provides functional improvement in the peri-
infarct myocardium with improved global function. These results suggest that selective 
COX-2 inhibition promotes late recovery of function in ischemic CHF.
9:00 a.m.
1016-57	 Gender	Specific	Responsiveness	to	Aldosterone	
Receptor	Antagonism	Following	Myocardial	Infarction
Rosemeire M. Kanashiro-Takeuchi, Joshua M. Hare, Johns Hopkins University, 
Baltimore, MD
Background: Aldosterone antagonists reduce mortality and improve post-myocardial 
infarction (MI) remodeling. Female sex steroids such as estrogen and progesterone 
are known modulators of the renin-angiotensin-aldosterone system. However, gender 
specific responsiveness has not been explored in rats post-myocardial infarction.
Methods	 and	 Results: MI induced by coronary artery ligation or sham surgery was 
performed in female and male 6-month-old Wistar rats. Animals were randomly assigned 
to receive either a 4-week course of eplerenone (100 mg/kg per day, in food) or placebo 
starting 3 days post-surgery and up to sacrifice 4 weeks later, while the other two groups 
received placebo. MI led to an increase in chamber dimension (from 7.35±0.01 to 
10.0±0.03 mm, p<0.05). This increase was reduced by eplerenone in females (8.85±0.04 
mm, p<0.01) but not in males (9.70±0.03 mm, p>0.05). Similarly a reduction in ejection 
fraction (EF) from 82±1.2 to 44±3.7% (p<0.05) due to MI was ameliorated in females 
(57±3.3 %, p<0.05) but not in males (51±6.2% p>0.05). Eplerenone also reduced infarct 
size in females (47.7±3.8% vs. 31.6±2.9%, p<0.01) but not in males (37.9±4.2% vs. 
31.6±2.9%, p=ns).
Conclusion: Together these data support a selective responsiveness of aldosterone 
receptor antagonist in females compared to males following MI. These findings support 
the idea that the mineralocorticoid pathway may be more active in females with left 
ventricular dysfunction and therefore have important therapeutic implications.
9:00 a.m.
1016-58	 Differential	Activation	of	JAK-STAT	Signaling	in	Cardiac	
Dysfunction	Due	to	Myocarditis	vs.	Pressure	Overload
Cassandra Talerico, Karin Mauer, Wendy E. Sweet, Christine S. Moravec, Cleveland 
Clinic, Cleveland, OH, Cleveland State University, Cleveland, OH
Background: The JAK-STAT (Janus Kinase-Signal Transducers and Activators of 
Transcription) signaling pathway can be stimulated in cardiomyocytes by cytokines, 
angiotensin II and mechanical stretch, all of which are increased during cardiac stress. 
Studies suggest that the pathway is activated in cardiac hypertrophy and may protect against 
the transition to heart failure (HF). It remains unclear, however, if the JAK-STAT pathway is 
involved in all forms of cardiac hypertrophy and whether it always protects against HF. We 
have examined activation of the JAK-STAT pathway in two mouse models of the progression 
from hypertrophy to HF: autoimmune myocarditis (AIM) and pressure overload (PO).
Methods: AIM was induced by immunizing mice with porcine cardiac myosin. Controls 
were injected with an equal volume of vehicle. Mice were sacrificed weekly for 42 
days; disease was verified histologically. PO was induced in mice by transverse aortic 
constriction; in sham-operated mice, the ligature was not placed. PO mice were sacrificed 
starting at post-op day 7 and continuing to HF, which was determined by echo. STAT1, 
3 and 5 dimer presence and composition were assessed by gel shift and supershift. P-
STAT3, STAT3, P-JAK2, JAK2, sarcoendoplasmic reticulum calcium ATPase (SERCA2A) 
and calsequestrin (CSQ) were quantified by Western blot. P-STAT3 localization to cardiac 
myocyte nuclei was ascertained by immunofluorescence.
Results: STAT dimer formation in cardiac nuclear extracts was observed in both AIM 
and PO. In AIM, STAT3/STAT3 and STAT3/STAT1 dimers were present on days 14, 21 
and 28 after immunization - days on which inflammation was present. In PO, activation 
appeared earlier - at day 7 after constriction, and continued through HF. P-STAT3 was 
also increased in both groups of treated mice as compared to controls (AIM, P < 0.0001; 
PO, P = 0.02). In PO mice, CSQ, SERCA2A and P-JAK2 levels did not differ between 
groups, but in AIM, CSQ was elevated in treated mice (P = 0.02).
Conclusions: While JAK-STAT signaling is activated in both models, it occurs earlier in 
PO than in AIM. Activation also persists in PO until HF whereas in AIM it returns to basal 
levels as inflammation resolves.
9:00 a.m.
1016-59	 Angiotensin	1-7	Protects	Against	Angiotensin	II	
Mediated	Apoptotic	Cell	Death	in	Cardiomyocytes	and	
Might	Partly	Explain	Benefits	of	ACE-Inhibition
Aparna Godavarthy, Ruth Anway, Inder Anand, Y. Chandrashekhar, VAMC/University of 
Minnesota, Minneapolis, MN
Background:	ACE inhibition (ACE-I), in addition to decreasing Angiotensin II (Ang II), 
may also utilize other pathways of cardioprotection.
Hypothesis: Angiotensin 1-7 (increased during ACE-I) would decrease Ang II mediated 
cardiomyocyte apoptosis. Moreover, Angiotensin 1-7 would also amplify the ACE-2 gene 
& further enhance cardioprotection.
Methods: 2 sets of experiments were done. (1). Cultured rat cardiomyocytes were 
exposed to Angiotensin 1-7 (50-250 nM) with or without pre-exposure to Ang II (100 nM) 
& tested for apoptosis (TUNEL & Caspase 3 tag), ACE-2 mRNA (RT-PCR) & protein 
(Western) levels. (2). Myocardial ACE-2 mRNA, protein & Ang 1-7 levels and apoptosis 
were measured in rats at 4 weeks (n=6) post MI with & without ACE Inhibition.
Results: Ang II induced significant apoptosis. Co-administering Ang 1-7 attenuated Ang II 
induced cardiomyocyte apoptosis, decreased Bax/Bcl2 ratio & increased in ACE-2 mRNA 
& protein in cardiomyocytes. In-Vivo ACE-I increased Ang 1-7 levels & up-regulated ACE-
2 mRNA & protein (152% & 87% more than untreated MI) in remote myocardium of rats 
with MI. This was accompanied by decreased apoptosis.
Conclusion: Angiotensin 1-7 protects against Ang II induced cardiomyocyte apoptosis. 
Furthermore, it augments ACE-2 gene & protein levels which would further augment 
Ang 1-7 levels. Since ACE inhibition increases Ang 1-7 levels, anti apoptotic effects of 
Angiotensin 1-7 might play a role in ACE-I mediated cardioprotection in the failing heart. 
9:00 a.m.
1016-60	 Gender	Differences	In	The	Cardiac	Response	To	
Pressure	Overload	In	Mice
Carola Schubert, Daniela Fliegner, Adam Penkalla, Ulrich Kintscher, Jan-Ake 
Gustafsson, Vera Regitz-Zagrosek, Charité-Universitätsmedizin Berlin, Berlin, Germany, 
Karolinska Institute, Stockholm, Sweden
Background: Myocardial hypertrophy and heart failure (HF) are induced by aortic stenosis 
(AS). Gender differences in the manifestation of myocardial hypertrophy in patients with 
AS are well documented. Comparably, sex-differences in myocardial morphology and 
function have been found in an animal model of pressure overload. It has been suggested 
that estrogen receptors (ER) are involved in these sex-differences.
Aim:	We investigated the pathophysiological and molecular mechanisms underlying the 
sex-differences in the response to pressure overload and the influence of ERβ.
Methods:	 We performed transverse aortic constriction (TAC) or SHAM surgery in 
male and female wild-type (WT) mice and mice lacking functional ERβ (BERKO). 
Echocardiographical measurements were done after week 2, 3, 4, 6 and 9 and 
hemodynamic measurements after 9 weeks. Animals were killed 2 or 9 weeks post-
surgery. Hearts were removed for histology and expression analyses.
Results:	We observed a significant increase in LVW/TL (left ventricular weight/tibia length) 
ratio (131-154%) in all TAC animals after 2 weeks. Ejection fraction (EF) was unchanged 
after 2 weeks in all animals (EF: 48-52%). After 9 weeks, the increase in LVW/TL was 
comparable in WT females and males. The increase of LVW/TL in BERKO females was 
significantly stronger than in BERKO males (Fem: 96%, M: 59 %; p<0,01). After 9 weeks, 
WT males and females showed a significant decrease in EF after TAC without gender 
differences (EF
m.
=34%; EFfem.=36%). 9 weeks after SHAM surgery, BERKO males had a 
significantly lower EF than WT males (EFBERKO=40%; EFWT=48%, p<0,05). 9 weeks after 
TAC, BERKO males had a lower EF than BERKO females.
Conclusion:	2 weeks after TAC normal systolic function was maintained in the presence 
of significant hypertrophy in all groups. After 9 weeks, deletion of ERβ increased 
hypertrophy to a greater degree in female than in male mice. EF decreased in SHAM-
operated BERKO males and in TAC males and females. The decrease in EF in TAC 
males was stronger than in females in WT and BERKO animals. The loss of ERβ led to a 
loss in EF in unstressed males, but not females, and to a stronger loss in cardiac function 
in male than in female animals with pressure load.
9:00 a.m.
1016-61	 Desmin	Content	In	Right	and	Left	Ventricle	in	
Congenital	Heart	Disease,	an	Indicator	of	Heart	Failure
Alistair Phillips, Gretel Monreal, Angela Cook, John Bauer, Mark Galantowicz, Mark Gerhardt, 
Columbus Children’s Hospital, Columbus, OH, The Ohio State University, Columbus, OH
Background: Mechanical overload secondary to chronic heart failure induces 
progressive cytoskeletal remodeling characterized by increased desmin protein. The 
effects of congenital defects such as patent ductus arteriosus (PDA) and ventricular 
septal defect (VSD), which also result in cardiac overload, on cytoskeletal remodeling 
remain unknown. We measure myocardial desmin protein in the left and right ventricles 
(LV, RV) in porcine models of PDA and VSD.
Methods: 38 pigs underwent either creation of a mid-muscular VSD (LV approach) or 
PDA (balloon angioplasty) for one week duration. Myocardium from healthy pigs was 
used for controls. Wall thickness measurements were obtained from explanted hearts. 
SDS-PAGE and western blot were performed on LV and RV myocardial samples (mid-
papillary, lateral walls) using desmin antisera.
Results: VSD myocardium demonstrated a 65% increase in LV desmin and negligible 
changes in RV desmin compared to controls. PDA myocardium demonstrated the 
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reciprocal: negligible changes in LV desmin, but a 73% increase in RV desmin content 
compared to controls. LV wall thickness in VSD and PDA hearts increased 9% and 26%, 
respectively, compared to controls. RV wall thickness in VSD and PDA hearts increased 
18% and 30%, respectively, compared to controls.
Conclusions: VSD and PDA result in differential ventricular cytoskeletal alterations. 
There is different expression of desmin in the right and left ventricle in heart failure models 
of left to right shunts. Desmin may be an important indicator of worsening heart faiulre in 
congenital heart defects.
9:00 a.m.
1016-62	 Levosimendan	Does	Not	Adversely	Impact	Mortality	in	
Patients	with	Increased	Serum	Creatinine:	REVIVE	II
John R. Teerlink, Roopal Thakkar, James B. Young, Jeffrey E. Salon, Leticia Delgado-
Herrera, Robert J. Padley, SFVAMC/University of California-San Francisco, San 
Francisco, CA
Background: Worsening renal function (WRF) during treatment for acute decompensated 
heart failure (ADHF) has been associated with an increased mortality risk. We 
hypothesized that levosimendan therapy would not adversely impact mortality in ADHF 
patients who developed WRF.
Methods:	REVIVE II was a randomized, double-blind study of 600 patients with ADHF 
treated with levosimendan (a vasodilator and enhancer of cardiac contractility) or placebo, 
each in addition to standard of care. Post-hoc analyses were performed on data from patients 
with WRF, defined as serum creatinine (Cr) increases of ≥0.5 mg/dL or 25% above baseline.
Results:	In the ITT population, mean change in Cr from baseline and mortality through 31 
d were not statistically different between treatment groups. Mean change from baseline 
in BUN was similar at 24 hrs and lower in the levosimendan group at day 5 (+0.9 vs. +5.4 
mg/dL for levosimendan and placebo, respectively; p=0.001). The proportion of patients 
with WRF differed at 24 hrs [9.0% (25/277), levosimendan vs. 3.8% (10/265), placebo; 
p=0.013)], but not at 5, 14, 31, or 90 d. For those patients with WRF at 24 hours, more 
levosimendan-treated patients experienced hypotensive events in the first 24 hours [64% 
(16/25) vs. 40% (4/10), respectively]; however, mortality was similar between the two 
treatment groups at 31 and 90 days.
Conclusion: Levosimendan-treated patients with WRF at 24 hours had similar short- and 
long-term mortality compared to placebo-treated patients with WRF at 24 hours.
All-Cause Mortality
Days after start of study drug 
infusion Patient Group
Deaths	n	(%)
Levosimendan Placebo
31
All patients1 20 (6.7) 12 (4.0)
Met WRF criteria2 1 (4.0) 1 (10.0)
Did not meet WRF 
criteria3 17 (6.7) 9 (3.5)
90
All patients1 45 (15.1) 35 (11.6)
Met WRF criteria2 1 (4.0) 1 (10.0)
Did not meet WRF 
criteria3 41 (16.3) 31 (12.2)
1n=299 levosimendan and 301 placebo.
2WRF, worsening renal function, defined as an increase of ≥0.5 mg/dL or 25% in 
serum creatinine (Cr) above baseline at 24 hours; n=25 levosimendan and 10 placebo; 
excludes patients with missing Cr values.
3n=252 levosimendan and 255 placebo; excludes patients with missing Cr values.
9:00 a.m.
1016-63	 Pooled	Mortality	for	the	First	31	Days	Following	Treatment	
With	Levosimendan	is	Similar	to	Comparator	Therapies
Ferenc J. Follath, Markku S. Nieminen, Milton Packer, Wilson S. Colucci, Jeffrey E. 
Salon, Roopal Thakkar, Leticia Delgado-Herrera, Patricia Frank, Michael Marshall, 
Bidan Huang, Toni Sarapohja, Robert J. Padley, University Hospital, Zurich, Switzerland
Background: Levosimendan (LS) produces both vasodilation and enhanced myocardial 
contractility. The reported effect of LS on mortality in patients with acute heart failure 
(AHF) has varied. Data from LS studies were pooled to determine the average effect of LS 
on all-cause 31-day mortality when added to standard-of-care (SOC) therapy.
Methods: Six efficacy studies that enrolled 2512 patients with NYHA class III-IV AHF 
were included. All studies prospectively collected 31-day mortality data and had a 
treatment arm that added LS to SOC therapy for at least 24 hours. Relative risk (RR) for 
all-cause 31-day mortality was calculated within and across studies.
Results: After a loading dose of 6 to 36 µg/kg, LS infusion rates were 0.05 to 0.6 µg/
kg/min. The RR for all-cause 31-day mortality favored LS in 5 of 6 studies; the 95% CI 
included 1.0 in all 6 studies. Pooled all-cause 31-day mortality for LS was 8.5% (vs. 10.6%; 
RR = 0.85; 95% CI, 0.67-1.08; p=0.18) for all studies combined and 4.6% (vs. 4.5%; RR 
= 1.17; 95% CI, 0.65-2.08) and 10.2% (vs. 13.9%; RR = 0.79; 95% CI, 0.61-1.03) for the 
placebo-controlled and dobutamine-controlled studies, respectively.
Conclusion: Although pooled analyses have limitations (eg, differing patient populations, 
infusion rates), the RR for all-cause 31-day mortality indicated no significant increase in 
mortality. Combined with previous reports of improvements in symptoms and hemodynamics, 
the results suggest LS is an acceptable add-on therapy for patients with AHF. 
9:00 a.m.
1016-64	 Preserving	Systolic	Function:	Two	Studies	
Demonstrate	Safety	of	Pioglitazone	in	Patients	With	
Type	2	Diabetes	Mellitus	and	Heart	Failure
Thomas D. Giles, Alan Miller, Uri Elkayam, Mondira Bhattacharya, Alfonso Perez, 
Takeda Global Research & Development Center, Deerfield, IL
Background: Type 2 diabetes (T2D) is a progressive disease of metabolic abnormalities 
carrying a high risk for CV morbidity and mortality. Thiazolidinediones are insulin-
sensitizing agents used to treat T2D. Therapy with thiazolidinediones in patients with 
CV disease has been hindered by dose-related fluid retention that may result in edema; 
however, this edema is not associated with adverse effects on cardiac structure or 
function. Two studies were conducted to compare effects of pioglitazone (PIO) and 
glyburide (GLY) in patients with T2D and heart failure (HF).
Methods: Both randomized, double-blind studies assessed the progression of HF in 
patients with T2D and HF by evaluating change in echocardiographic parameters as a 
measure of cardiac structure and function. One study was in patients with NYHA class 
I (N=300) with preserved ejection fraction receiving PIO or GLY for 1 year. The primary 
endpoint was change in distance covered in the 6-minute walk test. The other study 
(N=518) had patients with NYHA class II or early class III and depressed ejection fraction 
(<30%) after 6 months of PIO or GLY with or without insulin for 24 weeks. The primary 
variable was the composite endpoint of the first occurrence of death due to CV causes, 
emergency room visit for, or overnight hospitalization for worsening HF.
Results: In both studies (N=818) results of the 6-minute walk test showed no significant 
differences in mean score between treatments. Results of ECG tests showed no 
deterioration in systolic function or remodeling in either treatment group in these studies. 
In the second study PIO was associated with an earlier time to onset and higher rate of 
composite endpoint vs GLY (P<0.05). Contributing disproportionately to the composite 
endpoint was overnight hospitalization for worsening HF, but most cases were treatable 
and reversible without discontinuation of study drug. The increased incidence for 
composite endpoint with PIO did not result in increased morbidity or mortality vs GLY.
Conclusions: PIO for treatment of T2D associated with HF symptoms in patients with 
preserved or depressed left ventricular systolic function is associated with no deterioration 
of exercise time, systolic function or remodeling.
9:00 a.m.
1016-65	 Mortality	after	Serious	Heart	Failure:	Results	from	
PROactive
Erland Erdmann, Robert Wilcox, Alfonso Perez, John Yates, Robert Spanheimer, John 
Dormandy, Takeda Global Research and Development Center, Deerfield, IL
Background: PROactive, a long-term cardiovascular (CV) outcome study, showed a 
trend of benefit of pioglitazone (PIO) in reducing major CV events in patients with type 2 
diabetes (T2D) and significant CV disease who are also at high risk for heart failure (HF). 
We evaluated death after investigator-reported serious HF (IRSHF) to see if the CV benefits 
observed in PROactive might be offset by the risk of increased mortality after HF.
Methods:PROactive was a randomized, double-blind, placebo (PBO)-controlled study 
in patients with T2D and macrovascular disease randomized to PIO or PBO on top of 
existing glucose-lowering and CV medications. Mean follow-up was 34.5 months.
Results: More PIO than PBO patients had non-adjudicated IRSHF (149 [5.7%]; 108 
[4.1%]) during the study. However, investigator-determined death due to HF was similar in 
PIO vs PBO (25/2605 [1.0%] vs 22/2633 [0.8%]). Moreover, the event rate for all-causet 
ower with PIO (40/149 [26.8%]) vs PBO (37/108 [34.3%]).
Conclusions: PIO was associated with a trend of decreased risk of CV events in 
patients with T2D and significant underlying CV disease, despite an increase in IRSHF. 
Proportionally fewer PIO vs PBO patients died after IRSHF. Therefore, the overall benefit 
of reduction of macrovascular events with PIO is not offset by worsened HF sequelae in 
these high-risk patients.
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1016-66	 Longer	Hospitalization	Observed	in	Black	
Women	Hospitalized	with	Impaired	or	Preserved	
Decompensated	Heart	Failure
Alfred Loka, Judith E. Mitchell, Meriam F. Caboral, Locquessa Okpala, Luther T. Clark, 
SUNY Downstate Medical Center, Brooklyn, NY
Background: Ejection fraction (EF) is one of the strongest prognostic factors in patients 
(pts) with heart failure (HF). Our objectives were: 1) to seek if gender differences exist in 
EF of black pts admitted with decompensated HF, 2) to determine the association of EF to 
length of stay (LOS) and other parameters [anemia, renal insufficiency, b-type natriuretic 
peptide (BNP) level] linked to increased morbidity.
Methods: Retrospective analysis of 1522 pts consecutively admitted with the diagnosis 
of decompensated HF between 5/2003 and 3/2006 was performed. Excluded were pts 
on hemodialysis, and those without BNP or quantitative EF. Nine hundred and ten pts 
met the inclusion criteria.
Results: The cohort consisted of 57% women, 89% blacks, mean age 68, and mean 
EF 37%. Women were older with a mean EF 9% points higher than EF observed in 
men (Table 1). The measured predictors of morbidity were not uniformly directional 
with the increased EF noted in women. For example, compared to men, women had 
statistically higher EFs and lower BNP and creatinine (CR) levels. However, women had 
a significantly lower Hgb and a one day longer LOS. When analyzed by EF< 45% vs EF> 
45%, the findings were analogous.
Conclusions: Black women admitted with decompensated HF despite significantly 
higher EFs, lower BNP and lower CR levels had longer LOS compared to black men, 
irrespective of whether systolic function was impaired or preserved.
Table 1
Parameters evaluated Men (n=393) Women (n=517) P value
Mean age (years) 66+ 13.6 70 + 14.6 p<0.001
Mean weight (kgs) 84 + 22.4 81 + 25.6 p<0.001
Mean EF (%) 32 + 15.7 41 + 18.1 p<0.001
Mean BNP (pg/ml) 959 728 p=0.013
Mean BUN (mg/dl) 28 + 17.6 25.6 + 15.2 NS
Mean Creatinine (mg/dl) 1.6 + 0.05 1.4 + 0.05 p= 0.026
Mean Hemoglobin (g/dl) 13 + 6 11.7 + 4 p<0.001
Serum sodium(mmol) 139 + 7.4 140 + 4.8 NS
LOS (days) 5 6
9:00 a.m.
1016-67	 Effect	of	Anemia	Treatment	with	Epoetin	alfa	or	
Darbepoetin	alfa	on	Left	Ventricular	Mass	in	Patients	
with	Chronic	Kidney	Disease	not	on	Dialysis	in	Japan.
Makoto Suzuki, Makoto Akaishi, Yoshiyuki Hada, Michiaki Hiroe, Kazutaka Aonuma, Yoshiharu 
Tsubakihara, Tadao Akizawa, Toho University Ohashi Medical Center, Tokyo, Japan
Background: Left ventricular hypertrophy (LVH) is recognized as an independent risk 
factor for cardiovascular disease. Anemia is common in patients with chronic kidney 
disease (CKD) and is also well-known to induce LVH. We conducted the prospective 
multi-center study to clarify the favorable effect of anemia correction on left ventricular 
mass (LVM) in patients with CKD.
Methods: One hundred seventy one patients with CKD not on dialysis with serum 
creatinine levels >2 mg/dL and hemoglobin (Hb) <10 g/dL were treated with subcutaneous 
Erythropoiesis-stimulating agents (Epoetin alfa once a week or Darbepoetin alfa once 2 
weeks) for 16 weeks to achieve and maintain a target Hb of 12 g/dL. Two-dimensional 
echo-guided M-mode echocardiograms were obtained before and after 16 weeks treatment, 
and 3 cardiologists reviewed the quality of records and measured the left ventricular 
dimensions independently without knowledge of clinical profiles of patients, according 
to the recommendation of the American Society of Echocardiography. LVM index (LVMI) 
corrected for body surface area was calculated by using the Devereux formula.
Results: Of 171 patients, 127 patients were qualified to assess echocardiograms, and 
finally 77 pairs of satisfactory echocardiograms were obtained. In these 77 patients, Hb 
increased to 11.2 from 9.1 g/dL (P<0.001). LVMI decreased to 114.7 from 121.3 g/m2 
(P=0.012) regardless of natural course of worsening of renal function. Systolic and 
diastolic blood pressure levels were stable during the treatment. Furthermore patients 
were divided into 3 groups according to the change in Hb (ΔHb<1: group 1, 1<ΔHb<2: 
group 2, 2<ΔHb: group 3). In the group 3 with prominently improved anemia that Hb 
increased to 12.0 g/dL from 8.9 g/dL, LVMI markedly decreased to 107.5 from 117.7 g/m2 
(P=0.003). Adjusted mean values of changes in LVMI were +0.7 g/m2 in group 1 (n=12), 
-1.3 g/m2 in group 2 (n=24), -11.8 g/m2 in group 3 (n=41), respectively (Ptrend=0.001). Thus 
the elevation of Hb level was strongly associated with reduction of LVMI.
Conclusions: We suggest that aggressive treatment of anemia suppresses the progression 
of LVH. Further randomized prospective studies are warranted to validate our results.
9:00 a.m.
1016-68	 Comparing	Early	and	Delayed	Enalapril	Therapy	on	
Long-Term	Cardiovascular	Morbidity	and	Mortality	in	
Patients	with	Reduced	Ejection	Fractions	From	SOLVD
Philip Jong*, Sylvie A. Ahn, Michel F. Rousseau, University of Louvain, Brussels, 
Belgium, University of Toronto*, Toronto, ON, Canada
Background:	The Studies of Left Ventricular Dysfunction (SOLVD) showed that enalapril 
therapy reduced in-trial cardiovascular (CV) morbidity and mortality. In an extended 
follow-up of SOLVD, we investigated the effect of early in-trial treatment with enalapril on 
long-term morbidity and mortality post trial.
Methods:	Among Belgium patients from SOLVD randomized to either in-trial enalapril 
or placebo, post-trial morbidity and mortality data were collected on all 433 survivors at 
closeout. All patients were placed on enalapril after the trial. We compared the composite 
outcome of CV morbid event or death between patients who received early enalapril 
therapy and those whose enalapril therapy was delayed for 3-4 years.
Results:	No patient was lost to follow-up. The median duration of follow-up was 14.8 
(range 14.6-15.6) years. The composite outcome of CV morbidity and mortality was 
significantly reduced among patients treated early with enalapril as compared with those 
treated late (75% of 218 vs. 82% of 215, p=0.02). In the Prevention arm, early therapy 
with enalapril significantly reduced CV morbid events and deaths by 27% as compared 
to delayed therapy (HR 0.73, p=0.007). Post-trial use of ACE inhibitors (82%) was similar 
in both groups (p=0.32).
Conclusion:	In patients with reduced ejection fractions, delayed treatment with enalapril 
for 3-4 years in SOLVD increased the late risks of CV morbidity and mortality at 15 years, 
supporting the importance to start ACE inhibitor therapy as early as possible. 
9:00 a.m.
1016-97	 The	Administration	of	Subcutaneous	Erythropoietin	in	
Anemic	Elderly	Patients	with	Heart	Failure	and	Normal	
Ejection	Fraction	over	Three	Months	Is	Associated	with	
Improvement	in	Exercise	Capacity	and	Quality	of	Life.
Rose S. Cohen, Paula Karlin, Raja Wajahat, Inna Titova, Ellie Coromilas, Donna Mancini, 
Mathew S. Maurer, New York Presbyterian Hospital - Columbia University, New York, NY
Background: Anemia is a significant co-morbidity among patients with heart failure and a 
normal ejection fraction (HFNEF). To date, little is known about the effect of subcutaneous 
erythropoietin on exercise performance, left ventricular structure and quality of life in the 
subset of elderly patients with HFNEF and anemia.
Methods:	Twelve anemic (68 ± 10 years; 83% female) patients with HFNEF defined by 
EF ≥ 50% and NHANES score of ≥ 3 were recruited for prospective, open label, weekly 
subcutaneous erythropoietin injections over three months. Principal measures included 
physical exams, 6-minute walk, blood volume determination with radiolabelled albumin assay, 
cardiopulmonary exercise testing, Kansas City Cardiomyopathy Questionnaire (KCCQ) and 
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three dimensional echocardiography. Weekly hemoglobin values were obtained and dosing 
was adjusted not to exceed a rate of hemoglobin rise ≥ 0.4 g/dL per week.
Results:	 To date 10 patients have completed the protocol. No adverse events were 
noted. Hemoglobin increased from 10.9±0.9 to 12.2±0.8 g/dL (p=0.002). Red cell volume 
increased by 145 ml (p=0.0008). Six minute walk tests improved significantly with treatment 
(289±81 to 321±69 meters, 11% improvement, p=0.0003). Peak VO2 improved significantly 
with treatment (7.5±1.8 to 8.7±2.1 ml/kg/min, 15% improvement, p=0.003). Exercise time 
improved significantly with treatment (448±192 seconds to 531±164 seconds). Eight of nine 
composite quality of life scores on the KCCQ were found to be significantly improved. End 
diastolic volume reduced from a baseline (107±11 mL to 101±10 mL, 6% decrease, p=0.02) 
without a significant change in LV mass (170±23 to 169±22 grams).
Conclusions:	 Erythropoietin administration to elderly anemic patients with HFNEF 
results in significant increases in hemoglobin and red cell volume and is associated with 
significant improvement in submaximal and maximal exercise capacity and quality of life. 
Significant reduction in end diastolic volume was observed, suggestive of the amelioration 
of an anemia related volume overloaded state in patients with HFNEF.
9:00 a.m.
1016-98	 Acoustic	Cardiography	Correlates	with	Invasive	
and	Echocardiographic	Systolic	and	Diastolic	
Hemodynamic	Parameters.
Stilianos Efstratiadis, Mia Shapiro, Sarah G. Weeks, Elyse Foster, Andrew D. Michaels, 
University of Utah School of Medicine, Salt Lake City, UT, University of California at San 
Francisco School of Medicine, San Francisco, CA
Background: We assessed the correlates of diastolic heart sounds and systolic time intervals 
using non-invasive and invasive hemodynamic measurements in heart failure patients.
Methods: 25 patients with symptomatic heart failure (15 with LVEF<40%; 10 with LVEF>50%) 
underwent echocardiography and left heart catheterization using a pressure-volume catheter 
(CD Leycom, Zoetermeer, Netherlands) at baseline and 30-min after a 2mcg/kg bolus and 
0.01mcg/kg/min IV nesiritide infusion. We measured LVEF, maximum +dP/dT, end-systolic 
elastance (Ees), LV dyssynchrony (LVD), and the relaxation time constant (tau). Computerized 
phonocardiography (Audicor®, Inovise Medical, Portland, OR) assessed the S3, S4, and the 
electromechanical activation time (EMAT), a systolic interval from the Q-wave onset to the 
peak S1. A heart rate adjusted %EMAT ≥15 is abnormal.
Results: The mean age was 60±11 years, 48% were male, 56% had CAD and 64% had HTN. 
The +dP/dT and the Ees were lower in patients with an S3. The presence of an S4 was associated 
with a lower LVEF, lower +dP/dT, increased LVD and increased tau. An abnormal %EMAT was 
strongly associated with impaired contractility (decreased LVEF, +dP/dT, Ees) and LVD.
Phonocardiographic Parameters and Hemodynamics
Variables	 No	S3(N=32)
+	S3	
(N=18)
No	S4	
(N=34)
+	S4	
(N=16)
%EMAT
<15(N=30)
%EMAT	
≥15(N=20)
LVEF	(%)	 47.9±16.8 41.6±21.1 50.7±16.9† 35.0±17.8† 55.4±16.5‡	 31.0±9.8‡	
+dP/dT	†† 1,080±251* 851±279* 1,064±265* 856±271* 1,107±272‡	 836±214‡	
Ees(mmHg/ml) 2.72±1.56† 1.43±0.89†	2.59±1.43 1.70±1.48 2.87±1.59† 1.45±0.79†	
LVD	(%) 26.4±7.4 28.8±6.6 25.8±7.5* 30.2±6.2* 25.0±6.9†	 30.5±6.7†	
Tau	(msec)	 39.7±8.7 44.5±9.5 39.6±8.5* 45.3±9.6* 41.8±9.5 41.0±8.9
Legend:	 *	p<0.05 †	p<0.01 ‡	p<0.001	 ††mmHg/s
Conclusions: The S3, S4 and abnormal EMAT measured by computerized acoustic 
cardiography correlate with invasive and non-invasive parameters of systolic and diastolic 
dysfunction. Therefore, acoustic cardiography can be used effectively for the bedside 
assessment of heart failure patients.
9:00 a.m.
1016-99	 Could	Female	Gender	Have	A	Protective	Role	In	
Transthyretin-Related	Cardiac	Amyloidosis?
Letizia Riva, Paolo Ciliberti, Maddalena Graziosi, Simone Longhi, Candida C. Quarta, 
Barbara Bordoni, Marinella Ferlito, Fabrizio Salvi, Elisabetta Petracci, Carla Lofiego, 
Elena Biagini, Angelo Branzi, Claudio Rapezzi, Institute of Cardiology,University of 
Bologna, Bologna, Italy
Background:	We investigated whether gender could influence the frequency/severity of 
ventricular myocardial amyloid deposition in primary (AL) and in hereditary transthyretin-
related amyloidosis (ATTR).
Methods:	We compared gender frequencies in patients with TTR-related amyloidosis 
(senile/wild-type TTR, n=10; ATTR, n=68) and AL amyloidosis (n=85) in a referral center. 
Myocardial involvement was echocardiographically defined.
Results: All patients with senile amyloidosis were men. Among all ATTR patients, female 
prevalence was 51%; it was higher (77%) in the subgroup with vitreal involvement and 
lower (24%) in the subgroup with carpal tunnel syndrome (p<0.03). In ATTR, women 
had lower LV mass (149 +/- 48 g/m2 versus 190 +/- 66 g/m2, p=0.04) and a greater LV 
ejection fraction (67% +/- 13% versus 56% +/- 11%, p=0.003). We stratified the ATTR and 
AL groups according to tertiles of left ventricular (LV) mass-volume ratio and of mean LV 
wall thickness (LVWT). Regarding LV mass-volume ratio in ATTR, female prevalence was 
45% in both the lowest and central tertiles as compared with 12% in the highest (p=0.02). 
For LVWT in ATTR, female prevalence was 48% and 43% in the lowest and central 
tertiles, and 13% in the highest (p=0.03). At regression analysis, the only independent 
predictors of increasing LVWT were male gender (p=0.001) and type of TTR mutation 
(p=0.0001). Among AL patients, no relation was apparent between gender and LV mass 
or type of involved organ.
Conclusions:	In ATTR (but not in AL), male gender was associated with greater frequency 
and severity of myocardial involvement. Female gender may provide some protection 
from myocardial infiltration. Organ-specific gender-related associations (including carpal 
tunnel syndrome and vitreal involvement) deserve further study. Such associations could 
be relevant for pathophysiological research and new pharmacological strategies.
9:00 a.m.
1016-100	 SCN5A	Variant	in	Japanese	Patients	with	Left	
Ventricular	Noncompaction	and	Arrhythmia
lishen shan, Toyama University hospital, Toyama, Japan
Background:Left ventricular noncompaction (LVNC) is a genetically heterogenous 
cardiomyopathy. Clinical manifestation includes high incidence and wide variety of 
arrhythmias beside heart failure. Mutations in the human cardiac sodium channel alpha-
subunit gene (SCN5A) have been recently reported to related to cardiomyopathy. Single-
nucleotide polymorphisms (SNPs) in SCN5A have also been shown to cause phenotypic 
varibility of these channelophthies.
Methods: DNA was isolated from the peripheral blood of 60 Japanese patients including 
15 familial cases and 45 sporadic cases. Arrhythmia included AV block, atrial fibrillation, 
long QT, WPW syndrome, sick sinus syndrome, ventricular tachycardia and premature 
ventricular contraction, paroxysmal supraventricular tachycardia. Patient samples were 
screened for variants in SCN5A using single-strand conformational polymorphism 
analysis (SSCP) and DNA sequencing.
Results: Six DNA variants were identified in 6 familial and 10 sporadic cases. In the 
cases with arrhythmia and LVNC, thirty there percent of the cases with arrthymia have 
been identified to have DNA variant, while only 3 sporadic case and 2 familial cases 
without arrthythmia has variant. Among them, 453C>T(His151His), 1141-3C>A, 
1673A>G(His558Arg), 3269C>T(Pro1090Leu), and 5457T>C(Asp1819Asp) were 
identified . These five variants have been previously reported as SNPs. In a sporadic 
case of isolated LVNC with complete AV block, a 3996C>T(Pro1333Pro) in exon 23 of 
SCN5A has been detected as a novel variant.
Conclusions: The prevalence of SCN5A variant is high in patients with LVNC and 
arrhythmia, supporting that SCN5A variant may promote arrhythmia susceptibility in 
LVNC. Further study is needed to clarify a mechanistic link of SCN5A between LVNC and 
a predisposition to arrhythmia
9:00 a.m.
1016-101	 Proximal	Aortic	Stiffness	Is	Associated	With	Advanced	
Diastolic	Dysfunction	In	Dilated	Cardiomyopathy
Alexander P. Patrianakos, Frangiskos I. Parthenakis, Nickolaos C. Klapsinos, Dimitrios 
Arfanakis, Evangelos Zacharis, Panagiotis E. Vardas, Heraklion University Hospital, 
Heraklion, Greece
Background: We assessed the relationship of the proximal aortic (AO) pulse wave 
velocity (PWV) and the diastolic Left Ventricular (LV) function in patients with idiopathic 
dilated cardiomyopathy (IDC) and mild to moderate HF (NYHA II-III).
Methods: We examined 35 patients (52,6 ±13,9 years), with angiographically proven IDC, 
in sinus rhythm, LV Ejection fraction 30.1±8.6 % and 14 controls. All patients underwent 
an echocardiographic study and a cardiopulmonary exercise test. Echocardiographic 
data were stored and analysis was made post-processing using the EchoPac 7 archiving 
application software of Vivid 7 dimension (GE). Maximal exercise duration, maximal and 
predicted for age and body mass index oxygen consumption (VO2) was also calculated. 
We evaluated the segmental PWV in the region of AO arch with a new echo-method 
measuring from the suprasternal view the distance between ascending and descending 
AO with 2D-ultrasound and the AO flow wave transit time (TT) with pulsed-wave Doppler 
(recording sweep speed at 200 mm/s). PWV was calculated as AO distance/TT.
Results: According to Doppler early (E) to late (A) transmitral velocity and E deceleration 
time (DTE) pts was divided into advanced (restrictive or pseudonormal filling pattern, 
Group I, 14 pts) or mild diastolic dysfunction (delayed relaxation filling pattern, 21 pts, 
group II) groups. Patients showed increased PWV (6.7±2.1 vs 5.2±1.4 m/s, p=0.01), 
compared to controls. Group I patients showed increased PWV (8.1±1.6 vs 5,7± 1.9 
m/s, p=0.01), reduced VO2 (18,1± 2,1 vs 23,1±1,9 ml/kgr/min, p< 0,001) and predicted 
VO2 (75,3±6,2 vs 88,8±8,3 %, p<0.001) compared to Group II. PWV was significantly 
correlated with LV diastolic filling pattern (r=0.59,p<0.001) max (r=-0,48, p=0,004) and 
predicted VO2 (r=-0.63,p<0.001).
Conclusions: IDC patients showed increased proximal aortic stiffness which
promotes an augmentation in LV afterload and subsequently aggravation of the diastolic 
dysfunction and decreased exercise VO2. The echocardiographic assessment of the 
regional aorta PWV , seems to be clinically important and may become an additional 
therapeutic target in these patients.
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1016-102	 Acute	and	Chronic	Additive	Beneficial	Effects	of	
Dual-Chamber	Pacing	Combined	With	Disopyramide	
in	patients	with	Obstructive	Hypertrophic	
Cardiomyopathy
Yuichiro Minami, Katsuya Kajimoto, Hiroshi Kasanuki, Tokyo Women’s Medical 
University, Tokyo, Japan
Background: It is no clear whether a combined therapy of disopyramide and dual 
chamber pacing (DDD-P) is effective for left ventricular outflow tract pressure gradient 
(LVOT-PG) in patients (pts) with obstructive hypertrophic cardiomyopathy (HOCM). This 
study examines acute and chronic efficacy of the combined therapy of disopyramide and 
DDD-P for LVOT-PG in HOCM refractory to both disopyramide alone and DDD-P alone.
Methods: In 27 pts with HOCM (mean LVOT-PG=96 mmHg) refractory to optimal medical 
treatment, we prospectively analyzed LVOT-PG at DDD-P, an intravenous administration 
of disopyramide, and combined therapy of disopyramide and DDD-P. Moreover, we 
evaluated the long-term efficacy of this combined therapy.
Results:	Among 27 pts, 10 pts had a significant improvement of LVOT-PG<30mmHg by 
DDD-P alone. In the remaining 17 pts, the combined therapy of disopyramide and DDD-P 
was compared with their alone therapy. The percent reduction of LVPG was -29±17% with 
DDD-P alone, -34±15% with disopyramide alone, and -72±20% with combined therapy 
of disopyramide and DDD-P (Figure). Furthermore, during a mean follow-up of 4.2 years, 
the percent reduction of LVOT-PG in pts (N=10) treated with the combined therapy was 
significantly higher than those in pts (N=7) with disopyramide or DDD-P alone therapy 
(-73±25% vs. -44±30%, p<0.05).
Conclusion: This study suggests that the combined therapy of disopyramide and DDD-P 
significantly reduced LVOT-PG in HOCM refractory to both disopyramide alone and DDD-P alone. 
9:00 a.m.
1016-103	 Early	Impairment	of	Left	Atrial	Kinetic	Energy	in	
Transfusion-Dependent	Beta-Thalassemic	Patients	
With	Preserved	Ventricular	Function
Constadina Aggeli, Constadina Cosma, Georgios Giannopoulos, George Roussakis, 
Euaggelia Christoforatou, Vasilios Ladis, Markisia Karagiorga, Christodoulos Stefanadis, 1st 
Cardiology Dept., Athens University Medical School, Hippokration Hospital, Athens, Greece
Background: In transfusion-dependent patients with beta-thalassemia, iron overload is related 
to myocardial dysfunction. Aim of this work was to investigate the performance of the left atrium 
in beta-thalassemic patients according to their left ventricular function. The performance of 
the left atrium was echocardiographically assessed by calculation of left atrial kinetic energy 
(LAKE), an index which has been shown to accurately represent left atrial function.
Methods: We studied 88 patients (25.6±6 years old) with beta thalassemia major, divided 
in two groups according to their left ventricular ejection fraction (LVEF) and 22 age - and 
sex - matched controls. Transthoracic echocardiography was performed in all patients, 
whereupon LVEF was assessed and left atrial (LA) volumes were measured as: maximal 
at mitral valve opening (LAmax); minimal at valve closure (LAmin); and at onset of 
atrial systole (P-wave on ECG, LAP). Transmitral Doppler E and A wave velocities were 
recorded. Tissue Doppler imaging was employed to measure early (Ea) and late (Aa) 
diastolic velocities at the mitral valve annulus. LA stroke volume (LASV) (cm³), LA ejection 
fraction (LAEF) (%) and LAKE (kdynes*cm) were calculated: LASV= LAP - LAmin, LAEF 
= LASV/LAP and LAKE= ½ x LASV x 1.06 (specific gravity of blood) x v², where v = 
transmitral Doppler A velocity. Group 1 consisted of sixty six patients who had preserved 
LV systolic function (EF≥35%), group 2 consisted of twenty two patients who had LVEF< 
35% and group 3 consisted of twenty two controls.
Results: LAKE was similar in group 1 and in group 2 (2.1±0.58 vs1.9±0.6, p=NS), 
significantly lower than in control group 3 (9.1±1.7, p<0.01). The Pearson’s correlation 
coefficient between LASV and LAEF was 0.76 (p<0.01). LAKE was positively correlated 
to Aa (β =2.1, p<0.01) and negatively correlated to LAmax (β= - 0.28, p < 0.01).
Conclusions: Our findings indicate that beta-thalassemia is associated with impaired left atrial 
kinetic energy, even in subjects with preserved left ventricular function, which implies that left 
atrial systolic function may be affected by iron overloading earlier that the left ventricle. 
9:00 a.m.
1016-104	 Predictors	of	Mortality	in	Patients	with	Acute	Myocarditis
Kye Hun Kim, Jong Chun Park, Nam Sik Yoon, Sun Ho Hwang, Jae Yeon Moon, Seo Na 
Hong, Sang Rok Lee, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Youngkeun 
Ahn, Myung Ho Jeong, Jeong Gwan Cho, Jung Chaee Kang, Chonnam national 
university hospital, Gwangju, South Korea
Background: The aim of this study was to identify the predictors of mortality in patients 
with acute myocarditis.
Methods: From 1995 to 2005, 65 patients who had been diagnosed as acute myocarditis 
were enrolled. The patients were divided into the survival group (group I: n=53, 38.5±16.7 
years old, 37 males) and the fatal group (group II: n=12, 51.6±25.6 years old, 8 males). 
Various clinical, laboratory, echocardiocardiographic parameters, and therapeutic 
modalities were compared between the groups.
Results: Group II was more older (51.6±25.6 vs 38.5±16.7 years old, p<0.001) and had 
more higher incidence of diabetes mellitus (53.7 vs 16.3 %, p=0.038) than group I. Group II 
had more higher Killip class (3.4±0.8 vs 2.4±1.5, p=0.011), lower systolic and diastolic blood 
pressure (91.3±22.3 vs 111.2±28.7 mmHg, 58.3±17.4 vs 73.5±19.6 mmHg, p=0.045), and 
depressed ejection fraction (EF) (29.6±9.6 vs 41.5 ± 16.2 %, p=0.038) on admission than 
group I. The level of C-reactive protein (CRP) was significantly elevated in the group II than 
group I (9.5±5.4 vs 4.8±4.9, p=0.014). However, treatment modalities were not different 
between the groups. By multivariate analysis, depressed left ventricular EF, higher Killip class, 
higher CRP level, and older age at admission were independent predictors of mortality.
Conclusions: Our results demonstrated that depressed EF, higher Killip class, older 
age at admission, and elevated CRP level were significant predictors of mortality in 
patients with acute myocarditis.
9:00 a.m.
1016-105	 A985G	Polymorphism	of	the	Endothelin-2	Gene	and	Atrial	
Fibrillation	in	Patients	With	Hypertrophic	Cardiomyopathy
Takayuki Nagai, Akiyoshi Ogimoto, Hideki Okayama, Yasuhiro Sasaki, Susumu Shigemi, 
Teppei Fujita, Yosuke Izoe, Teruyoshi Uetani, Makoto Saito, Shinji Inaba, Kazuhisa 
Nishimura, Akira Kurata, Tomoaki Ohtsuka, Yuji Shigematsu, Tetsuro Miki, Jitsuo Higaki, 
Ehime University Graduate School of Medicine, Toon, Japan
Background: Patients with hypertrophic cardiomyopathy (HCM) have a small left 
ventricular cavity due to hypertrophy. Therefore, reduction of venous return and 
intravascular volume in patients with HCM leads to low cardiac output and several 
symptoms contrary to those of most other cardiovascular diseases. We reported that one 
genotype related to the inhibitory renin-angiotensin-aldosterone system is a significant 
risk factor for atrial fibrillation (AF) in patients with HCM. Recently, endothelin-2 (EDN-2) 
gene polymorphism, which plays an important role in the modulation of cardiovascular 
physiology, has been reported to be associated with hemodynamics in patients with 
essential hypertension. The A985 allele for the EDN-2 gene is considered to be a non-
risk allele for cardiovascular disease. Hypothesis: The A985 allele has an adverse 
effect on developing AF in patients with HCM. Methods	and	Results: Using the TaqMan 
chemical method, we genotyped A985G polymorphism in 110 patients with HCM who 
had no clinically documented AF before medical treatment. We compared the genotypes 
of the EDN-2 gene, baseline characteristics, electrocardiographic, and echocardiographic 
parameters between patients who subsequently developed AF during long-term follow 
up (group A, n=26) and patients who remained in sinus rhythm (group B, n=84). The 
distribution of the EDN-2 genotypes (G/G, G/A, and A/A) among all HCM patients was 
77.3%, 19.1%, and 3.6%, respectively. Allele frequency for the A allele was 0.21 in the 
group A and 0.11 in the group B. When data were analyzed based on the dominant A 
allele model, a chi-square test revealed that there was a significant difference between 
the distribution of genotypes of the two groups (42.3% vs. 16.7%, p=0.014). On the 
multivariate model, both the dominant A allele as well as dispersion of QRS duration were 
associated with increased risk of AF after adjustment for the left ventricular mass index 
and interventricular wall thickness (p=0.016, 0.019; respectively). Conclusion: The A985 
allele, which has been recognized as a protective polymorphism against cardiovascular 
disease, may actually be a risk factor for AF in patients with HCM.
9:00 a.m.
1016-106	 One-Year	Outcomes	following	Percutaneous	Left	
Ventricular	Assist	Device	Reversal	of	Severe	Refractory	
Cardiogenic	Shock.
Gary M. Idelchik, Leo Simpson, Igor Gregoric, Pranav Loyalka, Biswajit Kar, Texas 
Heart Institute, Houston, TX
Background: Cardiogenic shock is still associated with significant mortality despite the use 
of intra-aortic balloon pump (IABP) support. Recently, the TandemHeart™, a percutaneously 
placed continuous-flow left ventricular assist device (PVAD) capable of complete hemodynamic 
support, has become available. We present one-year outcomes in cardiogenic shock patients 
receiving PVAD-assistance following failure of IABP and pressor support.
Methods:	From May 2003 to August 2005, PVADs were placed in 36 consecutive patients in 
severe refractory cardiogenic shock. One year follow-up data were available for all patients.
Results: The average patient age was 57.8 ± 15.4 years; 24 were male. Twenty-one 
had ischemic cardiomyopathy. Thirty-two (89%) were on IABP support with persistent 
shock and 18 (50%) were actively undergoing cardiopulmonary resuscitation during 
PVAD placement. Mean hemodynamic and biochemical parameters prior to PVAD 
support were a cardiac index of 0.62 ± 0.65 L/min/m2, systolic blood pressure of 67 ± 
11 mmHg, systemic venous oxygenation of 39 ± 11 mmHg, and lactic acid of 65 ± 54 
mg/dL. In the course of their hospitalization, 12 patients underwent percutaneous/surgical 
revascularization, 12 went on to left ventricular assist device (LVAD) placement, and 
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one patient received an orthotopic heart transplant. The primary cause of death was 
removal of life support secondary to anoxic encephalopathy (10 patients). One patient 
died secondary to left atrial perforation during PVAD placement and 2 patients died during 
surgical LVAD placement due to air emboli. At 30 days, 20 (56%) patients were still alive 
with 4 additional patients dead at 6 months follow-up secondary to non-cardiac causes. 
At one year, 16 (44%) patients were still alive with 2 patients previously receiving LVADs 
going on to heart transplantation. Seven of the 16 patients alive at one year had PVAD 
placement during active cardiopulmonary resuscitation.
Conclusion:	Percutaneous left ventricular assist device support reverses the terminal 
hemodynamic compromise in patients with severe refractory cardiogenic shock, even in 
patients undergoing active resuscitation; one year mortality was 56%.
9:00 a.m.
1016-107	 Evidence	Does	Support	Glomerular	Filtration	Rate	<	40	ml/
min	as	a	Relative	Contraindication	to	Heart	Transplantation
Mark J. Russo, Jonathan M. Chen, Kimberly N. Hong, Alan J. Moskowitz, Timothy 
Martens, Deborah V. Ascheim, Michael Argenziano, Mehmet C. Oz, Annetine C. Gelijns, 
Yoshifumi Naka, Columbia University College of Physicians and Surgeons, New York, NY
Background:	 The newly revised guidelines for listing heart transplant candidates 
suggest that an estimated glomerular filtration rate (eGFR) < 40 ml/min is a relative 
contraindication. The purpose of this study was (1) to determine if post-orthotopic heart 
transplant (OHT) survival and morbidity is associated with pre-OHT eGFR, and (2) to 
define ranges of pre-OHT eGFR associated with differences in post-OHT survival.
Methods:	UNOS provided de-identified patient-level data. Primary analysis focused on 
20,325 first-time OHTs aged 18 years transplanted 1/1/95-12/31/05. Patients undergoing 
heart-kidney transplantation (n=349) were excluded from analysis. Using the MDRD 
Study Equation, eGFR was calculated from pre-OHT serum creatinine. Kaplan-Meier 
survival functions and multivariable Cox proportional hazards regression were used 
for time-to-event analysis. Survival expressed as incidence rate of death (IRD) per 100 
patient-years. Receiver-operating characteristic curves and stratum-specific likelihood 
ratios (SSLR) were generated to compare 5-yr survival at various eGFR thresholds.
Results:	 In multivariable Cox regression, pre-OHT eGFR was directly related to post-
OHTsurvival (p<0.001), time to chronic dialysis (p<0.001), and time to first infection 
requiring hospitalization (p<0.001); however there was no statistical relationship between 
pre-OHT eGFR and time to clinically apparent TCAD (p=0.936). Threshold analysis 
generated 3 statistically significant survival strata for eGFR: <33 SSLR 95%CI: 1.59-2.26), 
33-53 (1.04-1.23), and >53 (0.88-0.94); the IRDs were 13.8, 8.3, and 6.6 respectively.
Conclusions:	Worse pre-OHT eGFR is associated with worse post-OHT survival. This 
analysis supports the suggested criteria of eGFR<40 as a relative contraindication.
9:00 a.m.
1016-108	 Evidence	Does	Not	Support	Obesity	as	a	Relative	
Contraindication	to	Heart	Transplantation
Mark J. Russo, Alan J. Moskowitz, Jonathan M. Chen, Kimberly N. Hong, Ryan Davies, 
Deborah V. Ascheim, Allan S. Stewart, Mehmet C. Oz, Annetine C. Gelijns, Yoshifumi 
Naka, Columbia University College of Physicians and Surgeons, New York, NY
Background: Recently revised guidelines for listing heart transplant candidates 
suggested that BMI >30 kg/m2 is a relative contraindication to transplantation . The 
purpose of this study was to determine the effect of pre-orthotopic heart transplant (OHT) 
BMI on post-OHT survival and morbidity, including onset of diabetes mellitus (DM) and 
clinically-apparent TCAD.
Methods:	 UNOS provided de-identified patient-level data. The study population 
included 18,662 first-time OHTs aged 18 years transplanted 1/1/95-12/31/05. Recipients 
were stratified based on BMI according to categories described by the NHLBI: >18.5 
(underweight), 18.5-25.99 (normal), 25-29.99 (overweight), 30-34.99 (obese), 35-39.99 
(severely obese), and >40 (morbidly obese). Incidence rates (IR) were expressed per 100 
patient-years, and groups were compared using 95% confidence intervals.
Results:	Results summarized in Table1.
Conclusions:	The IR of death of the obese (BMI 30-34.99) group was not statistically 
different than either the overweight (BMI 25-29.99) or underweight (BMI < 18.5) group . 
This analysis does not support BMI>30 as a relative contraindication to OHT.
Table 1
Underweight 
(BMI <18.5)
Normal 
(BMI: 18.5-
24.99)
Overweight 
(BMI: 25-
29.99)
Obese (BMI: 
30-34.99)
Severely 
Obese (BMI: 
35-39.99)
Morbidly 
Obese 
(BMI>=40)
Number 
(%) 713 (3.82%)
7,539
(40.0%)
6,915
(37.0%)
2,857
(15.31%)
515  
(2.78%)
120
(0.64%)
Incidence 
Rate of 
Death
8.36
(7.35-9.52)
6.74
(6.45-7.03)
7.37
(7.04-7.71)
7.81
(7.28-8.39)
9.51
(8.12-11.1)
10.7
(7.86-14.4)
Incidence 
Rate of 
Diabetes 
Mellitus
5.20
(4.34-6.20)
7.80
(7.50-8.21)
13.1
(12.6-13.6)
20.0
(18.8-21.1)
25.7
(21.9-28.3)
15.4
(11.4-20.7)
Incidence 
Rate of 
TCAD
6.04
(5.10-7.16)
7.00
(6.66-7.34)
7.42
(7.05-7.80)
8.43
(7.81-9.12)
9.13
(7.60-11.0)
9.01
(6.24-13.1)
Incidence rates were expressed per 100 patient-years (95% Confidence Interval)
9:00 a.m.
1016-109	 Velocity	Vector	Imaging	Characterizes	Systolic	and	
Diastolic	Augmentation	of	the	Failing	Heart	During	Non-
blood	Contacting	Ventricular	Actuation
Curtis J. Wozniak, Anthony J. Pothoulakis, Shawn M. Gargac, Rebecca J. Darner, Mark P. 
Anstadt, Wright State University Department of Surgery, Dayton, OH
Background: Direct Mechanical Ventricular Actuation (DMVA) is a unique non-blood contacting 
cardiac compression device that augments both systolic and diastolic ventricular function. The 
purpose of this study was to characterize systolic and diastolic actuation during DMVA of the 
failing rabbit heart using novel echocardiographic speckle tracking technology.	
Methods: New Zealand White rabbits (n=7) underwent sternotomy and were instrumented for 
hemodynamic monitoring. A 10 MHz ultrasound probe was positioned for 2-chamber long-axis 
left ventricular (LV) transesophageal echocardiography. Heart failure was induced by Esmolol 
to achieve a cardiac output <50% baseline. Mean arterial pressure was kept at 60-70 mmHg 
using phenylephrine. DMVA was then applied to support the heart. Steady state conditions were 
analyzed with Axius Velocity Vector Imaging.
Results: DMVA significantly augmented LV ejection fraction vs. failure (46% +/- 2.7 vs. 37% 
+/- 2.3 respectively, p=0.0126). Regional peak systolic and diastolic myocardial wall velocities 
were compared between heart failure and DMVA (table): 
Basal
Septum
Mid	
Septum
Apical	
Septum
Apical	
Free	Wall
Mid	Free	
Wall
Basal	Free	
Wall
Systolic
Velocity	
(cm/s)
Failure 1.36 (+/-.28)
1.08 
(+/-.23)
0.67 
(+/-.20)
.91 
(+/-.23)
1.35 
(+/-.35)
1.23 
(+/-.23)
DMVA 3.48 (+/-.80)
1.99 
(+/-.23)
1.75 
(+/-.55)
1.77  
(+/-.61)
2.17 
(+/-.38)
2.13 
(+/-.25)
p* 0.0541 0.0064 0.1437 0.2039 0.0500 0.0471
Diastolic
Velocity
(cm/s)
Failure 1.54 (+/-.38)
1.06 
(+/-.21)
0.87 
(+/-.18)
1.12 
(+/-.26)
1.68 
(+/-.43)
1.67 
(+/-.43)
DMVA 3.50 (+/-.71)
1.86 
(+/-.22)
1.42 
(+/-.38)
1.70 
(+/-.41)
2.39 
(+/-.44)
2.39 
(+/-.44)
p* 0.0612 0.0062 0.2518 0.1965 0.2384 0.0467
* failure vs. DMVA; values expressed as mean +/- SEM
Conclusion: DMVA uniquely provides effective systolic and diastolic augmentation. This 
contrasts to other cardiac compression devices which only assist systole and characteristically 
impair diastolic filling. DMVA’s ability to address both systolic and diastolic venticular dysfunction 
may have added therapeutic benefits for the failing heart.
9:00 a.m.
1016-110	 Elevated	Pulmonary	Arterial	Pressures	Predict	Mortality	
and	Heart	Failure	Admission	in	Cardiac	Resynchronization	
Therapy-Defibrillator	Recipients
Andrew Voigt, Aiman El-Saed, Samir Saba, Alaa A. Shalaby, University of Pittsburgh Medical 
Center, Pittsburgh, PA, Veterans Affairs Medical Center, Pittsburgh, PA
Background: Pulmonary hypertension (PH) is a marker of advanced heart failure (HF) 
that confers a poor prognosis. It is not known whether the poor prognosis imparted by 
PH would mitigate survival or HF benefit from cardiac resynchronization therapy (CRT) 
in otherwise eligible patients.
Methods: Consecutive patients from 2003 through 2004 at two hospitals having echocardiographic 
assessment of systolic pulmonary arterial pressure (PAP) prior to implantation of a CRT-
defibrillator were included. Patients were divided into tertiles according to baseline PAP. Patients 
in the highest (Group I, 47-85 mmHg) and lowest (Group II, 22-31 mmHg) tertiles were compared 
for the endpoints of death or transplant, and for HF hospital admission.
Results:	We evaluated 195 patients, of whom 94.8% were Caucasians and 82.6% males. 
Mean age was 66.5±12.0 years, QRS 159.1±29.5 ms, LVEF 22.0±9.4 %, and NYHA 
class 3.0±0.3. Compared to group II, group I were older, had more severe tricuspid and 
mitral regurgitation, and larger left atrial (LA) size. Otherwise there were no clinical or 
echocardiographic differences. Multivariate adjustment included age, baseline LVEF, MR 
and TR severity, LA size, history of diabetes, hypertension, or AF. Death or transplant was 
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significantly more likely in Group I (HR=5.0, 95% CI 1.5-16.5; p=0.008) as was HF admission 
(HR=4.6, 95% CI 1.6- 12.9; p=0.004).
Conclusion: Elevated baseline PAP in patients undergoing CRT is an independent predictor of 
all cause mortality or transplant and HF admission.  
9:00 a.m.
1016-139	 Lack	Of	Clinical	Response	In	Diabetic	Patients	
After	Transendocardial	Injection	Of	Bone	Marrow	
Mononuclear	Cells.
Pilar Jimenez-Quevedo, Guilherme V. Silva, Ricardo Sanz-Ruiz, Franca S. Angeli, 
Edie M. Oliveira, Marlos R. Fernandes, Fred A. Baimbridge, Deidre Smith, Lynette 
Westbrook, Hans F. Dohmann, Cristiano O. Cardoso, Yi Zheng, John F. Canales, James 
T. Willerson, Emerson C. Perin, Texas Heart Institute, Houston, TX
Background: Diabetic patients (pts) have impaired endothelial precursor cell function. 
Previous studies have suggested a therapeutic benefit of transendocardial bone marrow 
mononuclear cells (BMMNC) transplantation in the treatment of ischemic heart failure 
(HF). We compared the clinical response following cell transplantation in diabetic (DM) 
versus non-DM pts.
Methods: : Twenty five consecutive pts (n= 12 DM; 13 non-DM) from 2 phase-I studies 
performed in end-stage ischemic HF pts (not amenable to revascularization) were 
included. All pts were treated with electromechanical guided transendocardial injection 
of BMMNC, targeting viable myocardium. New York Heart association class (NYHA), 
left ventricular ejecton fraction (LVEF) by echocardiogram and peak maximal oxygen 
consumption (MVO2) were assessed at baseline and 6 months of follow up (f/u).
Results:Baseline characteristics were comparable between groups. The mean number of 
cells injected (total=28.5±4.5 x 106 with 2.3±1.0% of CD34+) and cell viability of 97±4% 
were similar in both groups. From baseline to f/u, no significant changes were observed 
in LVEFs in DM (39±10% vs 41±14%, p=0.4) and non-DM groups (31.9 ± 9 vs 34 ± 9%, 
p=0.2). A statistically significant improvement in NYHA and MVO2 was seen exclusively 
in the non-DM pts (figure).
Conclusions:	These data suggest that the effect of bone marrow derived cell therapy 
in end stage ischemic HF patients seems to be diminished in DM. Larger studies are 
needed to confirm the present study results. 
9:00 a.m.
1016-140	 Influence	of	Etiology	and	Left	Ventricular	Systolic	
Function	on	Acute	Heart	Failure	Outcomes:	A	Report	
from	OPTIMIZE-HF
James D. Flaherty, Joseph S. Rossi, Charles J. Davidson, Eduardo Nunez, Wendy 
Gattis Stough, William T. Abraham, Nancy M. Albert, Barry H. Greenberg, Christopher 
M. O’Connor, Clyde W. Yancy, James B. Young, Gregg C. Fanarow, Mihai Gheorghiade, 
Northwestern University, Chicago, IL
Introduction:	The purpose of this study was to compare the influence of heart failure (HF) 
etiology stratified by left ventricular (LV) function on in-hospital and post-discharge outcomes.
Methods:	OPTIMIZE-HF is a national registry of patients hospitalized with HF. In-hospital 
mortality data was obtained in all patients and post-discharge data in a pre-specified 10% 
sample. Two sets of analyses were performed: ischemic vs. nonischemic for patients with 
preserved systolic function (PSF) (EF > 40%) or LV systolic dysfunction (LVSD) (EF < 
40%). Cox proportional hazard modeling with propensity score adjusting was used.
Results:	41,263 patients with EF documented were analyzed. 21,147 (51%) had PSF 
(54% ischemic); 20,116 (49%) had LVSD (66% ischemic). In-hospital mortality was similar 
for ischemic vs. nonischemic in those with PSF and in those with LVSD (Table).
At 90 days, there was no difference in the composite of death or rehospitalization in those 
with PSF when comparing ischemic vs. nonischemic (Table). However, this composite 
endpoint was significantly worse in those with LVSD and ischemic HF (Table).
Ischemic Nonischemic HR (95% CI)
p-
value
Preserved
Systolic
Function
In-hospital
Mortality 2.9% 2.8%
1.07
(0.90-1.28) 0.63
90-day Post-discharge
Death or
Rehospitalization
25.8% 25.5% 1.02(0.87-1.19) 0.82
Left	Ventricular
Systolic
Dysfunction
In-hospital
Mortality 3.8% 3.9%
0.99
(0.82-1.17) 0.83
90-day Post-discharge
Death or
Rehospitalization
30.9% 25.8% 1.27(1.09-1.48) 0.002
Conclusions:	 Ischemic and nonischemic HF has a relatively low in-hospital mortality 
rate regardless of LV systolic function. However, event rates in all HF patients are high 
in the early post-discharge period. In patients with LVSD, post-discharge event rates are 
significantly higher in ischemic HF compared to nonischemic HF.
Acute	Heart	Failure	Outcomes	According	to	Etiology	and	LV	Systolic	Function 
9:00 a.m.
1016-141	 First	Experience	With	Remote	LV	Mapping	and	Cell	
Injection	Utilizing	a	Novel	Integrated	NOGA	XP/
Stereotaxis	Platform
Emerson C. Perin, Guilherme V. Silva, Torrey Munger, Ashwini Pandey, Ruchir Sehra, 
Michael Talcott, Chris Bichard, Jerett Creed, Jonathan Wong, Edie M. Oliveira, Yi 
Zheng, John Canales, Franca S. Angeli, Cristiano O. Cardoso, Marlos R. Fernandes, 
James T. Willerson, Texas Heart Institute, Houston, TX
Background: Electromechanical mapping is a useful platform for cell therapy delivery 
because of its 3-D navigation and targeting capabilities. However, it is limited by a 
long learning curve, procedural time and demanding technical expertise. Stereotaxis 
magnetically guided technology has emerged as a novel manner of manipulating 
catheters. The combination of these technologies could yield a simplified interface for 
precise, programmable mapping and targeted delivery of left ventricular (LV) therapies.
Methods: A merged NOGA XP and Stereotaxis interface was created in which “point 
and click” manipulation of directional vectors allowed for guidance of a prototype hybrid 
NOGA/Stereotaxis catheter. From a control room, remote LV mapping was performed in 
7 pigs. After LV mapping, a newly developed prototype hybrid NOGA/Stereotaxis injection 
catheter was directed to 27 predetermined injection sites according to a 17 segment LV 
polar map .A total of 126 injections of iodinated contrast were performed in 3 pigs and 
successful injection was documented by fluoroscopic presence of myocardial staining. 
In another 4 animals, injection of DAPI labeled allogenic mesenchymal precursor cells 
was performed at 4 sites (Anterior, Septal, Lateral and Inferior) with 5 injections per site. 
Animals were sacrificed for pathological analysis.
Results: The average mapping time was 32 min (29 sec per map point). 94.4% (119/126) 
of contrast injections resulted in intramyocardial staining on fluoroscopy.The injected 
and labeled cells were identified in 93.8% (15/16) of injected segments. The success 
rate of the injections was equivalent for all 4 segments (apex=100%; septum=96.4%; 
anterior=89.5%; inferior=90.5%; lateral=95.8%, p=0.64). There was no pericardial 
effusion or tamponade.
DAPI labeled cells were identified in the epicardial fat in 1 segment in a low weight animal.
Conclusion: The combination of NOGA and Stereotaxis platforms resulted in a simplified 
user interface which allowed for rapid mapping acquisition and precise targeted injection 
in all LV walls. Successful intramyocardial injection with resultant cell retention was 
documented. Further development of this platform is warranted.
9:00 a.m.
1016-142	 No	Delay	in	Sudden	Death	but	Contribution	Diminishes	
in	Advanced	Heart	Failure:	Comparison	from	SCD-
HeFT	to	ESCAPE
Lynne W. Stevenson, Christopher M. O’Connor, George Sopko, Anne S. Hellkamp, 
Kerry Lee, Douglas L. Packer, Daniel B. Mark, Gust H. Bardy, SCD-HeFT Investigators, 
Brigham and Women’s Hospital, Boston, MA, Duke Clinical Research Institute, Duke 
University Medical Center, Durham, NC
Background:	Decisions regarding ICD in heart failure (HF) are influenced by HF clinical 
status and an apparent delay of benefit. To better understand early fatal events, we compared 
causes of death from 2 contemporary trials in HF, the Sudden Cardiac Death in Heart Failure 
(SCD-HeFT), which enrolled patients with New York Heart Association (NYHA) Class II and III, 
and the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization 
Effectiveness (ESCAPE) trial of patients hospitalized with Class IV symptoms.
Methods:	Sudden deaths were defined as arrhythmic deaths, as adjudicated in SCD-
HeFT, and sudden deaths as reported by ESCAPE investigators. Sudden deaths and total 
mortality were assessed for the first 6 mos in SCD-HeFT patients randomized to placebo 
or amiodarone without ICD, classified as NYHA Class II (n=1195) or III (n=497), and in 
433 hospitalized ESCAPE patients (initial Class IV HF) randomized to therapy to relieve 
congestion guided by pulmonary artery catheter or by clinical assessment alone. All 
groups received optimal medical therapy with beta-blockers and angiotensin-converting 
enzyme inhibitors (ACEI) as tolerated.
Results:	Patients in SCD-HeFT and ESCAPE were similar in age (60 yrs vs. 56), etiology 
(52% vs. 50% ischemic), ACEI/angiotensin receptor blockers (97 vs. 90%), and beta-
blockers (69 vs. 62%), with higher left ventricular ejection fraction in SCD-HeFT (0.25 vs. 
0.19). Mortality on medical therapy at 6 months was 3.4% for Class II, 6.0% for Class III, 
and 19% for initial Class IV, although status improved after hospitalization. The absolute 
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incidence of early sudden death without ICD was the same for Class II (2.7%) and Class 
III (2.8%) and higher in Class IV (7.5%), but the contribution of sudden death to total early 
mortality declined from 78% for Class II to 47% for Class III to 39% for recent Class IV.
Conclusion.	Sudden death is prominent even within the first 6 months of observation, 
but its contribution to early mortality declines sharply after HF has progressed despite 
current medical therapy. Therapy to decrease mortality should be initiated rapidly but the 
selection of therapy to prevent early death may differ based on HF clinical status.
9:00 a.m.
1016-143	 Improvement	in	Right	Ventricular	Function	Following	
Cardiac	Resynchronization	Therapy
Navin Rajagopalan, Matthew S. Suffoletto, Masaki Tanabe, Marc A. Simon, Raveen 
Bazaz, John Gorcsan, III, Angel Lopez-Candales, University of Pittsburgh Medical 
Center, Pittsburgh, PA
Background: The effect of cardiac resynchronization therapy (CRT) on right ventricular 
(RV) function is uncertain. Our aim was to assess improvement in RV function following 
CRT utilizing tissue Doppler imaging (TDI).
Methods: We studied 27 heart failure patients (age 65 ± 10 yrs; 20 males; 16 ischemic) 
who underwent color TDI with imaging of the RV free wall both immediately prior to CRT 
as well as > 3 months (mean 7 ± 3 months) following CRT. Myocardial systolic velocity of 
the RV free wall (RV S
m
) was measured at the basal and mid-ventricular segments and 
averaged to obtain a measure of global RV function. LV ejection fraction was measured 
via biplane Simpson’s method before and after CRT.
Results:	RV S
m 
significantly improved following CRT (4.9 ± 2.0 to 6.7 ± 2.9 cm/s; p < 0.01) 
as did LV ejection fraction (27 ± 6 to 33 ± 10%; p < 0.01). Seventeen of the 27 patients 
(63%) demonstrated an increase in RV S
m
 of 1 cm/s with 10 of those patients (37%) 
increasing by 2 cm/s. The improvement in RV S
m 
was seen in patients with baseline RV 
S
m
 < 4 cm/s (n = 9; 2.7 ± 0.7 to 3.9 ± 1.9 cm/s; p <0.05) as well as those patients with 
baseline S
m
 between 4 - 6 cm/s (n = 11; 5.1 ± 0.7 to 7.6 ± 2.6 cm/s; p < 0.05), and > 6 
cm/s (n = 7; 7.1 ± 0.7 to 8.7 ± 1.3 cm/s; p < 0.01). This improvement was independent of 
the improvement in LV ejection fraction.
Conclusions: CRT results in improvement in RV function as measured by RV S
m
. CRT 
has beneficial effects on RV function even in those patients with severe baseline RV 
dysfunction, and is independent of the improvement in LV ejection fraction. 
9:00 a.m.
1016-144	 Characterization	Of	Intraventricular	Dyssynchrony	By	
Tissue	Doppler	Echocardiography:	Is	There	Sufficient	
Test-retest	Reliability?
Mark R. Vesely, Shuying Li, Alison Reese, Carol Ma, Stephen R. Shorofsky, Stephen 
S. Gottlieb, Mandeep R. Mehra, John S. Gottdiener, University of Maryland School of 
Medicine, Baltimore, MD
Background:	Intraventricular dyssynchrony (IVD) by Tissue Doppler Imaging echocardiography 
(TDI) may predict benefit from resynchronization. Whether the utility of TDI to diagnose IVD & 
determine improvement is affected by test-retest reliability remains uncertain.
Methods: We prospectively performed repeat TDI (7 +/- 6, range 2-23 days apart) in 25 
subjects: 10 patients (pts) with QRS >120 msec, LVEF <35% & 15 normals (nls) using 
the same machine (GE Vivid 7), sonographer & blinded reader for both tests. There 
was no change in clinical status or treatment between tests. Segmental activation time 
was measured in 4 basal segments (septal, lateral, inferior, anterior) from QRS to peak 
velocity. IVD criteria were septal-lateral delay (SLD) ≥ 60 msec, or the greatest difference 
(GD) between any of 4 segments ≥ 65 msec. Test-Retest reliability was assessed by 
linear correlation, Bland Altman analysis & agreement for IVD. Intrareader reproducibility 
was determined by blinded reread of 10 studies.
Results: Per SLD criteria, IVD was present in 1 study for 3 pts & 0 nls and both studies for 
1 pt & 1 nl. Per GD criteria, IVD was present in 1 study for 3 pts & 2 nls and both studies 
for 2 pts & 4 nls (see table).
Linear correlation
(r)
Bland Altman
95% agreement limits
(msec)
%
Agreement
Test-retest: SLD 0.52 -78, 75 88%
Test-retest: GD 0.48 -66, 57 80%
Intra-reader: SLD 0.98 -20, 22 100%
Intra-reader: GD 0.98 -17, 14 100%
Conclusions: 1. Large test-retest variation in quantitation of IVD by TDI may impair 
accurate detection of IVD & determination of true interval change, even with good reader 
reproducibility and utilization of same machine and sonographer. 2. GD criteria for IVD 
may be inappropriate given its detection in many normals.
9:00 a.m.
1016-145	 Changes	in	Diastolic	Function	Induced	by	Surgical	
Ventricular	Restoration	in	Patients	with	Ischemic	
Dilated	Cardiomyopathy
Serenella Castelvecchio, Marco Ranucci, Lorenzo Menicanti, Marisa Di Donato, 
Policlinico San Donato, IRCCS, San Donato Milanese, Italy, University of Florence, 
Florence, Italy
Background: Surgical Ventricular Restoration (SVR) is a successful technique for 
restoring left ventricle (LV) shape, size and function in patients with ischemic dilated 
cardiomyopathy. However, limited data are available on LV diastolic function in patient 
submitted to SVR. Experimental studies suggest an adverse effect on diastolic function 
induced by surgical volume reduction.
Aim of the present	was to assess the prevalence of diastolic dysfunction in patients with 
ischemic dilated cardiomyopathy eligible for SVR and to evaluate changes in diastolic 
function induced by SVR.
Methods:	A consecutive series of 146 patients (119 men, mean age 65 ± 9) with previous 
anterior myocardial infarction (AMI) and secondary LV dilatation were evaluated by two-
dimensional and M-mode echocardiography and Doppler echo-assessment before 
SVR and at the time of discharge. Patients needing mitral valve repair were excluded. 
Standard echo was used to calculate LV diameters, volumes and ejection fraction, LV 
mass, wall thickness, inter-papillary distance and left atrium dimension. According to the 
left ventricular filling pattern, obtained from trans-mitral flow velocity curve, four groups 
have been identified: normal (N), abnormal relaxation (AR), pseudo-normal (PN) and 
restrictive (RP).	After surgery, diastolic function was defined unchanged (no difference in 
diastolic pattern), improved (at least one class less) or worsened (at least one class more 
or from reversible to irreversible RF).
Results:	trans-mitral diastolic filling pattern before SVR was: N in 7 patients (4.8%), AR 
in 99 (68%), PN in 28 (19%) and RP in 12 (8.2%). After SVR, diastolic filling pattern was 
unchanged in 105 patients (72%), improved in 14 (9.6%) and worsened in 27 (18.4%). No 
preoperative echocardiographic parameter tested at univariate analysis was associated 
to a diastolic pattern worsening.
Conclusions: The prevalence of diastolic dysfunction in patients with ischemic dilated 
cardiomyopathy is high. Diastolic function is worsened by SVR in a small proportion of patients.
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625-5	 Mid-regional	Pro-atrial	Natriuretic	Peptide	(MR-proANP)	
Predicts	Survival	in	Patients	with	Mild	to	Moderate	
Chronic	Heart	Failure
Stephan von Haehling, Ewa A. Jankowska, Nils G. Morgenthaler, Mariantonietta Cicoira, 
Piotr Rozentryt, Gerasimos S. Filippatos, Wolfram Doehner, Friedrich Kohler, Joachim 
Struck, Piotr Ponikowski, Andreas Bergmann, Stefan D. Anker, Division of Applied 
Cachexia Research / Dept. of Cardiology / Charite Medical School, Berlin, Germany, 
B.R.A.H.M.S AG, Research Department, Hennigsdorf / Berlin, Germany
Background: Natriuretic peptides are powerful predictors of survival in chronic heart 
failure (CHF). Their prognostic power is less well established in clinical “gray areas”, e.g. 
in patients in NYHA II and III.
Methods: We analysed a total of 774 CHF patients (age 62±11, NYHA class 2.4±0.8, LVEF 
30±8%, NT-proBNP 2826±5486 pg/mL, serum creatinine 110±37 µmol/L, 93% male, 70% 
ischemic etiology) from 6 European centers in order to predict survival. In EDTA plasma we 
analysed NT-proBNP (ELICIA, Roche Diagnostics) as well as the novel natriuretic peptide 
marker mid-regional pro-atrial natriuretic peptide (MR-proANP, luminescence immuno 
assay) which is stable at room temperature for up to 7 days.
Results:	We restricted the analysis to 645 CHF patients in NYHA II (n=350) and III (n=295). 
Mean levels of MR-proANP were 218±178 in NYHA II and 344±274 pmol/L in NYHA III 
(p<0.0001), respectively. The corresponding values for NT-proBNP were 1708±2735 and 
3287±4365 pg/mL (p<0.0001). During follow-up (mean 39 months), 114 patients died. The 
1- and 5-year mortality were 12% (95% CI 9-15%) and 36% (95% CI 30-42%).
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In single predictor Cox proportional hazard analysis, both markers predicted survival (MR-
proANP: hazard ratio (HR) per 100 pmol/L increase 1.19 [95% CI 1.15-1.23], chi2 =105.0, 
p<0.0001; NT-proBNP: HR per 1000 pg/mL increase 1.11 [1.08-1.14], chi2=70.5, p<0.0001). 
In multivariable Cox analysis, MR-proANP remained a significant predictor of survival after 
adjusting for age, LVEF, NT-proBNP, NYHA class, and creatinine (hazard ratio 1.10 [1.02-
1.18], p<0.05), while NT-proBNP did not (HR 1.03 [0.98-1.08], p=0.21). The area under the 
receiver operator curve for 24-month mortality was 0.76 (95% CI 0.72-0.80) for MR-proANP 
and 0.75 (95% CI 0.71-0.79) for NT-proBNP. Optimal prognostic accuracy was given at a 
cutoff of 221 pmol/L for MR-proANP (sensitivity: 73%, specificity: 68%) and 1370 pg/mL for 
NT-proBNP (sensitivity: 72%, specificity: 71%).
CONCLUSIONS:	In CHF patients in NYHA class II and III, NT-proBNP is not an independent 
predictor of mortality. In contrast, the new natriuretic peptide marker MR-proANP is a 
powerful independent prognosticator in CHF patients in NYHA classes II and III.
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1022-55	 Neuronal	Nitric	Oxide	Synthase	Deficiency	Increases	
Calcium	Leakage	From	the	Sarcoplasmic	Reticulum	in	
Ventricular	Myocytes
DANIEL R. GONZALEZ, Koenraad Vandeager, Joshua M. Hare, Johns Hopkins Medical 
Institutions, Baltimore, MD
Background:The exact mechanisms by which NO regulates EC coupling remain 
unresolved. One theory is that neuronal nitric oxide synthase (NOS1) preferentially 
regulates the ryanodine receptor (RyR) open probability due to its location in the 
sarcoplasmic reticulum (SR). While is known that NOS1 translocates from the SR during 
cardiac injury, the impact of this on cardiac function is controversial. We hypothesized that 
NOS1 deficiency leads to RyR dysregulation, producing diastolic Ca2+ leakage.
Methods:	 To test this hypothesis, we enzymatically isolated ventricular myocytes from 
wild type (WT), NOS1-/-, NOS3-/- and double NOS1/3-/- knock out mice and assessed Ca2+ 
transients using fura-2 AM.
Results:	Diastolic Ca2+ levels were elevated in NOS1-/- myocytes mice paced a 2, 4, 6 and 
8 Hz, but not in NOS3-/- cells compared to WT (p<0.05), suggesting diastolic ca leakage. 
Also, SR Ca2+ content was decreased in NOS1-/- and NOS1/3-/- but not in NOS3-/- cells 
compared to WT (p<0.05), consistent with the idea of leakage. To quantify this precisely, 
we used tetracaine, a RyR blocker, which shifts Ca2+ from the cytosol to the SR allowing 
measurement of Ca2+ leak. As predicted, this was increased in NOS1-/- and NOS1/3-
/-
 myocytes but not in NOS3-/- cells compared to WT (p<0.05). In order to restore levels 
of NO in NOS1-/- cells, we used DETA/NO, an NO donor. Treatment with DETA/NO (100 
µM) significantly restored the Ca2+ content in the SR of NOS1-/- cells (p <0.05 compared to 
control condition), consistent with attenuation of SR leak. Finally, we also inhibited NOS1 
with S-Methyl-thiocitrulline (1µM). This treatment decreased the Ca2+ content in the SR 
and increased the leakage of WT myocytes, compared to control condition (p <0.05), 
confirming the findings from the NOS1-/- myocytes.
Conclusions: We conclude that NOS1 derived NO regulates the activity of RyR during 
diastole and its deficiency leads to Ca2+ leakage, with important consequences for 
myocardial contractile reserve. These findings highlight the detrimental aspects of loss of 
NOS1 from the SR in cardiomyopathy and following myocardial infarction
1:30 p.m.
1022-56	 Plasma	Detection	of	Cofilin-1	in	Human	Heart	Failure:	
A	New	Cardiac	Biomarker?
Brenda K. Huntley, Denise M. Heublein, Sharon M. Sandberg, John C. Burnett, Jr., 
Mayo Clinic, Rochester, MN
Background: Heart failure (HF) is characterized by activation of the natriuretic peptide 
system. In particular, BNP has emerged as a useful biomarker of human HF. In an attempt 
to identify new possible biomarkers of cardiac disease, including altered forms of BNP, we 
investigated the presence of a new protein we identified in plasma of patients with HF and 
elevated levels of BNP which was not detected in plasma of normal humans.
Methods: Plasma from normal (n=5) and HF patients (n=10) was first subjected to 
albumin depletion using the SwellGel Blue Albumin Removal Kit (Pierce, Rockford, IL) 
to remove albumin from the plasma samples which could interfere with analysis. Protein 
concentrations were determined using the BCA assay. For protein detection, gels were 
stained with Coomassie blue stain (Bio-Rad, Hercules, CA). Protein sequencing was then 
performed by the Mayo Proteomics Core Facility. Western blotting was performed on 
PVDF membranes with human cofilin-1 antibody and phosphorylated cofilin-1 antibodies. 
(abcam, Cambridge, MA).
Results: Albumin depleted human plasma on Coomassie blue stained gels revealed an 
approximately 20kDa protein band in heart failure plasma which was not evident in normal 
plasma samples. This band was excised and sequenced. Using database analysis, the 
sequence of this protein was determined to be Cofilin-1. To verify the identity of the 
band, plasma samples were then western blotted for Cofilin-1 and this was positive. To 
determine whether the Cofilin-1 identified was the active and/or inactive form of Cofilin-1, 
the western blots were stripped and re-probed using an antibody that is specific for the 
phosphorylated form of Cofilin-1. No bands were detected suggesting that the Cofilin-1 
expressed in HF plasma is active dephosphorylated Cofilin-1.
Conclusions: Our studies identify for the first time that Cofilin-1 is present in human 
HF plasma while it is not found in normals. We further demonstrate that Cofilin-1 in HF 
patients is in its active form. Studies to date have implicated Cofilin-1 in cell proliferation 
and hypertrophy. Additional studies are warranted to determine the utility of Cofilin-1 as a 
possible biomarker in HF and other cardiovascular syndromes.
1:30 p.m.
1022-57	 BNP	Inhibits	Cardiac	Fibroblast	Proliferation	via	the	
Natriuretic	Peptide	C	Receptor	and	Modulates	FAK	
Signaling	and	p21	and	Cyclin	D1	Expression
Brenda K. Huntley, Lisa C. Costello-Boerrigter, John C. Burnett, Jr., Mayo Clinic, 
Rochester, MN
Background: Interactions between the extracellular matrix and membrane receptors such 
as integrins play important roles in the integration of external and internal cellular signals. We 
observed that membrane bound natriuretic peptide receptors (NPRs) have similarities to integrins 
suggesting they may utilize common signaling pathways in the control of cell growth such as focal 
adhesion kinase (FAK) signaling and downstream targets such as p21. Importantly, the natriuretic 
peptides, such as BNP 1-32 which activate the NPRs, possess differential cellular actions, as 
integrin signaling increases cellular proliferation while NPR activation is anti-proliferative. Based 
on these observations, we hypothesized that BNP 1-32 would affect FAK signaling in cultured 
human cardiac fibroblasts (CF). We also assessed cell proliferation and the effect of BNP 1-32 on 
cell cycle progression proteins p21 and cyclinD1.
Methods: CF proliferation was assessed by BrdU using the Roche cell proliferation 
ELISA kit. FAK, cyclin D1, and p21 were analyzed by western blot and expression levels 
measured using densitometry.
Results: BNP 1-32 suppressed CT-1 stimulated proliferation of cardiac fibroblasts assessed by 
BrdU. This response was enhanced by the NPR-A/B receptor antagonist HS-142-1 while it was 
abrogated by NPR- C antagonism. In addition, immunohistochemistry revealed an increase of 
NPR-C in dividing fibroblasts. We observed a decrease in FAKY397 phosphorylation in response 
to BNP 1-32, which was enhanced by HS-142-1. BNP 1-32 increased the cell cycle protein p21 
while it decreased cyclin D1.
Conclusions: BNP 1-32 is anti-proliferative in human cardiac fibroblasts via the natriuretic peptide 
receptor C. BNP 1-32 decreases FAK Y397 phosphorylation suggesting the FAK signaling 
pathway may be involved in the anti-proliferative actions of BNP. In addition, cell cycle proteins 
p21 and cyclin D1 were affected in an anti-cell cycle progression manner by BNP 1-32.
1:30 p.m.
1022-58	 Reverse	Remodeling	Of	Failing	Myocardium	Is	
Associated	With	Decreased	Deposition	Of	Anti-Cardiac	
Antibodies:	Observations	In	Patients	Following	CRT.
Christian Assad-Kottner, David Chen, Francisco Cordova, Keith Youker, Guillermo Torre-
Amione, The Methodist DeBakey Heart Center, Houston, TX
Background: We previously demonstrated that reverse remodeling was associated with decreased 
cardiac cytokine expression. More recently we found increased anti-cardiac IgG deposition in 
the failing human heart; thus, we suggest that normalization of hemodynamic stress or reverse 
remodeling may also decrease the formation and deposition of anti-cardiac IgG Ab.
Methods: Forty patients with end stage HF and normal controls were randomly chosen to screen 
for anti-cardiac IgG deposition. Then we determined anti-cardiac IgG expression in paired 
myocardial samples of patients who underwent placement of a CRT device (EF<30% and 
symptomatic heart failure) at baseline and at 3 months (n=12). Right ventricular biopsies were 
obtained prior to device implantation and at 3 months.
Results:Anti-cardiac IgG staining was present in 27/40 patients with end stage HF and absent 
in normal controls. Anti-cardiac IgG deposition decreased in 8/12 patients at 3 months post 
CRT implantation. Figure 1A shows an example of anti-cardiac IgG staining in responders at 3 
months. Reductions in myocyte size were observed in 7/12 patients. All of these patients also 
demonstrated decrease in IgG deposition (Fig 1B).
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Conclusion: Anti-cardiac Abs are prevalent in the failing human myocardium. Reverse 
remodeling which occurs following CRT as demonstrated by a reduction in myocyte size 
over-time, is associated with decreased deposition of anti-cardiac IgG. 
1:30 p.m.
1022-59	 High	Resolution	Echocardiography	Indicates	Diastolic	
Dysfunction	Without	Hypertrophy	In	A	Novel	Murine	
Model	of	Hypertrophic	Cardiomyopathy
Hsin-Yueh Liang, Patrick Eulitt, Danuta Szczesna-Cordary, Theodore P. Abraham, Johns 
Hopkins University, Baltimore, MD, University of Miami Miller School of Medicine, Miami, FL
Background:	Some ventricular myosin regulatory light chain (R58Q) mutations in familial 
hypertrophic cardiomyopathy (HCM) are associated with arrhythmias and sudden death. 
We report the unique hemodynamic and morphologic profile of a transgenic model of a 
R58Q missense mutation as assessed by high resolution echocardiography.
Methods	 and	 Results:	We generated R58Q mice expressing high levels (>95%) of 
mutant protein and compared them to non transgenic (NTg) animals. All mice underwent 
echocardiography under anesthesia using an ultrasound machine with a 25 MHz probe 
(Visual Sonics, Toronto, CN). Mean age at the time of echocardiography was 9.9± 3.4 
months. Acceptable images were obtained in all animals. There were no significant 
differences between R58Q and NTg animals with regards to left ventricular (LV) end 
diastolic (3.9± 0.4 vs 3.9± 0.4 mm, p= 0.7) or end systolic (2.4± 0.2 vs 2.6± 0.4 mm, p= 
0.4) dimensions, septal (0.81± 0.10 vs 0.86± 0.09 mm, p= 0.5) or posterior wall (0.75± 
0.18 vs 0.85± 0.10 mm, p= 0.3) thickness , LV mass (0.69± 0.04 vs 0.70± 0.01 g, p= 
0.6) and ejection fraction (0.56± 0.07 vs 0.64± 0.03, p= 0.1). However, deceleration time 
(Figure) was significantly prolonged in R58Q compared to NTg suggesting impaired 
relaxation (42±9 vs. 32±6 ms, p=0.037).
Conclusions: High resolution echocardiography indicates the presence of diastolic 
dysfunction in the absence of significant ventricular hypertrophy in a novel transgenic 
model of a HCM associated mutation known to cause sudden death in humans.
1:30 p.m.
1022-60	 The	Expression	Of	Cadiac	Ankyrin	Repeat	Protein(carp)	
In	Animal	Model	Of	Adriamycin-induced	Cardiomyopathy
Woo-Baek Chung, Ho-Joong Youn, Chul-Soo Park, Yong-Seog Oh, Wook-Sung Chung, 
Jae-Hyung Kim, Kyu-Bo Choi, Soon-Jo Hong, Jung-Hwa Lee, The catholic university of 
Korea, Seoul, South Korea
Background: Cardiac ankyrin repeat protein(CARP) is an embryonic protein which 
increases its expression on myocytes in pressure overloaded conditions and failing 
heart. Adriamycin (AD), a cardiotoxic chemotherapeutic agent, suppresses CARP 
expression. We compared expression of CARP in cardiac tissues of normotensive rats 
and spontaneously hypertensive rats(SHR) with AD-induced cardiomyopathy.
Materials: Normotensive Wistar-Kyoto rats (WKY) and SHR were divided into AD-treated 
and saline-treated groups. AD (2.5mg/kg) was injected 6 times intraperitoneally for 3 weeks 
then sacrificed 3 weeks later. Rat CARP peptide was synthesized and injected to rabbit, then 
CARP antibody was extracted from rabbit serum. Immunohistochemical stain was performed 
on left ventricles of four groups and CARP expression was quantified by measuring volume 
fraction of CARP (CVF) using image analysis program (Image Pro-Plus 4.5).
Results: 1.CARP was expressed diffusely in cytoplasm of myocytes. (Figure) 2. CVF was 
5.96±5.11% in WKY and 9.04±6.26% in SHR.(p=0.014) 3.CVF was 2.26±4.74% in AD-
treated WKY and 1.24±4.32% in AD-treated SHR.(p=0.32) 4. AD-treated WKY and SHR 
showed significantly decreased CARP expression, compared to saline-treated groups. 
(p<0.001, p<0.001 respectively).
Conclusion: This results suggest CARP is closely related to the pathogenesis 
of AD-induced cardiomyopathy and especially, has a pivotal role of AD cardiac 
toxicity in hypertensives.
1:30 p.m.
1022-61	 Apelin	Improves	Myocardial	Performance	In	MCT-
Induced	Pulmonary	Hypertension
Inês Falcão-Pires, Tiago Henriques-Coelho, Nádia Gonçalves, Daniel Moreira-
Gonçalves, Adelino Leite-Moreira, Porto, Portugal
Background: Apelin (AP) is the endogenous vasoactive ligand of APJ receptor. It’s 
widely expressed in the heart and lungs and has some cardiovascular functions such as 
endothelium-dependent vasodilatation and positive inotropic effect. The aim of this study 
was to evaluate the chronic effects of apelin administration on biventricular function in a 
model of pulmonary hypertension (PH) induced by monocrotaline (MCT).
Methods: Male Wistar rats were randomly injected with MCT (60mg/Kg, sc) or vehicle 
(day 0). One week later, animals treated with MCT were randomly divided and treated 
with Pyr-apelin-13 (0.2mg/Kg/day, ip) or a similar volume of vehicle. The study resulted in 
3 groups: CTRL; MCT and MCT+Apelin. At day 24, animals were instrumented to record 
right (RV) and left ventricle (LV) peak systolic (Pmax) and end-diastolic (ED) pressures, 
dP/dtmax, dP/dtmin, and time constant Tau. Also, heart and lungs were weighted.
Results: Results are summarized on table 1 as mean±SEM. p<0,05: a vs CTRL; b vs MCT.
Conclusions: Chronic administration of apelin has beneficial effects on MCT model 
namely, decreasing PH, right ventricle (RV) diastolic function and hypertrophy. These 
results reveal the importance of apelin-APJ system in the pathophysiology of PH, 
suggesting that apelin is a potential therapeutic target in this disease.
CTRL MCT MCT+AP
RV/LV+Septum (g/g) 0.205±0.05 0.59±0.04 a 0.40±0.06 a,b
Lungs/body weight (g/Kg) 3.87±0.03 8.05±0.50 a 6.30±0.52 a,b
RVPmax (mmHg) 22.2±1.93 45.2±3.34 a 30.8±2.77 a,b
EDRV 1014±107 1646±90.7 a 1175±120 b
PVDtele (mmHg) 0.8±0.3 1.9±0.66 2.4±0.31 a
RV tau (ms) 26.6±2.1 22.1±1.96 13.5±0.90 b
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1022-62	 Black	Patients	With	Symptomatic	Heart	Failure	Have	
Similar	Outcomes	and	Response	to	Angiotensin	
Receptor	Blockade	As	White	Patients
Eldrin F. Lewis, Marc A. Pfeffer, Bertil Olofsson, Eric L. Michelson, Scott D. Solomon, 
Christopher B. Granger, Salim Yusuf, Karl Swedberg, John J.V. McMurray, Brigham and 
Women’s Hospital, Boston, MA, Western Infirmary, Scotland, United Kingdom
Background:	Controversy exists about the efficacy of renin-angiotensin inhibition and 
outcomes in black patients with heart failure (HF), with disparate results from post-
hoc analyses of clinical trials. The objectives of this analysis were: a) to determine the 
outcomes of black vs. white patients with chronic HF and b) to assess the relative efficacy 
of candesartan in both cohorts.
Methods:	Patients enrolled in the Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity (CHARM) program with symptomatic HF who self-classified 
their ethnicity as European origin (“white”, n=6870) or black (n=326) were included in 
this analysis. Patients were randomized to candesartan or placebo in 3 component trials: 
CHARM-Alternative (ejection fraction<40%, ACE-intolerant), -Added (ejection fraction<40%, 
ACE-treated), and -Preserved (ejection fraction>40%) with a primary endpoint of time to 
cardiovascular (CV) death or HF hospitalization (median follow-up 37.7 months).
Results:	Overall, black patients had similar risk of CV death or HF hospitalization as 
white patients: HR 1.01 (Overall), HR 0.94 (Alternative), HR 1.07 (Added), and HR 0.98 
(Preserved) with p-value for interaction of 0.33. The impact of candesartan on reducing 
the risk of CV death or HF hospitalization was similar regardless of ethnicity (Table).
Conclusions:	Despite younger age, blacks with chronic, symptomatic HF had similar 
outcomes to white patients. Candesartan had similar benefit in black and white patients.
Comparisons of Outcomes in CHARM Patients
Characteristics	and	Outcomes White	Patients Black	Patients
Mean Age (years) 66.6 59.0
Mean Left Ventricular Ejection Fraction 39.0% 38.0%
Number of Patients (OVERALL) 6870 326
Crude Rate of CV Mortality/HF 
Hospitalization (OVERALL) 2182 (31.8%) 105 (32.2%)
Number of Patients (LVEF<40%) 4103 200
Crude Rate of CV Mortality/HF 
Hospitalization (LVEF<40%) 1557 (37.9%) 78 (39%)
Primary Outcomes P	for	Interaction
Impact of Candesartan on CV Mortality/
HF Hospitalization (OVERALL)
HR 0.82 (95% 
CI 0.78-0.89)
HR 0.71 (95% 
CI 0.48-1.05) 0.58
Impact of Candesartan on CV Mortality/
HF Hospitalization (LVEF<40%)
HR 0.81 (95% 
CI 0.73-0.89)
HR 0.59 (95% 
CI 0.37-0.94) 0.24
1:30 p.m.
1022-63	 Intravenous	Nesiritide	Decreases	Contractility	in	
Humans:	Observations	from	Pressure-Volume	Analysis
Sanjiv J. Shah, Sarah G. Weeks, Mia Shapiro, Elyse Foster, Andrew D. Michaels, University 
of California, San Francisco, San Francisco, CA, University of Utah, Salt Lake City, UT
Background: Controversy exists regarding the clinical use of nesiritide. Although nesiritide 
is a potent vasodilator, recent studies utilizing myocytes and isolated muscle strips have 
shown that that recombinant B-type natriuretic peptide (BNP) decreases contractility. We 
sought to understand the effect of nesiritide infusion on cardiac contractility in humans by 
pressure-volume analysis.
Methods: 25 patients with symptomatic heart failure (15 with EF<40% and 10 with 
EF>50%) underwent echocardiography and right and left heart catheterization using 
a pressure-volume conductance catheter (CD Leycom, Netherlands) at baseline and 
after a 2 mcg/kg bolus and 30-minute infusion (0.01 mcg/kg/min) of nesiritide. From 
invasive and non-invasive measurements, we calculated peak isovolumic pressure 
(P
max
), invasive and non-invasive end-systolic elastance (E
es
; single-beat methods), and 
preload-recruitable stroke work (PRSW; non-invasive, single-beat method). We used 
paired t-tests to compare differences in these indices pre- and post-nesiritide infusion.
Results:	The mean age was 60±11 years, 48% were male, 56% had coronary disease, 
and 64% had hypertension. Consistent with prior studies, nesiritide infusion decreased 
left ventricular (LV) end-diastolic pressure (20.6±9.3 mmHg at baseline to 13.3±8.0 
mmHg after infusion; p<0.001) and mean aortic pressure (93±16 mmHg to 78±16 mmHg; 
p<0.001). P
max
 decreased from 286±93 to 233±75 mmHg; p<0.0001. Although nesiritide 
did not acutely change LV ejection fraction (45±19% to 46±19%; p=0.22), it did decrease 
LV contractility measured by load-independent measures on pressure-volume analysis. 
Non-invasive E
es
 decreased from 2.6±1.6 to 2.0±1.4 mmHg/ml (p=0.02). Using the 
single-beat (P
max
) invasive method, E
es
 trended down from 2.2±1.5 to 1.9±1.2 mmHg/ml 
(p=0.18). PRSW decreased from 76±37 to 62±28 g/cm2 (p=0.003), a change that was 
independent of ejection fraction.
Conclusions: Concordant with findings in myocytes and isolated muscle preparations, 
nesiritide infusion acutely decreased contractility and systolic function in humans, as 
measured by load-independent measures on pressure-volume analysis.
1:30 p.m.
1022-64	 Use	of	Inotropic	Drugs	On	First	Day	Hospitalization	
for	Acute	Heart	Failure	Is	Associated	With	Higher	in	
Hospital	All	Cause	Mortality.
Angela Franchi, Giancarlo Bellanti, Francesco Chiofalo, Ornella De Donno, Lucio 
Gonzini, Pasquale Guarini, Rita Piazza, Aldo P. Maggioni, on behalf of the Acute Heart 
Failure Investigators, ANMCO Research Center, Florence, Italy
Aims.	 Evaluating the association between use of inotropic drugs on the first day of 
hospitalization and in-hospital all cause mortality in pts of the Italian Survey of Acute 
Heart Failure (AHF). 
Methods.	Data from 2807 pts from March 2004 to May 2004 were analyzed. Univariate, 
multivariate analysis, Multiple Input and Propensity Score were performed to compare pts 
receiving inotropic drugs (Group A n=576;20.5%) or not (Group B n=2231;79.4%).
Results.	Patients of Group A with respect to pts in Group B had hypertension (67.5% vs 
57.9%;p<0.0001), renal failure (33.1% vs 22.4%;p<0.0001) previos AMI (43.7% vs 34.6%; 
p=0.0002), with ICD (7.9% vs 3.5%; p<0.0001). Patients in Group A were hospidalized 
more frequently for cardiogenic shock (24.4% vs 3.4%; p<0.0001), with new onset AMI 
(42.5% vs 30.4%; p<0.0001) and with worsening HF (66.4% vs 53.2%; p<0.0001). The 
etiology of AHF was more often ischemic (56.6% vs 43.2%; p<0.0001) with left ventricular 
EF <30% (48.8% vs 23.8%; p<0.0001). Patients in Group A had more frequently low Hb 
levels (<10g/dl: 25.1% vs 13.8%; p<0.0001), high creatininemia (<2.5mg/dl: 25.0% vs 
10.3%; p<0.0001). Group A had higher in-hospital all cause mortality (20.6% vs 3.8%; 
p<0.0001). The independent association between all cause death and use of inotropic 
drugs is reported in the Table.
Conclusion.	Therapy with inotropic drugs on first day of hospitalization was independently 
associated with significantly higher mortality in-hospital all cause mortality in pts with AHF.
Event	rate Hazard	ratio	(95%CI)
Inotropic	
drugs
No	
inotropic	
drugs
Multivariate	
analysis	(all	
variables)
Propensity	
score	
adjustement
All	variables	and	
propensity	score	
adjustement
All	variables	
(Multiple	Input	
adjustement)
In-hospital	
mortality 20.6% 3.8%
2.86
(1.90-4.29)
2.63
(1.78-3.89)
2.94
(1.96-4.42)
2.86
(1.90-4.29)
1:30 p.m.
1022-65	 Glycemic	Control	and	the	Length	of	Hospital	Stay	in	
Patients	with	Diabetes	and	Heart	Failure:	A	Prospective	
Cohort	Study
Yohannes A. Gebreegziabher, Chard Bubb, John Makaryus, Naveen Anand, Vijay 
Divakaran, Samy I. McFarlane, SUNY-Downstate Medical Center, Brooklyn, NY, King 
County Hospital Center, Brooklyn, NY
Background: Diabetes and heart failure (HF) are major causes of hospitalization. 
Whether glycemic control affects length of hospital stay in diabetic patients with heart 
failure is largely unknown. The objective of this study is to assess the hospital length of 
stay as it relates to glycemic control in patients with HF with or with out diabetes.
Methods: In a prospective cohort study, we followed patients hospitalized at 2 university- 
affiliated hospitals for acute HF exacerbation as the primary admitting diagnosis over a 
period 12 weeks. Patients with acute co-morbidity were excluded. Demographic, clinical 
and laboratory data were prospectively collected including data on glycemic control 
among diabetic and non-diabetic population. Data is presented as the mean ± SEM.
Results: Of the 212 patients with acute HF exacerbation followed, 119 (56%) also had 
the diagnosis of diabetes. Mean age of the entire cohort was 63±0.87 years, mean BMI 
was 29.3Kg/m2 and 92% had hypertension. HF patients with diabetes had significantly 
longer hospital stay, compared to non-diabetic cohort (5.0±0.29 vs 3.4±0.19, P<0.001). 
For diabetic patients the mean HgbA1c was 8.3%, admission blood glucose (BG) was 
169 ± 7.7 mg/dl and average inpatient BG was 196 ± 8.1 mg/dl. After adjusting for age, 
sex, weight and presence for hypertension, hospital stay significantly correlated with 
admission BG (r=0.31, P<0.001) and average inpatient BG (r=0.34, P=0.001).
Conclusions: In Patients with acute HF exacerbations admitted to hospital, diabetes 
significantly prolonged hospital stay. Both admission BG and average inpatient BG 
significantly correlated with length of hospitalization. Further studies are needed to 
assess the effect of tight glycemic control on hospital stay in HF patients with diabetes.
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1:30 p.m.
1022-66	 Negative	Impact	of	Nesiritide	in	combination	with	
inotropic	therapy	among	Patients	Admited	with	Acute	
Heart	Failure
David Putney, Lea Ann Matura, Kurt Daniel, Vinay Thohan, The Methodist Hospital, 
Houston, TX, Wake Forest University, Winston Salem, TX
Background: Clinical trials involving the use of nesiritide exclude positive inotropic 
agents. The clinical utilization of inotropic therapy with nesiritide has been anecdotal and 
usage is left to clinical discretion. Concerns regarding the safety of nesiritide have led to 
a re-examination of strategies used to treat ADHF. Sparse data exists on combination 
therapy for the treatment of ADHF
Methods: Retrospective chart review of 1035 consecutive patients admitted (1/04 to 
12/05) with ADHF who received inotropic agent in combination with nesiritide or inotropic 
agent alone within 24 hours of admission
Results: Mean hospital LOS between monotherapy and combination therapy was 19.8 d 
vs 24 d, p=0.84. ICU LOS was10 d versus 12.7 d, p=0.99). During day 1 the mean 24-hour 
urine output was significantly higher in the combination group (2000 mL versus 1372 mL, 
p=0.02) with no difference in overall urine output (7d). Daily mean serum creatinine and 
heart rate were not statistically different. Combination therapy revealed a trend toward 
higher BUN (46.2 + 28 vs. 33.6 19.4, p=0.06) and an increased in-hospital mortality was 
observed (17.24% vs 7.6%, p=0.11)
Conclusions: No favorable impact on total or ICU LOS and a concerning trend 
toward worsening renal function and increased hospital mortality was observed among 
hospitalized patients treated with combination nesiritide and inotropic therapy. The 
present study does not support the use of combination of inotropic support and nesiritide 
for the treatment of ADHF 
1:30 p.m.
1022-67	 Prognostic	Role	of	Left	Atrial	Volume	in	Elderly	
Patients	With	Symptomatic	Stable	Chronic	Heart	
Failure:	Comparison	With	Left	Ventricular	Diastolic	
Dysfunction	and	B-Type	Natriuretic	Peptide
Bogdan A. Popescu, Andreea C. Popescu, Francesco Antonini-Canterin, Daniela Rubin, 
Piero Cappelletti, Rita Piazza, Carmen Ginghina, Doina Dimulescu, Gian L. Nicolosi, 
Ospedale Civile, Cardiologia, A.R.C., Pordenone, Italy, Institute of Cardiovascular 
Diseases, Bucharest, Romania
Background: Left atrial volume and B-type natriuretic peptide (BNP) represent powerful 
outcome predictors in patients with heart failure (HF). We assessed the determinants of 
left atrial volume (indexed to body surface area, LAVi), and the comparative prognostic 
role of LAVi, left ventricular (LV) diastolic dysfunction, and BNP levels on long-term 
outcome in patients with symptomatic but stable chronic HF.
Methods: We studied consecutively 46 patients with symptomatic, stable chronic HF (73 ± 
10 years, 30 men), in sinus rhythm, without significant valvular disease. Primary end-point 
was combined: all-cause mortality and hospitalization for worsening HF. Echocardiographic 
measurements included: LV mass, LV volumes, LV ejection fraction and LAVi. LV diastolic 
function was graded using a comprehensive algorithm, previously validated, incorporating 
measurements of transmitral flow parameters at baseline and during a standardized 
Valsalva maneuver, pulmonary venous flow parameters and flow propagation velocity Vp. 
Blood taken before echocardiography was assayed for BNP levels.
Results: At univariate analyses LAVi correlated with LV diastolic dysfunction, BNP levels, 
E/Vp ratio, E deceleration time, LV volumes and LV mass (p<0.02 for all). At stepwise 
multiple regression LV diastolic dysfunction was the only independent predictor of LAVi 
(β=0.70, p<0.001). During 20±14 months of follow-up 19 events occurred: 8 deaths, and 
11 hospitalizations for HF. At univariate analyses LAVi, LV diastolic dysfunction, BNP 
levels, LV ejection fraction, LV volumes and LV mass were significant outcome predictors 
(p<0.05). At multivariate regression LAVi was the only independent predictor of outcome 
(hazard ratio: 1.03 per 1 ml/m2 increase, 95% CI: 1.01-1.06, p=0.02).
Conclusions:	 Although directly related to LV diastolic dysfunction and to BNP levels, 
only LAVi emerged as an independent outcome predictor in this cohort of patients with 
chronic stable HF. While BNP levels and Doppler measurements provide information at one 
moment in time and are sensitive to acute loading changes LAVi allows a long-term view 
into the cardiac status, irrespective of loading conditions and this could explain our results.
1:30 p.m.
1022-97	 Effects	of	Atorvastatin	Therapy	in	Heart	Failure:	
Oxidative	Stress,	Inflammation,	Endothelial	
Dysfunction	and	Exercise	Capacity
Rodrigo Miranda, Pablo Castro, Hugo Verdejo, Douglas Greig, Hernan Alcaino, Carlos 
Bustos, Jose Luis Vukasovic, Ivan Godoy, Guillermo Diaz-Araya, Sergio Lavandero, 
Pontificia Universidad Catolica de Chile, Santiago, Chile, Universidad de Chile, 
Santiago, Chile
Background: Chronic heart failure (CHF) is associated with increased oxidative stress 
(OS), leading to inflammation and endothelial dysfunction. Statins have antinflammatory 
and antioxidant actions. However, their use in CHF is still controversial.
Objective:	To evaluate the effect of statin use on OS, inflammation, endothelial function 
and exercise parameters in CHF patients.
Methods: Prospective study. Fifteen patients with compensate CHF, left ventricular 
ejection fraction (EF) <40% and normal cholesterol who had not received statins 
previously were included. All patients received a 4 week course of placebo and then 
atorvastatin 20 mg daily for 8 weeks. At baseline, 4 and 12 weeks blood samples were 
obtained for malondialdehide (MDA), endothelial-bound superoxide dismutase (ecSOD), 
Metalloprotinase-9 (MMP-9), TIMP-1, usPCR and TNF-α. At each visit patients underwent 
endothelial vasodilation reactive hyperemia test and six-minute walk test.
Results: Mean age was 59±10. Twelve (80%) were men. CHF was ischemic in seven 
patients (46%). Mean EF was 30±7%. A significant correlation was found between 
changes in ecSOD and EV (r=0.64, p= 0.01). Main results are summarized in the table. 
Baseline Placebo Atorvastatin P 
ecSOD (U
*
mL-1
*
min1) 143 ± 22* 132 ± 11* 226 ± 46 0.001
MDA (μM) 0.74 ± 0.1* 0.9 ± 0.1* 0.73 ± 0.06 0.71
MMP-9 0.38 ± 0.1* 0.42 ± 0.1* 0.31 ± 0.1 0.01
TIMP-1 1.06 ± 0.3* 1.1 ± 0.1* 1.2 ± 0.2 0.03
PCR us (pg/mL) 5.1 ± 9* 6.0 ± 10* 2.3 ± 2.2 0.01
TNFα (pg/mL) 0.81 ± 1.3* 1.1 ± 1.5* 0.64 ± 1.2 0.007
VE (%) 4.3 ± 1.6* 4.57 ± 2.1* 6.9 ± 2.6 0.004
Six-minute walk (mts) 430 ± 73* 425± 60* 480 ± 80 0.03
* Baseline vs. placebo Wilcoxon rank sum test p=NSConclusion: Atorvastatin therapy in 
CHF is associated with a decrease of inflammation and extracellular matrix remodeling 
parameters and increased ecSOD levels, improving endothelial function and exercise 
capacity. Fondecyt 1050768-FONDAP15010006
1:30 p.m.
1022-98	 Anaemia	And	Its	Impact	On	Use	Of	Hospital	Resources	In	
Heart	Failure:	Results	Of	The	Euroheart	Failure	Survey
Lwin L. Tin, Alan S. Rigby, Kevin Goode, Nasrin Khan, Priya Reddy, Poay H. Loh, Karl 
Swedberg, Michael Komajda, F. Follath, Andrew Clark, John G. Cleland, University of 
Hull, Hull, United Kingdom
Background: : Anemia plays an important role in determining prognosis and quality 
of life in patients with chronic heart failure, yet no detailed account of how anemic 
patients admitted with acute heart failure differ from those who are not anemic has been 
described.
Methods: The EuroHeart Failure survey screened 46 788 consecutive deaths and 
discharges during 2000 in 115 hospitals from 24 countries belonging to the European 
Society of Cardiology. Of these 11 327 had suspected or confirmed heart failure. Anemia 
was defined according to WHO criteria (Hb < 13 g/dl in men and < 12 g/dl in women).
Results: The average age was 71 (±13) years, 53% were men and 54% of those who had 
LV function assessed had LVSD. Hb was recorded in > 90% of patients. Mean hemoglobin 
in men was 13.2 (± 2.3) and in women was 12.3 (±2.1) g/dl and serum creatinine was 138 
(±11)umol/l. The prevalence of anemia was 41% (n= 1886). Anemic patients were older, 
71 (±12) v 68 (±13) years (p<0.001) and had higher serum creatinine 155(±12) v 128(±10) 
umol/l, (p<0.001). In men, independent associations with baseline anemia included age, 
dilated cardiomyopathy, use of nitrates and creatinine; loop diuretics were protective. In 
women independent associations included age, ACE inhibitors, beta blockers and urea. 
Carvedilol had a stronger association with anemia than other beta blockers. Anemic 
patients were more likely to have presented to hospital with ventricular arrhythmias,(p 
= 0.045 ) and cardiac arrest, (p = 0.001), or to develop cardiogenic shock during their 
admission, (p = 0.014). They also had a longer stay in hospital, 12 (±2) days v 10 (±4) 
days, (p < 0.001) and spent longer periods on intensive care (median 3 v 2 days,p < 0.001 
) and coronary care units (6 v 3 days, p < 0.001), and on IV inotropes (p=0.009). 75 men 
(6%) and 43 women (7%) with anemia died during the index admissions compared to 98 
(5%) and 60 (6%) without.
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Conclusions: These results show that anemic patients present with more severe heart 
failure, have a worse prognosis and use more resources.
1:30 p.m.
1022-99	 Possible	Genotype-Phenotype	Correlations	in	
Transthyretin-Related	Hereditary	Amyloidosis
Claudio Rapezzi, Letizia Riva, Fabrizio Salvi, Francesca Pastorelli, Paolo Ciliberti, 
Candida C. Quarta, Simone Longhi, Maddalena Graziosi, Barbara Bordoni, Enrica 
Perugini, Marinella Ferlito, Elena Biagini, Angelo Branzi, Institute of Cardiology, 
University of Bologna, Bologna, Italy, Department of Neurology, Bellaria Hospital, 
Bologna, Bologna, Italy
Background. Hereditary transthyretin-related amyloidosis (ATTR) is genotypically/
phenotypically heterogeneous. We studied frequency/severity of neurologic/cardiac 
involvement and clinical outcome in Italian ATTR patients (nationwide) and explored 
possible genotype-phenotype correlations.
Methods.	 We evaluated 104 consecutive ATTR patients (62 men) diagnosed (DNA 
analysis) in a 16-year period (follow-up, 51±44 months). Cardiac involvement was defined 
in terms of ECG and/or echocardiographic abnormalities.
Results.	 Frequent mutations were	 Val30Met (n=35), Glu89Gln (n=18) and Thr49Ala 
(n=9) (the other 42 patients had 11 different mutations). At first observation, prevalence of 
cardiac involvement was 78% in both Glu89Gln and Thr49Ala and only 43% in Val30Met 
(P=0.03); mean age was 56±9 yr for Glu89Gln, 42±7 for Thr49Ala and 49±16 for Val30Met 
(p=0.06); no difference was apparent for disease duration and prevalence of advanced 
autonomic impairment. The Figure shows Kaplan Meier overall survival curves censored 
at transplantation (OLT n=29; combined OLT/HT n=6). 
At multivariate analysis, “main mutations” was an independent prognostic variable, in 
addition to disease duration and advanced autonomic impairment.
Conclusions. A high degree of phenotypic-genotypic heterogeneity was observed in 
this nonendemic area. Genotype may influence clinical outcome. In particular, Glu89Gln 
seems to have a severe, heart-driven prognosis.
1:30 p.m.
1022-100	 Beta-blocking	Agents	Have	Codon	389	Arg/gly	Genotype	
Specific	Effects	In	Isolated	Human	Heart	Preparations.
Bradley C. Nelson, Jennifer M. Morrison, Jonathan D. Port, Alastair D. Robertson, 
Michael R. Bristow, University of Colorado at Denver and Health Sciences Center, 
Denver, CO
We have previously reported that in isolated human right ventricular trabeculae hearts that 
are homozygous for beta1 Arg 389 have much greater beta-agonist contractile responses 
than heterozygotes or Gly homozygotes. To determine if the 389 Arg/Gly polymorphism 
also affects the response to beta-antagonists, we examined the effects of beta receptor 
anatagonists on the systolic force responses in isolated right ventricular trabeculae taken 
from 28 end-stage failing human hearts removed at the time of transplantation. Nineteen 
of these hearts were Arg homozygotes, and 15 Gly carriers were either heterozygotes 
or Gly homozygotes (n = 2). Responses were measured at 0.5 log unit intervals over 3 
log unit dose ranges.Responses were classified as either agonist (A), neutral antagonist 
(NA), or inverse agonist (IA) based on dose-response slopes that were respectively either 
positive, not different from 0, or negative. To facilitate the detection of agonist effects 
responses were determined in the absence and presence of forskolin, which is able to 
unmask the effects of weak partial agonists:
metoprolol bucindolol carvedilol xamoterol
Genotype: without forskolin
Arg/Arg IAp=0.02 NA NA NA
Gly carrier IAp=0.001 NA
IA
p=0.001
IA
p=0.002
with forskolin
Arg/Arg IAp=0.03
IA
p=0.01 NA
A
p=0.008
Gly carrier NA NA NA NA
Conclusions: These data demonstrate that 1) the codon 389 Arg/Gly polymorphism 
influences the response to beta-antagonists as well as agonists, 2) the responses to all 
4 agents are genotype-specific and unique for each antagonist, and 3) the partial agonist 
effects of xamoterol are only seen in Arg/Arg hearts, in the presence of forskolin.
1:30 p.m.
1022-101	 Impact	of	Pericardiectomy	in	Quality	of	Life	of	Patients	
With	Recurrent	Pericarditis
Mauricio A. Villavicencio, Thoralf M. Sundt, III, Richard C. Daly, Joseph A. Dearani, 
Christopher G. A. McGregor, Charles J. Mullany, Thomas A. Orszulak, Francisco J. 
Puga, Hartzell V. Schaff, Mayo Clinic, Rochester, MN
Background. Recurrent pericarditis is a troublesome problem that may require multiple 
and long-term drug therapy in a young population. The benefits of pericardiectomy have 
been shown only in small series, and consequently, we studied our clinical experience in 
this challenging disease.
Methods. Between 1980 and 2004, fifty-five patients underwent pericardiectomy for 
recurrent pericarditis. The mean age was 43+/-16 years, 58% of them were male, and 
65% were in NYHA class III-IV. The etiology was idiopathic 62%, post-surgery 20%, 
viral 9%, rheumatologic 6%, and trauma 4%. This group was followed with quality of life 
questionnaires during 2005 (mean follow-up 5.7 +/- 4.3 years).
Results. Operative mortality was 0%. Two patients had re-exploration for bleeding but none 
had stroke, mediastinitis, intra-aortic balloon pump, and /or dialysis. Length of hospital 
stays 6 +/-2 days. Survival was 96 +/- 3%, 79 +/- 10%, and freedom from recurrences 
was at 96 +/- 3%, 96 +/- 3%, at 5 and 10 years, respectively. During follow-up patients 
graded NYHA functional class from 1-4, chest pain 0-10, and dyspnea 0-10. Mean scores 
were for: NYHA 2.9 +/- 1; 1.5 +/- 0.9; 1.4 +/- 0.8, before surgery, the first year after, and 
currently, respectively. Chest pain: 8.4 +/- 0.5, 2.7+/-0.5, 1.6 +/- 0.4. Dyspnea: 7.4+/-3.1; 
2.1+/-2.3; 1.9+/-2.3. Mean scores were better the first year after and currently with a p 
value of 0.001 or less in all cases. Quality of life before surgery was defined as poor in 
67% before and 0% after the operation. In addition, quality of life rated as excellent, very 
good, or good, increased from 12% to 81%.
Conclusions. Pericardiectomy is an effective tool in the treatment of recurrent pericarditis 
and it could be carried out with very low morbidity and mortality. These encouraging 
results suggest that surgery should be indicated earlier in the course of the disease.
1:30 p.m.
1022-102	 Energy	Deprivation	In	Apical	Ballooning	As	Possible	
Pathomechanism	Of	Contractile	Dysfunction	And	
Structural	Degeneration.
Holger M. Nef, Helge Möllmann, Christian Troidl, Michael Weber, Nina Ogurek, Thorsten 
Dill, Roland Brandt, Christian Hamm, Albrecht Elsässer, Kerckhoff Heart Center, Bad 
Nauheim, Germany
Background: Apical ballooning is characterized by an acute but reversible contractile 
function.Whether this phenomenon is accompanied by structural alterations remains 
unknown. Thus, the aim of the present study was to investigate the myocardial structure 
in the acute phase of apical ballooning and after functional recovery.
Methods: We studied 8 patients presenting with apical ballooning validated by coronary 
angiography, ventriculography, and magnetic resonance imaging and echocardiography. 
Intramural biopsies were taken during the phase of severely impaired left ventricular function 
(group A) and after functional recovery (group B). Both were compared to non-diseased human 
heart (LV). In all samples, electron microscopy and immunohistochemistry were performed.
Results: All patients showed the typical contractile pattern of apical-ballooning and a 
complete functional recovery within 12±3 days. Obstructive coronary artery disease 
and myocarditis were excluded. In group A structural degenerations characterized by 
disorganization of the contractile and cytoskeletal proteins (actin, alpha-actinin, dystrophin) 
were shown. Many unfilled perinuclear vacuoles were found disappearing after functional 
recovery. In group A extracellular matrix proteins (collagen I, fibronectin) were increased.
Group B showed a nearly complete reversibility of these alterations. In lipid staining 
specimens of group A showed an increase in triglycerides as compared to group B. 
Additionally, PAS staining revealed intracellular accumulation of glycogen in group A.
Conclusions: In apical ballooning reversible cellular and structural degeneration were 
observed. Accumulation of fatty acids and glycogen as signs of energy depletion identify 
a possible pathomechanism leading to the contractile dysfunction.
1:30 p.m.
1022-103	 Expression	Profiling	Of	Cardiac	Genes	In	Tako-tsubo	
Cardiomyopathy:	Insight	In	A	New	Cardiac	Entity
Holger M. Nef, Christian Troidl, Helge Möllmann, Michael Weber, Nina Ogurek, Thorsten 
Dill, Roland Brandt, Christian Hamm, Albrecht Elsässer, Kerckhoff Heart Center, Bad 
Nauheim, Germany
Background: The specific pathomechanism of Tako-Tsubo cardiomyopathy characterized 
by transient contractile dysfunction remains unknown. Therfore, the aim of this study was 
to perform a systematic expression profiling of genes documented by microarray during 
the acute phase and after functional recovery.
Methods: We studied 4 patients presenting with apical-ballooning diagnosed by coronary 
angiography, ventriculography, magnetic resonance imaging, and echocardiography. 
Using oligonucleotide microarrays (HG U 133 Plus 2.0, Affymetrix, Inc, CA) complementary 
RNA isolated from transmural biopsies taken in the acute phase (group A) and after 
functional recovery (group B) was profiled for gene expression in comparison to non-
failing heart. 301 genes were differentially expressed in group A and 297 in group B (fold 
change ≥ 2). Validation of selected genes was performed using real-time PCR.
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Results:	Using gene set enrichment analysis three functional groups (female genes, cell 
cycle and cell proliferation) were significantly over-represented among the up regulated 
targets in group A. Up-regulation of RPS6 and RPS9 was confirmed by RT-PCR. 
Genes involved in energy metabolism (electron transport chain, mitochondrial genes, 
cytokines) showed a significant depression in group A whereas in group B these targets 
were over-expressed. Validation was performed for NADH dehydrogenase Fe-S protein 
3 (NDUFS3). Noteworthy, the cytokine exogenous high-mobility group box 1 (HMGB1) 
protein showed a 2.2-fold expression in group 2.
Conclusions:	The expression profiling of cardiac genes in tako-tsubo cardiomyopathy 
indicates an impaired energy metabolism and an increased protein biogenesis. After 
functional recovery genes encoding for cytokines, especially HMBG1, are a potential 
indicator for myocardial regeneration.
1:30 p.m.
1022-105	 Comparison	of	Delayed	Enhanced	MRI	with	F	18-
FDG-PET	and	Te-99m	SPECT	for	Detection	of	Cardiac	
Sarcoidosis
Binju Joel, James Corbett, Benoit Desjardins, Aman Chugh, Frank Pelosi, Jr., Eric 
Good, Krit Jongnarangsin, Hakan Oral, Hakan Oral, Fred Morady, Frank M. Bogun, 
University of Michigan Health System, Ann Arbor, MI
Background: Diagnosis of cardiac sarcoidosis is challenging. Both cardiac magnetic 
resonance imaging with gadolinium-DTPA-enhancement (DEMRI) and FDG PET 
imaging have shown a high sensitivity in detecting cardiac involvement in patients with 
sarcoidosis. The purpose of this study was to compare DEMRI with F-18 FDG PET / 
Tc-99m technetium tetrofosmin SPECT for characterization of cardiac myocardial 
metabolism and perfusion in consecutive patients with clinical cardiac sarcoidosis.
Methods: Eight patients (5 males, age 53±12years, ejection fraction: 42±16%) with the 
diagnosis of cardiac sarcoidosis based on the Japanese Ministry of Health criteria were 
studied. F-18 FDG PET and gated resting Tc-99m tetrofosmin SPECT as well as DEMRI 
(1.5 Tesla, GE) studies were performed and compared. A 19-segment polar map model 
was used to semi-quantitatively assess PET and SPECT results. None of the patients had 
prior myocardial infarction; 1 patient had documented coronary artery disease. Coronary 
artery disease was ruled out in 7 patients by coronary angiography or stress / rest cardiac 
SPECT.
Results: All studies showed some abnormalities in all modalities in every patient. In 
the DEMRI 69/152 segments were abnormal; 70/152 segments were abnormal in the 
SPECT scans and 66/152 segments were abnormal in the PET scans. Abnormalities 
in DEMRI were associated with abnormalities in SPECT and PET images (p<0.0001). 
In 59/70 segments with DEMRI (84%) corresponding defects could be identified in both 
radionuclide techniques. In 22/59 segments F-18-FDG uptake was relatively increased 
as compared to perfusion. FDG up-take was decreased with respect to perfusion in 16/59 
segments (27%) and perfusion was similarly decreased compared to FDG uptake in 
21/59 segments (36%).
Conclusion: In patients with clinical sarcoidosis, cardiac metabolism and perfusion are 
frequently abnormal as assessed by FDG PET and tetrofosmin SPECT. PET and SPECT 
abnormalities correlate well with delayed enhanced segments on MRI studies. Assessment 
of cardiac metabolism and perfusion using nuclear techniques may be helpful in detecting 
cardiac involvement and assessing disease activity of cardiac sarcoidosis.
1:30 p.m.
1022-106	 Aggressive	Prophylaxis	Against	Cytomegalovirus	
Plays	a	Key	Role	in	Preseving	Epicardial	Artery	Flow	
Early	After	Cardiac	Transplantation
Ryota Sakurai, Masao Yamasaki, Luciano Potena, Atsushi Hirohata, Yasuhiro Honda, 
Paul G. Yock, Peter J. Fitzgerald, Alan C. Yeung, Hannah A. Valantine, William F. 
Fearon, Stanford University, Stanford, CA
Background:	The factors influencing changes in physiology of the epicardial artery and 
of the microvasculature early after cardiac transplantation are unclear.
Methods:	 Fractional flow reserve (FFR) and the index of microcirculatory resistance 
(IMR) were performed in the left anterior descending artery of 35 asymptomatic cardiac 
transplant recipients within 8 weeks and at 1 year after transplantation. To investigate 
possible determinants of changes in coronary physiology during the first year after 
transplant, clinical parameters of donors and recipients were recorded prospectively.
Results:	At 1 year, FFR worsened (0.89±0.06 to 0.85±0.06, p<0.01), while IMR improved 
(25.5±14.0 to 18.4±7.3 units, p<0.01), despite no angiographic evidence of coronary 
disease. Absence of aggressive prophylaxis against cytomegalovirus (CMV) infection/
reactivation with a 3-month course of CMV hyperimmune serum and an maximum 80-day 
course of valganciclovir was the only determinant of greater FFR worsening from baseline 
to 1-year follow-up by univariate analysis (p<0.05), while there was no determinant of 
greater IMR improvement in that period. Between the patients with and without aggressive 
prophylaxis against CMV, other clinical parameters were similar.
Conclusion: During the first year after cardiac transplantation, epicardial artery 
physiology worsens, whereas microvascular physiology improves. Aggressive prophylaxis 
against CMV appears to preserve epicardial artery flow in that period. 
1:30 p.m.
1022-107	 High	Mortality	Of	UNOS	Status	1	Heart	Transplant	
Candidates	-	Call	For	Consideration	Of	Mechanical	
Circulatory	Support
Katherine Lietz, Leslie W. Miller, Georgetown University - Washington Hospital Center, 
Washington, DC
Background: The medical and device therapy of advanced heart failure (HF) has made 
a tremendous progress during the last two decades.
Methods: Using data of 52,672 adult pts listed for HT btw 1988-2006 we describe trends in 
candidate selection, medical and device therapy and their impact on survival on HT waiting lists.
Results: Survival of UNOS Status 1 and Status 2 HT candidates has markedly improved 
since early 1990s (Figure). Changes that contributed to these improvements included 
increased use of AICD *, more favorable hemodynamics * and improved outcomes 
of mechanical circulatory support *. Only Status 1 pts whose mortality remained high 
(68% at 1-yr) continued to derive significant survival advantage with early cardiac 
replacement, whereas for Status 2 pts survival benefit of HT significantly decreased. 
Status 1 candidates at highest risk of death included: Status 1B candidates, on inotropes 
*, ventilator or circulatory support *, restrictive or valvular CM *, non-Caucasians *, age > 
40 yrs *, certain allocation regions *. Notably, the vast majority of Status 1 pts who died 
were not on mechanical circulatory support (77% of 4,037 pts).
Conclusions: The sickest UNOS Status 1 HT candidates continue to depend on 
immediate cardiac replacement despite the overall improved survival on HT waiting lists. 
Since mechanical circulatory support can achieve excellent outcomes in well selected 
pts, it is important to identify those high risk pts who could potentially benefit from device 
implantation.
* p < 0.001
1:30 p.m.
1022-108	 New	Generation	Axial-flow	Left	Ventricular	Assist	
Device	Can	Support	Patients	With	Various	Degrees	of	
Right	Ventricular	Dysfunction
George V. Moukarbel, Stephanie C. Ennis, Stephanie A. Moore, Thomas E. MacGillivray, 
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background: In patients undergoing implantation of pulsatile-flow left ventricular assist 
device (LVAD), decreased right ventricular stroke work index (RVSWI) before surgery is 
associated with the need for right ventricular assist device (RVAD) and poor prognosis. 
We examined the outcomes following implantation of an axial-flow LVAD in patients with 
different degrees of right ventricular dysfunction.
Methods: Fourteen patients enrolled in the HeartMate II Continuous Flow LVAD Pivotal Trial at 
our center were divided into two groups according to RVSWI: Group A included patients with low 
RVSWI (< 500 mmHg.ml/m2) while Group B included those with high RVSWI. Hemodynamic 
parameters and clinical outcomes were compared between the two groups. Results are 
reported as mean ± SD. Statistical analysis was performed using Student’s t test.
Results: There were 6 patients in Group A and 8 patients in Group B. Both groups had 
comparable age, left ventricular ejection fraction, renal and liver function tests at baseline. 
Group A patients had a significantly lower RVSWI (358±73 vs. 814±261 mmHg.ml/m2; 
P=0.001) and cardiac index (1.65±0.32 vs. 2.32±0.41 L/min/m2; P=0.007), and a trend 
towards lower systolic pulmonary artery pressure (53.6±4.1 vs. 62.2±10.0 mm Hg; P=0.07) 
compared with Group B patients. Following HeartMate II implantation, none of the patients 
required RVAD. Group A and Group B patients had no differences in the duration of post-
operative inotropic support (3.3±1.6 vs. 4.0±4.1 days; P=0.72) or in the cardiac index off 
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inotropes (2.5±0.5 vs. 2.9±0.6 L/min/m2; p=0.17). Both groups had similar average pump 
speeds (8950±526 vs. 8857±321 rpm; P=0.7) in the early post-operative period.
Conclusions: Axial-flow LVAD can provide adequate hemodynamic support in patients 
with end-stage heart failure and varying degree of right ventricular dysfunction.
1:30 p.m.
1022-109	 Are	Initial	Indications	for	Left	Ventricular	Assist	
Support	Necessary?
Stephanie C. Ennis, Stephanie A. Moore, Cynthia A. Ennis, George V. Moukarbel, Thomas E. 
MacGillivray, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background: Left ventricular assist devices are routinely placed for intractable heart 
failure, dependence on a temporary device or failure to wean off bypass, as a bridge 
to transplantation or as destination therapy. A patient’s initial indication for mechanical 
circulatory support does not always match the final indication for support.
Methods: We performed a chart review of patients presenting to our center over the past 18 
months who underwent permanent device implantation. A comparison was made between 
the patient’s initial indication for implantation of the device and eventual outcome.
Results: A total of 23 patients had a permanent left ventricular assist device placement 
at our institution. The initial indication in 15 patients for placement of the LVAD was as a 
bridge to transplantation (BTT). The initial indication for 8 of the patients was LVAD for 
destination therapy (DT). There were 16 males and 7 females. The group was evenly 
divided between nonischemic and ischemic etiology. The mean age of all patients was 
51 years old. The average age for the BTT group was 47 and the average age of the 
DT group was 59. There were 9 first generation devices and 14 second generation 
devices implanted. Eight patients required intra-aortic balloon pump support prior to 
LVAD placement. Only two patients did not require inotropic support. For 26% of the 
patients initial indication proved to be incorrect. Four patients deemed destination therapy 
ultimately were listed for transplant. One BTT patient recovered ventricular function and 
the device was removed. One BTT patient became destination therapy.
Conclusions: Currently the practice is to label the patient as bridge to transplant or 
destination therapy to utilize permanent mechanical support. The review of our center 
s indications and outcomes revealed a 26% failure rate in the accurate determination of 
indication at time of implant. The routine practice of labeling patients at time of implant 
has a potentially high failure rate. More patients may be eligible for clinical studies if the 
indication of bridge to transplant and destination therapy were not critical determinants 
and perhaps should be abandoned.
1:30 p.m.
1022-110	 Improvement	of	Clinical	Status	and	Cardiac	Function	
by	Cardiac	Contractility	Modulation	for	Patients	with	
Advanced	Heart	Failure
Cheuk-man Yu, Joseph YS Chan, Qing Zhang, Gabriel WK Yip, Anna KY Chan, SP 
Poon, Jeffery WH Fung, The Chinese University of Hong Kong, Hong Kong, People’s 
Republic of China
Background: Cardiac contractility modulation (CCM) is a new device-based therapy 
for heart failure in which large electric currents delivered during the absolute refractory 
period are intended to enhance intrinsic contractility of the myocardium. To date clinical 
experience of CCM is limited. This study examined clinical and echocardiographic benefits 
of CCM in heart failure.
Methods: Twelve patients with advanced heart failure (all in NYHA class III), systolic 
dysfunction with ejection fraction <35% and remained symptomatic despite optimal 
medical therapy were included. Clinical and echocardiographic assessments were 
performed before and 3 months after CCM.
Results: There was significant improvement of NYHA class, 6-Minute Hall Walk (6MHW) 
distance and exercise capacity (metabolic equivalent achieved on treadmill, or METs) 
after CCM for 3 months (Table), and a trend of improvement in Minnesota Living With 
Heart Failure quality of life score (MLWHF-QoL). There was significant reduction of 
left ventricular end-diastolic (LVEDV) and end-systolic volumes (LVESV), resulting in 
improvement of ejection fraction (LVEF).
Conclusion: Our pilot results confirmed the clinical and echocardiographic benefits of 
CCM in patients with advanced heart failure. 
Parameters Baseline CCMx3m P	value
NYHA class 3.0±0.0 2.2±0.4 <0.001
6MHW, m 326±89 373±74 0.01
Exercise capacity, METs 3.8±0.8 4.6±1.3 0.04
MLWHF-QoL 35±18 28±20 0.2
LVEDV, ml 148±34 143±34 0.04
LVESV, ml 109±32 98±32 0.002
LVEF, % 27.0±6.8 32.1±6.6 0.001
1:30 p.m.
1022-139	 Fragmented	QRS	and	Dyssynchrony	in	Heart	
Failure	Patients
Abbas Y. Rampurwala, Mariya A. Shaad, Irmina Gradus-Pizlo, Mithilesh K. Das, Krannert 
Institute of Cardiology, Indiana University, Indianapolis, IN
Background: Fragmented QRS complex (fQRS) on a 12-lead ECG detects myocardial 
scar even in presence of narrow QRS complexes. We postulated that fQRS predicts the 
presence of left ventricular (LV) dyssynchrony in advanced heart failure (HF) pts with 
ejection fraction (EF) < 35% who do not qualify for cardiac resynchronization therapy 
(CRT) only due to narrow QRS complex. 
Methods:	Out of 97 pts, 71 pts (age 53 ± 17 years, male, 47) with NYHA class III- IV 
HF, EF < 35% (mean 24 ± 6), and QRS < 130 ms (mean 104 ± 17) were studied (rest 
excluded due to wide complex or paced rhythm). fQRS included various morphologies 
of QRS (figure) in at least 2 contiguous leads corresponding to a major coronary artery 
territory. Dyssynchrony on echocardiography was defined as either septal-posterior wall 
motion delay (SPWMD) >130 ms or tissue Doppler lateral-septal delay (Ts L-S) > 60 ms.
Results:	34 (48% of total) pts had dyssynchrony, and of these, a significantly higher 
proportion of pts had fQRS (28 [82%] vs. 6 [18%], p =0.018). Pts without fQRS had a 
significantly higher incidence of lack of dyssynchrony, when compared to pts with fQRS 
(16 [72%] vs. 21 [42%]), p=0.02).
Conclusions: fQRS on 12-lead ECG strongly correlates with the presence of LV 
dyssynchrony in advanced HF patients with EF < 35% and narrow QRS complex. It 
identifies an additional group of patients who have LV dyssynchrony but do not meet 
current criteria for CRT because of narrow QRS. More importantly, absence of fQRS 
signifies lack of dyssynchrony in these patients.
1:30 p.m.
1022-140	 Nasal	Continuous	Positive	Airway	Pressure	Can	
Improve	Global	Left	Ventricular	Dysfunction	Assessed	
By	Tei-index	In	Obstructive	Sleep	Apnea	Syndrome
Seiji Koga, Satoshi Ikeda, Jungo Urata, Risa Chijiwa, Shigeru Kohno, Second Department 
of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan
Background: Conflicting results have been reported regarding the influence of obstructive sleep 
apnea syndrome (OSAS) and the effect of nasal continuous positive airway pressure (CPAP) on 
left ventricular (LV) function. The aim of this study was to clarify the influence of OSAS on global LV 
function assessed by Tei-index, and to determine the short-term effects of CPAP on Tei-index.
Methods: Twenty-seven (26 male, 1 female) OSAS patients with a mean (± SD) apnea-
hypopnea index of 37 ± 22 episodes/h, confirmed by polysomnography, and treated with 
CPAP were enrolled. Tei-index, a sensitive echocardiographic parameter of global LV 
function, was calculated by adding isovolumic contraction time and isovolumic relaxation 
time and then divided by ejection time determined using Doppler echocardiography. We 
also measured plasma brain type natriuretic peptide (BNP), a sensitive marker of cardiac 
damage, before, at 1 month and 3 months after starting CPAP. We defined global LV 
dysfunction (GLVD) as Tei-index ≥ 0.50, and high-BNP as ≥ 20 pg/ml. Twenty-five patients 
without OSAS, matched for age, were used as control group.
Results: Compared to control group, OSAS had a significantly increased Tei-index 
(controls, 0.37 ± 0.04 versus OSAS, 0.44 ± 0.09, p = 0.006). GLVD was observed in 26 % 
of OSAS and none of control (p = 0.033). BNP levels were higher in OSAS (21.3 ± 0.09 
pg/ml) than in control (8.1 ± 4.3 pg/ml), but the difference was not statistically significant 
(p = 0.103). High-BNP was observed in 41 % of OSAS and 6% of control (p = 0.015). In 
OSAS, Tei-index improved significantly after 1 month of CPAP (from 0.44 ± 0.09 to 0.38 
± 0.06, p = 0.003). A significant improvement in Tei-index was also found after 3 month 
of CPAP (p = 0.001); thus, the prevalence of GLVD decreased significantly from 25% to 
4 % (p = 0.025). BNP concentrations tended to decrease, though not significantly, after 
1 month of CPAP; there was a significant decrease after 3 months (from 25 ± 33 to 16 ± 
22 pg/ml, p = 0.010). The prevalence of high-BNP decreased from 41 % to 27 %, but this 
difference was not significant (p = 0.083).
Conclusion: OSAS impaired global LV function assessed by Tei-index. However, global 
LV function quickly improved after the start of CPAP treatment.
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1022-141	 Comparison	of	BNP	to	Handcarried	Ultrasound	
Assessment	of	IVC	Size	and	Collapsibility	to	Predict	
Hospital	Re-admission	in	Patients	with	Acute	
Decompensated	Heart	Failure.
Sascha N. Goonewardena, Anthony Gemignani, Adam Ronan, Samip Vasaiwala, John Blair, 
J. Matthew Brennan, Dipak P. Shah, Kirk T. Spencer, University of Chicago, Chicago, IL
Serial testing of N-terminal ProBNP (BNP) levels, which correlate with LV filling pressures, 
maybe useful in acute decompensated heart failure (ADHF). Likewise, inferior vena caval 
(IVC) size along with its percent inspiratory collapse (IVCCI) correlate with elevated 
central venous pressure. We evaluated whether serial assessment of BNP or the IVC 
could be used to predict ER/hospital visits after discharge for ADHF.
Methods: 50 pts hospitalized with ADHF were enrolled. BNP levels where drawn on 
admission and discharge. The IVC was evaluated using a handcarried ultrasound device 
(Optigo, Philips). Maximal IVC diameter and IVCCI were measured. ER visits and re-
hospitalizations within 30 days post discharge were recorded.
Results: 24/50 patients with ADHF met endpoint during the 30-day follow-up. Admission 
and discharge BNP failed to differentiate between groups. The % change in BNP did 
differ between the subjects with and without ER/hospital visits. At discharge, IVC size 
was larger and collapsibility lower in patients who had subsequent ER/hospital visits. 
Discriminative power for IVC size, IVCCI and % change in BNP (ROC analysis) were 
0.80, 0.74, and 0.70, respectively.
Conclusions: In patients admitted to the hospital with ADHF, bedside evaluation of the 
IVC with a handcarried ultrasound and % change in BNP differentiated between patients 
with and without subsequent 30-day ER/hospital visits. Whether these parameters can 
serve as potential therapeutic targets warrants further investigation. 
(-) 30-day ER/hospital visits (+) 30-day ER/hospital visit
Admit Discharge Admit Discharge
BNP 9566±11960 4537±8031 13152±16155 6588±6951
% Δ BNP -- 51±31 -- 30±40 *
IVC size (cm) 2.1±0.3 1.7±0.5 2.5±0.5 * 2.3±0.5 *
IVCCI (%) 31±22 58±27 23±16 36±23 *
(* p < 0.05 vs. (-) 30-day ER/hospital visits)
1:30 p.m.
1022-142	 Early	Ventricular	Restraint	After	Myocardial	Infarction:	
Cautionary	Results
Hiroaki Sakamoto, Hirotsugu Hamamoto, Liam P. Ryan, Landi M. Parish, Theodore 
J. Plappert, Martin G. St. John Sutton, Joseph H. Gorman, III, Robert C. Gorman, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Background: We have previously demonstrated in animal models that ventricular 
restraint with the Acorn CSD® 1 week after a myocardial infarction (MI) attenuates further 
remodeling and preserves global function. Since significant remodeling occurs in the first 
week after a large transmural MI, we sought to determine if immediate ventricular restraint 
provided additional benefit.
Methods: 24 sheep underwent a pattern of coronary ligation that reliably results in a 
transmural anteroapical infarction involving between 20% and 25% of the LV mass. 10 
animals served as a control group and underwent no additional therapy, while 14 animals 
underwent placement of the CSD® within 1 hour of the infarction. Quantitative two-
dimensional echocardiography was used to assess left ventricular end systolic and end 
diastolic volumes (ESV and EDV) at baseline, immediately after infarction and 8 weeks 
after infarction. Volumes at each time point were normalized to baseline values.
Results: 9 of the 10 control subjects survived to the study’s completion, while only 4 
of 14 of the subjects to which ventricular restraint was applied survived survived to the 
study’s completion (p = 0.01). The single death in the control group occured 35 days after 
infarction. The average time of death in the treatment group was 15.2 ± 4.7 days after 
infarction. ESV at 8 weeks increased by 202 ± 21% and 151 ± 25% in the control and 
treatment groups, respectively (p = 0.1) while EDV increased by 154 ± 13% and 116 ± 
12% (p < 0.05).
Conclusions: While a statistically significant decrease in ventricular dilatation was 
observed at the time of 8 week follow-up in those subjects that underwent application 
of the CSD® device, there was also a substantial increase in their mortality over the 
same follow-up interval when compared to control subjects. We therefore conclude that 
immediate ventricular restraint after a moderately sized transmural myocardial infarction 
is potentially dangerous. Compensatory LV dilatation for up to one week after infarction 
seems to be necessary.
1:30 p.m.
1022-143	 Late	Effects	of	a	Disease	Program	Management	
on	Mortality,	Hospitalization	,	and	Quality	of	Life	in	
Heart	Failure	Patients	Followed	by	Cardiologists	
with	Experience	in	Heart	Failure	-	A	Randomized	and	
Prospective	Trial
Edimar A. Bocchi, Fatima Cruz, Guilherme Guimarães, Sara M. Brandão, Priscila 
Costa, Silvia M A Ferreira, Victor S. Issa, Heart Institute (InCor), University of São Paulo 
Medical School, São Paulo, Brazil
Background Disease management programs (DMP) can benefit heart failure (HF). 
However, whether long-term effects are also obtained in HF pts already followed by 
cardiologists with experience with HF is unknown. Also,effects of DMP on quality of life 
are not well studied.
Methods 350 HF pts were included in a randomized(2:1) prospective study with 2 groups:
DMP group with 233 pts included in the DMP and a control group with 117 pts.DMP 
consisted of repetitive education sessions about topics of HF, and two-weeks interval 
nurse-follow-up monitoring telephone-based. All pts were followed by cardiologists with 
experience in HF that prescribed optimized treatment and oriented all aspects of HF.The 
primary end-points were reduction of hospitalization or mortality, and improvement of 
quality of life. The secondary end-point was reduction of mortality.
Results DMP reduce mortality (Figure A) but did not reduce combined end-point 
hospitalization or mortality (Figure B). The Minnesota HF questionnaire score was at 
randomization, 6,12,18,24, and 36 months follow-up 58±23, 31±23, 27±20, 30±19, 
28±19, and 26±18 respectively in the DMP group (p<0.03) and 50±22, 45±20, 44±21, 
49±31, 42±24, and 42±24 in the control group (p=ns).
Conclusion DMP can improve quality of life and reduce mortality of HF pts followed 
by cardiologists with experience with HF. However, DMP did not determine additional 
beneficial effects concerning mortality or hospitalization in HF already followed by 
cardiologist with experience in HF.
1:30 p.m.
1022-144	 Bedside	Prediction	of	Elevated	Filling	Pressures	with	
Acoustic	Cardiography	in	Dyspneic	Patients
Sean P. Collins, Christopher J. Lindsell, Michael C. Kontos, Michel Zuber, Christine 
H. Attenhofer Jost, Peter Kipfer, Douglas Kosmicki, Andrew D. Michaels, University of 
Cincinnati, Cincinnati, OH, University of Utah, Salt Lake City, UT
Background: Acute dyspnea can present a diagnostic dilemma. A bedside measure that 
accurately estimated elevated left ventricular (LV) filling pressures could rapidly diagnose 
acute heart failure (HF). We evaluated acoustic cardiography for this purpose.
Methods: Studies on 4 cohorts of patients (pts) were pooled: two groups of emergency 
department pts with HF or MI; HF pts presenting for left heart catheterization; and 
outpts with possible HF referred to cardiology. Inclusion required acoustic cardiography 
(Audicor®, Inovise Medical, Inc) at evaluation and echocardiography within 24 hours. 
Demographics, history, and baseline BNP were obtained. Elevated filling pressure was 
defined as a pseudonormal or restrictive filling pattern on echocardiography. Significant 
univariable predictors of elevated filling pressure were evaluated in a multivariable model. 
Area under the receiver operating characteristic curve (AUC) assessed accuracy.
Results: The mean age of the 294 included pts was 61 (±13), 67% were male and 80% 
had a history of HF. The model included: LV systolic time; S3 intensity; and maximum 
negative area of the P wave (AUC=0.80). (Table) At 90% specificity, sensitivity was 57%. 
Adding BNP did not improve model accuracy. In the subset of patients with indeterminate 
BNP, the acoustic model was more accurate.
Conclusions: Bedside acoustic cardiography predicted elevated pressures with high accuracy, 
which was similar or higher than BNP. Prospective model validation is warranted. 
Model Area	under	ROC	curve 95%	CI
All patients
Acoustic Model 0.80 0.74-0.85
BNP Alone 0.80 0.75-0.86
BNP + Acoustic Model 0.82 0.77-0.88
Patients with Indeterminate BNP (100-500 
pg/ml)
Acoustic Model 0.80 0.72-0.88
BNP 100-500 pg/ml 0.70 0.60-0.80
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1022-145	 Percutaneous	Transluminal	Septal	Ablation	Therapy	
For	Hypertrophic	Obstructive	Cardiomyopathy:	
Procedural	Success	and	In	Hospital	Complications	
From	The	Emory	University	Experience.
Michael McDaniel, Habib Samady, Reza Fazel, Matthew McKay, Thomas Arnold, John 
Douglas, Jr., Emory University Hospital, Atlanta, GA
Background: Percutaneous Transluminal Septal Ablation (PTSA) has been proposed 
as an alternative to surgical myectomy for patients with hypertrophic obstructive 
cardiomyopathy (HOCM) refractory to medical therapy. Small series of PTSA have 
reported variable procedural success and in hospital complication rates. We hypothesized 
that PTSA would be a safe and effective procedure for reducing left ventricular outflow 
track (LVOT) gradients in selected patients with HOCM.
Methods: Patients referred to Emory University Hospital with HOCM were eligible for PTSA if 
they had NYHA heart failure class III-IV, symptoms refractory to medical therapy, septal thickness 
>1.8 cm by echocardiography, and peak to peak catheter LVOT gradients >30 mmHg at rest 
or >50 mmHg with provocation. PTSA was performed by administration of 3-5mls of ethanol 
through an inflated balloon catheter into one or more septal perforator arteries under contrast 
echocardiographic guidance. A prospective registry was used to report the current data.
Results: 141 PTSA procedures were performed in 128 patients between 1999-2006. 
Mean age was 59±13 years (range 20-94 years). Baseline LVOT gradients were 61±35 
mmHg at rest and 102±28mmHg with provocation. Procedural success, defined as > 
50% reduction in rest or provocable LVOT gradient, was 98.5%. After PTSA, there was 
a significant reduction in rest LVOT gradients (61±35 mmHg to 12±14 mmHg, p<0.0001), 
with final rest gradients < 30mmHg in 92% and < 20mmHg in 82% of patients. Provocable 
LVOT gradients were also significantly reduced (102±28mmHg to 25±22mmHg, p<0.0001). 
The average peak CK release post-procedure was 1078 + 548 units/L. The in-hospital 
complication rates included 0% cardiac death, 1.4% non-cardiac death (n=2, 1 sepsis, 1 
retroperitoneal bleed), 0.7% arrhythmia requiring cardioversion, 0.7% coronary occlusions, 
0% coronary dissections, and 18.5% rate of heart block requiring permanent pacemaker.
Conclusion: This relatively large series demonstrates that PTSA can safely and 
effectively reduce LVOT gradients associated with HOCM. Long-term outcomes data and 
comparison with surgical myectomy are needed for the further evaluation of PTSA.
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821-3	 Different	Relationships	Between	Conduction	Delay	and	
Ventricular	Remodeling	in	Men	and	Women	With	Heart	
Failure:	The	Penn	Heart	Failure	Study
Leonard Ilkhanoff, David Surrey, Walid Fahssi, David Wolfe, Victor Marwin, Justin 
Averna, Francis E. Marchlinski, Susan Wiegers, Susan Brozena, Thomas P. Cappola, 
University of Pennsylvania, Philadelphia, PA
Background:	Conduction delay, defined by prolonged QRS duration (QRSd), associates with 
ventricular remodeling and identifies candidates for CRT, yet numerous studies have reported 
gender-specific differences in remodeling. We tested the hypothesis that the relationship between 
QRSd and remodeling differs between men and women, independent of other clinical factors.
Methods:	 Patients (n=320;105 women) with no ventricular pacing were identified in 
a prospective cohort with a broad spectrum of heart failure (HF) etiology. QRSd was 
determined by 12-lead EKG. LV end-diastolic dimension indexed to body surface area 
(LVEDDI) was assessed using 2-D echo. We analyzed relationships between QRSd and 
LVEDDI using univariate and multivariable linear regression.
Results:	Mean QRSd (111±30 vs.116±22 msec) and LVEDDI (3.1±0.6 vs. 3.1±0.6 cm) did 
not differ between men and women (p=NS). However, men showed twice the increase in 
LVEDDI per increase in QRSd than women (Figure). Multivariable models showed a statistically 
significant interaction between QRSd and gender in predicting LVEDDI, verifying a steeper 
slope among men (P for interaction = 0.04), even after adjustment for multiple confounders.*
Conclusion: Our findings demonstrate a disconnect between conduction delay and ventricular 
remodeling in women with HF. While further work is needed to define the mechanisms 
responsible for this gender difference, the uniform application of QRS criteria in female CRT 
candidates should be re-examined. 
4:15 p.m.
821-4	 Scintigraphic	Abnormalities	by	Myocardial	Perfusion	
Imaging	Predict	Echocardiographic	Response	to	Cardiac	
Resynchronization	Therapy	in	Nonischemic	Cardiomyopathy
Evan C. Adelstein, Samir Saba, University of Pittsburgh Medical Center, Pittsburgh, PA
Background: Myocardial scar in the posterolateral left ventricle mitigates response to 
cardiac resynchronization therapy (CRT) in patients with coronary artery disease. The 
effect of myocardial perfusion imaging (MPI) abnormalities upon echocardiographic 
outcomes in CRT patients with nonischemic cardiomyopathy (NICM) is unknown.
Methods: Twenty-one patients [mean age 64.4 ± 13.3; 71.4% male; mean left ventricular 
ejection fraction (LVEF) 20.2 ± 6.9%] with NICM who underwent CRT implantation and 
thallium-201 single positron emission computed tomography MPI were included. MPI studies 
were read quantitatively, assigning each of 17 myocardial segments a perfusion score (0-
4) and cumulatively generating a summed perfusion score (SPS). Echocardiograms were 
performed before and after (median 12 months) CRT in 15 patients.
Results: Echocardiographic response, defined as ≥15% relative increase in LVEF, 
occurred in 8 (53.3%) of 15 patients. All (5/5) patients with an SPS≤6 were CRT 
responders, compared to only 30% (3/10) with an SPS>6 [odds ratio 3.3 (95% CI 1.3-8.6), 
p=0.01]. An SPS≤6 was associated with significant absolute and relative LVEF increases 
and a trend toward decreased mitral regurgitation. All non-responders had inferior MPI 
defects. Defects near the CRT lead tip did not affect outcomes.
Conclusions: The presence of significant myocardial perfusion defects negatively 
influences echocardiographic response to CRT in NICM. These findings warrant 
prospective clinical confirmation.
Summed Perfusion Score (SPS) by MPI Predicts Response to CRT in 
NICM.
SPS	0-6	(n=5) SPS>6	(n=10) p-value
LVEF Responders 5 (100%) 3 (33.3%) 0.02
Absolute LVEF Change (%) 36.2 ± 5.1 5.0 ± 10.9 <0.001
Relative LVEF Change (%) 142.7 ± 52.3 26.3 ± 54.4 0.002
LVESD Change (cm) -0.95 ± 0.21 0 ± 0.90 0.2
LVEDD Change (cm) -0.30 ± 0.57 0 ± 0.81 0.7
Mitral Regurgitation (grade) -0.9 ± 1.0 0 ± 0.5 0.08
Inferior Perfusion Defect Present 0 10 (100%) <0.001
Inferior Perfusion Score 0 ± 0 7.6 ± 2.8 <0.001
4:30 p.m.
821-5	 Clinical	and	Echocardiographic	Characterization	of	
Nonresponders	to	Cardiac	Resynchronization	Therapy
Nini C. Thomas, Jeroen J. Bax, Matthew S. Suffoletto, Masaki Tanabe, Samir Saba, 
Martin J. Schalij, Laurens F. Tops, John Gorcsan, III, University of Pittsburgh, Pittsburgh, 
PA, University of Leiden, Leiden, The Netherlands
Background: Although clinical trials of cardiac resynchronization therapy (CRT) have indicated 
about 30% patients (pts) are non-responders, their features are not clearly understood.
Methods: We studied 173 NYHA III-IV heart failure pts undergoing CRT; ejection fraction 
(EF) 23±7%, QRS 168±27ms all >120ms, 61% ischemic disease. Dyssynchrony was 
assessed by both tissue Doppler (TDI) longitudinal velocity and speckle tracking radial 
strain. Significant dyssynchrony was considered as septal-lateral or opposing wall delay 
> 65 ms for TDI or > 130 ms for radial strain. Non-response was defined as neither 15 % 
increase in EF nor 10% decrease in end-systolic volume after 6±3 months.
Results:	Of 173 pts, 119 were responders (69%) and 54 Non-Responders (31%). QRS 
width was slightly wider in responders (171±27 vs.162±27ms, p<0.05). Non-responders 
more often had ischemic disease (78%) vs. responders (54%), p<0.05. Non-responders 
had significantly less dyssynchrony than responders by either method: 42±32 vs.106±49ms 
for TDI and 98±84 vs. 241±131ms for speckle tracking, respectively (p<0.05); 70% of non-
responders had no dyssynchrony by any method. The non-responders with dyssynchrony 
had lesser degrees of dyssynchrony than responders.
Conclusions:	Non-responders to CRT were characterized by more often having ischemic 
disease, slightly less wide QRS and significantly less dyssynchrony than responders. 
These observations may have clinical importance. 
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821-6	 Cardiac	Resynchronization	Therapy	Normalizes	
Suction	Filling	in	Heart	Failure	Patients
Susan M. Ellery, Lynne K. Williams, Rob Bleasdale, Berthold Stegemann, Kiran C. 
Patel, Francisco Leyva, Vince Paul, Paul Steendijk, Michael P. Frenneaux, University of 
Birmingham, Birmingham, United Kingdom
Background: According to Katz, suction filling of the left ventricle (LV) is the phenomenon 
whereby the LV relaxes faster than it can fill, resulting in a fall in pressure as the LV 
enlarges. Counterintuitively, we have recently shown that suction filling (defined as the 
percentage of total filling occurring during the period in which LV pressure is falling) 
is increased in patients with advanced heart failure. We hypothesized that cardiac 
resynchronisation therapy (CRT) would acutely reduce suction filling, and enhance non-
suction filling in patients with congestive heart failure.
Methods: Twenty-three patients with NYHA Class III heart failure and a left ventricular 
ejection fraction <35% who received CRT underwent pressure-volume (PV) loop studies 
prior to device programming to assess suction filling before and during biventricular 
pacing. Left ventricular end diastolic pressure (LVEDP), Isovolaemic relaxation time 
(IVRT), -dp/dt and % suction filling were determined from analysis of the PV loop.
Results: The percentage of suction filling fell with CRT in 18 of the 23 patients. The 
reduction was highly significant for the group as a whole (38.17 ± 19.73 to 23.38 ± 
11.83; p=0.0016). IVRT lengthened in 19 of the 23 patients, remained the same in 2, and 
shortened in 2 (129.74 ± 29.64 to 149.78 ± 28.46; p=0.0001). LVEDP fell acutely with CRT 
in 18 patients (from 20.13 ± 7.05mmHg to 17.64 ± 6.47mmHg; p=0.014). Maximum -dp/dt 
remained unchanged after CRT (-895.10 ± 344.29 to -884.48 ± 340.96; p=0.56 ns).
Conclusions: In patients with severe heart failure a substantial fraction of filling occurred 
during pressure decline. Acute CRT resulted in a reduction in the percentage of suction 
filling and was associated with a decrease in LVEDP and an increase in IVRT.
5:00 p.m.
821-7	 Left	Ventricular	Twist	Is	an	Important	and	Sensitive	
Marker	of	Cardiac	Performance	During	Cardiac	
Resynchronization	Therapy
Muhammad Ashraf, Kesavan Prakash, David J. Sahn, Oregon Health & Science 
University, Portland, OR
Background: We studied the impact of pacing the left and right ventricles (LV, RV) at 
different sites on pressures, strain and twisting in the LV.
Methods: 5 piglets (3-5kg) were anesthetized and subjected to midline sternotomy to 
expose their hearts. Oxygen saturation and vital signs were monitored. Aortic and LV 
pressure was recorded with high fidelity tip catheters. Baseline short axis views were 
acquired in sinus rhythm. Epicardial RA-RV and RA-LV pacing was performed and images 
acquired at the same level using a pediatric 10 MHz probe at frame rate of >100/sec on a 
GE Vivid 7 system. The images were analyzed offline in EchoPac-PC for strain and twist 
using speckle tracking based motion analysis software.
Results: With RA-LV pacing, LV peak systolic dP/dt dropped to 640 ± 120mmHg/sec 
from 1430 ± 80mmHg/sec and aortic pressure dropped to 50 ± 4mmHg/sec from 90 ± 
2.5mmHg. Image based analysis of cardiac mechanics showed no significant change in 
peak radial segmental strain values and minor, insignificant changes in the time to peak 
for the timing to QRS complex. (P=NS) Global twist values were significantly reduced 
from 6.5º-9º during sinus rhythm to 1.5º-3.5º during LV pacing. Segmental twist was also 
dysynchronous in different segments of LV wall during LV pacing.
Conclusions: Global twist values and segmental twisting synchrony are important 
mechanical parameters that are directly correlated with hemodynamic status. The 
methods we used could provide important data during screening for optimization of CRT.
5:15 p.m.
821-8	 Coincidence	of	the	Left	Ventricular	Pacing	Site	to	the	
Region	of	Maximal	Contraction	Delay	Is	Crucial	to	Gain	
Optimal	Results	After	Cardiac	Resynchronization	Therapy
Yuko Toyoshima, Hiroshi Ito, Katsuomi Iwakura, Shigeo Kawano, Atsunori Okamura, 
Toshiya Kurotobi, Yasushi Koyama, Motoo Date, Koichi Inoue, Kenshi Fujii, Sakurabashi 
watanabe Hospital, Osaka, Japan
Background:	Cardiac resynchronization therapy (CRT) is effective to improve cardiac 
performance in patients with pump failure and ventricular dyssynchrony. The presence 
of non-responder to CRT remains a major problem and inappropriate position of left 
ventricular (LV) lead is a cause of non-responder. This study was aimed to investigate 
whether the coincidence of LV lead position and the site of maximal contraction delay can 
bring the better outcome of CRT.
Methods:The study consisted of 33 patients undergoing CRT. We determined the 
segment showing the latest contraction using 12-segment model at baseline with tissue 
Doppler. LV pacing site was confirmed from both RAO and LAO views. Tissue Doppler 
was performed 1 week after CRT to measure time to peak systolic velocity (Ts, msec) 
of 12 segments from apical window. Serum brain natriuretic peptide (BNP, pg/ml) was 
measured at baseline, 1, 3, 6 months after CRT.
Results:	Mean follow-up period was 12 months. In 20 patients (61%), LV pacing site 
coincided with the site of maximal contraction delay, and they were defined as coincident 
group. One week after CRT, the maximal difference in Ts among 12 segments, septal-to-
lateral difference in Ts, and standard deviation of Ts among 12 segments were significantly 
(p<0.01) greater in non-coincident group than in coincident group (128 +/- 56 vs. 70 +/- 
33, 79 +/- 39 vs. 44 +/- 29, 49 +/- 21 vs. 27 +/- 14, respectively). LV end-diastolic volume 
(244 +/- 99 vs. 160 +/- 67 ml) and LV end-systolic volume (196 +/- 105 vs. 108 +/- 65 ml) 
at 6 months after CRT were significantly greater in non-coincident group. Serum BNP 
level was also significantly higher in non-coincident group at 1, 3, 6 month after CRT (554 
+/- 456 vs. 335 +/- 438 pg/ml, 658 +/- 519 vs. 233 +/- 255, 700 +/- 409 vs. 310 +/- 409, 
respectively). The incidence of hospitalization due to heart failure was significantly higher 
in non-coincident group (62% vs. 25%, p = 0.02).
Conclusions:	Coincidence of LV lead position to the site of maximal contraction delay is 
crucial to gain optimal results after CRT. It is associated with smaller LV volume, reduced 
BNP level and better clinical outcomes. Tissue Doppler is useful to determine the optimal 
LV pacing site.
ACC.ORAL CONTRIBUTIONS
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822-3	 Effect	of	Cell-Based	Intercellular	Delivery	of	GATA-4	on	
Ischemic	Cardiomyopathy
Jing Bian, Zoran B. Popovic, Carlos Benejam, Mathew Kiedrowski, Leonardo 
Rodriguez, Marc S. Penn, Cleveland Clinic, Cleveland, OH
Background: Significant alterations in cellular function are possible following the 
introduction of transcription factors. Recent loss-of-function studies highlight the 
importance of the transcription factor GATA4 in the myocardial response to injury in 
the adult heart. However, the importance and therapeutic potential of gain-in-function 
of GATA-4 over-expression and transcription factors in general is hindered by the 
fact that transcription factors are neither secreted nor taken up by cells. Chimeric 
proteins incorporating motifs of cell penetrating proteins (CPP) are secreted from cells 
and internalized by surrounding cells potentially making possible the local delivery of 
transcription factors of interest.
Methods: We engineered a chimeric protein consisting of GATA4 and CPP VP22. 
Cardiac fibroblasts (CF) stably transfected with the GATA4:VP22, GFP:VP22 or GFP 
constructs were transplanted into Lewis rats 1 month after LAD ligation in order to obtain 
sustained delivery of functional GATA4 to the infarct border zone.
Results: Immunofluorescence demonstrated VP22 chimeric proteins in cardiac 
myocytes surrounding areas of engrafted CF. GATA4:VP22 expression in the border 
zone was associated with increased cardiac myosin expression and cardiac myocyte 
size (30 μm vs. 19 μm, p<0.01). Compared with the GFP:VP22 control group, animals 
that received GATA4:VP22 expressing CF had increased i) shortening fraction (percent 
change from baseline 54% vs. -15%, p<0.05), ii) inferior wall thickening (65% vs. 35%, 
p<0.05), and reduced area of collagen deposition (19% vs. 39%, p<0.01) six weeks after 
CF transplantation (10 weeks after MI).
Conclusions: These data demonstrate a novel strategy for transcription factor delivery 
to injured myocardium and indicate that the delivery of GATA4 locally to the infarct border 
zone induces multiple local effects in the border zone cardiac myocytes resulting in 
beneficial ventricular remodeling and improved global left ventricular function.
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822-4	 Human	Menstrual	Blood-Derived	Mesenchymal	Stem	
Cell	Can	Restore	Impaired	Cardiac	Function	by	
Cardiomyogenesis	In	Vivo
Shunichiro Miyoshi, Shinichiro Kira, Nobuhiro Nishiyama, Naoko Hida, Taisuke Mori, 
Yukinori Ikegami, Kazuma Okamoto, Taro Uyama, ChangHao Cui, Kenji Miyado, 
Michiko Uchiyama, Kaoru Segawa, Hiroko Tsuji, Michiie Sakamoto, Akihiro Umezawa, 
Satoshi Ogawa, Cardiology, Keio University School of Medicine, Tokyo, Japan, National 
Research Institute for Child Health and Development, Tokyo, Japan
Background: Mesenchymal stem cell (MSC) transplantation slightly improved impaired 
cardiac function, but the improvement was insufficient, because the main effect of MSC 
was attributable to neovascularization, not to cardiomyogenesis. Human menstrual blood-
derived MSC (MMC) has higher efficacy of cardiomyogenic differentiation (33%) in vitro 
than marrow-derived MSC(0.3%), thus MMC can be a new promising cellular source for 
cardiac stem cell therapy. However, the effect on cardiac function of engrafted MMC in 
vivo has not been elucidated.
Methods: MMC was obtained from human menstrual blood. LAD was ligated in open-
chest anesthesized nude rat to make a myocardial infarction (MI). Two weeks after MI, 
GFP-labeled MMC was isolated, then injected into the MI area (3x106 cells) and (CELL; 
n=10). In 11 animals, the culture medium was injected (MI). In 6 animals, sham operation 
was done (SHAM). Four weeks after the initial operation, echocardiogram and histological 
analysis were performed.
Results: Data was shown in table. Immunohistochemial analysis revealed cardiac 
troponin-I positive (with clear striation pattern) and GFP-positive tissue mass of the MMC-
derived differentiated cardiomyocyte in the MI area.
Conclusions: MMC transplantation decreased fibrosis area and restored the LV systolic 
function in the MI-model in vivo. Engrafted MMC transdifferentiated into cardiomyocyte 
within MI area. MMC can be a major cell source for stem cell therapy to achieve 
cardiomyogenesis. 
LVEDd(mm) LVESd(mm) %FS %MI volume
CELL 6.9 +- 0.3 3.8 +- 0.3* 45 +- 2* 10.7 +- 1.4*
MI 7.1 +-0.2 4.8 +- 0.2 33 +- 2 18.0 +- 1.1
SHAM 6.1 +- 0.2 3.0 +- 2.3 52 +- 3 1.1 +- 0.6
4:30 p.m.
822-5	 Cardiogenic	Differentiation	of	Very	Small	Embryonic-
Like	Cells	Isolated	From	Adult	Bone	Marrow
Wojciech Wojakowski, Magda Kucia, Ewa Zuba-Surma, Janina Ratajczak, Boguslaw 
Machalinski, Michal Tendera, Mariusz Z. Ratajczak, Silesian School of Medicine, 
Katowice, Poland, Stem Cell Biology Program University of Louisville, Louisville, KY
Background: Adult bone marrow contains the population of very small embryonic-like 
cells (VSEL) which can be expanded in vitro, form embryoid bodies and express markers 
of pluripotent stem cells (Oct-4, Nanog, SSEA-1).
Methods:	VSELs were isolated from bone marrow-derived mononuclear cells of C57BL 
mice. Lin-/Sca-1+/CD45- (non-hematopoietic) and Lin-/Sca-1+/CD45+ (hematopoietic) cells 
were isolated by multiparameter, live cell sorting (MoFlo, Dako). VSELs were examined 
by transmission electron microscopy. To generate embryoid bodies VSELs were co-
cultured with murine rhabdomyosarcoma cell line C2C12 where ~5-10% of VSELs form at 
day 5-7 spheres (VSEL-DS) that are composed of several hundreds of primitive cells. To 
obtain single cell suspension VSEL-DS werel trypsinized. Cardiomyocytes differentiation: 
5x102 GFP+ VSEL-DS cells plated in DMEM with 4 mM L-glutamine, 4.5 g/l glucose, 
10% heat-inactivated FBS and 10ng/ml bFGF, 10ng/ml VEGF, 10ng/ml TGF. VSEL-DS-
derived cardiomyocytes were stained with antibodies to Oct4, SSEA-1, Nanog, Troponin 
I, α - sarcomeric actinin, Actn2, Actn3. Expression of embryonic and cardiomyogenic 
markers was assessed by real time RT-PCR. Transcriptional activity was assessed by 
microarrays (Miltenyi) comparing the expression in VSEL, VSEL-DS and on days 4, 6, 9, 
12 and 16 of cardiogenic differentiation. Genes that are >1.7-fold up- or downregulated 
represent putative candidate genes.
Results: VSEL were enriched in cardiac markers Nkx2.5/Csx and GATA-4 and during 
differentiation of VSEL-DS expressed mRNA for troponin I, Mybpc3, a-sarcomeric actinin 
2 and 3 genes. Presence of cardiac markers was confirmed by fluorescent staining. 
Microarray analysis showed 257 genes with significant changes of expression. Up-
regulated genes: connexins 31, 37, 40, 45, CD34, VEGF and suppression of genes 
coding cytokines and receptors (IL-1, 4, 6, VEGFR, TNF, CXCR4, HGF, SDF-1, c-met, 
c-kit, PDGF) and metaloproteinases.
Conclusions: Adult bone marrow contains expandable population of non-hematopoietic 
very small embrionic-like cells which ungergo differentiation into cardiomyocytes 
expressing cardiac markers and connexins.
4:45 p.m.
822-6	 Gene	Transfer	of	SERCA2a	by	Intracoronary	Delivery	of	
Adeno-Associated	Virus	Type	1	Vector	in	a	Pre-Clinical	
Model	of	Heart	Failure
Yoshiaki Kawase, Hung Q. Ly, Fabrice Prunier, Djamel Lebeche, Yanfen Shi, Ryuichi 
Yoneyama, Kozo Hoshino, Yoshiaki Takewa, Jean-Claude Tardif, Robert A. Levine, 
Jean-François Tanguay, Roger J. Hajjar, Massachusetts General Hospital, Boston, MA, 
Montreal Heart Institute, Montreal, PQ, Canada
Background: While prior studies have reported short-term beneficial effects, little long-
term data exists on SERCA2a gene transfer in heart failure (HF).
Methods: Our aim was to study effects of SERCA2a overexpression with adeno-
associated type 1 vector (AAV1), in volume-overload HF, created by percutaneously 
severing mitral valve chordae in pigs. At 2 months (2M), pigs were randomized to 
intracoronary delivery of AAV1.SERCA2a (n=6; group 1) or saline (n=5; group 2). 
Serial cardiac function measurements were performed by Millar catheter, transthoracic 
echocardiography, and brain natriuretic peptide (BNP) measurements. Tissue expression 
of SERCA2a was documented at 4 months (4M).	
Results: At 2M, diastolic dysfunction was suggested by a prolonged time constant of 
isovolumic relaxation (Tau) in all animals. At 4M, Tau was further deteriorated in group 2 
but, in group 1, was restored to baseline. Relative to baseline and 2M, (1) 4M-ejection 
fraction was decreased in group 2 but was improved in group 1; (2) 4M-ventricular 
volumes were dilated in group 2, without deterioration in group 1. (3) 4M- BNP increased 
in group 2, without change in group 1. Significant differences between groups for the 
same parameters also favored group 1. Cardiac SERCA2a expression was significantly 
decreased in group 2 but, in group 1, was restored to baseline (Fig).
Conclusions: Long-term overexpression of AAV1.SERCA2a by gene transfer in HF 
preserved systolic and diastolic functions and improved ventricular remodeling. 
5:00 p.m.
822-7	 Evaluation	of	the	Viability	of	Stem	Cells	Delivered	
Into	Different	Zones	of	Myocardial	Infarction	and	the	
Resultant	Myocardial	Restoration
Yoriyasu Suzuki, Ta-chuan Hung, Takashi Urashima, Grant Hoyt, Ahmad Sheikh, David P. 
Lee, Alan C. Yeung, Robert C. Robbins, Phillip C. Yang, Stanford University, Stanford, CA
Background: The viability of stem cells delivered into the myocardium following an 
acute myocardial infarction (MI) is unknown. Viability of the mouse embryonic stem cells 
(mESC) delivered into 3 different zones of the infarcted myocardium and the resultant 
myocardial restoration are studied.
Methods: 28 SCID mice underwent LAD ligation to induce MI. Direct injection of 0.25x106 
of mESC transfected by luciferase gene was performed into 3 different zones of MI: 
intra-infarct, peri-infarct, remote (normal) and control (no cells). Bioluminescence imaging 
(BLI) detected luciferase activity to evaluate cell viability on Days 2, 6, and 14. Pressure-
volume (P-V) loop analyzed restoration of myocardial function. Echocardiography of 
fractional shortening (%FS) measured regeneration of myocardial tissue.
Results: BLI data demonstrated that cell viability in the remote group was significantly 
higher than peri- or intra-infarct group on Days 2, 6, and 14 (Figure1A). P-V loop data 
demonstrated significant improvement of end-systolic elastance (Ees) in the intra-infarct 
vs. remote group (3.79±0.10 vs. 2.95±0.07, p<0.005) and non-significant but improved 
Ees in the peri-infarct vs. remote groups. No difference in % FS among the 4 groups was 
seen (Figure1B).
Conclusions: Although significant difference in cell viability is detected in the 3 zones, 
functional restoration occurs only when the cells are delivered into the intra-infarct zone. 
No evidence of myocardial regeneration was detected. 
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822-8	 Hemodynamic	Load-Dependent	Activation	of	
Cardiac	Stem	Cells	and	Myocyte	Turnover	in	Mitral	
Regurgitation
Federico Quaini, Raffaella Rusconi, Gallia Graiani, Alessio Giazzon, Laura Rota Nodari, 
Giorgio Viganò, Francesco Maisano, Giovanni La Canna, Ottavio Alfieri, Piero Anversa, Attilio 
Maseri, University Vita-Salute San Raffaele, Milan, Italy, University of Parma, Parma, Italy
We used a model of volume overload in humans, represented by degenerative mitral 
regurgitation not complicated by heart failure, to assess the role of the hemodynamic load 
on myocyte apoptosis and regeneration in individual cardiac chambers. Furthermore, 
since a resident population of Cardiac Stem Cells (CSCs) may control myocardial 
homeostasis, we investigated whether differences in work load were associated with a 
paralleled enhancement of this primitive cell population. The number and distribution of 
CSCs was determined in samples of the left atrial (LA), left ventricular (LV), right atrial 
(RA) and right ventricular (RV) myocardial wall biopsies from 16 patients undergoing 
valve repair for mitral regurgitation. Echocardiography demonstrated volume overload 
LV hypertrophy with preservation of mass/chamber volume ratio. CSCs and their 
early committed progeny were identified by the surface antigen c-kit in the presence 
or absence of the nuclear cardiac transcription factors GATA-4 and MEF2C. Mitotic 
myocytes, detected by phospho-histone H3 expression, were considered amplifying 
precursors. Chronic collagen accumulation and ongoing apoptotic cell death were higher 
in atria than in ventricles and a 2.5-fold increase in myocyte death rate was found in LA 
and LV compared to the corresponding right chambers. The incidence of c-kitpos-Linneg 
cells was 3-fold greater in LA and 2-fold higher in LV than in RV. Commitment to cardiac 
lineages was also load-dependent since the number of progenitor cells was 2-fold greater 
in LA and LV compared to controlateral chambers. Myocytes mitosis was highest in LA 
samples and was 2-fold higher in LV than RV samples. The prevalence of CSCs and 
cardiomyocyte proliferation was associated with a significantly higher number of small 
cells (CSA < 300 µm2) in LA and LV samples. This study is the first documentation in the 
human heart that activation of CSCs and myocardial cell turnover appear to be dependent 
on the hemodynamic load of the individual chamber and may dictate the compensatory 
response to volume overload.
ACC.ORAL CONTRIBUTIONS
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Topics	in	Cardiac	Transplantation	and	
Ventricular	Assist	Devices
Tuesday, March 27, 2007, 7:00 a.m.-8:30 a.m.
Room 206-207
7:00 a.m.
828-3	 In	Vivo	Intravascular	Ultrasound	Derived	Cardiac	
Allograft	Vasculopathy	Characterization	Using	
Ultrasound	Radiofrequency	Analysis
Jose M. de la Torre Hernandez, Fermin Sainz Laso, Virginia Burgos, Francisco 
Gonzalez Vilchez, Marta Ruiz Lera, Leticia Fernandez Friera, Javier Ruano, Rafael 
Martin Duran, Monica Fernandez Valls, Jose A Vazquez de Prada, H. U. Marques de 
Valdecilla, Santander, Spain, Fundacion Marques de Valdecilla, Santander, Spain
Introduction: Cardiac allograft vasculopathy (CAV) remains as one of the main causes 
of morbidity and mortality late after cardiac transplantation. Intravascular ultrasonography 
(IVUS) is a sensitive diagnostic tool in CAV, and recently has been refined by the 
addition of spectral analysis of the ultrasonic signals, allowing the evaluation of plaque 
composition, known as “virtual histology”.
Methods: We studied 35 cardiac transplant with IVUS and virtual histology (Volcano, 
Inc.), 20 at short-medium (<5 years) and 15 at long term (>10 years). The left anterior 
descending artery was imaged from the distal segment to the coronary ostium. Virtual 
histology analysis was performed in the 3 most affected sectors for each patient. The 
results were compared with those obtained in a group of 10 patients with stable angina 
and other group of 10 patients with acute coronary syndrome (in non-culprit lesions).
Results: Data from IVUS and virtual histology are shown in Table, in %, calcium and 
necrotic core were statistically different being higher in the long term group.
Conclusions: We observed two different “histologic” patterns: at short-medium term (<5 
years), a fibrotic pattern with a small necrotic core (similar to stable angina and suggestive of 
allograft vasculopathy) and at long-term (>10 years), more calcification and larger necrotic 
core (similar to acute coronary syndrome and suggestive of coronary atherosclerosis). 
Plaque burden Fibrous Fibro-fatty Calcium* Necrotic core*
Trasplant<5y 43±10% 72±11% 21±12% 0.8±1% 5 ±4%
Trasplant>10y 47±12% 67±15% 15±7% 5±6% 14±12%
Stable angina 43±12% 71± 9% 19± 8% 1,3±1,8% 7,7 ± 6%
Acute C Synd. 48±11% 64± 9% 20±7% 1,8±1,5% 14 ± 8%
* p<0,05 for comparison between Trasplant<5y and Trasplant >10y.
7:15 a.m.
828-4	 Central	Aortic	Stiffness	Is	Increased	in	Stable	Heart	
Transplant	Patients	and	Is	Associated	With	Higher	
Mortality
Svend Aakhus, Torbjørn Holm, Johannes Soma, Lars Gullestad, Rikshospitalet 
University Hospital, Oslo, Norway, St. Olavs Hospital, University Hospital, Trondheim, 
Norway
Background: Hypertension and vascular disease are prevalent in heart transplant pts (Tx), 
but their systemic arterial properties are not well defined. Thus, we compared pulsatile 
systemic arterial function in 38 stable Tx (mean (SD)) 6(3) years after transplantation, 
with 32 hypertensive pts (HT), and 83 healthy individuals (N).
Methods: We used validated noninvasive techniques obtaining simultaneous central aortic 
flow data from Doppler echocardiography, and pressure data from calibrated external 
subclavian pulse tracing. Peripheral arterial resistance (R), total arterial compliance (C) 
and characteristic impedance (Zc), a parameter of central aortic stiffness, were obtained 
by mathemathical solution of an electrical analogue 3 element vascular model using 
central aortic flow and pressure data as input variables.
Results:
Tx HT N ANOVA p
R (d s cm-5) 1383(389)*# 1226(166) 1126(245) <0.001
C (mL/mmHg) 1.37(0.42)# 1.42(0.35) 1.57(0.46) <0.05
Zc (d s cm-5) 152(50)*# 80(30) 88(34) <0.001
MAP (mmHg) 104(15)*# 113(11)# 88(13) <0.001
HR (b/min) 92(13)*# 69(10) 66(9) <0.001
SI (L/min/m2) 31(6)*# 54(8) 51(9) <0.05
Age (years) 57(8) 49(6) 50(16) <0.05
Values are mean (SD), *=p<0.05 vs HT, # = p<0.05 vs N
R and Zc were significantly higher in Tx than in HT in spite of lower mean arterial pressure 
in Tx. In Tx, Zc was related to stroke index and pulse pressure, but not to age (regression 
model R2 = 0.83, p<0.001). During a follow-up of 7.5(2.5) years, 12 pts died in the Tx 
group, and 10 deaths occurred among those with Zc above group median (p<0.01).
Conclusion: Systemic arterial properties in stable Tx are characterized by elevated 
peripheral resistance and central aortic stiffness, and differs markedly from N and HT. In 
Tx, elevated central aortic stiffness is associated with higher mortality.
7:30 a.m.
828-5	 Biochemical	Evidence	of	Resensitization	of	the	
Failing	Left	Ventricular	Myocardium	to	β-Adrenergic	
Stimulation	Following	Extended	Therapy	With	the	Orqis	
Medical	Cardiac	Recovery	System
Sudhish Mishra, Sharad Rastogi, Robert Brewer, Michael S. Sabbah, Tony Viole, Marvin 
A. Konstam, Hani N. Sabbah, Henry Ford Health System, Detroit, MI, Orqis Medical, 
Inc., Lake Forest, CA
Background: Sustained sympathetic drive in heart failure (HF) leads to cardiac adrenergic 
desensitization characterized by decreased expression of β1-adrenergic receptors (AR), 
elevated levels of β-adrenergic receptor kinase (βARK) and decreased LV tissue levels 
of norephinephrine (NE). We previously showed that extended therapy with the Orqis 
Medical Cardiac Recovery System (CRS) unloads the failing LV. This study examined 
the effects of CRS therapy on biochemical markers of β-adrenergic desensitization in LV 
myocardium of dogs with microembolization-induced HF.
Methods: The CRS was implanted in a femoral-to-carotid flow configuration with 
constant pump flow of 400 ml/min thus superimposing an element of continuous flow on 
existing pulsatile aortic flow. LV tissue homogenate was prepared from 3 CRS-treated 
HF dogs (11-18 days therapy), 3 untreated-HF dogs, and 3 normal (NL) dogs. Protein 
expression of β1-AR and βARK was measured using Western blots and bands quantified 
in densitometric units (du). Tissue NE (pg/mg) was measured using an enzyme-
immunoassay kit.
Results: Expression of β1-AR decreased, βARK increased and NE levels decreased in 
untreated HF dogs compared to NL. Expression of β1-AR and βARK and tissue NE levels 
normalized with CRS therapy (Table).
Conclusions: Extended CRS therapy results in biochemical recovery of the failing LV 
myocardium consistent with β-adrenergic resensitization. CRS therapy CRS may be 
useful as bridge to recovery and/or destination therapy in advanced HF.
NL HF-Untreated HF	+	CRS
β1-AR	(du) 525 ± 10 445 ± 21 640 ± 10
βARK	(du) 378 ± 12 462 ± 33 382 ± 10
NE	(pg/mg) 1502 ± 98 618 ± 6 984 ± 83
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828-6	 Peripheral	Blood	Leukocyte	Gene	Expression	
Correlates	With	Cardiac	Allograft	Function
Mario C. Deng, Seema Mital, Martin Cadeiras, Dorota Gruber, Manuel P. Bayern, Hanli 
Wang, Khin liu, JoAnn Padilla, Denise B. Groff, Charles C. Marboe, Linda Addonizio, 
Columbia University, New York, NY
Background:	 Non invasive Surveillance of Cardiac Allograft Rejection has been an 
unmet goal over the last decade. The CARGO study (Deng MC, AJT 2006) developed 
and validated a molecular classifier using gene expression profiling (GEP) from PBMC. A 
score threshold 30 during the first year or less than 34 thereafter had a negative predictive 
value (NPV) greater than 99.5% for the presence of ISHLT grade 3A/2R rejection.
Methods:	Data from all patients undergoing non invasive monitoring for cardiac allograft rejection 
were prospectively collected into a registry. Clinical data, hemodynamics and endomyocardial 
biopsies were correlated with the AlloMap Molecular Test scores. For statistical comparisons we 
used T-test, Chi-square test and Pearson’s correlation when appropriate.
Results:	At the time of the clinical encounter from cardiac transplant recipients > than 
6 months after transplantation GEP testing was done concurrently with biopsy and right 
heart catheterization in 75 patients at a large heart transplant center. Correlation analysis 
of all patients with 0R and 1R grade rejection demonstrated an inverse correlation 
between GEP scores and right atrium pressures (p=0.06), cardiac output (p=0.06) and 
pulmonary cappillary O2 Saturation (p=0.001; figure).
Conclusions:	Non invasive monitoring of acute cardiac allograft rejection is feasible for 
cardiac transplantation monitoring and correlates with intragraft dysfunction as assessed 
by invasive hemodynamics. 
8:00 a.m.
828-7	 Omega-3	Fatty	Acids	Cause	Blood	Cells	to	Become	
Insensitive	to	Mechanical	Stress	in	Patients	With	
Cardiac	Assist	Devices
Johannes Mueller, Martin Brodde, Kersten Brandes, Peter Goettel, Beate Kehrel, 
Medical University Muenster, Muenster, Germany, Berlin Heart, Berlin, Germany
Background:	The application of all kind of mechanical cardiac support systems induces 
some degree of blood cell trauma which has to be compensated by anticoagulation and/
or platelet inhibition. Omega-3 fatty acids are known to have a protective effect on blood 
cells; however, they will only rarely be administered in patients with cardiac assist devices. 
To measure the effect of omega-3 fatty acids on platelets, we investigated the impact of 
omega-3 fatty acids on human blood.
Methods:	Human blood from four healthy subjects without any blood cell abnormalities 
was analysed twice. Before and after a ten weeks period of daily administration of 1,200 mg 
omega-3 fatty acids. To test the blood, 500 ml of blood from each subject was exposed to 
a commercially available rotary blood pump as part of a test circuit. The blood sample were 
taken after the blood was pumped in the circuit over a period of four hours. The pump has 
clinically been used in 300 patients since June 2002. To keep the conditions for the blood 
constant, for all tests, the same pump was used, and the test parameters (4 liter flow per 
minute against a pressure of 80 mmHg) were kept the same in all serial test procedures.
Results:	Functional capacity of the platelets after the intake of omega-3 fatty acids improved 
significantly as seen when stimulating with ADP by 51%, stimulating the PAR-1 receptor 
with the thrombin receptor activating peptide (TRAP) by 66%. The development of platelet 
associates dropped by 56%. The MAC-1 expression on the surface of the platelets declined 
by 35%. With regards to the generation of micro-particles, no difference could be detected. 
Aggregation after stimulation with ADP and TRAP was significantly more pronounced in the 
blood from the subjects after the ten weeks omega-3 fatty acids intake.
Conclusions:	 The platelet trauma in patients after they have taken omega-3 fatty 
acids over a period of 10 weeks was significantly less when exposed to a commercially 
available rotary blood pump which naturally creates some degree of shear stress. Derived 
from these results the administration of omega-3 fatty acids should be recommended to 
patients supported by mechanical cardiac assist devices.
8:15 a.m.
828-8	 Center	Experience	and	Outcomes	of	Left	Ventricular	
Assist	Device	Implantation	as	Destination	Therapy	
(DT):	Analysis	of	Thoratec	DT	Registry	1998-2005
Katherine Lietz, James Long, Abdallah Kfoury, Mark Slaughter, Marc Silver, Carmelo 
Milano, Joseph Rogers, Yoshifumi Naka, Donna Mancini, Leslie W. Miller, Georgetown 
University - Washington Hospital Center, Washington, DC
Background: Over 50 U.S. centers implanted left-ventricular assist devices (LVADs) as 
Destination Therapy (DT) after the REMATCH (RM) trial showed superiority of LVAD support 
over medical therapy in heart failure pts who were not transplant candidates. The impact of 
a “learning curve” and center experience on outcomes of DT has not been defined.
Methods: We reviewed outcomes of DT in 379 end-stage heart failure pts who underwent 
LVAD implantation btw 1998 and 2005. This includes 311 recipients of HeartMate-XVE in 
the post-RM era and 68 recipients of HeartMate-VE followed from the RM trial. Pts were 
followed until Jun 2006.
Results: The majority (54%) of DT pts were recipients of the first four implantations at 
given center. Their survival was inferior to recipients of subsequent implants (47.1% to 
63% at 1-yr, p=0.003). By multivariable analysis the era of implantation, device type or 
center size were not independent predictors of survival. In a subanalysis of 208 pts, using 
the preoperative risk score for in-hospital mortality after DT, we show that the success of 
DT was primarily determined by pt selection. The risk of death associated with selection of 
high-risk operative candidates (RR=8.7, p<0.001) exceeded 5-fold that of the first four DT 
implantations at given center (RR=1.7, p=0.008). Since centers initiating DT tended to select 
higher risk candidates (Spearman test, p=0.11), this contributed to their inferior outcomes. 
As center experience increased beyond the first four implantations, survival improved only 
in the lower-risk candidates (69.2% vs. 83.6%, 1-yr survival, p=0.001), wheras in high-risk 
pts outcomes remained poor (11.4% vs. 20.5% 1-yr survival, p=0.20).
Conclusions: The DT center “learning curve” does not appear to affect pt survival 
beyond the first four LVAD implantations. Outcomes of the first four DT implants approach 
70% 1-yr survival in well selected pts. As center experience increases, 1-yr survival of 
optimal candidates further improves to 84%. High risk pts have extremely poor outcomes 
regardless of center experience.
ACC.ORAL CONTRIBUTIONS
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829-3	 Estrogen	Induces	Weight	Loss	and	Improves	Systolic	
Function	in	a	Mouse	Model	of	Obesity
Seema Nour, Alexander C Phan, Djahida Bedja, Kathleen Gabrielson, Michelle 
Kittleson, Lili Barouch, Johns Hopkins Hospital, Baltimore, MD
Background: Estrogen plays a protective role against the development of left ventricular 
(LV) hypertrophy, which can be a precursor to heart failure, and has variably reported 
effects on body weight. Female leptin-deficient mice (ob/ob) have obesity, low estrogen 
levels, and LV hypertrophy, all of which are reversed by leptin repletion. Accordingly, we 
sought to determine whether estrogen plays an independent role in weight regulation and 
maintaining normal cardiac structure and function.
Methods: We first compared 6-month-old male (n=19) and female (n=19) ob/ob mice 
by echocardiography. Weight was higher in females vs. males (75.3±1.0 vs. 72.6±1.0 g, 
p<0.005), although there were no significant differences in LV wall thickness, LV mass, 
or fractional shortening between the groups. Since repleting leptin in female ob/ob mice 
restores estrogen levels to normal, we designed a study to assess the cardiac effects of 
the two hormonal axes independently. 6-month-old female ob/ob mice underwent baseline 
echocardiography followed by: estrogen repletion alone (n=11) vs. ob/ob control (n=13); or 
ovariectomy plus leptin (n=6) vs. leptin repletion alone (n=8). Body weights were monitored 
regularly. Repeat echocardiography was performed after 1 month of treatment.
Results: Estrogen repletion resulted in a significant improvement in fractional shortening 
(65.8±2.5 vs. 63.3±1.4%, p<0.005) and weight reduction (56.5±1.3 vs. 74.0±2.0 g, 
p<0.005) compared to controls, but there was no change in LV wall thickness or LV 
mass between groups. The ovariectomy plus leptin group showed similar reductions in 
both wall thickness (21± 4 vs. 20±5%, p=NS) and LV mass (35±4 vs. 34±4%, p=NS), 
compared to leptin repletion alone.
Conclusions: We have shown that estrogen independently improved systolic function 
and reduced weight in a mouse model of obesity; however the cardiac structural effects 
seen with leptin repletion in ob/ob mice are independent of concomitant estrogen 
restoration. This study offers novel insights into the current proposed pathophysiology of 
heart failure and LV hypertrophy in postmenopausal women.
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829-4	 Restoration	of	Vagal	Tone	by	Donepezil	Markedly	
Prevents	Progression	of	Ventricular	Remodeling	
and	Dysfunction	in	Rats	With	Extensive	Myocardial	
Infarction
Meihua Li, Can Zheng, Toru Kawada, Masashi Inagaki, Toshiaki Shishido, Takayuki 
Sato, Masaru Sugimachi, National Cardiovascular Center Research Institute, Osaka, 
Japan, Japan Association for the Advancement of Medical Equipment, Tokyo, Japan
Background: We have demonstrated that chronic electrical stimulation of the vagal 
nerve improves long-term survival of rats with chronic heart failure (CHF) after myocardial 
infarction (MI), and that this beneficial effect is mainly exerted by acetylcholine through 
direct actions on cardiomyocytes but not by sympathetic antagonism. However, such an 
approach is invasive and its safety is unknown in clinical settings. To develop an alternative 
therapy with a clinically available drug, we examined the chronic effect of oral donepezil 
administration on remodeling and cardiac function in rats after MI.
Methods: Rats that survived after extensive (53 ± 1.0%) myocardial infarction were assigned 
to donepezil-treated (DT, 5 mg/kg/day in drinking water) or untreated (UT) groups.
Results: Donepezil treatment improved 140-day survival of CHF rats (30% to 54%, 
p<0.05), through the prevention of pumping failure (LV dp/dt max, +18%; Cardiac index, 
+29%; LVEDP, -22%) and cardiac remodeling (cardiac weight; -11%) as shown in Table.
Conclusions: Pharmaceutical restoration of vagal tone by donepezil markedly prevents 
the progression of ventricular remodeling and dysfunction even in rats with extensive MI, 
suggesting donepezil as a new alternative for CHF therapy. 
7:30 a.m.
829-5	 Chronic	Baroreflex	Activation	Therapy	Normalizes	
Gene	Expression	of	Nitric	Oxide	Synthase	in	Left	
Ventricular	Myocardium	of	Dogs	With	Chronic	Heart	
Failure
Ramesh C. Gupta, Sudhish Mishra, Robert J. Cody, Eric D. Irwin, Martin A. Rossing, 
Hani N. Sabbah, Henry Ford Health System, Detroit, MI, CVRx, Inc., Maple Grove, MN
Background: Endothelial nitric oxide synthase (eNOS) is decreased in heart failure (HF) 
leading to the release of pro-inflammatory cytokines and to cardiomyocytes apoptosis. 
Neuronal NOS (nNOS) and inducible NOS (iNOS-2) are increased in HF. The latter is 
partly responsible for the reduced responsiveness of the failing heart to exogenous 
catecholamines. We previously showed that chronic electrical carotid baroreflex activation 
therapy (BAT) with the RheosTM System (CVRx, Inc.) improves LV function in dogs with 
coronary microembolization-induced advanced HF (LV ejection fraction ~25%). This study 
examined the effects of BAT on mRNA expression of eNOS, nNOS, and iNOS in LV 
myocardium of dogs with HF.
Methods: Total RNA was extracted from LV myocardium of 8 BAT-treated HF dogs, 6 
untreated-HF dogs, and 6 normal (NL) dogs. mRNA expression of eNOS, nNOS and 
iNOS was measured using reverse transcriptase polymerase chain reaction (RT-PCR) 
and bands were quantified in densitometric units (du).
Results: The data are shown in the table. mRNA expression of eNOS decreased and that of 
nNOS and iNOS increased significantly in untreated HF dogs compared to NL dogs. Three 
months of monotherapy with BAT normalized mRNA expression of all NOS subtypes.
Conclusions: Long-term BAT with the RheosTM System normalizes mRNA expression of 
eNOS, nNOS and iNOS in LV myocardium of dogs with HF. This finding explains, in part, 
the observed improvement in LV function of HF dogs chronically treated with BAT.
mRNA Expression of NOS
NL HF-Untreated HF	+	BAT
eNOS	(du) 0.71±0.03 0.44±0.03* 0.56±0.02*†
nNOS	(du) 0.45±0.04 1.42±0.07* 0.72±0.04*†
iNOS	(du) 0.34±0.02 0.72±0.02* 0.43±0.02*†
*=p<0.05 vs. NL; †=p<0.05 vs. HF-Untreated
7:45 a.m.
829-6	 G-CSF	Inhibits	Doxorubicin-Induced	Cardiac	
Dysfunction	by	Suppressing	of	the	Generation	of	
Reactive	Oxygen	Species
Yoshimi Hiraumi, Souichi Adachi, Shirou Baba, Tatsutoshi Nakahata, Eri Iwai-Kanai, 
Department of pediatrics, Graduate of Medicine, Kyoto University, Kyoto, Japan, Kyoto 
Prefectural University of Medicine, Kyoto, Japan
Background: Doxorubicin (Dox) is a potent, widely used antineoplastic agent in cancer 
chemotherapy. However, the clinical application of Dox is limited by its cardiotoxicity, 
which results in irreversible cardiomyopathy and congestive heart failure. Recently, G-
CSF prevents cardiac remodeling after myocardial infarction by Jak-Stat pathway in 
cardiomyocyte. We investigated whether G-CSF inhibits Dox-induced cardiac dysfunction 
and proved a mechanism of effect of G-CSF for Dox-induced cardiac dysfunction.	
Methods	 and	 materials: C57/BL6 mice were randomly grouped into control (C), 
saline+G-CSF (G), Dox (D), Dox+G-CSF (DG) group. Dox (5.0mg/kg, 6 times for 2 weeks) 
was administered intraperitoneally in group D and DG mice. After 24 hours, the mice in 
group G and DG were injected with G-CSF (100ug/kg/day for 5 days) subcutaneously. 
Cardiac function was evaluated by echocardiogram and cardiac catheterization after 4 
weeks. The generation of ROS was evaluated by immunological staining of 4-hydroxy-2-
nonenal (HNE) and 8-hydroxy-2’-deoxyguanosine (8-OHdG).
Results: Echocardiography and cardiac catheterization revealed that Dox-treated mice 
had significant left ventricular dilatation (group C vs. D: LVDd; 3.07 ±0.31vs 3.41±0.29 
mm, p<0.05) and dysfunction (LVSF; 47.8 ± 3.25 vs39.0 ± 3.76 %, p<0.05, dP/dt 12830 ± 
2069 vs. 10762 ± 1418 mmHg/sec, p<0.05). The dilatation and systolic dysfunction of LV 
were prevented by treatment with G-CSF (group D vs. DG: LVDd; 3.41±0.29 vs. 3.0±0.23 
mm, p<0.05 LVSF; 39.0 ± 3.76 vs. 43.5 ± 4.31 %, p<0.05, dP/dt; 10762 ± 1418 vs. 11932 
± 1649 mmHg/sec, p<0.05). 4-HNE-modified proteins and production of 8-OHdG were 
significantly increased in Dox-treated mice. All changes were inhibited by treatment with 
G-CSF. Furthermore, G-CSF protected against Dox-induced myocardial ultrastructual 
alterations, such as cytoplasmic vacuolization, mitochondrial swelling. Conclusion: 
Our present study indicates protective effects of G-CSF against Dox-induced cardiac 
dysfunction induced by the generation of ROS.
8:00 a.m.
829-7	 Cellular	Basis	for	the	Negative	Inotropic	Effects	of	
High-Mobility	Group	Box	1	in	the	Adult	Mammalian	
Heart
Jinping Fan, Ping Yang, Douglas L. Mann, Baylor College of Medicine, Houston, TX
Background: High-Mobility Group Box 1 (HMGB1) is a nuclear DNA-binding protein 
that stabilizes nucleosome structure and regulates gene transcription. HMGB1 that is 
released from necrotic cells or macrophages functions as a late inflammatory mediator, 
and has been shown to induce cardiovascular collapse during sepsis. Thus far, however, 
the effect(s) of HMGB1 in the heart are not known.
Methods: The purpose of this study was to determine the effects of HMGB1 on isolated 
cardiac myocytes by measuring sarcomere shortening in contracting cardiac myocytes 
paced at 0.5 Hz, intracelluar Ca++ transients using fluo-3, and L-type calcium currents 
(ICa,L) using whole cell perforate configuration of patch clamp technique.
Results: Treatment of isolated myocytes with 1000 ng/ml HMGB1 induced a 70 % 
decrease in sarcomere shortening and a 50 % decrease in the height of the peak Ca++ 
transient within 5 min (p <0.01, paired t-test, n = 6 from 5 hearts). The immediate negative 
inotropic effects HMGB1 on cell contractility and calcium homeostasis were partially 
reversible upon washout of HMGB1. A similar inhibition on peak inward ICa, L and partial 
recovery post washout were also shown by the patch clamp technique.
Conclusions: These studies show for the first time that HMGB1 mediates negative 
inotropic effects by decreasing calcium availability in cardiac myocytes probably through 
modulating membrane calcium influx, and suggest HMGB1 maybe act as a novel 
myocardial depressant during cardiac injury. 
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829-8	 Antiplatelet	Therapy	Attenuates	Subcellular	Cardiac	
Remodeling	by	Modifying	Ca2+	Dynamics	in	Ischemic	
Heart	Failure
Santosh K. SanganalMath, Andrea P. Babick, Judit Barta, Hideo Kumamoto, Nobuakira 
Takeda, Naranjan S. Dhalla, Institute of Cardiovascular Sciences, St. Boniface Hospital 
Research Centre, University of Manitoba, Winnipeg, MB, Canada
Background: Antiplatelet agents, sarpogrelate (5HT2A receptor blocker) (SAR) and cilostazol 
(phosphodiesterase-III inhibitor) (CIL) are used to prevent thromboembolic complications. We 
investigated whether these agents, in addition to their antiplatelet moiety, could also mitigate 
sarcoplasmic reticulum (SR) and myofibrillar remodeling, thus maintaining the Ca2+ homeostasis 
and improving contractile dysfunction in ischemic heart failure (IHF).
Methods: After coronary occlusion for 3 wk, Sprague-Dawley rats were treated with either SAR 
(5mg/kg, MI+SAR, n=21) or CIL (5mg/kg, MI+CIL, n=21) or vehicle (MI+V, n=21) for 5 wk. Sham-
operated rats (n=19) served as controls. At the end of treatment, the consequences of sustained 
coronary occlusion on LV morphology and function were noninvasively and invasively assessed 
using echocardiography and a 2F Millar catheter. Also, in view of structural and functional 
alterations in the Ca2+ regulatory proteins present in SR and myofibrils in the pathogenesis of 
IHF, we assayed LV homogenates for SR Ca2+ uptake, Ca2+ release, SR Ca2+ATPase (SERCA), 
phospholamban (PLN), ryanodine (RyR), myofibrillar ATPase activity, α and β-myosin heavy 
chain (MHC) isoforms.
Results: By day 56, ejection fraction (%), SR Ca2+ uptake (nmol/mg/min), Ca2+ release (nmol/mg/
min) and myofibrillar Ca2+ATPase (μmol Pi/mg/h) activities were significantly increased in MI+SAR 
(61±2.2, 22.2±1.9, 22.3±7.9 and 8±0.3, respectively) and MI+CIL (60±1.6, 18.3±1.9, 18±1.7 and 
8±0.5, respectively), compared to MI+V rats (37±1.8, 12.2±1.6, 8.7±1.5 and 6±0.3, respectively). 
Also, compared to MI+V rats, mRNA levels for SERCA, PLN, RyR, α-MHC and β-MHC were 
significantly higher in MI+SAR (by 69%, 26%, 34%, 104% and 33%, respectively) and MI+CIL (by 
91%, 24%, 37%, 105% and 28%, respectively). Protein levels for SERCA, RyR, PLN and MHC 
isoforms in MI+SAR and MI+CIL also showed a siginificant increase compared to MI+V rats.
Conclusions: Thus, in strategies to reduce IHF, antiplatelet agents may occupy a unique niche 
temporally located between efforts to reduce platelet deposition and attenuating subcellular 
cardiac remodeling by restoring the perturbed intracellular Ca2+ handling.
ACC.ORAL CONTRIBUTIONS
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835-3	 Anemia	in	Chronic	Heart	Failure	Is	Not	Only	Related	to	
Impaired	Renal	Perfusion	and	Blunted	Epo	Production,	
But	to	Fluid	Retention	and	Impaired	Survival	as	Well
B. Daan Westenbrink, Folkert Visser, Adriaan A. Voors, Tom DJ Smilde, Hans L. Hillege, 
Gerjan Navis, Wiek H. van Gilst, Dirk J. van Veldhuisen, University Medical Center 
Groningen, Groningen, The Netherlands
Background:	Anemia is prevalent in chronic heart failure (CHF) although its cause 
is often unknown.
Aim:	We aimed to investigate the relation between anemia, renal perfusion, erythropoietin 
(EPO) production and fluid retention in CHF patients, and investigate the effect on mortality. 
Methods:	We studied 97 patients with CHF, of which 15 had anemia (Hb < 13.0 g/dL in Men 
and Hb < 12.0 g/dL in women), without hematinic deficiencies. Glomerular Filtration Rate 
(GFR) and extracellular volume (ECV) were measured as the clearance and the distribution 
volume of constantly infused 125I-iothalamate, respectively, and effective renal plasma flow 
(ERPF) as the clearance of 131I-Hippuran.
Results:	 Anemic CHF patients displayed significantly reduced GFR (p=0.002), ERPF 
(p<0.005) and EPO production (p=0.001), and an elevated ECV (p=0.015). Multivariate 
analysis demonstrated that lower GFR (p=0.003), lower ERPF (p<0.005), lower EPO 
production (p=0.006), and a higher ECV (p=0.001), were significant independent predictors 
of lower hemoglobin levels. Finally, anemia was associated with significantly impaired survival 
(adjusted hazard ratio 5.6 (1.6-19.8), p=0.07; figure 1)
Conclusions:	Anemia in CHF is not only independently associated with impaired renal 
perfusion and blunted EPO production, but to fluid retention as well. Therefore treatment with 
EPO and correction of fluid retention might both improve survival in anemic CHF patients. 
9:15 a.m.
835-4	 Effects	of	Standard	Heart	Failure	Medications	on	
Outcomes	of	Placebo-Treated	Patients	in	the	African-
American	Heart	Failure	Trial
Keith C. Ferdinand, Anne L. Taylor, S. William Tam, Michael L. Sabolinski, Manuel 
Worcel, Jay N. Cohn, Association of Black Cardiologists, Atlanta, GA, University of 
Minnesota, Minneapolis, MN
Introduction: The African-American Heart Failure Trial (A-HeFT) enrolled only self-
identified African Americans (AA) including 40% women. The fixed-dose combination of 
isosorbide dinitrate/hydralazine (I/H) added to standard heart failure (HF) medications 
was shown to reduce mortality and morbidity and improve patient’s self reported functional 
status in A-HeFT. However, most standard HF medications were studied in trials with very 
few AA patients or women. The A-HeFT placebo-treated group offered an opportunity to 
investigate the treatment outcomes with certain standard HF medications in AA patients.
Methods: Post hoc analyses were performed to evaluate the treatment effects of 
standard HF medications in the A-HeFT placebo-treated patients whose co-therapies 
were not randomized. Kaplan-Meier survival analyses were used for the 532 placebo-
treated A-HeFT patients. Baseline severity of disease, risk factors, and co-therapies were 
not controlled in this observational study.
Results: In placebo-treated AA patients, those receiving ACE-I and/or beta-blocker showed 
lower risk of death and improved event-free survival. Treatment with ARB, spironolactone 
or digoxin in the presence of other co-therapies did not improve outcomes.
Conclusion:	 In	 this population of AA patients with HF treated with evidence based 
therapy, ACE-I and/or beta-blockers demonstrated benefit. These analyses are 
hypotheses generating and would need to be investigated in prospective trials of AA 
patients with HF. 
Outcome Comparison	within	Placebo	Group	(n) Hazard	Ratio P
All-cause death ACE-I (400) vs. No ACE-I (132) 0.41 <0.001
All-cause death Beta-blocker (437) vs. No Beta-blocker (95) 0.33 <0.0001
All-cause death ARB (112) vs. No ARB (420) 1.45 0.23
All-cause death Spironolactone (201) vs. No Spironolactone (331) 1.13 0.67
All-cause death Digoxin (324) vs. No Digoxin (208) 1.65 0.10
Event-free 
survival ACE-I (400) vs. No ACE-I (132) 0.75 0.11
Event-free 
survival Beta-blocker (437) vs. No Beta-blocker (95) 0.58 0.002
Event-free 
survival ARB (112) vs. No ARB (420) 0.93 0.71
Event-free 
survival
Spironolactone (201) vs. No Spironolactone 
(331) 1.06 0.70
Event-free 
survival Digoxin (324) vs. No Digoxin (208) 1.24 0.20
9:30 a.m.
835-5	 Race/Ethnicity	and	Incident	Congestive	Heart	Failure:	
The	Multi-Ethnic	Study	of	Atherosclerosis
Hossein Bahrami, Richard Kronmal, David A. Bluemke, Jean Olson, Steven Shea, 
Kiang Liu, Greogry L. Burke, João A.C. Lima, Johns Hopkins University, School of 
Medicine, Baltimore, MD
Background:	 Race/ethnicity is associated with hospitalization for congestive 
heart failure (CHF). We determined the association of ethnicity with incident CHF, 
independent of traditional risk factors (table footnote) and left ventricular (LV) 
function at baseline.
Methods: Multi-Ethnic Study of Atherosclerosis is a cohort study of 6,814 
asymptomatic participants (aged 45-84 years) who identified themselves as 
Caucasians, African Americans, Hispanics, and Chinese Americans. Cox 
proportional hazards models were used for data analysis.
Results: 79 participants developed CHF during a median follow-up of 4 years 
(incidence rate: 3.1 per 1000 person-years).	These participants were more likely to 
be older, male, obese, smoker, hypertensive, and diabetic. African Americans had 
the highest incidence rate of CHF, followed by Hispanics, Caucasians, and Chinese 
(incidence rates: 4.6, 3.5, 2.4, and 1.0 in 1000 person-years, respectively). After 
adjusting for hypertension and/or diabetes the association of race/ethnicity with 
CHF was no longer significant (table). Ethnicity modified the association of LV mass 
with incident CHF (a certain increase in LV mass index was associated with higher 
increase in risk in Caucasians than in African Americans and Hispanics).
Conclusions: The incidence of CHF is higher in African Americans, compared 
to other ethnicities. However, ethnic differences in risk of CHF are related to 
established risk factors, particularly hypertension and diabetes mellitus.
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Table.	Unadjusted	and	Adjusted	Hazard	Ratios	of	Congestive	Heart	Failure	in	
Relation	to	Ethnicity	in	the	Multi-Ethnic	Study	of	Atherosclerosis	(N=6,814)
Hazard	Ratios	(95%	Confidence	Interval)§
Characteristic Unadjusted
Adjusted for 
Established Risk 
Factors*
Adjusted for 
Established Risk 
Factors and LV 
Function at Baseline**
Ethnicity
Caucasians 1.0 (reference) 1.0 (reference) 1.0 (reference)
Chinese Americans 0.37 (0.11-1.24) 0.42 (0.13-1.43) 0.78 (0.22-2.75)
African Americans 1.81 (1.07-3.07) 1.42 (0.81-2.48) 1.09 (0.55-2.16)
Hispanic 1.36 (0.75-2.47) 1.22 (0.66-2.25) 1.05 (0.50-2.21)
Abbreviations: N = number, LV = left ventricle
* Established risk factors: age, gender, hypertension, diabetes mellitus, LV hypertrophy, 
obesity, serum cholesterol, and current cigarette smoking.
** Left ventricular ejection fraction determined by MRI at baseline was used as a 
parameter of LV function.
9:45 a.m.
835-6	 Red	Cell	Distribution	Width	as	a	Novel	Prognostic	
Marker	in	Heart	Failure:	Data	From	the	CHARM	
Program	and	the	Duke	Databank
Larry A. Allen, G. Michael Felker, Stuart J. Pocock, Linda K. Shaw, John J.V. McMurray, 
Marc A. Pfeffer, Karl Swedberg, Salim Yusuf, Eric L. Michelson, Christopher B. Granger, 
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background: Although a variety of prognostic markers have been described in heart 
failure (HF), a systematic assessment of routine laboratory values has never been 
performed.
Methods: All 2679 symptomatic chronic HF patients from the North American Candesartan 
in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program 
had a wide range of laboratory measures performed at a core facility, enabling us to 
assess the relationship between routine blood tests and outcome. We then performed a 
validation analysis using 2140 HF patients from the Duke Databank.
Results: Among 36 laboratory values considered in CHARM, higher red cell distribution 
width (RDW) showed the greatest independent association with cardiovascular death or 
HF hospitalization (primary outcome, adjusted HR 1.17 per 1 SD increase, p <0.0001). 
Anemia only modestly correlated with RDW. Higher RDW was among the most powerful 
overall predictors, with only age and cardiomegaly showing stronger association with 
outcome. In a validation model using the Duke Databank, higher RDW was strongly 
associated with all-cause mortality (adjusted HR 1.29 per 1 SD, p<0.001), second only to 
age as a predictor of outcome.
Conclusions: In two large contemporary HF populations, RDW was unexpectedly found to be 
a very strong independent predictor of morbidity and mortality. Further study of the mechanisms 
underlying this association may provide novel insights into HF pathophysiology.
Strongest Predictors of Cardiovascular Death or HF Hospitalization in 
CHARM
Variable Hazard	Ratio Chi	Square P-value
Age (per 10 yrs over age 60) 1.32 41.32 <0.0001
Cardiomegaly 1.56 28.15 <0.0001
RDW	(%,	per	1	SD) 1.17 24.78 <0.0001
Prior CHF Hosp < 6 months 1.53 21.11 <0.0001
Bilirubin Total (µmol/l, per 1 SD) 1.14 20.72 <0.0001
NYHA Class IV 2.09 20.43 <0.0001
NYHA Class III 1.42 18.88 <0.0001
EF (per 5% decrease < 45) 1.59 18.24 <0.0001
10:00 a.m.
835-7	 Endogenous	Methylated	Arginine	Derivatives	
in	Patients	With	Chronic	Systolic	Heart	Failure:	
Relationship	With	Echocardiographic	Indices	and	
Clinical	Outcomes
W. H. Wilson Tang, Wilson Tong, Stanley L. Hazen, Kevin Shrestha, Bruce S. Levison, 
Brian Delfraino, Maureen G. Martin, Allen G. Borowski, Richard W. Troughton, Allan L. 
Klein, Cleveland Clinic, Cleveland, OH
Background: The aims of this study were to determine if levels of methylated arginine 
derivatives that serve as endogenous nitric oxide synthase inhibitors correlate with 
echocardiographic indices of systolic and diastolic dysfunction and predict mortality in 
patients with systolic heart failure (HF).
Methods: Relationships between levels of metabolites and echocardiographic indices 
(using Spearman’s correlation/ANOVA) and long-term clinical events (death, transplant, 
heart failure hospitalizations) were determined in 138 patients with chronic HF (LVEF 
≤35%) from the ADEPT study. Using HPLC with on-line tandem mass spectrometry, plasma 
levels of a panel of methylated arginine derivatives were analyzed: SDMA (symmetric 
dimethylarginine), ADMA (asymmetric dimethylarginine) and MMA (monomethylarginine). 
Creatinine clearance (CrCl) was estimated by Cockcroft-Gault equation.
Results: In a cohort of subjects with HF (age 61±14 years, mean LVEF 26 ±6%), 
increasing quartiles of ADMA and SDMA were indicative of worsening CrCl and 
progressive elevation in natriuretic peptide levels (both p<0.01).	Higher plasma ADMA 
levels were associated with increasing age (p=0.001), NYHA class (p=0.02), LVEF 
(p=0.036), mitral regurgitation (MR) severity (p=0.001), right ventricular dysfunction 
(p=0.013), and diastolic stages (p=0.003). SDMA and MMA showed similar associations. 
Only natriuretic peptides, CrCl, and MR severity were independent predictors of ADMA 
levels. Patients taking beta-blockers had lower plasma ADMA levels than those not 
taking beta-blockers (0.44 ±0.13 vs 0.53 ±0.16, p=0.001). Of all clinical and laboratory 
measures monitored within the cohort, only elevated ADMA levels remained a significant 
independent predictor of adverse clinical events (relative risk=1.42, 95% CI: 1.14 - 1.75, 
p<0.01; log-rank, p=0.012 between 1st and 4th ADMA quartiles), including following 
adjustments for CrCl, MR severity, or LVEF.
Conclusions: Among patients with chronic systolic heart failure, endogenous levels 
methylated arginine derivatives (particularly ADMA) correlate with diastolic dysfunction, 
right ventricular dysfunction, and increased risk for clinical events.	
10:15 a.m.
835-8	 One-Year	Outcome	in	Different	Types	and	Subclasses	of	Acute	
Heart	Failure:	Results	From	Euro	Heart	Failure	Survey	II
Veli-Pekka Harjola, Ferenc Follath, Markku S. Nieminen, Dirk Brutsaert, Kenneth 
Dickstein, Helmut Drexler, Matthias Hochadel, Michel Komajda, Jose L. Lopez-Sendon, 
Piotr Ponikowski, Luigi Tavazzi, Helsinki University Central Hospital, Helsinki, Finland
Background: Acute heart failure (AHF) is associated with poor prognosis. However, 
the outcomes in different types and subclasses of AHF are not well known.Methods: 
EuroHeart Failure Survey II is a prospective observational study, which included 3,580 
patients hospitalized for AHF in 133 centres in 30 European countries. For the analysis of 
long-term mortality, 3- or 12-month follow-up was available for 2,978 patients, classified 
in clinical classes, as defined in the ESC Guidelines .
Results: Mean age 69.9 (SD 12.5) years, 61% male, 63% of patients had a history 
of chronic heart failure (CHF), whereas 37% had de novo, new-onset HF. 66% of the 
patients had decompensated HF, 16% pulmonary oedema, 11% hypertensive HF, 4% 
cardiogenic shock and 3% had right HF. None had high-output HF. In-hospital mortality 
was higher in patients with de novo HF as compared to those with CHF, 8.1% vs 5.8% 
(P=0.006), but 1-year mortality after discharge lower 16.3% vs 22.4% (log-rank test, 
P<0.001). CHF patients more often had decompensated HF , 73.0% vs 52.4 % in de 
novo group, P<0.001, whereas they less often had pulmonary oedema (10.4% vs 26.0%, 
P <0.001) and cardiogenic shock (2.2% vs 6.4%, P<0.001). Patients with cardiogenic 
shock had the highest cumulative 1-year mortality (51.3%) as a result of high in-hospital 
mortality of 39.6%. In contrast, hypertensive HF was associated with the best short and 
long-term prognosis.
In multivariate analysis, independent predictors of mortality after discharge were HF 
history (HR 1.40, 95%CI 1.14-1.71), age, HR 1.29 per decade (1.18-1.42), creatinine 
> 1.3 mg/dl, HR 2.07 (1.71-2.51), admission systolic blood pressure (SBP)< 100mmHg, 
HR 1.57 (1.17-2.10). In contrast, the patients on ACE inhibitors (ACEI) or angiotensin 
receptor blockers (ARB), as well as those on beta blockers had better survival, HR 0.58 
(0.47-0.71) and 0.79 (0.66-0.9).
Conclusions: Although in-hospital mortality was higher in patients with de novo HF as 
compared to those with CHF, mortality at 1 year was lower. Cardiogenic shock was the 
main cause of early death. The main risk factors for 1-year mortality were CHF, age, 
serum creatinine and SBP < 100 mmHg. Prescription of ACEI/ARB and beta-blockers 
improved the survival.
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1028-55	 Calcium	Cycling	Proteins	in	Peripartum	
Cardiomyopathy
Wendy E. Sweet, Alex Grossman-McKee, Stephen F. Zohn, Christine S. Moravec, 
Cleveland Clinic, Cleveland, OH
Background: Heart failure due to cardiomyopathy or ischemic disease is accompanied 
by changes in intracellular calcium cycling proteins. This has resulted in gene therapy 
trials seeking to increase levels of sarcoplasmic-endoplasmic reticulum calcium ATPase 
(SERCA) and phospholamban (PLB). A less common form of heart failure is peripartum 
cardiomyopathy (PCM), arising during or after pregnancy. The cause of PCM is unknown, 
and it is unclear whether calcium cycling proteins are affected.
Methods: We studied left ventricular tissue from hearts of 9 organ donors (NF), 8 dilated 
cardiomyopathy patients (DCM), and 8 PCM patients. NF hearts were obtained from 
unmatched organ donors and DCM and PCM hearts at transplant. All patients were 
female. Groups were age matched. Quantitative immunoblotting was used to measure 
levels of SERCA, PLB, calsequestrin (CQ), sodium-calcium exchanger (NCX) and 
ryanodine receptor (RR). Data were normalized by actin, and statistical analysis was 
performed using 1-way ANOVA with post-hoc testing.
Results: Data for 4/5 calcium cycling proteins show similarities between PCM and DCM. 
SERCA was significantly decreased in both DCM and PCM vs NF (in densitometric units, 
0.64 ± 0.06 (SEM) in NF, 0.43 ± 0.04 in DCM, 0.38 ± 0.08 in PCM; p<0.05). PLB, CQ 
and NCX were unchanged in both DCM and PCM vs NF. RR, however, was significantly 
decreased in patients with PCM as compared to NF (0.72 ± 0.13 in NF, 0.27 ± 0.10 in PP; 
p<0.05), while there was no significant change in DCM (0.51 ± 0.11).
Conclusions: Data show alterations in calcium cycling proteins in PCM similar to those 
observed in DCM, such as decreased SERCA. Like DCM, PCM hearts demonstrate no change 
in PLB or CQ. Although we and others have previously shown increased NCX in DCM, neither 
DCM nor PCM showed an increase in NCX in this study. This discrepancy may be due to 
gender differences. Hearts with PCM demonstrated a significant reduction in levels of RR as 
compared to NF, which was not observed in DCM. RR releases calcium to initiate contraction 
and a decrease in this protein has obvious functional consequences. Significantly decreased 
RR may differentiate this form of heart failure from others and have therapeutic implications.
9:00 a.m.
1028-56	 S100B	Human	Heart	Expression	and	Myocardial	
Apoptosis	in	the	Peri-infarct	Viable	Myocardium	of	
Patients	Dying	After	Acute	Myocardial	Infarction
Giovanna Di Giannuario, Antonio Abbate, Giovanna Liuzzo, Anna Severino, Luigi M. 
Biasucci, Rossana Bussani, Lucia Calcagni, Michela Casella, Pietro Santarelli, Filippo 
Crea, Alfonso Baldi, Virginia Commonwealth University, Richmond, VA, Catholic 
University, Rome, Italy
Background:	S100B is a calcium-binding protein that exhibits tissue-specific expression. 
When released by cells, S100B functions as paracrine or autocrine modulator of 
hypertrophy and apoptosis. A recent study has established a negative-feedback 
regulation of the hypertrophic response after myocardial infarction and an association 
between S100B and increased apoptosis in animal model. The aim of this study was 
to assess human myocardial S100B expression and the presence of apoptosis in the 
myocardium of patients dying after acute myocardial infarction.
Methods:	 Twenty-five consecutive patients dying 1-28 weeks after AMI were enrolled at 
autopsy. Five control subjects who died of trauma without evidence of cardiac disease were 
also enrolled. Heart specimens were taken from the peri-infarct and remote regions. Myocardial 
expression was assessed at immunohistochemistry and, when positive, graded in 1-3 according 
to the intensity of staining. In the same samples apoptosis was measured using co-localization 
of TUNEL and activated caspase-3 to identify the area with greater apoptotic burden.
Results.	S100B cytoplasmic expression in cardiomyocytes was found in all subjects with AMI 
and in none of the controls (P<0.001). In 9 cases (36%) S100B was expressed both in the 
peri-infarct and remote areas, whereas in the remaining 16 (64%) it was limited to the peri-
infarct area (P=0.008). Mean S100B intensity in the peri-infarct area was 2.4±0.8 (mean±SD) 
, whereas in the remote areas it was 1.1±0.1 (P<0.001). S100B positive cardiomyocytes were 
mostly localized to the areas of myocardium with greater apoptotic rates.
Conclusion:	Our study shows S100B expression and presence of apoptosis in the peri-
infarct myocardium of subjects dying after AMI. These data suggest that S100B may be 
involved in the pathogenesis of post-infarction remodelling. The finding of higher S100B 
expression in the areas with apoptosis can be related to a putative pro-apoptotic effect or 
to a negative regulation of hypertrophy compensatory response. 
9:00 a.m.
1028-57	 Myogenic	Development	of	Adipose	Tissue-Derived	
Mesenchymal	Stem	Cells:	Co-Expression	and	
Interaction	of	Telemerase	and	Myocardin-A
Rosalinda Madonna, James T. Willerson, Yong-Jian Geng, Texas Heart Institute, 
Houston, TX, University of Texas Houston Medical School, Houston, TX
Background: Adult adipose tissue contains multipotent stem cells that are capable of 
producing myogenic cells in vitro. Telomerase acts as a reverse transcriptase that maintains 
nuclear telomere length and replication potential. Myocardin, a transcriptional coactivator of 
serum response factor, controls cardiovascular myogenesis. The purpose of this study was 
to characterize the mesenchymal stem cells (MSCs) from adipose tissue for expression of 
telomerase and myocardin and the potential link of the co-expression to myogenesis.
Methods	and	Results: MSCs isolated from the adipose tissue of adult mice, dogs, and pigs 
were cultured and proteins/RNA extracted for analysis of expression of the telomerase catalytic 
subunit or telomerase-reverse transcriptase (TERT) and myocardin-A. Murine embryonic 
stem cells (ESCs) were used as positive controls. The primarily cultured MSCs from all the 
species expressed TERT at a level comparable to that of murine ESCs. The TRAP assay 
for telomerase activity further demonstrated the presence of biologically active telomerase 
in the adipose tissue-derived MSCs. Telomerase-positive MSCs also produced significant 
quantities of mRNA and protein of the promyogenic transcription cofactor myocardin A. Similar 
to differentiating ESCs in embryoid bodies, MSCs co-expressing telomerase and myocardin 
developed colonies that contained contractile myogenic cells after 2-3 weeks in culture. The 
contractile, but not the non-contractile, colonies exhibited stronger immunoreactivity towards 
cardiac and vascular myogenic markers, e.g., cardiac α-sarcomeric actinin and smooth 
muscle α-actin. Telomerase and myocardin A could be coimmunoprecipitated with anti-TERT 
or anti-myocardin A antibodies in cardiovascular myogenic stem cells. Gel shift study revealed 
that TERT enhanced myocardin A-associated activation of serum response factor (SRF) 
and promoted the formation of SRF-DNA complexes in MSC-derived myogenic cells, while 
myocardin A augmented TERT-mediated telomere synthesis.
Conclusions: Coexpression of telomerase and myocardin A is an important biomarker 
that characterizes the myogenic potential of MSCs from adult adipose tissue.
9:00 a.m.
1028-58	 Haptoglobin	Genotype	Determines	Long-Term	Survival	
and	Affects	Left	Ventricular	Function	and	Cardiac	
Remodeling	After	Myocardial	Infarction	in	Diabetic	Mice
Roy Asaf, Shany Blum, Ariel Roguin, Shiri Kalet-Litman, Jad Kheir, Rachel Miller-Lotan, 
Andrew Levy, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 
Haifa, Israel, Rambam health care campus, Haifa, Israel
Background: Haptoglobin (Hp) genotype predicts long term survival and congestive heart 
failure after myocardial infarction (MI) in individuals with diabetes mellitus. We have determined 
that Hp genotype is a major determent of the extent of myocardial necrosis after Ischemia-
Reperfusion injury in diabetic mice.We hypothesize that Hp genotype would be a determent 
of cardiac remodeling and left ventricular (LV) dysfunction after MI in diabetic mice.
Methods: The Hp 2 allele exists only in man. Wild type C57bl/6 mice have the Hp 1 allele 
with a high homology to the human allele. We genetically engineered a murine Hp 2 allele and 
targeted its insertion by homologous recombination to the Hp locus to create Hp 2 mice.
MI was produced by a permanent occlusion of the left anterior descending artery in 
diabetic and non-diabetic C57bl/6 mice carrying the Hp 1 or 2 allele.
Left ventricular function and dimensions were assessed by 2-dimentional echocardiography 
before the MI, 4 days and 30 days after the MI.
Results: Mortality in the non diabetic mice was negligible; however in the setting of 
diabetes, mice with the Hp 2 genotype had a higher mortality than mice with the Hp 1 
genotype (50% vs. 30% at 30 days).
In the non-diabetic mice there were no differences in LV fractional shortening (FS) between 
the Hp 1 and Hp 2 mice both at 4 and 30 days after MI. Diabetic Hp 2 mice had a significantly 
impaired FS compared to diabetic Hp 1 mice both at 4 and 30 days after MI (20.6±1.4% vs. 
24.6±0.9%, P=0.03 after 4 days; 12.8±0.83% vs. 18.5±1.2%, P=0.01 after 30 days).
There was no difference in LV end-diastolic dimensions 30 days after MI between the 
non-diabetic Hp 1 and Hp 2 mice. In the presence of diabetes though, Hp 2 mice had a 
significantly larger LV end diastolic dimensions compared to Hp 1 mice 30 days after MI 
(4.63±0.28mm vs. 3.76±0.17mm, p=0.02).
Conclusions:	Hp 2 genotype is associated with more severe LV dysfunction and cardiac 
remodeling in diabetic mice after MI.
9:00 a.m.
1028-59	 Circulating	Hematopoietic	Progenitor	Cells	are	
Reduced	in	a	Canine	Model	of	Heart	Failure
BARRY A. BOILSON, Guido Boerrigter, Gail J. Harty, Adriana Harbuzariu, James E. 
Tarara, John C. Burnett, Jr., Robert D. Simari, Mayo Clinic, Rochester, MN
Background:	 Congestive heart failure (CHF) is increasing in prevalence in the 
developed world, and despite improvements in therapy, mortality has improved little 
in recent years. There is growing evidence that bone marrow-derived cells may have 
a reparative role in cardiovascular disease. The therapeutic potential of these cells in 
myocardial dysfunction remains a controversial issue and the response of healthy bone 
marrow to the development of CHF remains unclear. We hypothesized that circulating 
hematopoietic stem cells would be altered in number in response to progressive CHF in 
a canine model of progressive ventricular systolic dysfunction.
Methods:	Six young healthy male dogs had right ventricular epicardial pacing systems 
implanted via a left thoracotomy. Three weeks post surgery the devices were programmed 
to pace in VOO mode at 240 beats/minute which induced severe CHF. Five ml blood was 
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drawn at baseline and subsequently at 24 hours and 10 days. Whole blood was subjected 
to flow cytometric analysis for CD34+ and CD14+ cells. The ISHAGE criteria were used 
for enumeration of CD34+ cells. At 10 days cardiorenal function was assessed invasively 
under general anesthesia.
Results:	Hemodynamic parameters at 10 days revealed reduced mean cardiac output 
(1.9±0.3L/min), elevated mean pulmonary capillary wedge pressure (24±4 mmHg), 
marked renal hemodynamic and excretory impairment and neurohumoral activation. 
The CD34 count markedly decreased from baseline in all dogs at 10 days (58±15 to 
27±8 cells/ 100μL blood, p<0.05). There was a nonsignificant rise in the CD14 count 
at 24 hours (baseline 2799±675 to 9636±2952cells/ 100μL at 24 hours, p=0.07), which 
decreased to baseline at 10 days (1959±608 cells/ 100μL).
Conclusions: This study demonstrates a specific decrease in circulating hematopoetic 
progenitor cells as compared to CD14+ monocytes in response to experimental CHF. 
This decrease is associated with pathophysiologic features of advanced heart failure. 
Further studies are warranted to evaluate the precise mechanisms and potential humoral 
factors involved in hematopoietic progenitor cell regulation and the potential therapeutic 
impact of their pharmacologic manipulation.
9:00 a.m.
1028-60	 Cardiac	Troponin	Levels	Predicts	Left	Ventricular	
Dysfunction	and	Mortality	in	Septic	Shock	Patients
Ajay Yadlapati, Andrew Gard, Abdi A. Jama, Luciano Babuin, Bekele Afessa, Allan S. 
Jaffe, Krishnaswamy Chandrasekaran, Mayo Clinic, Rochester, MN
Background: The objectives of this study were to determine the prevalence and etiology 
of left ventricular (LV) dysfunction in septic shock patients with elevated troponin levels 
and whether there is a synergistic relationship to mortality.
Methods: Eighty-four patients (pts) with septic shock had serum troponin levels measured 
at various periods during their stay in the medical intensive care unit. Echocardiography 
was performed on fifty-seven of these pts to assess LV function.
Results: Forty-nine (58%) of the septic shock pts had an elevated troponin level above 
0.03 ng/mL. Pts whom presented with elevated troponin levels had markedly increased 
rates of mortality (63% vs. 20%, p < 0.001). Of the pts with echocardiograph information, 
forty-one pts with elevated troponin levels revealed higher rates of LV dysfunction (44% 
vs. 0%, p < 0.001) and mortality (61% vs. 31%, p < .04) compared to the sixteen pts 
without elevated troponin levels.
Conclusion: Elevated troponin levels in pts with septic shock portend adverse outcome 
and presence of LV dysfunction. The mortality is high irrespective of presence or absence 
of LV dysfunction in this group, but marked in the LV dysfunction group.
Table: 
Elevated	Troponin	
Group
Non-Elevated	Troponin	
Group
Key	Statistics:
Number of Patients 49 35
Mean Age 71.1 64.8
Mortality 31 (63%) 7 (20%)
Mean Troponin Levels (ng/mL) 0.30 0.01
Troponin Level Range (ng/mL) .04 - 1.56 .01 - .03
Patients Receiving 
Echocardiography 41 (84%) 16 (46%)
Mortality 25 of 41 (61%) 5 of 16 (31%)
LV Dysfunction 18 of 41 (44%) 0 of 16 (0%)
Mortality in LV Dysfunction 
Patients 12 of 18 (67%) 0 of 0
No LV Dysfunction 23 of 41 (56%) 16 of 16 (100%)
Mortality in non-LV Dysfunction 
Patients 13 of 23 (57%) 5 of 16 (31%)
Co-Morbities:
Hypertension 67% 54%
Diabetes 49% 31%
Hyperlipidemia 55% 31%
Chronic Obstructive Pulmonary 
Disease 43% 26%
CAD 49% 29%
Obstructive Sleep Apnea 46% 11%
Pulmonary Embolism 4% 0%
Liver Disease 12% 17%
Peripheral Vascular Disease 8% 3%
Cerebrovascular Accident 20% 11%
Atrial Fibrillation 46% 26%
Congestive Hear Failure 32% 20%
Renal Failure 53% 37%
9:00 a.m.
1028-61	 Clustered	Homeobox	Gene	Expression	During	
Cardiogenesis
Hal Skopicki, Don Chen, Andrew Greene, Evan Lau, Xiaoqin Qu, Asha Jacob, Mario 
Deng, Stony Brook University Medical Center, Stony Brook, NY, Columbia University 
College of Physicians and Surgeons, New York, NY
Background: Transdifferentiation of stem cells into cardiomyocytes may require a 
series of complex interactions between growth and differentiation factors resulting in the 
appearance of the mature cardiac phenotype. While multiple genes are responsible for 
cardiac specification, differentiation and proliferation during cardiogenesis in vivo, the 
regulation of these transcription and growth factors remains largely unknown. Homeobox 
genes are putative regulators of these processes and have been shown to be important 
in formation of the Drosophila dorsal aorta.
Methods: Using a murine cDNA library and cellular and in vivo models of cardiogenesis 
and myocardial infarction, we determined the expression pattern and activity of clustered 
homeobox genes in cardiac development
Results: Murine cardiac library screening revealed the presence of 11 clustered homeobox 
gene products. Temporal expression was determined during murine cardiogenesis with 
earliest expression followed by marked abrogation of HoxD3 and Hox C5 by day 12.5 
p.c. Temporally restricted expression of HoxA (1,2,3,5) and Hox B(1,2,3) peaked between 
days 12.5 to 15.5 p.c. HoxC9 and D9 were detected later in cardiogenesis. These same 
Hox genes were regulated during P19CL6 cell differentiation into beating cardiomyocytes. 
Moreover, reexpression of all Hox genes was detected and temporally regulated in a 
mouse model of infarction. Overexpression of HoxC5 in a myocyte cell line was able to 
regulate expression of Mef2c, GATA4 and βMHC.
Conclusions: These data indicate that the clustered homeobox genes may be critical 
regulators of murine cardiogenesis. Assessment of their role during bone marrow or 
embryonic cell maturation may be an important clue in determining the transdifferentiation 
potential of these cells into adult cardiomyocytes.
9:00 a.m.
1028-62	 Long-Term	Survival	of	Heart	Failure	in	Rural	
Community	Hospitals:	Can	We	Improve	Care?
Pablo Castro, Hugo Verdejo, Eduardo Garces, Roberto Concepcion, Fernando Lanas, 
Luis Sepulveda, Manuel Saavedra, Jose Luis Vukasovic, Angel Puente, Silvana 
Llevaneras, Chilean Heart Failure Registry (ICARO), Santiago, Chile
Background: Heart failure (HF) registries had shown differences in survival between 
urban and rural population.
Objective: Identify variables associated with long-term survival in HF patients in urban 
and rural areas in our country.
Methods: Prospective registry from 14 Chilean centers. Patients with decompensate HF 
on admission were incorporated between January 2002 and August 2006. Mortality at the 
end of follow-up was obtained from certificate databases. Demographic and laboratory 
results on admission, in-hospital treatment and prescriptions at discharge were recorded 
in order to identify variables influencing survival.
Results:	 341 urban and 292 rural patients were included. Mean age was 68.6±13.4 
and 69.4±13.05 years old, respectively (p=NS). 63% percent of urban patients were 
male vs. 49.3% in the rural group (p=0.001). On admission, 42.5% and 43.4% patients 
were in NYHA Class IV in rural and urban group, respectively (p=0.05). Demographic 
characteristics were similar, except for prevalence of hypertension (HTN) (78% rural 
vs. 67.4% urban group, p= 0.002). In-hospital therapy showed differences regarding the 
use of inotropic drugs (9.8% in rural vs. 29.3% in urban group, p=0.001). At discharge, 
prescription included beta blockers in 17.8% of rural vs. 32.5% of the urban patients 
(p= 0.001). ACE inhibitors were prescribed to 53.7% of the rural vs. 65.7% of the urban 
patients (p=0.003). Spironolactone was prescribed in 31.8% of the rural vs. 45.2% of 
the urban patients (p=0.002). Both in-hospital and one year mortality were higher in 
rural patients (7.2% vs. 3.5% and 20.8% vs. 4.4%); the difference remained significant 
after adjustment for age, sex, NYHA class and hypertension. Independent predictors 
of mortality in rural population were age >70 (HR 1.65, IC95% 1.10-2.70); Creatinine 
>1.25mg/dL on admission (HR 2.93, IC95% 1.91-4.50), HTN (HR 1.58, IC95% 1.00-2.41) 
and ACE inhibitors at discharge (HR 1.44, OR 1.01-2.13).
Conclusion: Regional differences in mortality of HF can be explained, at least partially, by 
low compliance with prescription guidelines. Educational programs should be developed to 
increase guideline adherence, improving primary care HF management in our country.
9:00 a.m.
1028-63	 Tissue	Angiotensin	Converting	Enzyme	Inhibitors	
for	Secondary	Prevention	of	Adverse	Cardiovascular	
Events	in	Patients	with	Preserved	Left	Ventricular	
Function:	A	Pooled	Bayesian	Meta-Analysis
Christopher D. Lang, Sandeep A. Saha, Janos Molnar, Rohit R. Arora, Chicago Medical 
School, North Chicago, IL
Background: Although the role of angiotensin converting enzyme (ACE) inhibitors in 
patients with depressed left ventricular function is well established, their role in patients 
with preserved ventricular function is uncertain. We conducted a Bayesian meta-analysis 
of recent clinical trials to evaluate the role of tissue ACE inhibitors in secondary prevention 
of cardiovascular disease in patients with preserved left ventricular function.
Methods: Randomized placebo-controlled clinical trials of at least 12 months duration, 
conducted in patients who had experienced an acute cardiovascular event or were at high risk 
for cardiovascular events were selected for analysis. A total of 31,555 patients from 4 selected 
trials were analyzed. Odds ratio estimations were made using pooled data from the 4 trials. 
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Bayesian meta-analysis and sensitivity analysis of therapeutic response were computed.
Results: When compared to placebo, the use of tissue ACE inhibitors was associated 
with high probabilities of benefit in reductions of all-cause mortality (Pb=0.999), 
cardiovascular mortality (Pb =0.999), fatal & non-fatal myocardial infarction (Pb=0.999) 
and stroke (Pb=0.999), as well as hospitalization for congestive heart failure (Pb =0.999) 
& occurrence of new-onset diabetes mellitus (Pb =0.999). The need for invasive coronary 
revascularization was also reduced (Pb =0.992), but the risk of hospitalization for angina 
was not significantly affected (Pb =0.692).
Conclusion:	Tissue ACE inhibitors decrease mortality and cardiovascular morbidity in 
high risk patients with cardiovascular disease and preserved left ventricular function in 
randomized placebo-controlled clinical trials.
9:00 a.m.
1028-64	 Reversal	of	Left	Atrial	Remodeling	in	Patients	with	
“Isolated”	Left	Ventricular	Diastolic	Dysfunction
Walter Abhayaratna, Marion Barnes, Andrew Langins, Stephen Cha, Tammy Green, 
Grace Verzosa, Yoko Miyasaka, Kent Bailey, Teresa Tsang, Mayo Clinic, Rochester, MN
Background:	Little is known with regard to the reversibility of left atrial (LA) remodeling 
that develops in response to chronic left ventricular (LV) diastolic dysfunction and is 
associated with adverse cardiovascular outcomes.
Methods:	Twenty-one patients (mean age 69 ± 8 years; 48% men) with isolated LV 
diastolic dysfunction and a maximum LA volume >=32 ml/m2 were randomly assigned 
to receive quinapril at a target dose of 60 mg/day or matching placebo for 6 months. LA 
size and phasic function were assessed by echocardiography at baseline and 6 months. 
Analysis was based on intention to treat.
Results:	 Baseline characteristics were comparable between treatment and placebo 
groups. Quinapril therapy was associated with reductions in maximum (-2.8 ml/m2 vs 0.17 
ml/m2; p=0.016) and minimum (-3.1 ml/m2 vs 0.75 ml/m2; p=0.0003) LA volumes (Table), 
and an improvement of LA reservoir function (measured as LA total emptying fraction, 
5.4% vs -2.0%; p=0.006), independent of changes in systemic blood pressure. There 
were no significant differences between groups with respect to changes in LA conduit 
function (ratio mitral E wave velocity time integral [VTI] / A wave VTI: 0.14 vs -0.10; 
p=0.06) or LA pump function (mitral annular and inflow velocities during late diastole; 
p=0.21 and p=0.93, respectively).
Conclusions: Despite a short study period, tissue angiotensin converting enzyme 
inhibition with quinapril was associated with reversal of LA remodeling, both in terms of 
structure as well as aspects of LA function. 
Quinapril	
(n=9)
Placebo
(n=12)	
Baseline 6 months Baseline 6 months
Brachial	blood	pressure,	mmHg 131/77 121*/71† 121/69 120/68
Septal	mitral	annular	e’,	cm/s	(SD) 7.6 (1.2) 10.7 (6.2)† 7.0 (1.9) 6.9 (2.5)
E/e’	ratio,	(SD) 11.4 (3.9) 9.9 (4.2) 10.9 (3.5) 11.8 (6.4)
Maximum	indexed	LA	volume,	mL/m2	
(SD) 40.6 (9.2) 37.9 (9.9)* 36.4 (5.7) 36.6 (4.9)
Minimum	indexed	LA	volume,	mL/m2	
(SD) 16.0 (6.0) 12.9 (5.7)* 14.8 (4.0) 15.5 (3.2)
LA	total	emptying	fraction,	%	(SD) 61 (8.9) 67 (8.8)* 60 (8.3) 58 (7.5)
Peak	mitral	A	velocity,	cm/s	(SD) 83 (6) 82 (5) 87 (35) 87 (36)
Mitral	annular	a’	velocity,	cm/s	(SD) 11.4 (1.9) 12.4 (2.6)† 10.9 (1.8) 10.7 (1.4)
Mitral	E	VTI	/	A	VTI	ratio,	(SD) 1.5 (0.3) 1.7 (0.2)† 1.4 (0.2) 1.3 (0.2)
Difference between baseline and 6-month level: *p<0.05; †p<0.20
9:00 a.m.
1028-65	 Iron	Metabolism	is	Impaired	in	Heart	Failure	Irrespective	
of	Hemoglobin	Concentration	and	Left	Ventricular	
Ejection	Fraction
Clare L. Murphy, Eileen M. Lundmark, Edward J. Fitzsimons, Alan G. Jardine, Naveed 
Sattar, John J. McMurray, University Of Glasgow, Glasgow, United Kingdom, The 
Western Infirmary, Glasgow, United Kingdom
Background: Anemia is associated with increased morbidity and mortality in heart failure 
(HF) and is often due to abnormal iron metabolism. Iron status has been described in 
anemic patients with HF, but not in non-anemic patients with HF. Assessment of iron 
status in all patients with HF may identify those patients at risk of developing anemia.
Methods: We measured left ventricular ejection fraction (LVEF- Simpson’s biplane), 
serum iron (umol/L), transferrin saturation (Tsat%), ferritin (ng/mL) and hemoglobin (Hb 
g/dL) concentration in 110 consecutive consenting patients hospitalized with HF. Anemia 
was defined as Hb <13 men, <12 women (WHO criteria) and a low Tsat was defined as 
<16% i.e. below the population reference range.
Results: Mean age 72 years, 50% male, 54% anemic, 76% reduced LVEF (<50%) and 
24% preserved LVEF. Almost three quarters of anemic and two thirds of non-anemic 
patients had a low Tsat. In all patient categories, Tsat and mean iron levels were low 
despite ferritin levels being normal or elevated i.e. reduced iron supply to the bone 
marrow and tissues (Table 1).
Table 1: Iron Status in Patients with Heart Failure
Anemic 
n=59
Non-anemic 
n=51
Reduced LVEF 
n=84
Preserved LVEF 
n=26
Tsat <16 46 (78%) 31 (61%) 58 (69%) 19 (73%)
Tsat <16 and ferritin 
<30 6 (10%) 3 (6%) 7 (8%) 1 (4%)
Tsat <16 and ferritin 
30-100 9 (15%) 10 (20%) 21 (25%) 12 (46%)
Tsat <16 and ferritin 
>100 21 (36%) 18 (35%) 30 (36%) 6 (23%)
Hb Mean
(S.D)
11.0
(1.0)
13.7
(1.1)
12.3
(1.7)
12.2
(1.9)
Iron Mean
(S.D)
7.9
(6.0)
9.2
(5.1)
8.2
(6.1)
9.0
(3.7)
Conclusions: Iron metabolism appears to be impaired in HF, irrespective of Hb 
concentration and LVEF. Assessment of iron status in all HF patients may identify, earlier, 
those at risk of developing anemia and the risk of developing anemia might be reduced by 
iron supplementation. These findings have potentially important clinical implications and 
this hypothesis requires prospective testing.
9:00 a.m.
1028-66	 Beta	Blocker	Dose	Adjustment	Upon	Hospitalization	for	
Acute	Decompensated	Heart	Failure
Saum Shamimi-Noori, David J. Whellan, Abhijit Dasgupta, Suzanne Adams, Paul 
Mather, Sharon Rubin, Jocelyn Andrel, Arthur M. Feldman, Thomas Jefferson University 
Hospital, Philadelphia, PA
Background:	Beta blockers (BB) are a mainstay of treatment in chronic heart failure but 
their role in the acutely decompensated patient remains undefined. This study examines 
current BB dosing practices upon admission for acute decompensated heart failure 
(ADHF) and the effect on hospital length of stay (LOS).
Methods:	We conducted a retrospective review of patients on outpatient BB therapy 
who were admitted for ADHF in 2004-2005. We compared daily outpatient BB dose 
to inpatient dose on the first day of admission and analyzed for associations between 
dosage changes and selected clinical measures, comorbidities, admitting specialty and 
LOS using logistic regression, adjusting for age, race and sex.
Results:	Of 464 subjects, 84% were continued on a BB during day one of hospitalization 
and 96% of these were continued on their outpatient agent. Excluding cases where the 
BB agent was changed, outpatient dose was decreased or held in 41%, unchanged in 
50% and increased in 9% of cases. Systolic blood pressure (p=0.004) and diastolic blood 
pressure (p=0.04) were significant predictors of BB dose reduction or cessation. Family 
medicine was more likely to reduce or stop BB than cardiology (OR=2.77, 95% CI 1.1-6.7, 
p=0.03). There was no significant difference in BB dosing between general cardiology, 
heart failure and internal medicine services. Admission heart rate, wheezing on initial 
exam, brain natriuretic peptide, ejection fraction and comorbidities including atrial flutter/
fibrillation, obstructive lung disease, coronary artery disease and hypertension were not 
significant predictors of BB dose reduction or cessation. Patients whose BB dose was 
reduced or stopped had a significantly increased LOS by a factor of 1.13 (p=0.01).
Conclusion:	Current BB management upon hospitalization for ADHF is varied and can 
be predicted by blood pressure and admitting specialty. Additionally, patients whose initial 
inpatient BB dose was reduced or stopped had a significantly increased LOS. It is unclear 
if a decrease in outpatient BB dosage upon hospitalization for ADHF is a surrogate 
marker for disease severity or is independently detrimental to ADHF patients. Further 
studies are required to evaluate this finding.
9:00 a.m.
1028-67	 Higher	Percent	BNP	Reduction	is	Required	in	Blacks	than	
Whites	to	Reduce	Event	Free	Survival	in	Heart	Failure
Amandeep Dhaliwal, Biykem Bozkurt, Michael E.DeBakey VA Medical Center, Houston, 
TX, Baylor College of Medicine, Houston, TX
Background: We reported earlier that > 50% reduction in BNP with treatment during HF 
hospitalization was associated with significantly lower rates of death or HF hospitalizations. 
However, it is not known whether this reduction is equally achievable and correlates with 
similar clinical outcomes across races.
Methods: Retrospective chart reviews were performed in 464 patients with HF admissions 
fulfilling Framingham criteria. Datasets with paired admission and discharge BNP were 
analyzed for % reduction in BNP for death or 1st HF hospitalization, according to race.
Results: Baseline characteristics were similar, except blacks had more prior 
hospitalizations (51 vs 29%, p=0.01). Admission and discharge BNP levels trended 
to be higher in blacks (p=0.07,p=0.06). No difference in % reduction in BNP during 
hospitalization was noted according to race. In whites, > 50% reduction in BNP during HF 
hospitalization was associated with lower rates of HF hospitalization or death at one year 
(p=0.03); whereas in blacks, it was not. In blacks, >65% reduction in BNP was required to 
demonstrate reduction in HF hospitalizations or death at 1year (p=0.03). (Fig)
Conclusions: In whites, > 50% reduction in BNP during HF hospitalization was associated 
with lower rates of HF hospitalization or death at 1 year. In blacks a higher, > 65 % BNP 
reduction was required to demonstrate a similar reduction. Further studies are needed to 
determine if higher BNP reduction should be targeted in black patients with HF. 
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1028-68	 Outpatient	Medication	Usage	is	Not	Associated	With	
Anemia	in	Patients	Hospitalized	for	Decompensated	
Heart	Failure
Saum Shamimi-Noori, Emmanuel D. Chryssos, Stephanie Cho, Abhijit Dasgupta, 
Suzanne Adams, Paul Mather, Sharon Rubin, Jocelyn Andrel, David J. Whellan, 
Thomas Jefferson University Hospital, Philadelphia, PA
Background:	 Anemia is a common problem in heart failure patients and has been 
identified as an independent risk factor for morbidity and mortality. Recent studies have 
suggested that medications commonly used in heart failure, particularly angiotensin 
converting enzyme (ACE) inhibitors, may exacerbate this anemia. This study explores the 
relationship between anemia and outpatient medication usage in patients hospitalized 
with acute decompensated heart failure (ADHF).
Methods: The Jefferson Outcomes Database integrates reports from administrative, clinical 
and financial data. First admissions for ADHF (DRG 127) between 2004 and 2006 were 
analyzed to determine associations between admission hemoglobin concentration and 
outpatient medication usage. Continuous variables were analyzed using linear regression 
and categorical variables using logistic regression, both adjusting for age, race, and sex.
Results: The study population included 1076 admissions with 759 unique patients (54% 
male, age 70 +/- 14.9 years). Hemoglobin concentration ranged from 4.7 to 20.2 g/dL 
with a mean of 11.6 g/dL. No significant difference in outpatient ACE-inhibitor/angiotensin 
receptor blocker (ARB) use (p=0.18), beta blocker use (p=0.12), aldosterone antagonist 
use (p=0.18) or loop diuretic use (p=0.57) was found across hemoglobin concentrations.
Conclusion:	In contrast to recent studies, we found no significant relationship between 
outpatient heart failure medications, including ACE-inhibitors and ARBs, and anemia in 
patients hospitalized for ADHF. This suggests that the rennin angiotensin system plays a 
less important role in the anemia associated with heart failure.
9:00 a.m.
1028-97	 Is	Blood	Volume	Analysis	Helpful	in	the	Investigation	of	
Anemia	in	Heart	Failure?
Clare L. Murphy, Eileen M. Lundmark, Edward J. Fitzsimons, Alan G. Jardine, Naveed 
Sattar, John J. McMurray, University Of Glasgow, Glasgow, United Kingdom, The 
Western infirmary, Glasgow, United Kingdom
Background: Hemodilution may contribute to anemia in heart failure (HF), especially in patients 
with acute decompensation. Plasma volume (PV) and red cell volume (RCV) have been 
measured in anemic HF patients, but not in non-anemic control patients with HF. The value of 
these investigations in the assessment of anemia is therefore uncertain. We measured PV and 
RCV in patients admitted with acute HF to examine the prevalence of true and dilutional anemia.
Methods: We measured haemoglobin (Hb g/dL), PV (I-125 human serum albumin) and 
RCV (Cr-51 erythrocytes) in 30 consecutive consenting patients hospitalized with acute 
HF. PV and RCV were measured a mean of 3 days after admission and expressed as 
% of predicted based on gender and body size. PV > 100% (increased), RCV < 95% 
(decreased). Anemia was defined as Hb <13 men, <12 women (WHO criteria).
Results: Mean age 70 years, 57% male and 47% anemic. The majority of patients had 
an increased PV - 57% of anemic and 69% of non-anemic patients. The majority of 
patients also had a reduced RCV - 64% of anemic and 44% of non-anemic patients. 21% 
of patients with a low Hb had a RCV ≥ 95% and increased PV ie. possible “dilutional” 
anemia, but 44% of patients with a normal Hb also had this pattern of results (Table 1).
Table 1 - Blood volume measurements in patients with acute HF
Increased PV RCV <95% RCV ≥95% and increased PV
All patients 19 (63%) 16 (53%) 10 (33%)
Anemic patients 8 (57%) 9 (64%) 3 (21%)
Non anemic patients 11 (69%) 7 (44%) 7 (44%)
Conclusions:	Blood volume analysis is of limited value as an investigation for the cause 
of anemia in acute HF. Current normal reference ranges for RCV have a low sensitivity 
and specificity for reduced Hb and an increased PV is common in acute HF, irrespective 
of Hb concentration.
9:00 a.m.
1028-98	 Ejection	Duration	Is	The	Predictor	Of	Acute	
Decompensation	In	Patients	With	Congestive	Heart	Failure
Namavathi Nandyala, Gregory L. Freeman, The university of Texas Health Science 
Center at San Antonio, San Antonio, TX
Background:Left Ventricular ejection duration (ED) is lower in patients with systolic dysfunction. 
However, it is unknown if ED varies with acute decompensation and with treatment.
Methods:Ejection duration corrected for heart rate was studied serially in 25 patients (54 
±10yrs, 80% male, LVEF 18± 3%) with acute decompensated CHF during the hospital 
stay from tonometry derived radial artery (RA) wave form and compared to 13 (48±9 
yrs, 92% male LVEF 16±3%) subjects with stable CHF on standard cardiac medications. 
ED is the time in msec from the wave foot to the incisura of the RA waveform. Central 
aortic pressures are derived from aortic wave form obtained by transfer function by 
Sphygmocor© pulse wave analysis.
Results:With the treatment for acute decompensated CHF; ED improved from 251±27 
at admission to 267±29 msec at the time of discharge (p value-0.012). There was no 
significant change in heart rate 80±15 to 80±14 bpm. SBP decreased from 126±20 to 
116±19 mmHg (p=0.058) Central SP from 111± 19 to 101± 15 mmHg (p=0.043), DBP from 
79±16 to 71±11mmHg (p=0.039), central DBP 82±15 to 71±11mm Hg (p=0.028). Body 
mass Index decreased from 33 to 31 kg/m2 (p=0.004). ED at admission was significantly 
lower (251±27 msec) than the subjects with stable CHF (276±19 msec p=0.012) with no 
significant difference at the time of discharge (267±29 vs. 276±19 msec p=0.256).
Conclusions:ED is shortened with acute CHF exacerbation and improved with treatment, suggesting 
that it might be a novel tool in predicting acute decompenstion and response to treatment.
9:00 a.m.
1028-99	 Is	Soluble	Lectin-like	Oxidized	Low-Density	Lipoprotein	
Receptor-1	A	Good	Indicator	For	Early	Detection	Of	
Myocardial	Fibrosis	In	Hypertrophic	Cardiomyopathy?
Masayoshi Takeno, Shinji Seto, Yuji Koide, Takeshi Baba, Noriaki Kume, Hirokazu 
Mitsuoka, Toshikazu Jinnai, Toru Kita, Katsusuke Yano, Nagasaki University, Nagasaki, 
Japan, Kyoto University, Kyoto, Japan
Background: Experimental studies reported that activation of lectin-like oxidized low-
density lipoprotein receptor-1 (LOX-1) induces cardiomyocyte apoptosis. Disorganazation 
of myocyte and replacement fibrosis may play a role on progression to end-stage phase 
of hypertrophic cardiomyopathy (HCM).
Methods: Twenty four non end-stage phase HCM patients (17 men, 7 women; age 
61.1±1.9) were examined left ventricle biopsy and sLOX-1 sampling in ascending aorta 
(Ao) and coronary sinus (CS). sLOX-1 was measured by a sandwich ELISA.
Results: According to pathological findings, we divided the patients to two groups: 14 
patients with perivascular and myocardial fibrosis of ≥ Grade 2 (fibrosis group) and 10 
patients with ≤ Grade 1 (no fibrosis group). Basic characteristics and laboratory findings 
were summarized in Table. Two groups had similar left ventricular ejection fraction, left 
ventricular end-diastolic dimension. Serum levels of sLOX-1in Ao and CS were not 
significantly different in 2 groups. However, no fibrosis group showed a decrease of 
sLOX-1 from Ao to CS, while fibrosis group did not change sLOX during the cardiac 
circulation. Subsequently, the difference of sLOX-1 between Ao and CS were lower in 
fibrosis group than in no fibrosis group.
Conclusion: The difference of sLOX-1 between Ao and CS were lower in non end-stage 
phase HCM with fibrosis compared to those without fibrosis. This finding suggests the Ao-
Cs difference of sLOX-1 may be useful for early detection of myocardial fibrosis in HCM.
Comparison of baseline clinical and laboratory characteristics of patients.
Variable Fibrosis(+) Fibrosis(-) p
Age (years) 61.8±2.4 60.1±3.4 0.68
Male, %(n) 57%(8) 90%(9) 0.07
Obsructive type, %(n) 43%(6) 20%(2) 0.24
Left ventricular ejection fraction (%) 70.8±2.7 68.7±2.8 0.60
Left ventricular end-diastolic dimension(mm) 44.6±1.7 46.1±1.7 0.55
Low density lipoprotein (mg/dl) 116.6±8.2 119.9±8.5 0.79
sLOX-1 in aorta (pg/ml) 72.0±11.3 119.0±23.8 0.06
sLOX-1 in coronary sinus (pg/ml) 82.3±13.3 70.1±17.4 0.58
sLOX-1 difference aorta and coronary sinus(pg/ml) -10.3±16.0 48.9±18.7 0.03
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1028-100	 Improved	Prognosis	in	Isolated	Left	Ventricular	
Noncompaction:	Follow-Up	Study	of	39	Patients
Timothy Dirks, Marc T. Ellingson, Matt Thielman, Terrence Longe, Robert Hauser, Abbott 
Northwestern Hospital, Minneapolis, MN
Background:	 Isolated left ventricular noncompaction (LVNC) is an inherited 
cardiomyopathy increasingly recognized with improved cardiac imaging. LVNC is 
characterized by numerous trabeculations and deep recesses of the left ventricle (LV) 
endomyocardium without other cardiac malformations. Most series have shown a poor 
prognosis from congestive heart failure (CHF), arrhythmias and systemic thromboemboli. 
The aim of the study was to determine the presentation and outcomes of patients 
diagnosed with LVNC by cardiac magnetic resonance imaging (CMRI).
Methods:	Consecutive patients from a community-based referral center were included 
for analysis if diagnosed with isolated LVNC by CMRI. The diagnostic criteria included 
a left ventricle (LV) with a noncompacted endocardium, having prominent trabeculations 
and deep recesses in continuity with only the LV cavity, in a ratio > 2:1 to the compacted 
epicardial layer at end systole with no other cardiac malformations.
Results:	From 2002 to 2006, 39 patients (20 men) aged 11-81 years old (median age 52) 
were diagnosed with isolated LVNC by CMRI. Median ejection fraction (EF) by CMRI was 
58% (range 21-79%) with EF<50% in 36% and LV dilatation in 54%. Additional history 
was obtained for an average follow-up of 32.5 ± 31 months from onset of diagnostic 
symptoms, or from time of diagnosis if asymptomatic. During follow-up, 3 patients were 
re-hospitalized for CHF, chest pain, or syncope, and 4 were diagnosed with CHF. No 
additional thromboembolic events were reported. Medical therapies included implantable 
cardioverter defibrillator (ICD) (n=12) and treatment with an ACE inhibitor/ARB (n=7), 
betablocker (n=17), or warfarin (n=9). There were no cardiac transplantations or deaths.
Conclusions:	 In contrast to other series, the 39 study patients with isolated LVNC 
were less symptomatic and had a better prognosis. This may be due to more frequent 
and earlier diagnosis along with use of standard treatments for LV systolic dysfunction, 
anticoagulation to prevent thromboemboli, and ICD therapy. Future research will be 
needed to determine patients at highest risk and optimal therapy.
9:00 a.m.
1028-101	 Clinical	Implications	of	Mid-ventricular	Obstruction	and	
Intravenous	Propranolol	Use	in	Patients	with	Transient	
Left	Ventricular	Apical	Ballooning,	so-called	Tako-tsubo	
Cardiomyopathy
Akiyoshi Hashimoto, Kazufumi Tsuchihashi, Yoshioka Takuji, Shinya Shimoshige, 
Eguchi Mariko, Takeru Wakabayashi, Satoshi Yuda, Mamoru Hase, Tomoaki Nakata, 
Kazuaki Shimamoto, Sapporo Medical University, Sapporo, Japan
Background: Persistent hypotension caused by dynamic midventricular obstruction 
(MVO) in patients with transient left ventricular (LV) apical ballooning, so-called “tako-
tsubo” cardiomyopathy is an important complication to be treated.	We tested the implication 
intravenous propranolol challenge against MVO in transient LV apical ballooning.
Methods: The effect of propranolol (0.05mg/kg, maximum 4 mg, n=13) in 34 patients 
with LV apical ballooning by non-cardiac illness, 14 males and 20 females, aged 64±17 
(ranging 22 to 84) years, were analyzed in correlation with plasma catecholamine levels.
Results: 1) MVO was confirmed in 8/34 (24%) and pressure gradient ranged from 28-
140 mmHg. 2) Patients with MVO had the same backgrounds and clinical characteristics 
(symptom, peak CK, plasma catecholamine levels); however, the prevalence of abnormal 
Q wave on ECG and hypotension were higher than in those without MVO. 3) Intravenous 
propranolol can change the pressure gradient (PG, from 90±42 to 22±9 mmHg), systolic 
blood pressure (SBP, from 85±11 to 116±20 mmHg) and LV ejection fraction (LVEF, 30±7 
to 43±4 %). 4) The changes of PG after propranolol injection had a significant linear 
correlation with those of SBP or LVEF: ΔSBP = 4.738 + 0.315 x ΔPG, r= 0.689, p<0.001, 
or ΔLVEF = 2.973 + 0.1321xΔPG, r = 0.715, p<0.001.
Conclusions: In patients with transient LV apical ballooning, intravenous β-blockade 
administration can provide therapeutic efficacy for reduction of dynamic MVO, resulting in 
an improvement of LV geometry, global function, and subsequently systemic hypotension.
9:00 a.m.
1028-102	 Cardiac	Myolysis	And	LV	Dysfunction	In	Patients	With	
Duchenne	Muscular	Dystrophy	-Inhibitory	Effect	Of	
Carvedilol	On	Cardiac	Myolysis-
Takao Nishizawa, Fumihiko Yasuma, Akiko Noda, Hideo Izawa, Kohzo Nagata, 
Mitsuhiro Yokota, Toyoaki Murohara, Nagoya University, Nagoya, Japan, Suzuka 
National Hospital, Suzuka, Japan
Background: Cardiac myolysis is observed in idiopathic dilated cardiomyopathy (DCM) 
and elevation of a biochemical marker leads to poor prognosis. Patients with Duchenne 
muscular dystrophy (DMD) often have cardiomyopathy. However it is unclear that how 
cardiac myolysis occurs in patients with DMD and how it relates to cardiac function.
Methods: Fifty-eight Duchenne muscular dystrophy patients were subjected of this study. 
Serum CPK and plasma cardiac troponin I (cTnI) were repeatedly (every 3 months) 
measured for 2 years and LV function was assessed by echocardiography.
Results: Patients with positive cTnI (Cut off 0.06ng/mL) showed lower LVEF(42± 
2%) than those of negative cTnI (52± 2%). However, 28% of the impaired LV function 
(LVEF<50%) never showed positive cTnI. The frequency of detecting positive cTnI was 
decreased according to age and decreased serum CPK level. Some patients in less 
than 20 years old showed positive cTnI with preserved LV function. On the other hand, 
patients with preserved LV function in more than 20 years old never showed positive cTnI. 
Administration in carvedilol (2.5-5 mg/day) in 12 patients with positive cTnI for 6 months 
decreased the frequency of positive cTnI (From 100% to 25%).
Conclusions: Plasma cTnI was associated with impaired LV function. Positive plasma 
cTnI precedes the impaired cardiac function and the frequency of detecting plasma cTnI 
decreased with decreased LVEF suggesting that persistent myolysis become intermittent 
as progression of LV dysfunction. Repeated measurements of plasma cTnI may be useful 
to predict development of LV dysfunction. Carvedilol administration is one of the effective 
therapies to prevent cardiac myolysis.
9:00 a.m.
1028-103	 Utility	of	Magnetic	Resonance	Imaging	Derived	End	
Diastolic	Volume	ratio	in	Diagnosis	of	Arrhythmogenic	
Right	Ventricular	Dysplasia
Harikrishna S. Tandri, Samanthapudi Daya, Darshan Dalal, Robson Macedo, Crystal 
Tichnell, Cynthia James, Sinha Sunil, Prakasa Kalpana, Hugh Calkins, David A. 
Bluemke, The Johns Hopkins University School of Medicine, Baltimore, MD
Background: Magnetic resonance derived ventricular volumes are often abnormal 
in arrhythmogenic right ventricular dysplasia (ARVD). However, routine clinical use of 
this parameter is hampered by lack of age-, gender-, and body surface area (BSA) - 
adjusted normal values. Most patients with ARVD have limited or no involvement of the 
left ventricle (LV). We hypothesized that the ratio of RV: LV end diastolic volume (EDV 
ratio) will better discriminate ARVD from non-ARVD subjects.
Methods: MRI was performed on 1.5 T scanner in 100 consecutive patients evaluated for 
ARVD either due to a family history or ventricular arrhythmias of RV origin. The protocol 
included black blood and cine imaging in the axial and short axis planes. Ventricular 
volumes were measured by manually contouring end diastolic and end systolic images, 
and were adjusted to BSA. Diagnosis of ARVD was made based on TASK force criteria.
Results: Of the 100 patients, 23 were diagnosed with ARVD. Mean age of ARVD patients 
was 36±13 and 70% were men. RV end diastolic volume index was significantly higher 
in ARVD compared with non-ARVD (100.4 ± 20 vs. 80.6± 12, p =0.001). RV EDV index 
had a sensitivity of 90% and a specificity of 65% in diagnosis of ARVD, and correctly 
classified patients 70% of the time. LV volumes were similar in the two groups. EDV ratio 
was significantly higher in ARVD compared to non-ARVD (1.48 ± 0.5 vs. 1.06 ± 0.12, 
p<0.01). None of the non-ARVD patients had an EDV ratio of > 1.2, whereas, 100% of 
ARVD patients had an EDV ratio of 1.2. On ROC analyses, an EDV ratio of >1.1 had 
the optimal sensitivity and specificity (79% and 85% respectively) in correctly classifying 
ARVD patients and controls.
Conclusions: We conclude that MRI derived EDV ratio has improved specificity 
compared to EDV index and may be a useful quantitative parameter in routine clinical 
practice for ARVD diagnosis. EDV ratio is easily obtained and overcomes the limitations 
of end diastolic volume, as the later parameter needs to be adjusted for demographic and 
anthropometric measures.
9:00 a.m.
1028-104	 Relation	Between	the	Type	of	Connective	Tissue	
Disease	and	Diastolic	Dysfunction
Mami Hirata, Atsushi Takagi, Hirota Watanabe, Natsuha Koike, Ken Shimamoto, 
Masatoshi Kawana, Institute of Geriatrics, Tokyo Women’s Medical University, Tokyo, 
Japan, Tokyo Women’s Medical University, Tokyo, Japan
Background: Connective tissue diseases can cause myocardial degeneration as systemic 
inflammation. However the incidence of diastolic dysfunction has not been addressed 
among the different type of connective tissue diseases. The purposes of this study are to 
clarify the incidence of early diastolic dysfunction by tissue velocity imaging in connective 
tissue diseases and to demonstrate the reration between the type of connective tissue 
disease and diastolic dysfunction by tissue velocity imaging.
Methods: We investigated 69 patients with connective tissue diseases [polymyositis 
(PM)/ dermatomyositis (DM): 9 patients, systemic sclerosis (SSc): 16 patients, systemic 
lupus erythematosus (SLE): 14 patients, rheumatoid arthritis (RA): 30 patients] who did 
not show obvious heart disease, systemic hypertension or ECG signs of left ventricular 
hypertrophy, comparing to 20 control subjects. E/A ratio and deceleration time of 
transmitral inflow were recorded. E/Ea ratio was also recoded in each group.
Results: There was no difference in E/A and deceleration time in each group. E/Ea of PM/ 
DM and SSc was significantly higher than that of control. In contrast, no difference in E/Ea 
of SLE and RA was observed compared to control. (Table 1)
Conclusions: Latent diastolic dysfunction was documented by tissue velocity imaging in 
PM/ DM and SSc, not in SLE and RA.
Table 1
E/Ea p value (compared to control)
Control 7.8+/-0.5 -
PM/DM 16.3+/-2.1 p=0.0004
SSc 13.1+/-2.1 p=0.0002
SLE 8.0+/-0.6 ns
RA 8.9+/-0.5 ns
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9:00 a.m.
1028-105	 Relation	of	Markers	of	Oxidative	Stress	and	
Inflammation	to	Body	Mass	Index	in	Heart	Failure
Audrey H. Wu, Todd M. Koelling, Jennifer C. Matthews, Suzanna M. Zick, Keith D. 
Aaronson, University of Michigan, Ann Arbor, MI
Background: While measures of oxidative stress and inflammation have been extensively 
studied in heart failure (HF) with reduced systolic function (RSF), less is known about 
these parameters in HF with preserved systolic function (PSF) and their relation to 
body mass index (BMI) in the setting of HF, particularly as obesity is known to be an 
inflammatory state.
Methods:	We retrospectively analyzed 120 outpatients with stable HF. RSF was defined 
as left ventricular ejection fraction ≤ 40%, while PSF was defined as > 40%. Isoprostane 
and C-reactive protein (CRP) levels were measured. Associations between these markers 
were independently tested with multivariable linear regression models, stratified by RSF 
versus PSF, and controlling for BMI, demographic, clinical, laboratory, and medication 
data. Continuous variables are expressed as mean ± SD.
Results:	Thirty-eight (32%) subjects had PSF, versus 82 (68%) with RSF. Ninty-one (76%) 
were males, 62 (52%) had prior myocardial infarction, 32 (27%) were diabetic, and 94 
(78%) were overweight or obese (body mass index > 25 kg/m2). Mean age was 56 ± 11 
years. Mean ejection fraction was 36 ± 15% and New York Heart Association class was 2.5 
± 0.5. CRP was 8.16 ± 6.5 mg/dl in the PSF group versus 9.5 ± 6.5 mg/dl in the RSF group. 
Isoprostane levels were 17,199 ± 8700 pg/ml in PSF versus 17,473 ± 8563 pg/ml in RSF. 
While elevated in both RSF and PSF, there were no significant differences demonstrated in 
univariable analysis or analysis adjusted for clinical factors including BMI.
Conclusions: Measures of oxidative stress and inflammation are elevated to similar degrees 
in HF with RSF versus PSF, and does not appear to be differentially influenced by obesity.
9:00 a.m.
1028-106	 Cardiomyocyte	Engraftment	In	Human	Gender-
mismatched	Heart	Transplantation	Preserves	
Microvascular	Function
Francesco Tona, Annalisa Angelini, Alida LP Caforio, Antonio Gambino, Roberta 
Montisci, Angelo Ramondo, Giuseppe Feltrin, Gino Gerosa, Gaetano Thiene, Sabino 
Iliceto, Cardiology, University of Padova, Padova, Italy
Background: Cardiomyocytes of recipient origin have been detected in patients who have 
received gender-mismatched heart. Aim of our study was to determine the relationship 
between extracardiac progenitor cell mobilization/homing and microcirculation.
Methods: 39 endomyocardial biopsies were obtained from 18 male patients (aged 42 ± 10 
years) who underwent gender-mismatched heart transplantation (HT). Five biopsies from 
non-transplanted male and from non-transplanted female were used as controls. Cells 
from recipient origin were identified by fluorescence in situ hybridization for combined XY-
chromosome (Vysis) on paraffin sections of each biopsy. Biopsies at different time points 
were examined. Coronary blood flow velocity in the left anterior coronary descending 
artery was detected by contrast-enhanced transthoracic echocardiography (CE-TTE) at 
rest and during intravenous infusion of adenosine (0.14 mg/kg/min) 6.3 ± 4.5 years after 
HT. Coronary flow reserve (CFR) was obtained as the ratio of hyperaemic diastolic peak 
velocity (DPV) to resting DPV. All patients had normal coronary angiography and a normal 
left ventricular mass.
Results: Cardiomyocytes of recipient origin were identified in the donor graft in a 
percentage of 0.507 ± 0.78. The nuclei of these Y-chromosome positive cardiomyocytes 
never showed more than two signal, one for Y-chromosome and one for X-chromosome. 
There was an increase of recipient-derived cells in the donor hearts over time. The mean 
values of cardiomyocytes engraftment per month for the entire population was 0.064 ± 
0.06 suggesting that there was a continuous recruitment and transdifferentiation. Mean 
CFR was 2.44 ± 0.83. A correlation between the number of engrafted cells and CFR was 
detected (r= 0.566; p= 0.01), therefore suggesting that high levels of chimerism may have 
a protective effect on microcirculation.
Conclusions: Cells mobilization and engrafting after HT seem to be associated with 
preserved microvascular function, as assessed by CFR. If we could learn to control 
chimerism, it might be possible to delay or prevent the progressive CFR impairment that 
has been shown to be an early marker of cardiac transplant vasculopathy development.
9:00 a.m.
1028-107	 Peripheral	Blood	Leukocyte	Gene	Expression	Signatures	
Of	Antibody	Mediated	Cardiac	Allograft	Rejection
Manuel Bayern, Martin Cadeiras, Anshu Sinha, Anatasia R. Gangadin, Sarfaraz Memon, 
Aliye S. Oz, Helen M. Baron, Charles Marboe, Nicole Suciu-Foca, Russel Dedrick, 
Califano Andrea, Mario C. Deng, Columbia University, New York, NY
Background: Antibody mediated Rejection (AMR) is associated with poor outcome. We 
hypothesized that specific gene expression profiles may correlate with Cardiac Allograft AMR.
Methods:	Based on the Columbia University cohort from the CARGO study, we analyzed 
PBMC gene microarrays from patients meeting criteria for AMR (Takemoto, 2004). 
We used SAM, Gene ontology analysis and hierarchical clustering. FDR<5-10% was 
considered significant.
Results:	 Five patients fulfilled criteria for AMR. We found dramatic changes in the 
expression profiles and coherent enrichment of gene ontology categories. Represented 
genes included BCL11A, BNIP3L, AGPTA1, HLA-DRA, CD1D, CD74, FADD, TNFRSF25, 
GZMB, IGHG-1 and 4, IGLL1, IL-4, IL7R , IRF4, ITK, OSM, PTPRC, TNFAIP6. Hierarchical 
clustering showed highly correlated expressions patterns in patients with AMR (figure: 
top=samples, side=genes; top rightest most cluster = AMR). Several gene ontology 
categories including those related to cell apoptosis, B-cell and T-cell differentiation and 
activation among others, were over represented by differentially expressed genes.
Conclusions:	Patients suffering AMR have specific gene expression profiles involving 
several B-cell but also T-Cell-related genes. These results should encourage the design 
of future studies aimed to dissect the cross-talk between the different known forms of 
rejection using genome wide functional genomics approaches. 
9:00 a.m.
1028-108	 Efficacy	of	Intravenous	Prothrombin	Complex	Concentrate	
for	Emergent	Reversal	of	Oral	Anticoagulation	in	Patients	
with	Left	Ventricular	Assist	System
Ayako Takahashi, Satoshi Wada, Noboru Oda, Akiko Mano, Tomoko S. Kato, Shigeki 
Miyata, Takeshi Nakatani, Soichiro Kitamura, National Cardiovascular Center, Suita, Japan
Background: A majority of patients (pts) on heart transplant waiting list required long time 
use of left ventricular assist system (LVAS) due to donor shortage. Although development 
of cerebral vascular hemorrhage (CVH) is one of the most serious complications in pts 
with LVAS who require extensive oral anticoagulant therapy, there are no guidelines on 
emergency treatment with respect to reversal of anticoagulation effects in these pts. The 
PPSB-SD is a concentrate prothrombin complex containing a high level of vitamin K-
dependent coagulation factor II, VII, IX, X, and reported to develop a safe acute reversal 
of anticoagulation within 15 minutes.
Methods: PPSB-SD in addition to FFP (fresh frozen plasma) was administered to 23 
pts with LVAS as candidates for heart transplant at National Cardiovascular Center from 
January 2001 due to CVH. Seventeen pts with LVAS, who developed CVH until 2000, were 
treated with only FFP. Either pts treated with PPSB-SD and FFP or with only FFP underwent 
neurosurgical therapy accompanied with intravenous drug administration if necessary.
Results: Eighty-three pts with LVAS were reviewed. Twenty-five pts developed 37 
CVH events (24 pts with Toyobo-extracorporeal LVAS, 1 patient with implantable LVAS) 
developed CVHs and required reversal of anticoagulation. In pts treated with PPSB-SD, 
the mean prothrombin time decreased from 3.62 to 1.01 International Normalized Ratio 
(INR) within 1 hour, compared with 3.80 to 1.01 within 8 hours without PPSB-SD (four 
to five times more rapidly when treated with PPSB-SD compared to FFP treatment). 
Fourteen pts developed 23 CVHs, which were treated with PPSB-SD, and 17 CVHs 
(69.5%) were successfully treated without major neurological complications. Eleven 
pts developed 14 CVHs that were treated without PPSB-SD, and 5 CVHs (35.7%) were 
treated without neurological complications (survival rate; p<0.005).
Conclusions:	Treatment with PPSB-SD reverses oral anticoagulation more rapidly than 
FFP, which prevent further bleeding in emergent situation. Pts with LVAS, who required 
intensified anticoagulation are at high risk for CVH, however, adequate use of PPSB-SD 
could be of importance for the survival of these pts.
9:00 a.m.
1028-109	 Long	Term	Results	of	a	Randomized	Multi-Center	Trial	
Comparing	Adaptive	Servo	Ventilation	Positive	Airway	
Pressure	to	Nasal	Oxygen	in	Heart	Failure	Patients	
With	Central	Sleep	Apnea
Lee R. Goldberg, Dieter Horstkotte, Simon F. Shakar, Brian D. Lowes, James M. Walker, 
Tom V. Cloward, Greg Maislin, Allan I. Pack, University of Pennsylvania, Philadelphia, PA
Background:	Central Sleep Apnea (CSA) is associated with increased morbidity and 
mortality in heart failure (HF) patients, but treatment of CSA to improve cardiovascular 
outcomes is controversial. Treatment of CSA in HF is challenging.
Methods:	A randomized, multi-national trial comparing the AutoSet CS adaptive servo 
ventilation device to Oxygen (O2) therapy was conducted at 8 sites to evaluate the safety 
and efficacy of the AutoSet CS in HF patients with CSA. The AutoSet CS device modifies 
positive airway pressure delivery using a novel adaptive servo ventilation algorithm, 
which adapts pressure support ensuring it is synchronized with the patient’s ventilation. 
Functional capacity and QOL were obtained at 3 months, safety assessed to a minimum 
of 6 months. 60 subjects were randomized to: AutoSet CS (32) and O2 (28). The primary 
safety objective was to demonstrate clinical non-inferiority of the AutoSet CS in terms of 
event-free survival (hospitalization, transplant or death) using a 10% delta. The primary 
efficacy outcomes compared functional and QOL measures.
Results:	 There were no significant differences in any demographic, disease score, 
functional or QOL measurements at baseline. 9 of 31 (29.0%) AutoSet CS and 11 of 28 
(39.3%) O2 experienced the safety endpoint, demonstrating clinical non-inferiority. Re-
hospitalization rates were not different. 6-minute walk test (6MWT) significantly increased 
in AutoSet CS (74.8±147.6 m, p<0.02) but not O2 (17.1±61.3 m). Among AutoSet CS, 
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LVEF increased (3.3%±7.2%, p=0.03), but decreased in O2 (-0.2%±7.3%). Similar 
findings were observed for QOL in the Physical Component Summary score of SF-36 
and for HF specific Minnesota Living with HF (LIhFE) physical dimension score.
Conclusions:	These results demonstrate that the AutoSet CS is safe to treat HF patients 
with CSA and provides improved physical functioning as evidenced by 6MWT, SF-36 
and LIhFE physical function after 3 months. There was a small but statistically significant 
increase in LVEF with AutoSet CS as compared to O2. These improvements were seen 
despite maximal medical and device management of HF prior to randomization and in 
comparison to an active control group treated with O2 during sleep.
9:00 a.m.
1028-110	 Accurate	Non-invasive	Calibration	of	an	Implantable	
Left	Atrial	Pressure	Monitoring	System	in	Heart	Failure	
Patients	during	Long-term	Follow-up
Jay Ritzema-Carter, Richard Troughton, Iain Melton, Robert Doughty, Jim Stewart, 
Henry Krum, Jim Whiting, Neal Eigler, Garrie J. Haas, William T. Abraham, for the 
HOMEOSTASIS Study Group, Christchurch Hospital, Christchurch, New Zealand, The 
Ohio State University, Columbus, OH
Background: Airway pressure (AP) during Valsalva maneuver (VM) has been shown to 
accurately predict cardiac filling pressures. We tested whether the VM could be used to 
calibrate a new permanent direct left atrial pressure (LAP) monitoring system.
Methods: 25 NYHA III-IV HF patients (age 68±10 years, LVEF 31±12%) enrolled in a 
multicenter trial underwent device implantation. At serial visits, VM was performed and 
the device recorded simultaneous airway and LAP. The difference between LAP and AP 
was attributed to zero offset drift and was used to recalibrate the device. Right heart 
catheterization (RHC) was performed at 3 and 12-months and simultaneous device LAP 
and catheter pulmonary capillary wedge pressure (PCWP) were measured.
Results: VMs were successful on 437/ 498 (90%) occasions and all patients achieved 
successful Valsalva calibration. At 11±5 months follow-up, 24/25 implants had minor offset 
drift (mean 2±5 mmHg, Figure), resolving at 3 months consistent with device healing. One 
patient with significant drift had a clinically usable device, as drift was predictable and 
easily corrected. During RHC device LAP measured PCWP within -0.2±5.7 mmHg. All 
offset drift since implantation was corrected by VM calibration.
Conclusion: The VM was well tolerated and allowed accurate, clinically useful non-
invasive calibration of a new LAP monitoring system. Minimal drift was reliably corrected 
using this simple method.
9:00 a.m.
1028-139	 Left	Ventricular	Reconstruction	Improves	Left	
Ventricular	Geometry	And	Systolic	Function	As	
Assessed	By	Cardiac	Magnetic	Resonance	Imaging.
James O. O’Neill, Randall C. Starling, Nicholas C. Smedira, Richard White, Tiffany 
Buda, Bruce W. Lytle, Cleveland Clinic Foundation, Cleveland, OH
Introduction:	 Left ventricular reconstruction (LVR) is a surgical procedure employed to 
change the shape and function of the post-infarct left ventricle with the aim of improving 
heart failure symptoms and prognosis. As left ventricular volume and systolic function are the 
targets of LVR, we sought to characterize morphologic changes following LVR at our center.
Methods: Using prospectively acquired databases, we analyzed the cardiac MRI data on 71 
patients who underwent LVR, in conjunction with a comprehensive surgical approach to patients 
with advanced heart failure, between January 1997 and July 2003 at a single institution.
Results: Of the 71 patients included in the study, (52 Male, 19 Female, mean age 
61±8 years), pre-operative left ventricular ejection fraction was 25±8% and increased 
postoperatively to 32±10% (p<0.001). Pre and post operative left ventricular end 
systolic volumes were 227±81 cm3 and 158±10 cm3 respectively (p<0.001). Pre and 
post operative left ventricular end diastolic volumes were 297±83 cm3 and 218±79 cm3 
respectively (p<0.001).
Conclusions: In patients undergoing LVR for heart failure, cardiac MRI indices of volume 
and left ventricular systolic ejection fraction are significantly improved. As left ventricular 
volume and ejection fraction are predictive of prognosis, these data may support the 
application of LVR to improve the outcome of patients with ischemic cardiomyopathy. A 
prospective, randomized trial is underway to determine whether LVR improves survival.
9:00 a.m.
1028-140	 Secondhand	Smoke	Exposure	Is	Associated	With	
Lower	Quality	Of	Life	In	A	Population	With	Heart	Failure
Sarah G. Weeks, Stanton Glantz, Teresa DeMarco, Alisa B. Rosen, Marina Flaskas, 
Kirsten E. Fleischmann, UCSF Medical Center, San Francisco, CA
Background: Heart failure (HF) results in significant morbidity and mortality. Previous 
studies have demonstrated an association between secondhand smoke (SHS) exposure 
and cardiovascular disease, primarily coronary atherosclerosis. Limited data are available 
on the association of SHS exposure and quality of life (QOL) measures in HF patients.
Methods: Nonsmoking patients with a diagnosis of heart failure were enrolled in a 
longitudinal cohort study assessing the effect of SHS on HF outcomes including QOL. 
Baseline demographics, clinical data and a validated smoke exposure questionnaire 
were collected at enrollment. Multidimensional health-related QOL was assessed with 
the Rand 36-item Health Survey, which assesses 8 domains on a scale of 0 (worst) to 100 
(best): physical functioning, bodily pain, role limitations due to physical health problems 
(role physical), role limitations due to emotional/personal problems (role emotional), 
emotional well being, social functioning, energy/fatigue and general health perceptions.
Results: Patient data were available on 205 heart failure patients at the time of analysis. 
Approximately 25% of the cohort reported SHS exposure; 76% of those reporting low 
levels of exposure (1-9 hrs/week). Exposure to SHS was associated with a reduction in 
overall QOL scores. Clinically significant reductions were noted in 3 subscale scores after 
adjustment for relevant clinical factors such as age, gender, NYHA functional class, and 
co-morbidities: role physical (mean score 19.5 points lower in exposed as compared with 
unexposed subjects, p=0.007), emotional well being (9.3 pts lower, p=0.004), and role 
emotional (16.3 pts lower, p=0.03).
Conclusion: SHS exposure is associated with a significant reduction in several aspects 
of health-related QOL in heart failure patients. QOL scores were reduced in both physical 
and emotional domains. The effect of SHS on the clinical outcomes of this patient cohort 
is currently being assessed.
9:00 a.m.
1028-141	 Evaluation	of	the	Clinical	Composite	Endpoint:	Results	
from	the	COMPANION	Study
John Boehmer, Teresa De Marco, Elizabeth Galle, Patrick Yong, COMPANION Study 
Investigators, Milton S Hershey Medical Center, Hershey, PA, Boston Scientific, Saint Paul, MN
Background: The Clinical Composite Endpoint (CCE) has been proposed as an 
outcome measure in heart failure clinical trials and has seen limited use in cardiac 
resynchronization therapy (CRT) studies. CCE was evaluated retrospectively using data 
from the COMPANION study, which demonstrated a significant reduction in time to all-
cause mortality or all-cause hospitalization with CRT.
Methods: The COMPANION database was analyzed on an intention-to-treat basis 
in patients (pts) randomized to CRT with defibrillation (CRT-D), without defibrillation 
(CRT-P), or optimal pharmacologic therapy alone (OPT) over a six month period post-
randomization. Pts were classified as Worsened if the pt died, were hospitalized for 
heart failure, or had worsened NYHA Class or global assessment. Pts were classified as 
Improved for improved NYHA Class or global assessment without death or heart failure 
hospitalization. Pts who neither Improved nor Worsened were classified as Unchanged. 
CCE was evaluated using a Mann-Whitney test.
Results: CRT-D and CRT-P demonstrated significant improvement in CCE when compared 
to OPT as shown below. No differences between CRT-D and CRT-P were observed.
Outcome CRT-D (n=595)
CRT-P 
(n=617)
OPT 
(n=308)
Statistical Significance
CRT-D vs 
OPT
CRT-P vs 
OPT
CRT-D vs 
CRT-P
Improved 376 (63.2%) 393 (63.7%) 90 (29.2%)
p<0.0001 p<0.0001 p=0.49Unchanged 49 (8.2%) 80 (13.0%) 94 (30.5%)
Worsened 170 (28.6%) 144 (23.3%) 124 (40.3%)
Conclusions: The Clinical Composite Endpoint corroborated the positive findings of the COMPANION 
study and is consistent with other CRT studies. These results provide further confirmatory evidence 
that CCE may be a useful endpoint in trials evaluating heart failure therapies.
9:00 a.m.
1028-142	 Long	Term	Benefits	of	the	Cor	Cap	Cardiac	Support	Device	
on	Left	Ventricular	(LV)	Remodeling:	3	Year	Results
Randall C. Starling, Mariell Jessup, Jae Oh, Hani N. Sabbah, Michael A. Acker, 
Douglas L. Mann, Spencer H. Kubo, Cleveland Clinic, Cleveland, OH, University of 
Pennsylvania, Philadelphia, PA
Background: Cardiac support devices (CSD) that reduce LV wall stress have been 
shown to promote reverse remodeling in 3 different experimental models of heart 
failure(HF). The Acorn Pivotal Trial enrolled 300 patients with HF, 85% NYHA 3,4. Results 
for an averaged 1-year endpoint have been previously reported. Compared to control, 
CSD treatment patients had a statistically significant improvement in a clinical composite 
score based on survival, need for additional major cardiac procedures and a change in 
a core lab assessment of NYHA functional class. Further, at 18 months, CSD treatment 
patients had significant reductions in LV size and greater increases in sphericity index, 
indicating a more elliptical LV shape.
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Methods:	The purpose of this report is to evaluate the long term (3 years) effects of the 
CSD on echocardiographic measures of LV remodeling.
Patients were seen at 3 months, 6 months and then every 6 months thereafter.
Echocardiograms were read in a blinded core lab.
Concurrent medical and ICD/CRT therapies were evidence based.
Results:	Echo	derived	LV	Volumes	and	Performance 
Endpoint Group Baseline
n=300
1	Year
n=185
2	Years
n=134
3	Years
n=78
p-value
(T	vs	C)
LVEDV
(ml)
Treat	(T) 277 ± 10 229 ± 6 218 ± 8 201 ± 12
0.005
Control	(C) 271 ± 9 244 ± 7 235 ± 9 239 ± 13
LVESV
(ml)
Treat	 204 ± 9 167 ± 6 163 ± 8 146 ± 11
0.01
Control	 203 ± 8 184 ± 6 171 ± 8 178 ± 12
LVEF
(%)
Treat	 28 ± 1 31 ± 1 29 ± 1 31 ± 2
ns
Control	 27 ± 1 28 ± 1 32 ± 1 30 ± 2
Sphericity index was significantly increased in T versus C group and maintained 
throughout the 3 year follow up p=0.018.
Conclusions: Implantation of the CorCap Cardiac Support Device leads to beneficial 
reverse remodeling, characterized by reduced LV volumes and a more elliptical shape. 
These effects have been maintained for 3 years, despite significant HF at baseline.
9:00 a.m.
1028-143	 Location	of	Injection	Determines	Whether	Negative	
Left	Ventricular	Remodeling	Occurs	Post	Skeletal	
Myoblast	Transplantation
Jonathan D. McCue, Cory Swingen, Daniel Gatlin, Tanya Feldberg, Adam Kolb, Brian Breviu, 
Somnath Prabhu, Gabriel Caron, Doris A. Taylor, University of Minnesota, Minneapolis, MN
Background: Intramyocardial skeletal myoblasts (SKMB) may become a potential 
therapy for ischemic cardiomyopathy. However, the results to date have been modest. 
We hypothesized that the effects of SKMB on left ventricular (LV) function could depend 
on the location of transplantation (periphery vs non-perfused central scar), importance 
of which is unknown.
Methods: 34 New Zealand White (NZW) rabbits underwent LAD ligation to create 
myocardial infarctions. Fe3+ -labeled autologous SKMB were injected at 1 month post-
injury in a 3-point peripheral (10), central (13) or sham (11) pattern (confirmed by MRI and 
Prussian Blue). Cardiac MRI (3T) assessed LV function post-treatment.
Results: Infarcts (scar volume by MRI) were homogeneous between groups. Central-scar SKMB 
injections resulted in significant negative LV remodeling [Figure 1 -- % change in LVESV (p=0.007), 
worsened LVEDV and LVmass (trend)], vs. peripheral injection or sham. In addition, the degree of 
negative LV remodeling correlated with quantity of SKMB in centrally-injected animals.
Conclusions: Location of intramyocardial myoblast transplantation determines occurrence 
of LV remodeling following SKMB therapy. Injections of SKMB into the center of the 
scar lead to negative LV remodeling, whereas peripheral administration appears to be 
preventive. Our observations may clarify modest benefits in trials to date as a targeted 
peripheral administration of SKMB may ensure favorable clinical outcomes. 
9:00 a.m.
1028-144	 Can	Myocardial	Perfusion	Imaging	Predict	Response	
To	Cardiac	Resynchronization	Therapy?
Michael V. Orlov, Michael Maysky, Michael R. Ujhelyi, Peter Hoffmeister, Peter 
Hoffmeister, Gunjan Shukla, Muqtada Chaudhry, Ibrahim Almasry, Charles Haffajee, St 
Elizabeths Medical Center, Boston, MA, Medtronic, Minneapolis, MN
Background:	Poor clinical response to cardiac resynchronization therapy (CRT) is not 
well understood . Poor myocardial viability and/or active ischemia may be, at least in part, 
responsible. We sought to determine whether pre-implant myocardial perfusion could 
predict clinical outcome with CRT.
Methods:	Myocardial perfusion (MP) imaging, LV volumes, 6-min walk test (6MWT) and 
other clinical variables were prospectively assessed at baseline and at 4 months in 18 
patients with LBBB and refractory CHF undergoing CRT implant without indication for 
revascularization. We determined if myocardial ischemia (MP stress minus rest score) or 
scar (rest MP score) predicted clinical response and/or associated (multiple regression) 
with clinical (BNP, QOL) or hemodynamic changes (end sytolic/diastolic volumes, EF). 
Clinical response was a > 10% increase in 6MWT distance from baseline to 4 months. 
MP was assessed by Tc-99M Sestamibi SPECT at rest and with adenosine stress pre-
implant. MP of individual segments was evaluated by a blinded reader based on 20-
segment model and 0-4 MP scale (0-normal MP, 4-no MP). Segmental MP was summed 
yeilding a stress and stress score.
Results:	Clinical improvement with CRT occured in 66% of patients. 6MWT increased 
from baseline to 4 month follow up by 19% (713±305 ft to 847±409 ft; p=0.005). Baseline 
mean stress SPS was: 26±11, rest: 22±12. Logistic regression demonstrated that clinical 
CRT responders had lower rest/stress MP scores (odds ratio of 1.62 ; 95% CI, 1.04-2.52). 
There was a close negative correlation such that less ischemia (i.e. lower stress/rest 
scores) associated with increase 6-min walk distance (R=-0.79, p<0.0003). Similarly, 
patients with lower myocardial scar (ie low rest MP scores) had a greater reduction in end 
systolic volume (R= 0.62, p<0.03) and predicted hemodynamic response to CRT. There 
was no relationship between MP rest score or rest/stress score with changes in ejection 
fraction, BNP, or QOL.
Conclusions: Baseline MP is associated with CRT clinical and hemodynamic response: 
higher ischemic burden is predictive of poor clinical response while greater myocardial scar 
is predictive of poor hemodynamic response in CRT patients with CAD, CHF and LBBB.
9:00 a.m.
1028-145	 Right	Atrial	Volume	Index	(RAVI)	identifies	RV	Systolic	
Dysfunction	in	Patients	with	Symptomatic	Heart	Failure
Sarinya Puwanant, Tiffany Priester, Farouk Mookadam, Krishnaswamy 
Chandrasekaran, Mayo Clinic, Rochester, MN
Background: Left atrial volume index (LAVI) has been associated with LV diastolic 
dysfunction in patients with heart failure (HF). However, the usefulness of RAVI in patients 
(pts) with HF is unknown.
Objectives: To evaluate the usefulness of RAVI in pts with HF to identify RV 
diastolic (D) and systolic (S) dysfunction.
Methods: Ninety-two pts with symptomatic HF were prospectively enrolled. RAV was 
calculated by 2D echo area-length method. RAVI = RAV/body surface area. RV D 
parameters include tricuspid (TV) inflow early (E) and late (A) velocities, TV E deceleration 
time, tricuspid early (TV e’), late diastolic (TV a’) annular velocity, and TV E/e’. RV S 
parameters include RV EF by 2D planimetry, TV annular motion (TAM), and TV annular 
tissue Doppler systolic velocity (Sa). RV D dysfunction was defined as TV e’ <7.8 cm/s. 
RV S dysfunction was defined as the presence of 2 of the 3 parameters: RVEF <50%, 
TAM <1.5 cm, and Sa <11.5 cm/s.
Results: Sixty-two of 92 pts (age 72±15) in sinus rhythm were included in the study. 
Mean RAVI was 35±17ml/m2 (range 7 -70). Forty-seven percent (29 of 62) and 48% (24 
of 50) had RV S and D dysfunction,respectively. RAVI was significantly greater in those 
with RV S dysfunction compared to normal RV S function, 40±17 vs. 28±13 ml/m2, p 
<0.01. In those with RV S dysfunction, pts with moderate or severe tricuspid regurgitation 
(TR ) had significantly greater RAVI than those with less than moderate TR, 51±16 vs. 
33±14, p <0.01. RAVI was similar in pts with and without RV D dysfunction, 33±17 vs. 
35±15, p=NS. However, among those with RV D dysfunction, RAVI was larger in pts with 
moderate or severe TR compared to mild TR, 48±16 vs. 27±13, p <0.01). RAVI correlated 
significantly with RVEF (r = -0.51, p<0.01), TAM (r = -0.51, p<0.01), TV A wave (r = -0.42, 
p<0.01), TV a’ (r = -0.34, p0.02) and TV e’/a’(r = 0.41, p<0.01)
: 1.RAVI identifies presence of RV S dysfunction in pts with symptomatic HF irrespective 
of the severity of TR. 2. RAVI was significantly associated with the worse RV S function 
and atrial mechanical function. 3. In contrast to LAVI, RAVI did not show significant 
correlation with RV D dysfunction.
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670-5	 Neurohormonal	Features	of	Stress-Induced	(Takotsubo)	
Cardiomyopathy	Versus	Acute	Myocardial	Infarction
Ilan S. Wittstein, Navin K. Kapur, James O. Mudd, Hunter C. Champion, The Johns 
Hopkins University School of Medicine, Baltimore, MD
Background: Stress-induced (Takotsubo) cardiomyopathy (SCM) is a syndrome of transient 
left ventricular dysfunction precipitated by acute emotional or physical stress. It is unknown 
whether enhanced sympathetic stimulation is central to the pathogenesis of this syndrome.
Methods: Plasma catecholamines (CA) and neuropeptides (NP) from 30 patients with 
SCM and 32 patients with acute myocardial infarction (AMI) were compared at the time of 
admission. Levels from 10 healthy controls were also measured.
Results: Patients with SCM and AMI were the same age (63±13 vs. 62±15 years, p=NS). 
There were more women in the SCM group (82% vs. 45%, p<0.02). Peak troponin I was 
lower in SCM (3±6 vs. 53±60 ng/ml, p<0.001) as was the admission ejection fraction 
(23±11% vs. 41±13%, p<0.001). None of the patients with SCM had coronary disease. 
Plasma CA and NP are shown in the table. Patients with SCM had marked elevations 
in dihydroxyphenylalanine, dihydroxyphenylglycol, and norepinephrine (NE), consistent 
with increased NE synthesis, neuronal reuptake, and spillover, respectively. NPY, co-
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released with NE and a marker of sympathoneural tone, was elevated in SCM but not 
in AMI. Adrenomedullary hormonal activation was also evident in patients with SCM with 
epinephrine levels 4 times higher than in AMI and more than 14 times normal levels.
Conclusion:	 Patients with SCM present with	 dramatic elevation in plasma CA. 
This suggests that the myocardial stunning characteristic of this syndrome may be 
sympathetically mediated. 
SCM AMI Normal
Dihydroxyphenylalanine 2,195±594* 1,376±252 1,457±489
Epinephrine 945 ± 369* 231 ± 144** 67 ± 34
Norepinephrine 2,024 ± 836* 563 ± 392** 183 ± 62
Dopamine 104 ± 52* 45 ± 16 22 ± 14
Dihydroxyphenylglycol 2,352 ± 732* 1,225 ± 299 990 ± 185
Metanephrine 172 ± 49* 94 ± 19 70 ± 17
Normetanephrine 200 ± 85* 116 ± 32** 64 ± 14
Neuropeptide	Y 180 ± 57* 61 ± 18 42 ± 16
All plasma levels are in pg/ml and are expressed as mean ± standard deviation. 
*p<0.001 vs. AMI and Normal; **p<0.05 vs. Normal.
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845-3	 Predictors	of	Pump	Failure	Death	in	Heart	Failure	
Patients	in	the	CARE-HF	Study
Barry F. Uretsky, Kristian Thygesen, Jean-Claude Daubert, Erland Erdmann, Nick 
Freemantle, Daniel Gras, Lukas Kappenberger, Luigi Tavazzi, John GF Cleland, UTMB, 
Galveston, TX
Cardiac resynchronization therapy (CRT) improves symptoms, exercise performance, and 
survival in patients with moderate or severe heart failure and markers of left ventricular 
dyssynchrony. The CARE-HF study and extension phase showed that CRT reduced mortality 
in systolic heart failure (HF) patients with ventricular dyssynchrony by 13.4% (relative 
reduction 40%) during a mean follow-up through the extension phase of 36.4 months, due 
both to pump failure deaths(PFD) and arrhythmic sudden cardiac deaths (SCD).
Methods:We performed an analysis on 813 patients to determine factors predicting pump 
failure deaths during long-term follow-up using 16 pre-specified variables measured at 
baseline and at the 3 month examination.
Results: There were 255 deaths. Univariate PFD predictors [hazard ratio (HR), 95% 
confidence interval (CI)] included randomization to CRT HR 0.55 (CI 0.37-0.88; p=0.003)) 
and baseline values of plasma NT-proBNP 2.16 (1.81-2.57; p<0.0001), severity of 
mitral regurgitation (1.69-2.28; p=0.0006), LV end diastolic volume 1.002 (1.001-1.004; 
p=0.002), interventricular mechanical delay 0.991 (0.984-0.998); p=0.018), systolic 
arterial pressure 0.97 (0.96-0.98; p <0.0001), etiology of non-ischemic cardiomyopathy 
0.43 (0.28-0.66; p=0.00011), and quality of life score 0.23 (0.12-0.41; p<0.0001). The 
only predictors of PFD on multivariate analysis were randomization to CRT 0.59 (0.39-
0.91), baseline values of plasma NT-proBNP 2.10 (1.7-2.52; p<0.00011), and systolic 
arterial pressure 0.985 (0.974-0.997; p=0.01). The severity of mitral regurgitation at 3 
months predicted increased risk of subsequent SCD, but the use of 3-month values did 
not improve prediction of PFD.
Conclusions: CRT is effective in reducing long-term risk of PFD in patients with moderate 
or severe heart failure. Baseline parameters of the HF state as reflected in BNP and 
systolic BP appear to be the best predictors of long-term risk of PFD.
2:15 p.m.
845-4	 Microalbuminuria	in	Chronic	Heart	Failure:	Prevalence	
and	Determinants	in	More	Than	2,000	Patients	Enrolled	
in	the	GISSI-HF	Trial
Serge Masson, Roberto Latini, Simona Barlera, Luciano Moretti, Maria Grazia Rossi, 
Emanuele Carbonieri, Anna Frisinghelli, Alessandra Gualco, Massimiliano Valisi, Aldo 
P. Maggioni, Gianni Tognoni, Luigi Tavazzi, Istituto Mario Negri, Milan, Italy, ANMCO 
Research Center, Florence, Italy
Background: Microalbuminuria (MA) is a marker of renal/endothelial dysfunction, associated 
to cardiovascular mortality and morbidity in the general population and in patients with 
diabetes or hypertension; little is known in patients with chronic heart failure (HF).
Methods: MA (albumin/creatinine ratio, UACR) was measured in 2,190 patients with 
chronic HF enrolled in the GISSI-HF trial. Patients were divided into 3 categories of 
UACR (normal <30 mg/g, MA 30-299, and albuminuria ≥300). Plasma BNP and CRP were 
measured in a subset of patients. Associations between MA, clinical and neurohormonal 
variables were tested by univariable and multivariable analyses.
Results: 20.5% of the patients with HF had MA, 5.5% were albuminuric. Patients with 
MA were older, had more advanced NYHA class and were more likely to have diabetes, 
hypertension, COPD or atrial fibrillation compared to normoalbuminurics. The circulating 
concentrations of creatinine, BNP and CRP were significantly higher in patients with MA. 
Diabetes (OR 2.03 [1.51-2.73]), serum creatinine (1.99 [1.46-2.71]), heart rate (1.02 
[1.00-1.03]), SBP (1.007 [1.001-1.014]), age ≥70 y (OR 1.31 [1.02-1.68]) and BNP ≥ 
median (OR 1.58 [1.03-2.44]) were independently associated with MA.
Conclusions: The high prevalence of MA (20.5%) in these patients with HF coincides 
with the presence of other co-morbidities (diabetes, hypertension, COPD, atrial fibrillation) 
associated with inflammation, endothelial dysfunction and neurohormonal activation.
Normal Microalbuminuria Albuminuria p
N (%) 1620 (74.0) 449 (20.5) 121 (5.5)
Age ≥70 y (%) 45.1 56.1 58.7 <0.0001
NYHA III-IV (%) 29.0 39.2 39.7 <0.0001
Diabetes (%) 21.1 38.5 57.1 <0.0001
Hypertension (%) 53.9 63.9 66.1 <0.0001
COPD (%) 20.0 30.5 31.4 <0.0001
Serum creatinine,mg/dL 
(mean±SD) 1.13±0.33 1.44±0.60 1.27±0.50 <0.0001
BNP, pg/mL (median [IQR]) 116 [51-207] 154 [75-311] 213 [112-352] <0.0001
hsCRP, mg/L (median [IQR]) 1.99 [0.98-4.31] 3.03 [1.54-6.56]
4.09 [1.86-
7.85] <0.0001
2:30 p.m.
845-5	 Serum	Tenascin-C	Levels	Predict	Hospitalization	
for	Decompensated	Heart	Failure	in	Patients	With	
Dilated	Cardiomyopathy
Naoki Fujimoto, Katsuya Onishi, Kyoko Imanaka-Yoshida, Kaoru Dohi, Masaki Tanabe, 
Takeshi Takamura, Tairo Kurita, Naoki Isaka, Masaaki Ito, Mie University Graduate 
School of Midecine, Tsu, Japan
Backgrouds: Serum tenascin-C levels are correlated with New York Heart Association 
functional class in patients with dilated cardiomyopathy (DCM); however, characterization 
of DCM with elevated serum tenascin-C levels has not been described.
Purpose:	The purpose of this study is to examine the relation of serum tenascin-C levels 
to the cardiac function, hemodynamics and hospitalization for decompensated heart 
failure (HF) in patients with DCM.
Methods: Left ventricular (LV) function and hemodynamics obtained by conductance 
catheters with microtip-manometers, and serum tenascin-C levels were examined in 
consecutive 60 DCM patients (age; 58±14 y.o., male; 73 %) admitted to our hospital 
due to HF. After the follow-up periods (mean 39±23, 4-82 months), the optimal cut-off 
points for hospitalization for decompensated HF were determined by a receiver-operating 
characteristic (ROC) analysis.
Results:	The average	LV ejection fraction was 0.31±0.10, and plasma BNP levels were 
273±304 pg/ml. The ROC curves demonstrated tenascin-C > 98 ng/ml to be the best 
cut-off points for hospitalization for HF with sensitivity 88 %, specificity 81 %, and area 
under the curve: 0.81. Accordingly, patients were divided into two groups; high-tenascin-C 
(126±34 ng/ml; n=16) and low-tenascin-C (53±22 ng/ml; n=44). Seven in high-tenascin-C 
(44%) and one patient in low-tenascin-C (2%) were readmitted to the hospital due to the 
exacerbated HF. End-diastolic (234±79 vs. 186±50 ml) and end-systolic volume (169±70 
vs. 130±48 ml) were significantly larger in high-tenascin-C than low-tenascin-C without 
any differences in ejection fraction, stroke volume, arterial elastance, end-diastolic 
pressure and LV end-systolic elastance.
Conclusion:	Serum tenascin-C levels reflect LV remodeling and predict the hospitalization 
for decompensated HF in patients with DCM.
2:45 p.m.
845-6	 Circulating	Osteoprotegerin	Levels	in	the	General	
Population:	Relation	to	Left	Ventricular	Structure	
and	Function
Torbjorn Omland, Mark H. Drazner, Thor Ueland, Moeen Abedin, Pal Aukrust, Sabina 
A. Murphy, James A. de Lemos, Donald W. Reynolds Cardiovascular Research 
Center, University of Texas Southwestern Medical Center, Dallas, TX, 2. Department of 
Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway
Background: Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor 
superfamily, has pleiotropic effects on bone metabolism, endocrine function and the 
immune system. Myocardial expression and circulating levels of OPG are increased in 
heart failure. The relationship between OPG levels in the general population and indices 
of left ventricular (LV) anatomy and function is unknown.
Methods: Plasma OPG levels and cardiac magnet resonance imaging indices of LV 
anatomy and function were available in 2701 subjects (median age 44 y, 45.3 % male). 
The association between OPG concentration and indices of LV anatomy and function was 
assessed by linear regression analysis, adjusting for relevant confounders.
Results: By gender specific quartile analysis, higher OPG levels were significantly associated 
with higher LV mass indexed to body fat free mass or body surface area, LV wall thickness, LV 
concentricity index (mass/end-diastolic volume), and lower LV ejection fraction (p<0.001 for 
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all). After adjustment for age, race, free fat mass, fat mass, hypertension, diabetes, coronary 
artery disease, estimated glomerular filtration rate, total cholesterol, smoking status, hormone 
replacement therapy, coronary artery calcium score > 10, and presence of aortic plaque, 
OPG remained significantly associated with each of these indices in male (p<0.05 for each) 
but not female subjects. OPG was, however, independently associated with lower LV ejection 
fraction in both female (p<0.001) and male (p=0.003) subjects.
Conclusions: In the general population, plasma OPG levels are independently associated with 
indices of LV hypertrophy in men and inversely associated with LV ejection fraction in both genders. 
These findings are compatible with the hypothesis that OPG may play a pathophysiological role in 
the development of left ventricular hypertrophy and systolic dysfunction.
3:00 p.m.
845-7	 Increased	Oxidative	Stress	via	Activation	of	NADPH	Oxidase	
Mediates	Angiotensin	II-Induced	Skeletal	Muscle	Wasting:	
Potential	Mechanism	of	Cachexia	in	Congestive	Heart	Failure
Sergiy Sukhanov, Laura Semprun-Prieto, Joseph Huang, Makoto Akao, Patrick 
Delafontaine, Tulane University, New Orleans, LA
Congestive heart failure (CHF) is a leading cause of cardiovascular mortality and 
morbidity and is associated with elevated circulating levels of angiotensin II (ang II) and 
muscle wasting, which is an important predictor of poor outcome in patients with this 
disease. We have shown recently that ang II infusion in rats produces skeletal muscle 
wasting secondarily to increased muscle proteolysis and increased apoptosis. Since 
an increase in superoxides mediates pro-apoptotic and proteolytic effects in different in 
vitro models, we hypothesized that oxidative stress is associated with ang II-induced 
muscle wasting. FVB mice were infused with ang II (ANG, 500 ng/kg/min, n=6) or vehicle 
(SHM) and were pair-fed for 7d. Ang II decreased weight of gastrocnemius muscles 
(SHM, 141.8±5.9g vs. ANG, 129.8±7.5g, P<0.10, left muscle, wet weight and SHM, 
50.3±5.2g vs. ANG, 42.1±2.5g, P<0.05, right muscle, dry weight). Ang II-induced muscle 
wasting was associated with 52% increase in total superoxide levels (SHM, 124.4±67 
vs. ANG, 189.9±44 relative light units/mg protein, P<0.05) as measured by L-012-based 
luminescent assay of gastrocnemius muscle. Superoxide formation in skeletal muscles 
from SHM and ANG mice was completely suppressed (by 95±5% and 93±3% compared 
to DMSO control, respectively) with 290 µM apocynin, a specific inhibitor of NADPH 
oxidase (NOX). NOX activation by adding 2 mM NADPH substrate to muscle fragments 
produced a 3.7-fold greater superoxide burst from ANG muscle samples compared to 
control indicating a critical role for NOX in ang II-induced superoxide generation. Ang 
II increased relative gene expression of two NADPH oxidase subunits: p22phox and 
p47phox (by 55% and 88%, respectively) as measured with real-time PCR. These 
findings strongly suggest that ang II activates NADPH oxidase and via this mechanism 
increases superoxide formation in skeletal muscle. The link between NADPH oxidase, 
oxidative stress and ang II effects has widespread clinical implications for understanding 
mechanisms of catabolic conditions. Therapeutic interventions targeting cross-talk 
mechanisms between ang II and NADPH oxidase could provide new approaches for the 
treatment of muscle wasting and CHF.
3:15 p.m.
845-8	 Galectin-3,	a	Novel	Marker	of	Macrophage	Activity,	Predicts	
Outcome	in	Patients	With	Stable	Chronic	Heart	Failure
Dirk Lok, Peter van der Meer, Pieta Bruggink-André de la Porte, Erik Lipsic, Jan van 
Wijngaarden, Dirk Jan van Veldhuisen, Ygal Pinto, Deventer Hospital, Deventer, The 
Netherlands, Academical Hospital Maastricht, Maastricht, The Netherlands
Background: While it is known that in heart failure inflammation and activation of 
macrophages play a role, there are no reliable biomarkers that reflect cardiac macrophage 
activity . We recently identified Galectin-3 (gal-3) which is produced by activated cardiac 
macrophages and showed to mark prognosis in hypertrophied rat hearts as well as in 
patients with acute	heart failure. However, at this moment, no data are available regarding 
the value of Gal-3 in stable	Chronic Heart Failure (CHF).
Methods	and	results: We included 240 patients with stable treated heart failure, NYHA 
class III-IV, mean left ventricular ejection fraction 31% ±1, mean age 71 ± 0.6 years, 73% 
male. They were followed for a mean of 3.4 years. The primary endpoint was all cause 
mortality. During this follow up 88 (37%) patients died.
Gal-3 was measured at baseline. Mean Gal-3 level at baseline was 6.7 ng/ml (range: 1.8-
42).Elevated Gal-3 levels (>8ng/ml, highest quartile) were strongly related to outcome 
compared to the composite of the lower three quartiles HR 1.95, [95% CI 1.24-3.09], p=0.004 
(figure 1). Multivariate analyses showed a HR 1.65, [95% CI 1.01-2.71], p= 0.046.
Conclusions:	Gal-3, a marker of activated macrophages, predicts mortality in stable CHF 
patients. There seems to be a gradual relation between the level of gal-3 and survival. 
These findings may further help to elucidate the role of inflammation on prognosis in 
patients with heart failure. 
3:30 p.m.
845-9	 Efficacy	and	Safety	of	Conivaptan,	an	Arginine	
Vasopressin	Antagonist,	in	Patients	With	Hypervolemic	
Hyponatremia
Steven R. Goldsmith, Joseph G. Verbalis, Neila Smith, Abhijit Barve, Masakazu Andoh, 
Astellas Pharma US, Inc., Deerfield, IL
Background:	 Arginine vasopressin (AVP) regulates water balance but is often 
elevated in patients with hypervolemic hyponatremia. Conivaptan (CNV), an AVP 
V1A/V2-receptor antagonist, promotes aquaresis--the electrolyte-free excretion of 
water. Intravenous (IV) CNV was evaluated in a double-blind, placebo-controlled 
trial (DBPC) of 84 patients and an open-label (OL) study of 251 patients with 
euvolemic or hypervolemic hyponatremia. Reported here is a retrospective analysis 
of a subset of 97 patients from both studies with hypervolemic hyponatremia. 
Methods: Patients received either placebo or a 20-mg loading dose of CNV 
followed by continuous 4-day infusion of CNV 40 or 80 mg/d in the DBPC 
or 20 or 40 mg/d in the OL study. Efficacy endpoints included the change 
from baseline during treatment in the serum sodium concentration ([Na+])-
time curve (AUC); change from baseline in serum [Na+]; and others (Table). 
Results:	 Sixty of the 97 patients (62%) with hypervolemic hyponatremia had CHF, 
including 43 of 66 patients (65%) given CNV 40 mg/d. Patients treated with CNV 
20, 40, and 80 mg/d demonstrated increased serum [Na+] and improvement in all 
efficacy parameters (Table). Results were similar in the patients with CHF. The 
most common adverse events with CNV were infusion-site phlebitis, infusion-
site reactions, hypokalemia, vomiting, hypotension, and orthostatic hypotension. 
Conclusions: CNV effectively increased serum [Na+] in patients with hypervolemic 
hyponatremia, including those with CHF.
Efficacy of IV Conivaptan in Hypervolemic Hyponatremia
Parameter Placebo	(n=8)
IV	Conivaptan	
20	mg/d	
(n=14)
IV	Conivaptan	
40	mg/d	(n=66)
IV	
Conivaptan	
80	mg/d	
(n=9)
Baseline serum [Na+], mean 
± SD, mEq/L 124.2±4.6 123.6±4.6 123.5±4.9 124.3±4.0
Mean change (± SD) in 
serum [Na+] AUC, mEq•h/L
-74.8 
±134.3 490.9±383.9 565.3±437.7 798.6±245.7
Time from first dose to 
≥4 mEq/L increase in serum 
[Na+], median h
NE 58.5 24.1 23.8
Total time during which 
serum [Na+] increased ≥4 
mEq/L, mean ± SD h
3.6±10.3 42.9±36.2 54.9±35.6 81.0±7.5
Mean change (± SD) in 
serum [Na+] from baseline 
to end of treatment, mEq/L
-0.8±3.3 7.1±4.8 7.4±5.4 10.4±2.8
Patients with ≥6 mEq/L 
increase in serum [Na+] or 
serum [Na+] 
≥135 mEq/L, no. (%)
0 7 (50) 43 (65) 9 (100)
NE=not estimable; too few patients achieved a 4 mEq/L increase.
